Modified amino acids, pharmaceuticals containing these compounds and method for their production

ABSTRACT

The present invention relates to modified amino acids of general formula 
                         
wherein
 
A, Z, X, n, m, R, R 2 , R 3 , R 4  and R 11  are defined as in claims  1  to  5 , their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

This is a continuation of Ser. No. 10/119,875 filed Apr. 10, 2002, which is a continuation of Ser. No. 09/789,391 filed Feb. 21, 2001, now abandoned, which is a continuation of Ser. No. 09/254,281 filed Oct. 12, 1999, now U.S. Pat. No. 6,344,449, which is a 371 of PCT/P97/04862.

The present invention relates to modified amino acids of general formula

their tautomers, their diastereomers, their enantiomers, their mixtures and salts thereof, particularly physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them.

In the above general formula I

-   R denotes an unbranched C₁₋₇-alkyl group which may be substituted in     the ω-position     -   by a C₄₋₁₀-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         biphenylyl group,     -   by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-di-oxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-2H-2-oxoimidazopyridinyl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         1,3-dihydro-2H-2-oxoimidazol-1-yl or         3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, wherein the latter         two groups may each be mono- or disubstituted in the 4- and/or         5-position or in the 5- and/or 6-position by lower straight         chained or branched alkyl groups, by phenyl, biphenylyl,         pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl,         1,3-thiazolyl, isoxazolyl, pyrazolyl-1-methylpyrazolyl,         imidazolyl or 1-methylimidazolyl groups and the substituents may         be identical or different,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         which contains a nitrogen, oxygen or sulphur atom or, in         addition to a nitrogen atom, contains an oxygen, sulphur or         additional nitrogen atom, whilst a nitrogen atom of an imino         group may be substituted by an alkyl group,     -   or by a 6-membered heteroaromatic ring linked via a carbon atom,         which contains one, two or three nitrogen atoms,         -   whilst a 1,4-butadienylene group may be attached both to the             above-mentioned 5-membered heteroaromatic monocyclic rings             and to the 6-membered heteroaromatic monocyclic rings, in             each case via two adjacent carbon atoms, and the bicyclic             heteroaromatic rings thus formed may also be bound via a             carbon atom of the 1,4-butadienylene group,             an unbranched C₁₋₆-alkylamino group optionally substituted             at the nitrogen atom by a C₁₋₆-alkyl group or by a             phenylmethyl group, which may be substituted in the             ω-position     -   by a C₄₋₁₀-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         biphenylyl group,     -   by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl,         1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl,         3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or         1,3-dihydro-2H-2-oxoimidazo-[4,5-b]pyridin-3-yl- group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         which contains a nitrogen, oxygen or sulphur atom or, in         addition to a nitrogen atom, contains an oxygen, sulphur or an         additional nitrogen atom, whilst a nitrogen atom of an imino         group may be substituted by an alkyl group, or     -   by a 6-membered heteroaromatic ring linked via a carbon atom,         containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene         group may be attached both to the 5-membered and to the         6-membered heteroaromatic monocyclic rings, in each case via two         adjacent carbon atoms, and the bicyclic heteroaromatic rings         thus formed may also be bound via a carbon atom of the         1,4-butadienylene group,         whilst the phenyl, naphthyl and biphenylyl groups mentioned         above for the substitution of the alkyl and alkylamino groups in         the ω-position and optionally also partially hydrogenated mono-         and bicyclic heteroaromatic rings in the carbon skeleton may         additionally be mono-, di- or trisubstituted by fluorine,         chlorine or bromine atoms or by alkyl groups, C₃₋₈-cycloalkyl         groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl,         alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl,         dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino,         benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1H-azepin-1-yl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,         alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl or trifluoromethylsulphonyl groups,         wherein the substituents may be identical or different and the         above-mentioned benzoyl, benzoylamino and benzoylmethylamino         groups may in turn additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom or by an alkyl,         trifluoromethyl, amino or acetylamino group, or the group of         formula

wherein

-   -   p denotes the number 1 or 2,     -   o denotes the number 2 or 3 or, if Y¹ and Y² are not         simultaneously nitrogen atoms, o may also denote 1.     -   Y¹ denotes the nitrogen atom if R⁵ is a free pair of electrons,         or the carbon atom,     -   Y² is the nitrogen atom or the group >CH—,     -   R⁵ is a free pair of electrons if Y¹ denotes the nitrogen atom         or, if Y¹ denotes the carbon atom, R⁵ denotes a hydrogen atom, a         C₁₋₃-alkyl group, a hydroxy, cyano, aminocarbonyl, carboxy,         alkoxycarbonyl, aminocarbonylamino, phenylmethyl or phenyl         group,     -   R⁶ denotes the hydrogen atom or, provided that Y¹ is not a         nitrogen atom, R⁶ together with R⁵ may denote an additional         bond,     -   R⁷ denotes the hydrogen atom or, provided that Y¹ is not a         nitrogen atom and R⁵ and R⁶ together constitute an additional         bond, R⁷ together with R^(N) may also denote a 1,4-butadienylene         group,     -   R^(N) denotes a hydrogen atom or a C₁₋₆-alkyl group which may be         mono- or disubstituted in the ω-position         -   by a C₅₋₇-cycloalkyl group, by a 1-naphthyl, 2-naphthyl,             hydroxy, alkoxy, amino, alkylamino, dialkylamino,             piperidinyl, morpholinyl, pyrrolidinyl,             hexahydro-1H-1-azepinyl, aminocarbonyl, alkylaminocarbonyl,             acetylamino, cyano, aminocarbonylamino or             alkylaminocarbonylamino group or by phenyl, pyridinyl or             diazinyl groups, whilst these substituents may be identical             or different,     -   a C₅₋₇-cycloalkyl group, a phenyl, pyridinyl, cyano, amino,         benzoylamino, aminocarbonyl, alkylaminocarbonyl, alkoxycarbonyl,         phenylalkoxycarbonyl, aminocarbonylamino,         alkylaminocarbonylamino, dialkylaminocarbonylamino,         N-(aminocarbonyl)-N-alkylamino,         N-(alkylaminocarbonyl)-N-alkylamino,         N-(alkylaminocarbonyl)-N-phenylamino, phenylaminocarbonylamino,         [phenyl(alkylamino)]carbonylamino,         N-(phenylaminocarbonyl)-N-alkylamino,         N-(phenylaminocarbonyl)-N-phenylamino,         benzoylaminocarbonylamino, phenylalkylaminocarbonylamino,         pyridinylaminocarbonylamino, N-(aminocarbonyl)-N-phenylamino,         N-(alkylaminocarbonyl)-N-phenylamino,         N-(aminocarbonylaminocarbonyl)-N-phenylamino,         N-(pyridinyl)-N-(aminocarbonyl)amino,         N-(pyridinyl)-N-(alkylaminocarbonyl)amino, phenylamino,         pyridinylamino,         4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl or         diazinylamino group,     -   a saturated, mono- or diunsaturated 5- to 7-membered aza, diaza,         triaza, oxaza, thiaza, thiadiaza- or         S,S-dioxido-thiadiaza-heterocycle.         -   wherein the above-mentioned heterocycles may be linked via a             carbon or nitrogen atom and         -   may contain one or two carbonyl groups adjacent to a             nitrogen atom,         -   may be substituted at one of the nitrogen atoms by an alkyl,             alkanoyl, aroyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl,             phenylalkoxycarbonylalkyl, phenylmethyl or phenyl group,         -   may be substituted at one or two carbon atoms by a branched             or unbranched alkyl group or by a phenyl, phenylmethyl,             naphthyl, biphenylyl, pyridinyl, diazinyl, furyl, thienyl,             pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl,             pyrazolyl, 1-methylpyrazolyl, imidazolyl or             1-methylimidazolyl group, wherein the substituents may be             the same or different,         -   and wherein a C₃₋₆-alkylene group may additionally be             attached to the above-mentioned heterocycles via two             adjacent carbon atoms or an olefinic double bond of one of             the above-mentioned unsaturated heterocycles may be fused             with a benzene, pyridine, diazine, 1,3-oxazole, thiophene,             furan, thiazole, pyrrole, N-methyl-pyrrole, quinoline,             imidazole or N-methyl-imidazole ring,     -   or if Y¹ is not a nitrogen atom and R⁵ and R⁶ together denote an         additional bond, R^(N) together with R⁷ may also denote the         1,4-butadienylene group,     -   or, if Y¹ is a carbon atom, R^(N) together with R⁵, including         Y¹, also denotes a carbonyl group or a saturated or         mono-unsaturated 5- or 6-membered 1,3-diaza-heterocycle which         may optionally contain one or two carbonyl groups in the ring         and, if it is unsaturated, may be benzofused at the double bond         and may be substituted at one of the nitrogen atoms by a methyl,         aminocarbonyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl,         phenylalkoxycarbonylalkyl, phenylmethyl or phenyl group,     -   whilst the phenyl, pyridinyl, diazinyl, furyl, thienyl,         pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl,         1-methylpyrazolyl, imidazolyl- or 1-methylimidazolyl groups         contained in the residues mentioned under R⁵, R⁷ and R^(N), as         well as benzo, thieno, pyrido- and diazino-fused heterocycles in         the carbon skeleton may additionally be mono-, di- or         trisubstituted by fluorine, chlorine or bromine atoms, by alkyl         groups, C₃₋₈-cycloalkyl groups, nitro, alkoxy, alkylthio,         alkylsulphinyl, alkylsulphonyl, alkylsulphonylamino, phenyl,         phenylalkoxy, trifluoromethyl, alkoxycarbonyl,         alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl,         hydroxy, amino, acetylamino, propionylamino, benzoyl,         benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         hydroxyalkylaminocarbonyl, (4-morpholinyl)carbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1-azepinyl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, methylenedioxy,         aminocarbonylamino, aminocarbonylaminoalkyl,         alkylaminocarbonylamino, alkanoyl, cyano, trifluoromethoxy,         trifluormethylthio, trifluoromethylsulphinyl- or         trifluoromethylsulphonyl groups, wherein the substituents may be         identical or different and the above-mentioned benzoyl,         benzoylamino, benzoylaminocarbonylamino and benzoylmethylamino         groups may in turn additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom or by an alkyl,         trifluoromethyl, amino- or acetylamino group     -   and unless otherwise specified the alkyl groups contained in the         above-mentioned radicals may contain 1 to 5 carbon atoms,

-   X denotes an oxygen atom or 2 hydrogen atoms,

-   Z denotes a methylene group or the group —NR¹, wherein     -   R¹ denotes a hydrogen atom or an alkyl or phenylalkyl group,

-   R¹¹ denotes a hydrogen atom, a C₁₋₃-alkyl group, an alkoxycarbonyl     group having a total of 2 to 4 carbon atoms or a phenylmethyl group,

-   n denotes the number 1 or 2 or, if m is 1, n may also be 0,

-   m denotes the number 0 or 1,

-   R² denotes a phenyl, 1-naphthyl, 2-naphthyl,     1,2,3,4-tetrahydro-1-naphthyl, 1H-indol-3-yl,     1-methyl-1H-indol-3-yl, 1-formyl-1H-indol-3-yl,     1-(1,1-dimethylethoxycarbonyl)-1H-indol-3-yl, 4-imidazolyl,     1-methyl-4-imidazolyl, 2-thienyl, 3-thienyl, thiazolyl,     1H-indazol-3-yl, 1-methyl-1H-indazol-3-yl, benzo[b]fur-3-yl,     benzo[b]thien-3-yl, pyridinyl, quinolinyl or isoquinolinyl group,     -   whilst the above-mentioned aromatic and heteroaromatic groups in         the carbon skeleton may additionally be mono-, di- or         trisubstituted by fluorine, chlorine or bromine atoms or by         branched or unbranched alkyl groups, C₃₋₈-cycloalkyl groups,         phenylalkyl groups, alkenyl, alkoxy, phenyl, phenylalkoxy,         trifluoromethyl, alkoxycarbonylalkyl, carboxyalkyl,         alkoxycarbonyl, carboxy, dialkylaminoalkyl, dialkylaminoalkoxy,         hydroxy, nitro, amino, acetylamino, propionylamino, benzoyl,         benzoylamino, benzoylmethylamino, methylsulphonyloxy,         aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl,         alkanoyl, cyano, tetrazolyl, phenyl, pyridinyl, thiazolyl,         furyl, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups,         and the substituents may be identical or different and the         above-mentioned benzoyl, benzoylamino- and benzoylmethylamino         groups may in turn additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom, or by an alkyl,         trifluoromethyl, amino or acetylamino group,

-   A denotes a bond or the divalent group of formula

(which is linked to the NR³R⁴ group via the —CX group) wherein

-   -   R⁸ and R⁹ together denote an n-propylene group or     -   R⁸ denotes a hydrogen atom or an alkyl- or phenylalkyl group and     -   R⁹ denotes a hydrogen atom or a branched or unbranched         C₁₋₅-alkyl group which, if it is unbranched, may be substituted         in the ω-position by a hydroxy, mercapto, amino, alkylamino,         dialkylamino, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidinyl,         hexahydro-1-azepinyl, methylthio, hydroxycarbonyl,         aminocarbonyl, aminoiminomethylamino, aminocarbonylamino,         phenyl, 1H-indol-3-yl, 1-methyl-1H-indol-3-yl,         1-formyl-1H-indol-3-yl, 4-imidazolyl, 1-methyl-4-imidazolyl,         1-naphthyl, 2-naphthyl- or pyridinyl group, whilst the         above-mentioned heterocycles, phenyl and naphthyl groups may in         turn be mono-, di- or trisubstituted in the carbon skeleton by         fluorine, chlorine or bromine atoms or by methyl, alkoxy,         trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl,         cyano, trifluoromethoxy, methylsulphonyloxy,         trifluoromethylthio, trifluoromethylsulphinyl or         trifluoromethylsulphonyl groups, wherein the substituents may be         identical or different, and wherein the hydroxy, mercapto,         amino, guanidino, indolyl and imidazolyl groups contained in the         groups mentioned for R⁹ may be substituted with the protecting         groups commonly used in peptide chemistry, preferably with the         acetyl, benzyloxycarbonyl or tert.butyloxycarbonyl group,

-   R³ denotes a hydrogen atom,     a C₁₋₇-alkyl group which may be substituted in the ω-position by a     cyclohexyl, phenyl, pyridinyl, diazinyl, hydroxy, amino, alkylamino,     dialkylamino, carboxy, aminocarbonyl, aminocarbonylamino,     acetylamino, 1-pyrrolidinyl, 1-piperidinyl,     4-(l-piperidinyl)-1-piperidinyl, 4-morpholinyl,     hexahydro-1H-1-azepinyl, [bis-(2-hydroxyethyl)]amino,     4-alkyl-1-piperazinyl or 4-(ω-hydroxyalkyl)-1-piperazinyl group,     a phenyl or pyridinyl group,     -   wherein the above-mentioned heterocyclic groups and phenyl         groups may additionally be mono-, di- or trisubstituted in the         carbon skeleton by fluorine, chlorine or bromine atoms or by         methyl, alkoxy, trifluoromethyl, hydroxy, amino, acetylamino,         aminocarbonyl, cyano, methylsulphonyloxy, trifluoromethoxy,         trifluoromethylthio, trifluoromethylsulphinyl or         trifluoromethylsulphonyl groups and the substituents may be         identical or different,

-   R⁴ denotes a hydrogen atom or a C₁₋₃-alkyl group optionally     substituted by a phenyl or pyridinyl group or

-   R³ and R⁴ together with the enclosed nitrogen atom denote a group of     general formula

wherein

-   -   Y³ denotes a carbon atom or, if R¹² denotes a free pair of         electrons, Y³ may also be the nitrogen atom,     -   r denotes the number 0, 1 or 2,     -   q denotes the number 0, 1 or 2,     -   R¹⁰ denotes a hydrogen atom or an amino, alkylamino,         dialkylamino, alkyl, cycloalkyl, aminoalkyl, alkylaminoalkyl,         dialkylaminoalkyl, aminoiminomethyl, aminocarbonylamino,         alkylaminocarbonylamino, cycloalkylaminocarbonylamino,         phenylaminocarbonylamino, aminocarbonylalkyl,         aminocarbonylaminoalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,         carboxyalkyl or carboxy group,     -   a phenyl, pyridinyl, diazinyl, 1-naphthyl, 2-naphthyl,         pyridinylcarbonyl- or phenylcarbonyl-group which may be mono-,         di- or trisubstituted in the carbon skeleton by fluorine,         chlorine or bromine atoms, or by alkyl, alkoxy,         methylsulphonyloxy, trifluoromethyl, hydroxy, amino,         acetylamino, aminocarbonyl, aminocarbonylamino,         aminocarbonylaminomethyl, cyano, carboxy, carbalkoxy,         carboxyalkyl, carbalkoxyalkyl, alkanoyl,         ω-(dialkylamino)alkanoyl, ω-(dialkylamino)alkyl,         ω-(dialkylamino)hydroxyalkyl, ω-(carboxy)alkanoyl,         trifluoromethoxy, trifluoromethylthio, trifluoromethylsulphinyl         or trifluoromethylsulphonyl groups, whilst the substituents may         be identical or different,     -   a 1,3-dihydro-2-oxo-2H-imidazolyl, 2,4(1H,3H)-dioxopyrimidinyl         or 3,4-dihydro-2(1H)-oxopyrimidinyl group bound via a nitrogen         atom, which may be substituted by a phenyl group or fused at the         double bond to a benzene, pyridine or diazine ring,     -   a 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl group,     -   a 4- to 10-membered azacycloalkyl group, a 5- to 10-membered         oxaza, thiaza- or diazacycloalkyl group or a 6- to 10-membered         azabicycloalkyl group,         -   wherein the above-mentioned mono- and bicyclic heterocycles             may be bound via a nitrogen or carbon atom and         -   may be substituted by a C₁₋₇-alkyl group, by an alkanoyl,             dialkylamino, phenylcarbonyl, pyridinylcarbonyl,             carboxyalkanoyl, carboxyalkyl, alkoxycarbonylalkyl,             alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl,             alkylsulphonyl, cycloalkyl- or cycloalkylalkyl group, by a             cycloalkylcarbonyl, azacycloalkylcarbonyl,             diazacycloalkylcarbonyl or oxazacycloalkylcarbonyl group             optionally substituted in the ring,             -   whilst the alicyclic parts contained in these                 substituents may comprise 3 to 10 ring members and the                 heteroalicyclic parts may comprise 4 to 10 ring members                 and             -   the above-mentioned phenyl and pyridinyl groups may in                 turn be mono-, di- or trisubstituted by fluorine,                 chlorine or bromine atoms, by alkyl, alkoxy,                 methylsulphonyloxy, trifluoromethyl, hydroxy, amino,                 acetylamino, aminocarbonyl, aminocarbonylamino,                 aminocarbonylaminomethyl, cyano, carboxy, carbalkoxy,                 carboxyalkyl, carbalkoxyalkyl, alkanoyl,                 ω-(dialkylamino)alkanoyl, ω-(carboxy)alkanoyl,                 trifluoromethoxy, trifluoromethylthio,                 trifluoromethylsulphinyl or trifluoromethylsulphonyl                 groups, whilst the substituents may be identical or                 different, or     -   R¹⁰ together with R¹² and Y³ denotes a 4- to 7-membered         cycloaliphatic ring in which a methylene group may be replaced         by an —NH— or —N(alkyl)-group,         -   whilst a hydrogen atom bound to a nitrogen atom within the             group R¹⁰ may be replaced by a protecting group,     -   R¹² denotes a hydrogen atom,     -   a C₁₋₄-alkyl group, wherein an unbranched alkyl group may be         substituted in the ω-position by a phenyl, pyridinyl, diazinyl,         amino, alkylamino, dialkylamino, 1-pyrrolidinyl, 1-piperidinyl,         4-methyl-1-piperazinyl, 4-morpholinyl- or         hexahydro-1H-1-azepinyl group,     -   an alkoxycarbonyl, cyano or aminocarbonyl group or a free pair         of electrons, if Y³ denotes a nitrogen atom, and     -   R¹³ and R¹⁴ in each case denote a hydrogen atom or,     -   if Y³ is a carbon atom, R¹² together with R¹⁴ also denotes         another carbon-carbon bond, wherein R¹⁰ is as hereinbefore         defined and R¹³ denotes a hydrogen atom or     -   if Y³ is a carbon atom, R¹² together with R¹⁴ also denotes         another carbon-carbon bond and R¹⁰ together with R¹³ and the         enclosed double bond denotes a partially hydrogenated or         aromatic 5- to 7-membered mono- or bicyclic carbocycle or         heterocycle,         whilst all the above-mentioned alkyl and alkoxy groups and the         alkyl groups present within the other groups mentioned may         contain 1 to 7 carbon atoms, unless otherwise specified,         all the above-mentioned cycloalkyl groups and the cycloalkyl         groups present within the other groups named may contain 5 to 10         carbon atoms, unless otherwise specified, and         the term “aroyl group” used above denotes, for example, the         benzoyl or naphthoyl group.

The protecting groups mentioned in the foregoing definitions and hereinafter are the protecting groups which are commonly known from peptide chemistry, particularly

a phenylalkoxycarbonyl group having 1 to 3 carbon atoms in the alkoxy moiety, optionally substituted in the phenyl nucleus by a halogen atom, by a nitro or phenyl group or by one or two methoxy groups,

-   -   for example the benzyloxycarbonyl, 2-nitro-benzyloxycarbonyl,         4-nitro-benzyloxycarbonyl, 4-methoxy-benzyloxycarbonyl,         2-chloro-benzyloxycarbonyl, 3-chloro-benzyloxycarbonyl,         4-chloro-benzyloxycarbonyl,         4-Biphenylyl-α,α-dimethyl-benzyloxycarbonyl or         3,5-dimethoxy-α,α-dimethyl-benzyloxycarbonyl group,         an alkoxycarbonyl group having a total of 1 to 5 carbon atoms in         the alkyl moiety,     -   for example the methoxycarbonyl, ethoxycarbonyl,         n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl,         1-methylpropoxycarbonyl, 2-methylpropoxycarbonyl or         tert.butyloxycarbonyl group,         the allyloxycarbonyl,         2,2,2-trichloro-(1,1-dimethylethoxy)carbonyl or         9-fluorenylmethoxycarbonyl group or         the formyl, acetyl or trifluoroacetyl group.

The present invention relates to racemates, where the compounds of general formula I have only one chiral element. However, the application also covers the individual diastereomeric pairs of antipodes or mixtures thereof which occur when there is more than one chiral element in the compounds of general formula (I).

Particularly preferred are compounds of general formula I wherein Z denotes NR¹ and m assumes the value 0 and which are in the D- or (R)-configuration with regard to the partial amino acid structure of the formula

and which are in the L- or (S)-configuration with regard to the partial amino acid structure of formula

which may be present in the group A. As for the other compounds covered by general formula I, the preferred isomers are those which are spatially constructed analogously to the (R)-configured partial structure of formula V with regard to the partial structure of formula VI

The compounds of general formula I have valuable pharmacological properties based on their selective CGRP-antagonistic properties. The invention further relates to medicaments containing these compounds, their use and the preparation thereof.

A subgroup of compounds of general formula I which deserves special mention comprises those wherein

-   A, R², R³, R⁴, R¹¹, X, Z and m and n are as hereinbefore defined and -   R denotes an unbranched C₁₋₆-alkylamino group optionally substituted     at the nitrogen atom by a C₁₋₆-alkyl group or by a phenylmethyl     group, which may be substituted in the ω-position     -   by a C₄₋₁₀-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         biphenylyl group,     -   by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl,         1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl,         3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or         1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl-group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         which contains a nitrogen, oxygen or sulphur atom or, in         addition to a nitrogen atom, contains an oxygen, sulphur or an         additional nitrogen atom, whilst a nitrogen atom of an imino         group may be substituted by an alkyl group, or     -   by a 6-membered heteroaromatic ring linked via a carbon atom and         containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene         group may be attached both to the 5-membered and to the         6-membered heteroaromatic monocyclic rings via two adjacent         carbon atoms in each case and the bicyclic heteroaromatic rings         thus formed may also be bound via a carbon atom of the         1,4-butadienylene group,         whilst the phenyl, naphthyl and biphenylyl groups mentioned         above for the substitution of the alkylamino groups in the         ω-position and optionally partially hydrogenated mono- and         bicyclic heteroaromatic rings in the carbon skeleton may         additionally be mono-, di- or trisubstituted by fluorine,         chlorine or bromine atoms, by alkyl groups, C₃₋₈-cycloalkyl         groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl,         alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl,         dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino,         benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1H-azepin-1-yl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,         alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups,         whilst the substituents may be identical or different and the         above-mentioned benzoyl, benzoylamino- and benzoylmethylamino         groups in turn may additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom or by an alkyl,         trifluoromethyl, amino or acetylamino group,         whilst all the above-mentioned alkyl and alkoxy groups and the         alkyl groups present within the other groups mentioned may         contain 1 to 4 carbon atoms, unless otherwise stated,         their tautomers, their diastereomers, their enantiomers,         mixtures thereof and the salts thereof.

Another subgroup of compounds of general formula I deserving special mention comprises those wherein

-   R², R³, R⁴, R¹¹, X, Z and m and n are defined as for the first     subgroup hereinbefore, -   R denotes an unbranched C₁₋₇-alkyl group which may be substituted in     the ω-position     -   by a C₄₋₁₀-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl- or         biphenylyl-group,     -   by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-2H-2-oxoimidazopyridinyl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         1,3-dihydro-2H-2-oxoimidazol-1-yl- or         3,4-dihydro-2(1H)-oxopyrimidin-3-yl-group, whilst the latter two         groups may each be mono- or disubstituted in the 4- and/or         5-position or in the 5- and/or 6-position by lower         straight-chained or branched alkyl groups, by phenyl,         biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl,         1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl,         pyrazolyl-1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl         groups, and the substituents may be identical or different,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         which contains a nitrogen, oxygen or sulphur atom or in addition         to a nitrogen atom contains an oxygen, sulphur or an additional         nitrogen atom, whilst a nitrogen atom of an imino group may be         substituted by an alkyl group,     -   or by a 6-membered heteroaromatic ring linked via a carbon atom,         which contains one, two or three nitrogen atoms,         -   whilst a 1,4-butadienylene group may be attached both to the             above-mentioned 5-membered and to the 6-membered             heteroaromatic monocyclic rings, in each case via two             adjacent carbon atoms, and the bicyclic heteroaromatic rings             thus formed may also be bound via a carbon atom of the             1,4-butadienylene group,             whilst the phenyl, naphthyl- and biphenylyl-groups mentioned             hereinbefore for the substitution of the alkyl groups in the             ω-position and optionally partially hydrogenated mono- and             bicyclic heteroaromatic rings in the carbon skeleton may             additionally be mono-, di- or trisubstituted by fluorine,             chlorine or bromine atoms, by alkyl groups, C₃₋₈-cycloalkyl             groups, nitro, alkoxy, phenyl, phenylalkoxy,             trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl,             carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino,             acetylamino, propionylamino, benzoyl, benzoylamino,             benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl,             dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl,             (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl,             (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,             alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,             trifluoromethylsulphinyl or trifluoromethylsulphonyl groups,             whilst the substituents may be identical or different and             the above-mentioned benzoyl, benzoylamino and             benzoylmethylamino groups may in turn additionally be             substituted in the phenyl moiety by a fluorine, chlorine or             bromine atom or by an alkyl, trifluoromethyl, amino or             acetylamino group, and             A denotes a single bond,             whilst all the above-mentioned alkyl and alkoxy groups and             the alkyl groups present within the other groups mentioned             may contain 1 to 4 carbon atoms unless otherwise stated,             their tautomers, their diastereomers, their enantiomers and             the salts thereof.

Preferred compounds of the above general formula I are those wherein

-   R denotes an unbranched C₁₋₅-alkyl group which may be substituted in     the ω-position     -   by a C₄₋₇-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         (4-biphenylyl) group,     -   by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-2H-2-oxoimidazopyridinyl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         1,3-dihydro-2H-2-oxoimidazol-1-yl or         3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, whilst the latter two         groups may each be mono- or disubstituted in the 4- and/or         5-position or in the 5- and/or 6-positions by lower         straight-chained or branched alkyl groups, by phenyl,         biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl,         1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl,         pyrazolyl-1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl         groups, and the substituents may be identical or different,     -   by a 5-membered heteroaromatic ring linked via a carbon atom and         containing a nitrogen, oxygen or sulphur atom or, in addition to         a nitrogen atom, an oxygen, sulphur or additional nitrogen atom,         whilst a nitrogen atom of an imino group may be substituted by         an alkyl group,     -   or by a 6-membered heteroaromatic ring linked via a carbon atom         and containing one or two nitrogen atoms,         -   whilst a 1,4-butadienylene group may be attached both to the             5-membered and to the 6-membered heteroaromatic monocyclic             rings via two adjacent carbon atoms in each case and the             bicyclic heteroaromatic rings thus formed may also be bound             via a carbon atom of the 1,4-butadienylene group,             or an unbranched C₁₋₄-alkylamino group optionally             substituted at the nitrogen atom by a C₁₋₃-alkyl group or by             a phenylmethyl group, which may be substituted in the             ω-position     -   by a C₄₋₇-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         (4-biphenylyl) group,     -   by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl,         1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl,         3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl or         1,3-dihydro-2H-2-oxo-imidazo[4,5-b]pyridin-3-yl group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom and         containing a nitrogen, oxygen or sulphur atom or, in addition to         a nitrogen atom, an oxygen, sulphur or additional nitrogen atom,         whilst a nitrogen atom of an imino group may be substituted by         an alkyl group,     -   or by a 6-membered heteroaromatic ring linked via a carbon atom         and containing 1 or 2 nitrogen atoms, whilst a 1,4-butadienylene         group may be attached to both the 5-membered and to the         6-membered heteroaromatic monocyclic rings via two adjacent         carbon atoms in each case and the bicyclic heteroaromatic rings         thus formed may also be bound via a carbon atom of the         1,4-butadienylene group,         whilst the phenyl, naphthyl and biphenylyl groups mentioned         above for the substitution of the alkyl and alkylamino groups in         the ω-position and optionally also partially hydrogenated mono-         and bicyclic heteroaromatic rings in the carbon skeleton may         additionally be mono-, di- or trisubstituted by fluorine,         chlorine or bromine atoms or by alkyl groups, C₅₋₇-cycloalkyl         groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl,         alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl,         dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino,         benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1H-azepin-1-yl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,         alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl or trifluoromethylsulphonyl groups,         wherein the substituents may be identical or different and the         above-mentioned benzoyl, benzoylamino and benzoylmethylamino         groups may in turn additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom or by an alkyl,         trifluoromethyl, amino or acetylamino group, or the group of         formula

wherein

-   -   p denotes the number 1 or 2,     -   o denotes the number 2 or, if Y¹ and Y² are not simultaneously         nitrogen atoms, o may also denote 1.     -   Y¹ denotes the nitrogen atom if R⁵ is a free pair of electrons,         or the carbon atom,     -   Y² is the nitrogen atom or the group >CH—,     -   R⁵ is a free pair of electrons if Y¹ denotes the nitrogen atom         or, if Y¹ denotes the carbon atom, R⁵ denotes a hydrogen atom, a         C₁₋₃-alkyl group, a hydroxy, cyano, aminocarbonyl, carboxy,         alkoxycarbonyl, aminocarbonylamino, phenylmethyl or phenyl         group,     -   R⁶ denotes the hydrogen atom or, provided that Y¹ is not a         nitrogen atom, R⁶ together with R⁵ may denote an additional         bond,     -   R⁷ denotes the hydrogen atom or, provided that Y¹ is not a         nitrogen atom and R⁵ and R⁶ together constitute an additional         bond, R⁷ together with R^(N) may also denote a 1,4-butadienylene         group,     -   R^(N) denotes the hydrogen atom or a C₁₋₃-alkyl group, which may         be monosubstituted in the ω-position         -   by a C₅₋₇-cycloalkyl group or by a 1-naphthyl, 2-naphthyl,             hydroxy, alkoxy, amino, alkylamino,.dialkylamino,             piperidinyl, morpholinyl, pyrrolidinyl,             hexahydro-1H-1-azepinyl, aminocarbonyl, alkylaminocarbonyl,             acetylamino, cyano, aminocarbonylamino or             alkylaminocarbonylamino group, or may be mono- or             disubstituted by phenyl, pyridinyl or diazinyl groups,             whilst these substituents may be identical or different,     -   a cyclohexyl, phenyl, pyridinyl, cyano, amino, benzoylamino,         aminocarbonyl, alkylaminocarbonyl, alkoxycarbonyl,         phenylalkoxycarbonyl, aminocarbonylamino,         alkylaminocarbonylamino, dialkylaminocarbonylamino,         N-(aminocarbonyl)N-alkylamino,         N-(alkylaminocarbonyl)-N-alkylamino,         N-(alkylaminocarbonyl)-N-phenylamino, phenylaminocarbonyl-amino,         [N-phenyl(alkylamino)]carbonylamino,         N-(phenylaminocarbonyl)-N-alkylamino,         N-(phenylaminocarbonyl)-N-phenylamino,         benzoylaminocarbonylamino, phenylalkylaminocarbonylamino,         pyridinylaminocarbonylamino, N-(aminocarbonyl)-N-phenylamino,         N-(alkylaminocarbonyl)-N-phenylamino,         N-(aminocarbonylaminocarbonyl)-N-phenylamino,         N-(pyridinyl)-N-(aminocarbonyl)amino,         N-(pyridinyl)-N-(alkylaminocarbonyl)amino, phenylamino,         pyridinylamino, diazinylamino or         4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl group,     -   a saturated, mono- or diunsaturated 5- to 7-membered aza, diaza,         triaza, oxaza, thiaza, thiadiaza- or S,S-dioxidothiadiaza         heterocycle,         -   whilst the above-mentioned heterocycles may be linked via a             carbon or nitrogen atom and         -   may contain one or two carbonyl groups adjacent to a             nitrogen atom,         -   may be substituted at one of the nitrogen atoms by an alkyl,             alkanoyl, aroyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl,             phenylalkoxycarbonylalkyl, phenylmethyl or phenyl group,         -   may be substituted at one or two carbon atoms by a branched             or unbranched alkyl group, by a phenyl, phenylmethyl,             naphthyl, biphenylyl, pyridinyl, diazinyl, furyl, thienyl,             pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl,             pyrazolyl, 1-methylpyrazolyl, imidazolyl or             1-methylimidazolyl group, whilst the substituents may be             identical or different,         -   and wherein a C₃₋₄-alkylene group may additionally be             attached to the above-mentioned heterocycles via two             adjacent carbon atoms or an olefinic double bond of one of             the above-mentioned unsaturated heterocycles may be fused             with a benzene, pyridine, diazine, 1,3-oxazole, thiophene,             furan, thiazole, pyrrole, N-methyl-pyrrole, quinoline,             imidazole or N-methyl-imidazole ring,     -   or, provided that Y¹ is not a nitrogen atom and R⁵ and R⁶         together denote an additional bond, R^(N) together with R⁷ may         also denote the 1,4-butadienylene group or,     -   if Y¹ denotes a carbon atom, R^(N) together with R⁵, with the         inclusion of Y¹, may also denote a carbonyl group or a saturated         or monounsaturated 5- or 6-membered 1,3-diazaheterocycle which         may contain one or two carbonyl groups in the ring adjacent to a         nitrogen atom and, if it is unsaturated, may also be benzo-fused         at the double bond and substituted at one of the nitrogen atoms         by a methyl, aminocarbonyl, hydroxycarbonylalkyl,         alkoxycarbonylalkyl, phenylalkoxycarbonylalkyl, phenylmethyl or         phenyl group,     -   whilst the phenyl, pyridinyl, diazinyl, furyl, thienyl,         pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl,         1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl groups         contained in the residues mentioned under R⁵, R⁷ and R^(N), as         well as benzo-, thieno-, pyrido- and diazinofused heterocycles         in the carbon skeleton may additionally be mono-, di- or         trisubstituted by fluorine, chlorine or bromine atoms, by alkyl         groups, C₄₋₇-cycloalkyl groups, nitro, alkoxy, alkylthio,         alkylsulphinyl, alkylsulphonyl, alkylsulphonylamino, phenyl,         phenylalkoxy, trifluoromethyl, alkoxycarbonyl,         alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl,         hydroxy, amino, acetylamino, propionylamino, benzoyl,         benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         hydroxyalkylaminocarbonyl, (4-morpholinyl)carbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1-azepinyl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, methylenedioxy,         aminocarbonylamino, aminocarbonylaminoalkyl,         alkylaminocarbonylamino, alkanoyl, cyano, trifluoromethoxy,         trifluormethylthio, trifluoromethylsulphinyl or         trifluoromethylsulphonyl groups, wherein the substituents may be         identical or different and the alkyl groups contained in the         above-mentioned groups may contain 1 to 3 carbon atoms unless         otherwise specified,

-   X denotes the oxygen atom or 2 hydrogen atoms,

-   Z denotes the methylene group or the group —NR¹— wherein     -   R¹ denotes a hydrogen atom or a C₁₋₃-alkyl group,

-   R¹¹ denotes a hydrogen atom, a C₁₋₃-alkyl group or an alkoxycarbonyl     group having 2 to 4 carbon atoms altogether,

-   n denotes the number 1 or 2 or, if m is 1, n may also be 0,

-   m denotes the number 0 or 1,

-   R² denotes a phenyl, 1-naphthyl, 2-naphthyl,     1,2,3,4-tetrahydro-1-naphthyl, 1H-indol-3-yl,     1-methyl-1H-indol-3-yl, 1-formyl-1H-indol-3-yl,     1-(1,1-dimethylethoxycarbonyl)-1H-indol-3-yl, 4-imidazolyl,     1-methyl-4-imidazolyl, 2-thienyl, 3-thienyl, thiazolyl,     1H-indazol-3-yl, 1-methyl-1H-indazol-3-yl, benzo[b]fur-3-yl,     benzo[b]thien-3-yl, pyridinyl, quinolinyl or isoquinolinyl group,     -   whilst the above-mentioned aromatic and heteroaromatic groups in         the carbon skeleton may additionally be mono-, di- or         trisubstituted by fluorine, chlorine or bromine atoms, or by         branched or unbranched alkyl groups, C₄₋₇-cycloalkyl groups,         phenylalkyl groups, alkenyl, alkoxy, phenyl, phenylalkoxy,         trifluoromethyl, alkoxycarbonylalkyl, carboxyalkyl,         alkoxycarbonyl, carboxy, dialkylaminoalkyl, dialkylaminoalkoxy,         hydroxy, nitro, amino, acetylamino, propionylamino, benzoyl,         benzoylamino, benzoylmethylamino, methylsulphonyloxy,         aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl,         alkanoyl, cyano, tetrazolyl, phenyl, pyridinyl, thiazolyl,         furyl, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl or trifluoromethylsulphonyl groups, and         the substituents may be identical or different,

-   A denotes a bond or the divalent group of formula

(linked to the R³R⁴N-group of general formula (I) via the carbonyl group) wherein

-   -   R⁸ and R⁹ together denote an n-propylene group or     -   R⁸ denotes a hydrogen atom or a C₁₋₃-alkyl group and     -   R⁹ denotes a hydrogen atom or a branched or unbranched         C₁₋₄-alkyl group which, if it is unbranched, may be substituted         in the ω-position         -   by a hydroxy, mercapto, amino, alkylamino, dialkylamino,             1-azetidinyl, 1-pyrrolidinyl, 1-piperidinyl,             hexahydro-1-azepinyl, methylthio, hydroxycarbonyl,             aminocarbonyl, aminoiminomethylamino, aminocarbonylamino,             phenyl, 1H-indol-3-yl, 1-methyl-1H-indol-3-yl,             1-formyl-1H-indol-3-yl, 4-imidazolyl, 1-methyl-4-imidazolyl,             1-naphthyl, 2-naphthyl- or pyridinyl group, whilst the             above-mentioned heterocycles and phenyl groups may in turn             be mono-, di- or trisubstituted in the carbon skeleton by             fluorine, chlorine or bromine atoms, or by methyl, alkoxy,             trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl,             cyano, trifluoromethoxy, methylsulphonyloxy,             trifluoromethylthio, trifluoromethylsulphinyl or             trifluoromethylsulphonyl groups, whilst the substituents may             be identical or different and any hydroxy, mercapto, amino,             guanidino, indolyl and imidazolyl groups contained in the             groups mentioned for R⁹ may be substituted by a protecting             group,

-   R³ denotes a hydrogen atom,     a C₁₋₄-alkyl group which may be substituted in the ω-position by a     cyclohexyl, phenyl, pyridinyl, diazinyl, hydroxy, amino, alkylamino,     dialkylamino, carboxy, aminocarbonyl, aminocarbonylamino,     acetylamino, 1-pyrrolidinyl, 1-piperidinyl,     4-(1-piperidinyl)-1-piperidinyl, 4-morpholinyl,     hexahydro-1H-azepin-1-yl, [bis-(2-hydroxyethyl)]amino,     4-methyl-1-piperazinyl- or 4-(ω-hydroxyalkyl)-1-piperazinyl group,     a phenyl or pyridinyl group,     -   wherein the above-mentioned heterocyclic radicals and phenyl         groups may additionally be mono-, di- or trisubstituted in the         carbon skeleton by fluorine, chlorine or bromine atoms or by         methyl, alkoxy, trifluoromethyl, hydroxy, amino, acetylamino,         aminocarbonyl, cyano, methylsulphonyloxy, trifluoromethoxy,         trifluoromethylthio, trifluoromethylsulphinyl or         trifluoromethylsulphonyl groups and the substituents may be         identical or different,

-   R⁴ denotes a hydrogen atom or a methyl or ethyl group optionally     substituted by a phenyl or pyridinyl group

-   or R³ and R⁴ together with the enclosed nitrogen atom denote a group     of general formula

wherein

-   -   Y³ denotes a carbon atom or, if R¹² denotes a free pair of         electrons, Y³ may also be the nitrogen atom,     -   r denotes the number 0, 1 or 2,     -   q denotes the number 0, 1 or 2,     -   R¹⁰ denotes a hydrogen atom or an amino, alkylamino,         dialkylamino, alkyl, cycloalkyl, aminoalkyl, alkylaminoalkyl,         dialkylaminoalkyl, aminoiminomethyl, aminocarbonylamino,         alkylaminocarbonylamino, cycloalkylaminocarbonylamino,         phenylaminocarbonylamino, aminocarbonylalkyl,         aminocarbonylaminoalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,         carboxyalkyl or carboxy group,     -   a phenyl, pyridinyl, diazinyl, 1-naphthyl, 2-naphthyl,         pyridinylcarbonyl or phenylcarbonyl group which may be mono-,         di- or trisubstituted in the carbon skeleton by fluorine,         chlorine or bromine atoms, or by alkyl, alkoxy,         methylsulphonyloxy, trifluoromethyl, hydroxy, amino,         acetylamino, aminocarbonyl, aminocarbonylamino,         aminocarbonylaminomethyl, cyano, carboxy, carbalkoxy,         carboxyalkyl, carbalkoxyalkyl, alkanoyl,         ω-(dialkylamino)alkanoyl, ω-(dialkylamino)alkyl,         ω-(dialkylamino)hydroxyalkyl, ω-(carboxy)alkanoyl,         trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl-oder trifluoromethylsulphonyl groups,         whilst the substituents may be identical or different,     -   a 1,3-dihydro-2-oxo-2H-imidazolyl, 2,4(1H,3H)-dioxopyrimidinyl         or 3,4-dihydro-2(1H)-oxopyrimidinyl group bound via a nitrogen         atom, which may be substituted by a phenyl group or fused at the         double bond to a benzene, pyridine or diazine ring,     -   a 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl group,     -   a 4- to 10-membered azacycloalkyl group, a 5- to 10-membered         oxaza, thiaza or diazacycloalkyl group or a 6- to 10-membered         azabicycloalkyl group,         -   wherein the above-mentioned mono- and bicyclic heterocycles             may be bound via a nitrogen or carbon atom and         -   may be substituted by a C₁₋₇-alkyl group, by an alkanoyl,             dialkylamino, phenylcarbonyl, pyridinylcarbonyl,             carboxyalkandyl, carboxyalkyl, alkoxycarbonylalkyl,             alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl,             alkylsulphonyl, cycloalkyl or cycloalkylalkyl group, by a             cycloalkylcarbonyl, azacycloalkylcarbonyl,             diazacycloalkylcarbonyl or oxazacycloalkylcarbonyl group             optionally alkyl substituted in the ring,             -   whilst the alicyclic parts contained in these                 substituents may comprise 3 to 10 ring members and the                 heteroalicyclic parts may comprise 4 to 10 ring members                 and             -   the above-mentioned phenyl and pyridinyl groups may in                 turn be mono-, di- or trisubstituted by fluorine,                 chlorine or bromine atoms, by alkyl, alkoxy,                 methylsulphonyloxy, trifluoromethyl, hydroxy, amino,                 acetylamino, aminocarbonyl, aminocarbonylamino,                 aminocarbonylaminomethyl, cyano, carboxy, carbalkoxy,                 carboxyalkyl, carbalkoxyalkyl, alkanoyl,                 ω-(dialkylamino)alkanoyl, ω(carboxy)alkanoyl,                 trifluoromethoxy, trifluoromethylthio,                 trifluoromethylsulphinyl or trifluoromethylsulphonyl                 groups, whilst the substituents may be identical or                 different, or     -   R¹⁰ together with R¹² and Y³ denotes a 4- to 7-membered         cycloaliphatic ring in which a methylene group may be replaced         by an —NH— or —N(alkyl)-group,         -   whilst a hydrogen atom bound to a nitrogen atom within the             group R¹⁰ may be replaced by a protecting group,     -   R¹² denotes a hydrogen atom, a C₁₋₂-alkyl group which may be         substituted in the ω-position by a phenyl, pyridinyl, diazinyl,         amino, alkylamino, dialkylamino, 1-pyrrolidinyl, 1-piperidinyl,         4-methyl-1-piperazinyl, 4-morpholinyl or         hexahydro-1H-azepin-1-yl-group,     -   an alkoxycarbonyl, cyano- or aminocarbonyl group or a free pair         of electrons, if Y³ denotes a nitrogen atom, and     -   R¹³ and R¹⁴ in each case denote a hydrogen atom or,     -   if Y³ is a carbon atom, R¹² together with R¹⁴ also denotes         another carbon-carbon bond, wherein R¹⁰ is as hereinbefore         defined and R¹³ denotes a hydrogen atom or     -   if Y³ is a carbon atom, R¹² together with R¹⁴ also denotes         another carbon-carbon bond and R¹⁰ together with R¹³ and the         enclosed double bond denotes a partially hydrogenated or         aromatic 5- to 7-membered mono- or bicyclic carbocycle or         heterocycle,         whilst all the above-mentioned alkyl and alkoxy groups and the         alkyl groups present within the other groups mentioned may         contain 1 to 4 carbon atoms, unless otherwise specified,         all the above-mentioned cycloalkyl groups and the cycloalkyl         groups present within the other groups named may contain 5 to 7         carbon atoms, unless otherwise specified, and         the term “aroyl group” used above denotes, for example, the         benzoyl or naphthoyl group;         their tautomers, their diastereomers, their enantiomers and         their salts.

One subgroup of preferred compounds of general formula I deserving special mention comprises those wherein

A, R², R³, R⁴, R¹¹, X, Z and m and n are defined as given hereinbefore defined for the preferred compounds of general formula I,

-   R denotes an unbranched C₁₋₄-alkylamino group optionally substituted     at the nitrogen atom by a C₁₋₃-alkyl group or by a phenylmethyl     group, which may be substituted in the ω-position     -   by a C₄₋₇-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         (4-biphenylyl) group,     -   by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl,         1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl,         3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl or         1,3-dihydro-2H-2-oxo-imidazo[4,5-b]pyridin-3-yl group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         and containing a nitrogen, oxygen or sulphur atom or, in         addition to a nitrogen atom, an oxygen, sulphur or additional         nitrogen atom, whilst a nitrogen atom of an imino group may be         substituted by an alkyl group,     -   or by a 6-membered heteroaromatic ring linked via a carbon atom         and containing 1 or 2 nitrogen atoms, whilst a 1,4-butadienylene         group may be attached both to the 5-membered and to the         6-membered heteroaromatic monocyclic rings via two adjacent         carbon atoms in each case and the bicyclic heteroaromatic rings         thus formed may also be bound via a carbon atom of the         1,4-butadienylene group,         whilst the phenyl, naphthyl and biphenylyl groups mentioned         above for the substitution of the alkylamino groups in the         ω-position and optionally partially hydrogenated mono- and         bicyclic heteroaromatic rings in the carbon skeleton may         additionally be mono-, di- or trisubstituted by fluorine,         chlorine or bromine atoms, by alkyl groups, C₅₋₇-cycloalkyl         groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl,         alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl,         dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino,         benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1H-azepin-1-yl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,         alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl or trifluoromethylsulphonyl groups,         whilst the substituents may be identical or different and the         above-mentioned benzoyl, benzoylamino- and benzoylmethylamino         groups in turn may additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom or by an alkyl,         trifluoromethyl, amino or acetylamino group,         whilst all the above-mentioned alkyl and alkoxy groups and the         alkyl groups present within the other groups mentioned may         contain 1 to 4 carbon atoms, unless otherwise stated,         their tautomers, their diastereomers, their enantiomers,         mixtures thereof and the salts thereof.

Another subgroup of compounds of general formula I deserving special mention comprises those wherein

R², R³, R⁴, R¹¹, X, Z and m and n are defined as for the first preferred subgroup hereinbefore,

-   R denotes an unbranched C₁₋₅-alkyl group which may be substituted in     the ω-position     -   by a C₄₋₇-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         (4-biphenylyl) group,     -   by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-2H-2-oxoimidazopyridinyl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         1,3-dihydro-2H-2-oxoimidazol-1-yl or         3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, whilst the latter two         groups may each be mono- or disubstituted in the 4- and/or         5-position or in the 5- and/or 6-position by lower         straight-chained or branched alkyl groups, by phenyl,         biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl,         1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl,         pyrazolyl-1-methylpyrazolyl, imidazolyl or 1-methylimidazolyl         groups, and the substituents may be identical or different,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         which contains a nitrogen, oxygen or sulphur atom or in addition         to a nitrogen atom contains an oxygen, sulphur or an additional         nitrogen atom, whilst a nitrogen atom of an imino group may be         substituted by an alkyl group,     -   or by a 6-membered heteroaromatic ring linked via a carbon atom,         which contains one or two nitrogen atoms,         -   whilst a 1,4-butadienylene group may be attached both to the             5-membered and to the 6-membered heteroaromatic monocyclic             rings, in each case via two adjacent carbon atoms, and the             bicyclic heteroaromatic rings thus formed may also be bound             via a carbon atom of the l,4-butadienylene group,             whilst the phenyl, naphthyl and biphenylyl groups mentioned             hereinbefore for the substitution of the alkyl groups in the             ω-position and optionally partially hydrogenated mono- and             bicyclic heteroaromatic rings in the carbon skeleton may             additionally be mono-, di- or trisubstituted by fluorine,             chlorine or bromine atoms, by alkyl groups, C₅₋₇-cycloalkyl             groups, nitro, alkoxy, phenyl, phenylalkoxy,             trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl,             carboxy, carboxyalkyl, dialkylaminoalkyl, hydroxy, amino,             acetylamino, propionylamino, benzoyl, benzoylamino,             benzoylmethylamino, aminocarbonyl, alkylaminocarbonyl,             dialkylaminocarbonyl, (1-pyrrolidinyl)carbonyl,             (1-piperidinyl)carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl,             (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,             alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,             trifluoromethylsulphinyl or trifluoromethylsulphonyl groups,             whilst the substituents may be identical or different and             the above-mentioned benzoyl, benzoylamino and             benzoylmethylamino groups may in turn additionally be             substituted in the phenyl moiety by a fluorine, chlorine or             bromine atom or by an alkyl, trifluoromethyl, amino or             acetylamino group, and -   A denotes a single bond,     whilst all the above-mentioned alkyl and alkoxy groups and the alkyl     groups present within the other groups mentioned may contain 1 to 4     carbon atoms unless otherwise stated,     their tautomers, their diastereomers, their enantiomers, mixtures     thereof and the salts thereof.

Preferred compounds of the above general formula I are those wherein

-   R denotes an unbranched C₁₋₃-alkyl group which may be substituted in     the ω-position     -   by a C₅₋₇-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         (4-biphenylyl) group,     -   by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         1,3-dihydro-2H-2-oxoimidazol-1-yl or         3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, whilst the latter two         groups may be substituted in the carbon skeleton by a phenyl,         pyridinyl or diazinyl group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom and         containing a nitrogen, oxygen or sulphur atom or two nitrogen         atoms, wherein a nitrogen of an imino group may be substituted         by an alkyl group,     -   or may be substituted by a pyridinyl group,         -   whilst a 1,4-butadienylene group may be attached both to the             5-membered heteroaromatic monocyclic rings and to the             pyridinyl group, in each case via two adjacent carbon atoms,             and the bicyclic heteroaromatic rings thus formed may also             be bound via a carbon atom of the 1,4-butadienylene group,             or an unbranched C₁₋₄-alkylamino group optionally             substituted at the nitrogen atom by a methyl or ethyl group,             which may be substituted in the ω-position     -   by a C₅₋₇-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         (4-biphenylyl) group,     -   by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2(1H)-oxoquinolin-3-yl,         1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl,         3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl or         1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom and         containing a nitrogen, oxygen or sulphur atom or two nitrogen         atoms, whilst a nitrogen atom of an imino group may be         substituted by an alkyl group,     -   or by a pyridinyl group,         -   whilst a 1,4-butadienylene group may be attached both to the             5-membered heteroaromatic monocyclic rings and to the             pyridinyl group, in each case via two adjacent carbon atoms,             and the bicyclic heteroaromatic rings thus formed may also             be bound via a carbon atom of the 1,4-butadienylene group,             whilst the phenyl, naphthyl and biphenylyl groups mentioned             hereinbefore for the substitution of the alkyl and             alkylamino groups in the ω-position as well as optionally             partially hydrogenated mono- and bicyclic heteroaromatic             rings may additionally be mono- or disubstituted in the             carbon skeleton by fluorine, chlorine or bromine atoms or by             alkyl, nitro, alkoxy, trifluoromethyl, hydroxy, amino,             acetylamino, propionylamino, alkanoyl, cyano or             trifluoromethoxy groups, whilst the substituents may be the             same or different,             or the group of formula

wherein

-   -   p denotes the number 1 or 2,     -   o denotes the number 2 or, if Y¹ and Y² are not simultaneously         nitrogen atoms, it may also denote the number 1,     -   Y¹ denotes the nitrogen atom if R⁵ denotes a free pair of         electrons, or the carbon atom,     -   Y² denotes the nitrogen atom or the group >CH—,     -   R⁵ denotes a free pair of electrons if Y¹ denotes the nitrogen         atom or, if Y¹ denotes the carbon atom, R⁵ denotes a hydrogen         atom, a C₁₋₃-alkyl group, a hydroxy, cyano, aminocarbonyl,         carboxy, alkoxycarbonyl or aminocarbonylamino group or a         phenylmethyl or phenyl group optionally substituted at the         aromatic moiety by a fluorine, chlorine or bromine atom or by a         methyl, methoxy, ethoxy, trifluoromethyl, hydroxy, amino or         acetylamino group,     -   R⁶ denotes the hydrogen atom or, if Y¹ is not a nitrogen atom,         R⁶ together with R⁵ may also denote an additional bond,     -   R⁷ denotes the hydrogen atom or, provided that Y¹ is not a         nitrogen atom and R⁵ and R⁶ together denote an additional bond,         R⁷ together with R^(N) may also denote the 1,4-butadienylene         group,     -   R^(N) denotes the hydrogen atom or a C₁₋₃-alkyl group, which may         be monosubstituted in the ω-position         -   by a C₅₋₇-cycloalkyl group or by a 1-naphthyl, 2-naphthyl,             hydroxy, alkoxy, amino, alkylamino, dialkylamino,             piperidinyl, morpholinyl, pyrrolidinyl,             hexahydro-1H-1-azepinyl, aminocarbonyl, methylaminocarbonyl,             acetylamino, cyano, aminocarbonylamino or             alkylaminocarbonylamino group, or may be mono- or             disubstituted by phenyl, pyridinyl or diazinyl groups,             whilst these substituents may be identical or different,     -   a cyclohexyl, phenyl, pyridinyl, cyano, amino, benzoylamino,         aminocarbonyl, alkylaminocarbonyl, alkoxycarbonyl,         phenylalkoxycarbonyl, aminocarbonylamino,         alkylaminocarbonylamino, dialkylaminocarbonylamino,         N-(aminocarbonyl)-N-alkylamino,         N-(alkylaminocarbonyl)-N-alkylamino,         N-(alkylaminocarbonyl)-N-phenylamino, phenylaminocarbonylamino,         [N-phenyl(alkylamino)]carbonylamino,         N-(phenylaminocarbonyl)-N-alkylamino,         N-(phenylaminocarbonyl)-N-phenylamino,         benzoylaminocarbonylamino, phenylalkylaminocarbonylamino,         pyridinylaminocarbonylamino, N-(aminocarbonyl)-N-phenylamino,         N-(alkylaminocarbonyl)-N-phenylamino,         N-(aminocarbonylaminocarbonyl)-N-phenylamino,         N-(pyridinyl)-N-(aminocarbonyl)amino,         N-(pyridinyl)-N-(alkylaminocarbonyl)amino, phenylamino,         pyridinylamino, diazinylamino or         4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl group,     -   a saturated, mono- or diunsaturated 5- to 7-membered aza, diaza,         triaza, oxaza, thiaza, thiadiaza or S,S-dioxidothiadiaza         heterocycle,         -   whilst the above-mentioned heterocycles may be linked via a             carbon or nitrogen atom and         -   may contain one or two carbonyl groups adjacent to a             nitrogen atom,         -   may be substituted at one of the nitrogen atoms by an alkyl,             alkanoyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl,             phenylalkoxycarbonylalkyl, phenylmethyl or phenyl group,         -   may be substituted at one or two carbon atoms by a methyl,             phenyl, phenylmethyl, naphthyl, biphenylyl, thienyl,             pyridinyl or diazinyl group, wherein the substituents may be             identical or different,         -   and wherein a C₃₋₄-alkylene group may additionally be             attached to the above-mentioned heterocycles via two             adjacent carbon atoms or an olefinic double bond of one of             the above-mentioned heterocycles may be fused to a             thiophene, benzene, pyridine, quinoline or diazine ring,     -   or, if Y¹ is not a nitrogen atom and R⁵ and R⁶ together denote         an additional bond, R^(N) together with R⁷ may also denote a         1,4-butadienylene group or,     -   if Y¹ denotes a carbon atom, R^(N) together with R⁵ with the         inclusion of Y¹ may also denote a carbonyl group or a saturated         or monounsaturated 5- or 6-membered 1,3-diazaheterocycle which         may contain one or two carbonyl groups in the ring adjacent to a         nitrogen atom and, if it is unsaturated, may also be benzo-fused         at the double bond and may be substituted at one of the nitrogen         atoms by a methyl, aminocarbonyl, hydroxycarbonylalkyl,         alkoxycarbonylalkyl, phenylalkoxycarbonylalkyl, phenylmethyl or         phenyl group,         -   whilst the phenyl, pyridinyl or diazinyl groups contained in             the groups mentioned under R^(N) and the thieno-, benzo-,             pyrido- or diazino-condensed heterocycles in the carbon             skeleton may additionally be mono-, di- or trisubstituted by             fluorine, chlorine or bromine atoms, by methyl groups,             nitro, methoxy, ethoxy, methylsulphonylamino,             trifluoromethyl, alkoxycarbonyl, alkoxycarbonylalkyl,             carboxy, carboxyalkyl, hydroxy, amino, acetylamino,             propionylamino, aminocarbonyl, methylaminocarbonyl,             dimethylaminocarbonyl, hydroxyalkylaminocarbonyl,             (4-morpholinyl)-carbonyl, (1-pyrrolidinyl)carbonyl,             (1-piperidinyl)carbonyl, (hexahydro-1-azepinyl)carbonyl,             (4-methyl-1-piperazinyl)carbonyl, methylenedioxy,             aminocarbonylamino, aminocarbonylaminoalkyl,             methylaminocarbonylamino, acetyl, cyano or trifluoromethoxy             groups, whilst the substituents may be identical or             different,         -   and the alkyl groups contained in the above-mentioned             radicals may contain 1 to 3 carbon atoms, unless otherwise             specified,

-   X denotes an oxygen atom or 2 hydrogen atoms,

-   Z denotes a methylene group or the group —NR¹— wherein     -   R¹ is a hydrogen atom or a methyl group,

-   R¹¹ denotes the hydrogen atom or a methyl or methoxycarbonyl group,

-   n denotes the number 1 or 2 or, if m is the number 1, n may also     denote 0,

-   m denotes the number 0 or 1,

-   R² denotes a phenyl, 1-naphthyl, 2-naphthyl,     1,2,3,4-tetrahydro-1-naphthyl, 1H-indol-3-yl,     1-methyl-1H-indol-3-yl, 1-formyl-1H-indol-3-yl,     1-(1,1-dimethylethoxycarbonyl)-1H-indol-3-yl, 4-imidazolyl,     1-methyl-4-imidazolyl, 2-thienyl, 3-thienyl, thiazolyl, pyridinyl or     quinolinyl group,     -   wherein the above-mentioned aromatic and heteroaromatic groups         may additionally be mono-, di- or trisubstituted in the carbon         skeleton by fluorine, chlorine or bromine atoms, by branched or         unbranched C₁₋₅-alkyl groups, allyl, vinyl, methoxy, ethoxy,         propoxy, 1-methylethoxy, dimethylaminoethoxy, trifluoromethyl,         hydroxy, nitro, amino, acetylamino, propionylamino,         aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl,         acetyl, cyano, methylsulphonyloxy or trifluoromethoxy groups, by         tetrazolyl, phenyl pyridinyl, thiazolyl or furyl groups and the         substituents may be identical or different, or

-   A denotes a bond or the divalent group of formula

(linked to the NR³R⁴-group of general formula (I) via the carbonyl group) wherein

-   -   R⁸ and R⁹ together denote an n-propylene group or     -   R⁸ denotes the hydrogen atom or the methyl group and     -   R⁹ denotes a hydrogen atom or an unbranched C₁₋₄-alkyl group         which may be substituted in the ω-position         -   by a hydroxy, amino, methylamino, dimethylamino,             hydroxycarbonyl, aminocarbonyl, aminoiminomethylamino,             aminocarbonylamino, phenyl or pyridinyl group, wherein the             phenyl and pyridinyl group may in turn be substituted in the             carbon skeleton by a fluorine, chlorine or bromine atom or             by a methyl, methoxy, trifluoromethyl, hydroxy, amino,             acetylamino, aminocarbonyl or cyano group and wherein any             hydroxy, amino and guanidino groups contained in the groups             given for R⁹ may be substituted by a protecting group, e.g.             the phenylmethoxycarbonyl or tert.butyloxycarbonyl group,

-   R³ denotes a hydrogen atom,     a C₁₋₄-alkyl group optionally substituted in the ω-position by a     cyclohexyl, phenyl, pyridinyl, hydroxy, amino, methylamino,     dimethylamino, carboxy, aminocarbonyl, aminocarbonylamino,     acetylamino, 1-pyrrolidinyl, 1-piperidinyl or     4-(1-piperidinyl)-1-piperidinyl group,     a phenyl or pyridinyl group,     -   whilst the above-mentioned phenyl and pyridinyl groups may         additionally be substituted in the carbon skeleton by a         fluorine, chlorine or bromine atom or by a methyl, methoxy,         trifluoromethyl, hydroxy, amino, acetylamino, aminocarbonyl or         cyano group,

-   R⁴ denotes the hydrogen atom or a C₁₋₂-alkyl group optionally     substituted by a phenyl or pyridinyl group

-   or R³ and R⁴ together with the enclosed nitrogen atom denote a group     of general formula

wherein

-   -   Y³ denotes a carbon atom or, if R¹² denotes a free pair of         electrons, Y³ may also be a nitrogen atom,     -   r denotes the number 0, 1 or 2,     -   q denotes the number 0, 1 or 2,         -   with the proviso that the sum of the numbers given for r and             q is 0, 1, 2 or 3,     -   R¹⁰ denotes a hydrogen atom, an alkyl, cycloalkyl, dialkylamino,         aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl,         phenylaminocarbonylamino, alkoxycarbonyl, alkoxycarbonylmethyl,         carboxymethyl or carboxy group,     -   a phenyl, pyridinyl, diazinyl, pyridinylcarbonyl or         phenylcarbonyl group which may be mono- or disubstituted in the         carbon skeleton by fluorine, chlorine or bromine atoms, or by         methyl, ethyl, propyl, methoxy, hydroxy, ω-(dialkylamino)-alkyl,         ω-(dialkylamino)hydroxyalkyl or alkanoyl groups, whilst the         substituents may be identical or different,     -   a 1,3-dihydro-2-oxo-2H-imidazolyl, 2,4(1H,3H)-dioxopyrimidinyl         or 3,4-dihydro-2(1H)-oxopyrimidinyl group bound via a nitrogen         atom, which may be substituted by a phenyl group or may be fused         at the double bond to a benzene, pyridine or diazine ring,     -   a 5- to 7-membered azacycloalkyl group, a 4- to 7-membered         oxaza- or diazacycloalkyl group or a 7- to 9-membered         azabicycloalkyl group,         -   wherein the above-mentioned mono- and bicyclic heterocycles             are bound via a nitrogen or a carbon atom and         -   may be substituted by a C₁₋₇-alkyl group, or by an alkanoyl,             dialkylamino, phenylcarbonyl, carboxyalkanoyl, carboxyalkyl,             alkoxycarbonylalkyl or alkoxycarbonyl group having 1 to 4             carbon atoms in the alkoxy moiety, alkylsulphonyl,             cycloalkyl or cycloalkylalkyl group or by an             azacycloalkylcarbonyl or diazacycloalkylcarbonyl group             optionally alkylsubstituted in the ring,             -   whilst the alicyclic groups contained in these                 substituents may comprise 3 to 7 ring members and the                 heteroalicyclic groups may comprise 4 to 7 ring members                 and             -   the above-mentioned phenylcarbonyl group may be                 substituted by a fluorine, chlorine or bromine atom or                 by a methyl, methoxy, trifluoromethyl, hydroxy, amino or                 acetylamino group, or     -   R¹⁰ together with R¹² and Y³ denotes a 4- to 6-membered         cycloaliphatic ring in which a methylene group may be replaced         by an —NH— or —N(CH₃)-group,         -   whilst a hydrogen atom bound to a nitrogen atom within the             group R¹⁰ may be replaced by a protecting group, e.g. the             phenylmethoxycarbonyl or tert.butyloxycarbonyl group,     -   R¹² denotes a hydrogen atom, a C₁₋₂-alkyl group which may be         substituted in the ω-position by a phenyl, pyridinyl, amino,         alkylamino, dialkylamino, 1-pyrrolidinyl, 1-piperidinyl or         4-methyl-1-piperazinyl group,     -   a methoxycarbonyl or ethoxycarbonyl, cyano or aminocarbonyl         group or a free pair of electrons, if Y³ denotes a nitrogen         atom, and     -   R¹³ and R¹⁴ each denote a hydrogen atom or,     -   if Y³ is a carbon atom, R¹² together with R¹⁴ also denotes         another carbon-carbon bond, wherein R¹⁰ is as hereinbefore         defined and R¹³ denotes a hydrogen atom, or     -   if Y³ is a carbon atom, R¹² together with R¹⁴ also denotes         another carbon-carbon bond and R¹⁰ together with R¹³ and the         enclosed double bond denotes a partially hydrogenated or         aromatic 5- or 6-membered mono- or bicyclic carbocycle or         heterocycle, containing one or two nitrogen atoms,         whilst all the above-mentioned alkyl and alkoxy groups and the         alkyl groups present within the other groups named may contain 1         to 3 carbon atoms, unless otherwise stated, and         all the above-mentioned cycloalkyl groups and the cycloalkyl         groups present within the other groups named may contain 5 to 7         carbon atoms, unless otherwise specified,         their tautomers, their diastereomers, their enantiomers,         mixtures thereof and the salts thereof.

One subgroup of particularly preferred compounds of general formula I deserving special mention comprises those wherein

A, R², R³, R⁴, R¹¹, X, Z and m and n are defined as for the particularly preferred compounds of general formula I hereinbefore and

-   R denotes an unbranched C₁₋₄-alkylamino group optionally substituted     at the nitrogen atom by a methyl or ethyl group, which may be     substituted in the ω-position     -   by a C₅₋₇-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         (4-biphenylyl) group,     -   by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2(1H)-oxoquinolin-3-yl,         1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl,         3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl or         1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom and         containing a nitrogen, oxygen or sulphur atom or two nitrogen         atoms, whilst a nitrogen atom of an imino group may be         substituted by an alkyl group,     -   or by a pyridinyl group,         -   whilst a 1,4-butadienylene group may be attached both to the             5-membered heteroaromatic monocyclic rings and also to the             pyridinyl group, in each case via two adjacent carbon atoms,             and the bicyclic heteroaromatic rings thus formed may also             be bound via a carbon atom of the 1,4-butadienylene group,             whilst the phenyl, naphthyl and biphenylyl groups mentioned             hereinbefore for the substitution of the alkylamino groups             in the ω-position, as well as optionally any partially             hydrogenated mono- and bicyclic heteroaromatic rings, may             additionally be mono- or disubstituted in the carbon             skeleton by fluorine, chlorine or bromine atoms or by alkyl,             nitro, alkoxy, trifluoromethyl, hydroxy, amino, acetylamino,             propionylamino, alkanoyl, cyano or trifluoromethoxy groups,             whilst the substituents may be identical or different,             whilst all the above-mentioned alkyl and alkoxy groups and             the alkoxy groups present within the other named radicals             may contain 1 to 3 carbon atoms unless otherwise stated,             their tautomers, their diastereomers, their enantiomers,             mixtures thereof and the salts thereof.

Another subgroup of particularly preferred compounds of general formula I which deserves special mention comprises those compounds wherein

-   R², R³, R⁴, R¹¹, X, Z and m and n are as hereinbefore defined for     the first-mentioned particularly preferred subgroup, -   R denotes an unbranched C₁₋₃-alkyl group which may be substituted in     the ω-position     -   by a C₅₋₇-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         (4-biphenylyl) group,     -   by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         1,3-dihydro-2H-2-oxoimidazol-1-yl or         3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, whilst the latter two         groups may be substituted in the carbon skeleton by a phenyl,         pyridinyl or diazinyl group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom and         containing a nitrogen, oxygen or sulphur atom or two nitrogen         atoms, wherein a nitrogen atom of an imino group may be         substituted by an alkyl group,     -   or by a pyridinyl group,         -   whilst a 1,4-butadienylene group may be attached both to the             5-membered heteroaromatic monocyclic rings and also to the             pyridinyl group via two adjacent carbon atoms in each case             and the bicyclic heteroaromatic rings thus formed may also             be bound via a carbon atom of the 1,4-butadienylene group,             whilst the phenyl, naphthyl and biphenylyl groups mentioned             hereinbefore for the substitution of the alkyl groups in the             ω-position as well as optionally any partially hydrogenated             mono- and bicyclic heteroaromatic rings may additionally be             mono- or disubstituted in the carbon skeleton by fluorine,             chlorine or bromine atoms or by alkyl, nitro, alkoxy,             trifluoromethyl, hydroxy, amino, acetylamino,             propionylamino, alkanoyl, cyano or trifluoromethoxy groups             wherein the substituents may be identical or different, -   and A denotes a single bond,     whilst all the above-mentioned alkyl and alkoxy groups and the alkyl     groups present within the other groups mentioned may contain 1 to 3     carbon atoms unless otherwise specified,     their tautomers, their diastereomers, their enantiomers and their     salts.

More particularly preferred compounds of the above general formula I are those wherein

-   R denotes an unbranched C₁₋₃-alkyl group which may be substituted in     the ω-position     -   by a C₅₋₇-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         (4-biphenylyl) group, whilst the above-mentioned aromatic groups         may additionally be substituted by a fluorine, chlorine or         bromine atom or by a methyl, methoxy, amino or acetylamino         group,     -   by a 2-pyrrolyl, 3-pyrrolyl, pyridinyl, 1H-indol-3-yl,         quinolinyl or isoquinolinyl group,         or an unbranched C₁₋₄-alkylamino group which is optionally         additionally substituted at the nitrogen atom by a methyl or         ethyl group and which may be substituted in the ω-position     -   by a C₅₋₇-cycloalkyl group,     -   by a phenyl group which may be mono- or disubstituted by         fluorine, chlorine or bromine atoms, or by methyl, nitro,         methoxy, trifluoromethyl, hydroxy, amino or acetylamino groups,         whilst the substituents may be identical or different,     -   by a 2-pyrrolyl, 3-pyrrolyl, pyridinyl, 1H-indol-3-yl,         quinolinyl or isoquinolinyl group,         or the group of formula

wherein

-   -   p denotes the number 1 or 2,     -   o denotes the number 2 or, if Y¹ and Y² are not simultaneously         nitrogen atoms, it may also denote the number 1,     -   Y¹ denotes the nitrogen atom if R⁵ denotes a free pair of         electrons, or the carbon atom,     -   Y² denotes the nitrogen atom or the group >CH—,     -   R⁵ denotes a free pair of electrons, if Y¹ denotes the nitrogen         atom or, if Y¹ denotes the carbon atom, R⁵ may denote the         hydrogen atom, a C₁₋₂-alkyl group or the cyano or phenyl group,     -   R⁶ denotes the hydrogen atom or, provided that Y¹ is not a         nitrogen atom, R⁶ together with R⁵ may also denote an additional         bond,     -   R⁷ denotes the hydrogen atom or, provided that Y¹ is not a         nitrogen atom and R⁵ and R⁶ together denote an additional bond,         R⁷ together with R^(N) may also denote the 1,4-butadienylene         group,     -   R^(N) denotes the hydrogen atom or a C₁₋₃-alkyl group, which may         be substituted in the ω-position         -   by one or two phenyl or pyridinyl groups, wherein the             substituents may be identical or different,         -   or by a hydroxy or methoxy group,     -   a phenyl group which may be mono- or disubstituted by fluorine,         chlorine or bromine atoms or by methyl groups, nitro, methoxy,         ethoxy, trifluoromethyl, hydroxy or cyano groups, whilst the         substituents may be identical or different, or a phenyl group         substituted by a methylenedioxy group,     -   a 2-pyridinyl or 4-pyridinyl group,     -   an amino, benzoylamino, aminocarbonyl, methylaminocarbonyl,         methoxycarbonyl, ethoxycarbonyl, aminocarbonylamino,         methylaminocarbonylamino, N-(aminocarbonyl)-N-methylamino,         N-(methylaminocarbonyl)-N-methylamino,         N-(aminocarbonyl)-N-(4-fluorophenyl)amino,         N-(methyl-aminocarbonyl)-N-phenylamino,         phenylaminocarbonylamino, [N-phenyl(methylamino)]carbonylamino,         N-(phenylamino-carbonyl)-N-methylamino,         N-(phenylaminocarbonyl)-N-phenylamino,         benzoylaminocarbonylamino, N-(aminocarbonyl)-N-phenylamino group         or a phenylamino group optionally substituted in the phenyl ring         by an aminocarbonylamino or methylsulphonylamino group,     -   a 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, a         1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-2(2H)-oxobenzimidazol-1-yl,         1,3,3a,4,5,6,7,7a-octahydro-2(2H)-oxobenzimidazol-1-yl,         1H-indol-3-yl, 2,4(1H,3H)-dioxoquinazolin-3-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl,         1,3(2H)-dioxo-1H-isoindol-2-yl, 1H-benzimidazol-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 2(3H)-oxobenzoxazol-3-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-d]pyrimidin-3-yl,         2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl,         3,4-dihydro-2(1H)-oxopyrido[2,3-d]pyrimidin-3-yl,         2(1H)-bxoquinolin-3-yl, 3,4-dihydro-2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         3,4,4a,5,6,7,8,8a-octahydro-2(1H)-oxoquinazolin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         2,4(1H,3H)-dioxothieno[3,4-d]-pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl,         1,3-dihydro-5-methyl-4-phenyl-2(2H)-oxoimidazol-1-yl,         2,5-dioxo-4-phenylimidazolidin-1-yl,         2,5-dioxo-4-(phenylmethyl)-imidazolidin-1-yl,         3,4-dihydro-2,2-dioxido-2,1,3-benzothiadiazin-3-yl,         1,3-dihydro-4-(4-biphenylyl)-2(2H)-oxoimidazol-1-yl,         1,3-dihydro-4-(2-naphthyl)-2(2H)-oxoimidazol-1-yl,         1,3-dihydro-4,5-diphenyl-2(2H)-oxoimidazol-1-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         4-phenyl-2(1H)-oxopyrimidin-1-yl,         4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl,         3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2[1H]-oxopyrido[4,3-d]pyrimidin-3-yl or         2,3-dihydro-4(1H)-oxoquinazolin-3-yl group,         -   wherein the above-mentioned mono- and bicyclic heterocycles             may be substituted at one of the nitrogen atoms by a             methoxycarbonylmethyl group and/or         -   the above-mentioned mono- and bicyclic heterocycles may be             mono-, di- or trisubstituted in the carbon skeleton and/or             at the phenyl groups contained in these groups by fluorine,             chlorine or bromine atoms, or by methyl, trifluoromethyl,             methoxy, hydroxy, amino, nitro, phenyl, phenylmethyl,             carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl,             methylaminocarbonyl, hydroxyethylaminocarbonyl,             (4-morpholinyl)carbonyl, (1-piperidinyl)carbonyl or             (4-methyl-1-piperazinyl)carbonyl groups wherein the             substituents may be identical or different and multiple             substitution with the last three substituents is ruled out,     -   or, provided that Y¹ is not a nitrogen atom and R⁵ and R⁶         together denote an additional bond, R^(N) together with R⁷ also         denotes the 1,4-butadienylene group,     -   or, provided that Y¹ denotes a carbon atom, R^(N) together with         R⁵ with the inclusion of Y¹ may also denote a carbonyl group or         saturated or monounsaturated five- or six-membered         1,3-diaza-heterocycle,         -   which may contain a carbonyl group in the ring, adjacent to             a nitrogen atom,         -   may be substituted by a phenyl group at one of the nitrogen             atoms         -   and, if it is unsaturated, may also be benzo-condensed at             the double bond,

-   X denotes an oxygen atom or 2 hydrogen atoms,

-   Z denotes a methylene group or the group —NR¹, wherein     -   R¹ denotes a hydrogen atom or a methyl group,

-   R¹¹ denotes a hydrogen atom, a methoxycarbonyl, ethoxycarbonyl or     methyl group,

-   n denotes the number 1 and m denotes the number 0 or

-   n denotes the number 0 and m denotes the number 1,

-   R² denotes a phenyl, 1-naphthyl, 2-naphthyl,     1,2,3,4-tetrahydro-1-naphthyl, 1H-indol-3-yl,     1-methyl-1H-indol-3-yl,     1-(1,1-dimethylethoxycarbonyl)-1H-indol-3-yl, 2-thienyl, 3-thienyl,     thiazolyl or alkylthiazolyl group having 1 to 3 carbon atoms in the     alkyl moiety, a pyridinyl or quinolinyl group,     -   wherein the above-mentioned phenyl and naphthyl groups may be         mono-, di- or trisubstituted by fluorine, chlorine or bromine         atoms or by branched or unbranched C₁₋₅-alkyl groups, by         C₁₋₃-alkoxy groups, by vinyl, allyl, trifluoromethyl,         methylsulphonyloxy, 2-(dimethylamino)ethoxy, hydroxy, cyano,         nitro or amino groups, by tetrazolyl, phenyl, pyridinyl,         thiazolyl or furyl groups and the substituents may be identical         or different, and multiple substitution with the last five         substituents is ruled out,

-   A denotes a bond or the divalent group of formula

(linked to the group —NR³R⁴ of formula (I) via the carbonyl group) wherein

-   -   R⁸ and R⁹ together denote an n-propylene group or     -   R⁸ denotes the hydrogen atom or the methyl group and     -   R⁹ denotes the hydrogen atom or an unbranched C₁₋₄-alkyl group,     -   which may be substituted in the ω-position by an amino,         methylamino, dimethylamino, aminoiminomethylamino or         aminocarbonylamino group, whilst in the above-mentioned         substituents a hydrogen atom bound to a nitrogen atom may be         replaced by a protecting group, e.g. the phenylmethoxycarbonyl         or tert.butyloxycarbonyl group,

-   R³ denotes a hydrogen atom or     a C₁₋₄-alkyl group optionally substituted in the (ω-position by an     amino, methylamino, dimethylamino- or     4-(1-piperidinyl)-1-piperidinyl group,

-   R⁴ denotes a hydrogen atom or a methyl or ethyl group

-   or R³ and R⁴ together with the enclosed nitrogen atom denote a group     of general formula

wherein

-   -   Y³ denotes the carbon atom or, if R¹² denotes a free pair of         electrons, Y³ may also denote a nitrogen atom,     -   r denotes the number 1,     -   q denotes the number 1,     -   R¹⁰ denotes the hydrogen atom, an alkyl, dialkylamino,         aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl,         phenylaminocarbonylamino, alkoxycarbonyl, alkoxycarbonylmethyl,         carboxymethyl or carboxy group or a cycloalkyl group having 4 to         7 carbon atoms in the ring,     -   a benzoyl, pyridinylcarbonyl, phenyl, pyridinyl or diazinyl         group, each of which may be substituted in the carbon skeleton         by a fluorine, chlorine or bromine atom, or by an acetyl,         methyl, ethyl or methoxy group, or by a dimethylaminoalkyl group         having 1 to 4 carbon atoms in the alkyl moiety optionally         hydroxysubstituted in the alkyl moiety,     -   a 1,3-dihydro-2-oxo-2H-imidazolyl group bound via a nitrogen         atom, which may be fused to a benzene or pyridine ring at the         double bond,     -   a 1-pyrrolidinyl, 1-piperidinyl,         4-(dimethylamino)-1-piperidinyl, 4-piperidinyl or 4-morpholinyl         group, wherein the nitrogen atom of the 4-piperidinyl group may         be substituted by an alkanoyl- or alkyl group each having 1 to 7         carbon atoms or by a benzoyl, methylsulphonyl,         3-carboxy-propionyl, cyclopropylmethyl, alkoxycarbonylmethyl or         carboxymethyl group or by a protecting group, e.g. the         phenylmethoxycarbonyl or tert.butyloxycarbonyl group, or it may         represent a hexahydro-1H-1-azepinyl,         8-methyl-8-azabicyclo[3,2,1]oct-3-yl, 4-alkyl-1-piperazinyl,         hexahydro-4-alkyl-1H-1,4-diazepin-1-yl,         1-alkyl-4-piperidinylcarbonyl or 4-alkyl-1-piperazinylcarbonyl         group,     -   or     -   R¹⁰ together with R¹² and Y³ denotes a 5-membered cycloaliphatic         ring in which a methylene group may be replaced by an —NH— or         —N(CH₃)— group,     -   R¹² denotes a hydrogen atom, a C₁₋₂-alkyl group which may be         substituted in the ω-position by a 1-pyrrolidinyl, 1-piperidinyl         or 4-methyl-1-piperazinyl group,     -   a methoxycarbonyl or ethoxycarbonyl or a cyano group,     -   a free pair of electrons if Y³ denotes a nitrogen atom, and     -   R¹³ and R¹⁴ each denote a hydrogen atom or,     -   provided that Y³ is a carbon atom, R¹² together with R¹⁴ may         also denote an additional carbon-carbon bond, wherein R¹⁰ is as         hereinbefore defined and R¹³ denotes a hydrogen atom or,     -   provided that Y³ is a carbon atom, R¹² together with R¹⁴ may         also denote an additional carbon-carbon bond and R¹⁰ together         with R¹³ and the enclosed double bond denotes an indole group         fused on via the 5-membered ring,         whilst all the above-mentioned alkyl groups and the alkyl groups         present within the other named groups may contain 1 to 3 carbon         atoms, unless otherwise specified,         their tautomers, their diastereomers, their enantiomers and         their salts.

A subgroup of most particularly preferred compounds of general formula I deserving special mention comprises those wherein

A, R², R³, R⁴, R¹¹, X, Z and m and n are as hereinbefore defined for the most particularly preferred compounds of general formula I and

-   R denotes an unbranched C₁₋₄-alkylamino group optionally substituted     at the nitrogen atom by a methyl or ethyl group, which may be     substituted in the ω-position     -   by a C₅₋₇-cycloalkyl group,     -   by a phenyl group, which may be mono- or disubstituted by         fluorine, chlorine or bromine atoms or by methyl, nitro,         methoxy, trifluoromethyl, hydroxy, amino or acetylamino groups,         wherein the substituents may be identical or different, or     -   by a 2-pyrrolyl, 3-pyrrolyl, pyridinyl, 1H-indol-3-yl,         quinolinyl or isoquinolinyl group,         their tautomers, their diastereomers, their enantiomers,         mixtures thereof and salts thereof.

Another subgroup of most particularly preferred compounds of general formula I deserving special mention comprises those wherein

R², R³, R⁴, R¹¹, X, Z and m and n are as defined hereinbefore for the first-mentioned particularly preferred subgroup,

-   R denotes an unbranched C₁₋₃-alkyl group which may be substituted in     the ω-position     -   by a C₅₋₇-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         (4-biphenylyl) group, whilst the above-mentioned aromatic groups         may be substituted by a fluorine, chlorine or bromine atom or by         a methyl, methoxy, amino or acetylamino group,     -   or by a 2-pyrrolyl, 3-pyrrolyl, pyridinyl, 1H-indol-3-yl,         quinolinyl- or isoquinolinyl group, -   and A denotes a single bond,     their tautomers, their diastereomers, their enantiomers, mixtures     thereof and the salts thereof.

The following are mentioned as examples of most particularly preferred compounds:

-   (1)     1-[N²—[N-[[[2-(2-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (2)     1-[N²—[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (3)     1-[N²—[N-[[[2-(2,5-Dimethoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (4)     1-[N²—[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-arginyl]-4-(4-pyridinyl)-piperazine -   (5)     1-[N²—[N-[[[2-(2,3-dimethoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (6)     1-[N²—[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D,L-tyrosyl]-D,L-lysyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (7)     1-[N²—[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D,L-tyrosyl]-D,L-lysyl]-4-(4-piperidinyl)-piperazine -   (8)     1-[N²—[N-[[[2-(3,4-dihydroxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D,L-tyrosyl]-D,L-lysyl]-4-(4-pyridinyl)-piperazine -   (9)     1-[N²—[N-[4-(2-Methoxyphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (10)     1-[N²—[N-[4-(3-Methoxyphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (11)     1-[N²—[N-[[(2-Phenylethyl)amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (12)     1-[N²—[N-[[[2-(4-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (13)     1-[N²—[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3-(1-naphthyl)-D-alanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (14)     1-[N²—[N-[[[2-(3-Hydroxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (15)     1-[N²—[N-[3-(3-Methoxyphenyl)-1-oxopropyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (16)     1-[N²—[N-[[[2-(3-Methoxyphenyl)ethyl]methylamino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (17)     1-[N²—[N-(4-Phenyl-1-piperazinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (18)     1-[N²—[N-[4-(2-Methylphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (19)     1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (20)     1-[N²—[N-[[[2-(3-Methoxyphenyl)ethyl]amino]carbonyl]-3,5-dichloro-D,L-tyrosyl]-D,L-lysyl]-4-(4-pyridinyl)-piperazine -   (21)     1-[N²—[N-[4-(2-Methoxyphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidin -   (22)     1-[N²—[N-(4,4-Diphenyl-1-piperidinyl)carbonyl]-3,5-di-bromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (23)     1-[N²—[N-(4-Phenyl-1-piperidinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (24)     1-[N²—[N-[4-(4-Fluorophenyl)-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (25)     1-[N²—[N-[4,4-Diphenyl-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (26)     1-[N²—[N-[4-Cyclohexyl-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (27)     1-[N²—[N-[4-(4-Acetylaminophenyl)-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (28)     1-[N²—[N-[4-(2-Methoxyphenyl)-1-piperazinyl]carbonyl]-3,5-dichloro-D,L-tyrosyl]-D,L-lysyl]-4-(4-pyridinyl)-piperazine -   (29)     1-[N²—[N-[4-[3-(Trifluoromethyl)phenyl]-1-piperazinyl]-carbonyl]-3,5-dibromo-D,L-tyrosyl]-D,L-lysyl]-4-(4-pyridinyl)-piperazine -   (30)     1-[N²—[N-[4-(2-Chlorophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (31)     1-[N²—[N-[4-(3,4-Methylenedioxyphenyl)-1-piperazinyl]-carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (32)     1-[N²—[N-(4-Methyl-1-piperazinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (33)     1-[N²—[N-[4-(2-Hydroxyethyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (34)     1-[N²—[N-[4-(4-Pyridinyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (35)     1-[N²—[N-[4-(2-Pyridinyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (36)     1-[N²—[N-[4-(Diphenylmethyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (37)     1-[N²—[N-[4-(Phenylmethyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (38)     1-[N²—[N-[4-(4-Nitrophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (39)     1-[N²—[N-[4-(Ethoxycarbonyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (40)     1-[N²—[N-[[[3-(2-Methoxyphenyl)propyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (41)     1-[N²—[N-[[[2-(3-Bromophenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (42)     1-[N²—[N-[[[2-(3-Nitrophenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (43)     1-[N²—[N-[[[2-(3-Acetylaminophenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (44)     1-[N²—[N-[[[2-(3-Bromophenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-ly-syl]-4-(4-pyridinyl)-piperazine -   (45)     1-[N²—[N-[(1,2,4,5-Tetrahydro-3H-3-benzazepin-3-yl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (46)     1-[N²—[N-[[[2-[3-(Trifluoromethyl)phenyl]ethyl]amino]-carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (47)     1-[N²—[N-[[[2-(3-Fluorophenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (48)     1-[N²—[N-[4-(2-Methoxyphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-fluorophenyl)-piperazine -   (49)     1-[N²-[4-Amino-3,5-dibromo-N-[[(2-phenylethyl)amino]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (50)     1-[N²—[N-[4-(2-Methoxyphenyl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (51)     1-[N²—[N-[4-(3-Methoxyphenyl)-1,2,5,6-tetrahydro-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (52)     1-[N²—[N-[4-(2-Methoxyphenyl)-1,2,5,6-tetrahydro-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (53)     1-[N²—[N-[(4-Biphenylyl)acetyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (54)     1-[N²—[N-[4-(4-Bromophenyl)-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (55)     1-[N²—[N-[4-(1H-Indol-3-yl)-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (56)     1-[N²—[N-(4,4-Diphenyl-1-piperidinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (57)     1-[N²—[N-(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (58)     1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (59)     1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (60)     1-[N²—[N-[4-(2-Chlorophenyl)-1-piperazinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (61)     1-[N²—[N-[4-(2-Chlorophenyl)-1-piperazinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (62)     1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(2-pyridinyl)-piperazine -   (63)     1-[N²—[N-[[[2-(2-Cyclohexyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (64)     1-[N²—[N-[4-(2-Chlorophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (65)     1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (66)     1-[N²—[N-[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (67)     1-[N²—[N-[[[2-(1H-Indol-3-yl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (68)     1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(2-methoxyphenyl)-piperazine -   (69)     1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(2-pyridinyl)-piperazine -   (70)     1-[N²—[N-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(2-methoxyphenyl)-piperazine -   (71)     1-[N²—[N-(4,4-Diphenyl-1-piperidinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(2-pyridinyl)-piperazine -   (72)     1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D,L-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (73)     1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D,L-phenylalanyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine -   (74)     1-[N²—[N-[4-(2,3-Dichlorophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (75)     1-[N²—[N-[4-(3,5-Dichlorophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (76)     1-[N²—[N-[4-(2-Cyanphenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (77)     1-[N²—[N-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-3,5-dibromo-D,L-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (78)     1-[N²—[N-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-3,5-dibromo-D,L-phenylalanyl]-N⁶-(1,1-dimethyl-ethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine -   (79)     1-[N²—[N-[4-[4-Chloro-3-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (80)     1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine -   (81)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (82)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (83)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (84)     1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-[1-(1-methylethyl)-4-piperidinyl]-piperidine -   (85)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxo-benzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-phenylpiperazine -   (86)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-6-methyl-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (87)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-5-methyl-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (88)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-5,6-dichloro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenyl-alanyl]-4-(4-pyridinyl)-piperazine -   (89)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-3-(methoxy-carbonylmethyl)-2(2H)-oxobenzimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (90)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-piperidinyl)-piperidine -   (91)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3,3a,4,5,6,7,7a-octahydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (92)     1-[4-Amino-3,5-dibromo-N-[[4-(benzoylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (93)     1-[4-Amino-3,5-dibromo-N-[[4-(aminocarbonyl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (94)     1-[4-Amino-3,5-dibromo-N-[(4-Oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (95)     1-[3,5-Dibromo-N-[[4-(benzoylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (96)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-6-methyl-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (97)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-5-methyl-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (98)     3,5-Dibromo-N²-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosinamide -   (99)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-methylpiperazine -   (100)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)piperazine -   (101)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-phenylpiperazine -   (102)     3,5-Dibromo-N²-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N,N-diethyl-D-tyrosinamide -   (103)     3,5-Dibromo-N²-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-[(4-(dimethylamino)butyl]-D-tyrosinamide -   (104)     1-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (105)     1-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (106)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(1,1-di-methylethoxycarbonyl)-4-piperidinyl]piperazine -   (107)     1-[4-Amino-3,5-dibromo-N-[(4-cyan-4-phenyl-1-piperidinyl)carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (108)     1-[3,5-Dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro-[4,5]dec-8-yl)carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (109)     1-[3,5-Dibromo-N-[(4-cyan-4-phenyl-1-piperidinyl)carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (110)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-pyridinyl)-piperazine -   (111)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-pyrimidinyl)-piperazine -   (112)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(2-pyridinyl)-piperazine -   (113)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4(pyrazinyl)-piperazine -   (114)     1-[4-Amino-3,5-dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-phenylalanyl]-4-(2-pyridinyl)-piperazine -   (115)     1-[3,5-Dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro-[4,5]dec-8-yl)carbonyl]-D-tyrosyl]-4-(2-pyridinyl)-piperazine -   (116)     1-[4-Amino-3,5-dibromo-N-[[4-(2,4(1H,3H)-dioxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (117)     1-[3,5-Dibromo-N-[[4-(2,4(1H,3H)-dioxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (118)     1-[3,5-Dibromo-N-[[4-(aminocarbonyl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (119)     1-[4-Amino-3,5-dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-phenylalanyl]-4-(pyrazinyl)-piperazine -   (120)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(2-pyrimidinyl)-piperazine -   (121)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxo-imidazo-[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (122)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxo-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-phenyl-alanyl]-4-(4-pyridinyl)-piperazine -   (123)     cis-1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-cyclohexyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (124)     trans-1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-cyclohexyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (125)     1-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dimethyl-D,L-tyrosyl]-4-(4-pyridinyl)-piperazine -   (126)     1-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dimethyl-D,L-tyrosyl]-4-(4-pyridinyl)-piperidine -   (127)     1-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dimethyl-D,L-tyrosyl]-4-(1-piperidinyl)-piperidine -   (128)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-fluorophenyl)-piperazine -   (129)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(pyrazinyl)-piperazine -   (130)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-methoxyphenyl)-piperazine -   (131)     1-[4-Amino-3,5-dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-phenylalanyl]-4-(2-methoxyphenyl)-piperazine -   (132)     1-[4-Amino-3,5-dibromo-N-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)carbonyl]-D-phenylalanyl]-4-(4-fluorophenyl)-piperazine -   (133)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(2-methoxyphenyl)-piperazine -   (134)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (135)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (136)     1-[N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (137)     1-[4-Amino-N-[[4-(1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (138)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3(2H)-dioxo-1H-isoindol-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (139)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine -   (140)     1-[N²-[3,5-Dibromo-N-[[4-(2,4(1H,3H)-dioxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethyl-ethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine -   (141)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (142)     1-[N²-[3,5-Dibromo-N-[[4-(2,4(1H,3H)-dioxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (143)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (144)     1-[3,5-Dibromo-N-[(4′(3′H)-oxospiro[piperidine-4,2′(1′H)-quinazolin]-1-yl)carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (145)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxoimidazo-[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (146)     1-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D,L-3-(4-pyridinyl)alanyl]-4-(4-pyridinyl)-piperazine -   (147)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]carbonyl]-D-phenyl-alanyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (148)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (149)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (150)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-5-(methoxycarbonyl)-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (151)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-5-(hydroxycarbonyl)-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (152)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (153)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-5-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (154)     1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (155)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorophenyl)-piperazine -   (156)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(2-fluorophenyl)-piperazine -   (157)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-fluorophenyl)-piperazine -   (158)     1-[4-Amino-3,5-dibromo-N-[[4-(phenylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (159)     1-[4-Amino-3,5-dibromo-N-[[4-[N-(aminocarbonyl)-N-phenylamino]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (160)     1-[3,5-Dibromo-N-[[4-(aminocarbonylamino)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (161)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyrimidinyl)-piperazine -   (162)     1-[3,5-Dibromo-N-[[4-[2(3H)-oxobenzoxazol-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (163)     1-[N-[[4-(Aminocarbonylamino)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (164)     1-[4-Amino-3,5-dibromo-N-[[4-(phenylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (165)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyrimidinyl)-piperazine -   (166)     1-[3,5-Dibromo-N-[[4-(methylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (167)     1-[3,5-Dibromo-N-[[4-[N-(aminocarbonyl)-methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (168)     1-[N²—[N-[[4-(Aminocarbonylamino)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine -   (169)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(3-pyridinyl)-piperazine -   (170)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(3-pyridinyl)-piperazine -   (171)     1-[3,5-Dibromo-N-[[4-(phenylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (172)     1-[3,5-Dibromo-N-[[4-(phenylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (173)     1-[2,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (174)     1-[2,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (175)     1-[3,5-Dibromo-N-[[4-[N-(aminocarbonyl)-N-phenylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (176)     1-[N²-[3,5-Dibromo-N-[[4-(methylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine -   (177)     1-[N²-[3,5-Dibromo-N-[[4-[N-(aminocarbonyl)methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine -   (178)     1-[3,5-Dibromo-N-[[4-[N-(methylaminocarbonyl)-methyl-amino]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (179)     1-[N²—[N-[[4-(Aminocarbonylamino)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (180)     1-[N²-[3,5-Dibromo-N-[[4-[N-(methylaminocarbonyl)methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine -   181)     1-[N²-[3,5-Dibromo-N-[[4-[N-(aminocarbonyl)methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (182)     1-[N²-[3,5-Dibromo-N-[[4-[N-(methylaminocarbonyl)amino]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (183)     1-[N²-[3,5-Dibromo-N-[[4-[N-(methylaminocarbonyl)methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (184)     1-[N²—[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (185)     1-[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (186)     1-[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]-carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (187)     1-[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]-carbonyl]-3,5-dibromo-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (188)     1-[N²—[N-[[4-[2(3H)-Oxobenzoxazol-3-yl]-1-piperidinyl]-carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine -   (189)     1-[4-Amino-3,5-dibromo-N-[[4-(1H-indol-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (190)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-di-methylethoxycarbonyl)-L-lysyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (191)     1-[N²-[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine -   (192)     1-[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]-carbonyl]-3,5-dibromo-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (193)     1-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-phenylpiperazine -   (194)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-cyclohexyl-4-piperidinyl)-piperazine -   (195)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(1-piperidinyl)-piperidine -   (196)     1-[N²—[N-[[4-(2-Cyanophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(1-piperidinyl)-piperidine -   (197)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(1-piperidinyl)-piperidine -   (198)     1-[N²—[N-[[4-(2-Cyanophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(1-piperidinyl)-piperidine -   (199)     1-[3,5-Dichloro-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (200)     1-[3,5-Dichloro-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (201)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-6-hydroxy-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenyl-alanyl]-4-(1-piperidinyl)-piperidine -   (202)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-morpholinyl)-piperidine -   (203)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(ethoxycarbonyl)-piperidine -   (204)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(dimethylamino)-piperidine -   (205)     1-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (206)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-pyrrolidinyl)-piperidine -   (207)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(methoxycarbonyl)-4-phenylpiperidine -   (208)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-L-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (209)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-L-tyrosyl]-D-lysyl]-4-(4-pyridinyl)-piperazine -   (210)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-D-lysyl]-4-(4-pyridinyl)-piperazine -   (211)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hydroxycarbonyl)-piperidine -   (212)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶,N⁶-dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine -   (213)     1-[N²-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(1-piperidinyl)-piperidine -   (214)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-piperidinyl)-piperazine -   (215)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-piperidine -   (216)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1,3-dihydro-2(2H)-oxoimidazo[4,5-b]pyridin-3-yl)-piperidine -   (217)     1-[N²-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine -   (218)     1-[N²-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (219)     (R)-1-[2-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-methylamino]-3-(3,5-dibromo-4-hydroxyphenyl)-propyl]-4-(1-piperidinyl)-piperidine -   (220)     (R)-1-[2-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-propyl]-4-(1-piperidinyl)-piperidine -   (221)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N⁶,N⁶-dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine -   (222)     3,5-Dibromo-N²-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-[(2-(4-(1-piperidinyl)-1-piperidinyl]ethyl]-D-tyrosinamide -   (223)     1-[3,5-Dibromo-N-[[4-[5-[(4-morpholinyl)carbonyl]-1,3-dihydro-2(2H)-oxobenzimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (224)     1-[3,5-Dibromo-N-[[4-[5-[(4-methyl-1-piperazinyl)carbonyl]-1,3-dihydro-2(2H)-oxobenzimidazol-1-yl]-1-piperidinyl]-carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (225)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (226)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (227)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (228)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (229)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxoimidazo-[4,5-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (230)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (231)     1-[4-Amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (232)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(1-piperidinyl)-piperidine -   (233)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (234)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (235)     1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(1-piperidinyl)-piperidine -   (236)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (237)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(1-piperidinyl)-piperidine -   (238)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (239)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (240)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (241)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenyl-alanyl]-4-(1-piperidinyl)-piperidine -   (242)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (243)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (244)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (245)     (R)-1-[2-[N-[[4-(3,4-dihydro-2(1H)-oxopyrido[2,3-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]amino]-3-(4-amino-3,5-dibromophenyl)-propyl]-4-(1-piperidinyl)-piperidine -   (246)     (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,3-dihydro-2(2H)oxobenzimidazol-1-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (247)     1-[N²-[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N⁶-(1,1-di-methylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine -   (248)     1-[N²-[3,5-Dibromo-N-[[4-[2(3H)-oxobenzoxazol-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (249)     1-[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]-carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-4-[(1-piperidinyl)methyl]-piperidine -   (250)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (251)     1-[N²-[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (252)     1-[N²-[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-L-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (253)     1-[N²-[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (254)     1-[N²-[3,5-Dibromo-N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine -   (255)     1-[N²-[3,5-Dibromo-N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (256)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (257)     1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-glycyl]-4-(4-pyridinyl)-piperazine -   (258)     1-[4-Amino-3,5-dibromo-N-[[4-(benzoylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (259)     1-[4-Amino-3,5-dibromo-N-[[4-(benzoylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (260)     1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-β-alanyl]-4-(4-pyridinyl)-piperazine -   (261)     1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N-methylglycyl]-4-(4-pyridinyl)-piperazine -   (262)     1-[4-Amino-3,5-dibromo-N-[[4-[N-(phenylaminocarbonyl)-phenylamino)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (263)     1-(N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-[3-(2-thienyl)-D-alanyl]-4-(1-piperidinyl)-piperidine -   (264)     4-Amino-3,5-dibromo-N²-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]-D-phenylalaninamide -   (265)     1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-glycyl]-4-(1-piperidinyl)-piperidine -   (266)     1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-alanyl]-4-(4-pyridinyl)-piperazine -   (267)     1-[N²-[4-Amino-3,5-dibromo-N-((4-[N-(methylaminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-phenylalanyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl)-4-(1-piperidinyl)-piperidine -   (268)     1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-alanyl]-4-(1-piperidinyl)-piperidine -   (269)     1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperazinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (270)     1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperazinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (271)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-[N-(methylaminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(1-piperidinyl)-piperidine -   (272)     1-[N²-[[4-(1,3-Dihydro-2(2H)oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-1-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-(1-piperidinyl)-piperidine -   (273)     1-[N-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N-methylglycyl]-4-(1-piperidinyl)-piperidine -   (274)     1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinoxalin-3-yl]-1-piperazinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (275)     1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinoxalin-3-yl]-1-piperazinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (276)     1-[4-Amino-3,5-dibromo-N-[[4-[N-(aminocarbonyl)-N-(4-fluorophenyl)amino]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (277)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-4-methyl-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (278)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-4-methyl-1-piperidinyl]carbonyl]-D-phenylalanyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine -   (279)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[3-dimethylamino)propyl]-piperidine -   (280)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-4-methyl-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (281)     1-[N-[[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tryptyl]-4-(1-piperidinyl)-piperidine -   (282)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (283)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperazinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine -   (284)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (285) (R,S)-l     -[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperidine -   (286)     3,5-Dibromo-N²-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-[2-(4-methyl-1-piperazinyl)ethyl]-D-tyrosinamide -   (287)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (288)     1-[3,5-Dibromo-N-[[4-(7,9-dihydro-6,8-dioxo-1H-purin-9-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (289)     (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (290)     (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperidine -   (291)     (R,S)-1-[2-(4-Amino-3,5-dibromobenzoyl)-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-4-oxobutyl]-4-(4-pyridinyl)-piperidine -   (292)     (R)-1-[3-(3,5-Dibromo-4-hydroxyphenyl)-2-[N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine -   (293)     1-[N⁶-Acetyl-N²-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (294)     1-[N²-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N⁶,N⁶-dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine -   (295)     1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶,N⁶-dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine -   (296)     (R,S)-1-[2-(4-Amino-3,5-dibromobenzoyl)-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-4-oxobutyl]-4-(1-piperidinyl)-piperidine -   (297)     (R)-1-[3-(4-Amino-3,5-dibromophenyl)-2-[N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine -   (298)     (R)-1-[3-(4-Amino-3-bromophenyl)-2-[N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine -   (299)     (R)-1-[3-(4-Amino-3,5-dibromophenyl)-2-[N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine -   (300)     (R)-1-[3-(4-Amino-3-bromophenyl)-2-[N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine -   (301)     (R)-1-[3-(3,5-Dibromo-4-hydroxyphenyl)-2-[N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine -   (302)     (R,S)-1-[2-(4-Amino-3,5-dibromobenzoyl)-4-[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]-4-oxobutyl]-4-(1-piperidinyl)-piperidine -   (303)     1-[4-Amino-N-[[4-[2-(aminocarbonylamino)phenylamino]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (304)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (305)     1-(4-Amino-N-[[4-[2-(methylsulphonylamino)phenylamino]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (306)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (307)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxy-carbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (308)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4,4a,5,6,7,8,8a-octahydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (309)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (310)     1-[4-Amino-N-[[4-[7-(aminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinylicarbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (311)     1-[4-Amino-3,5-dibromo-N-[[4-[7-(2-hydroxyethylaminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (312)     1-[4-Amino-N-[[4-[7-(aminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (313)     1-[4-Amino-3,5-dibromo-N-[[4-[7-(2-hydroxyethylaminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (314)     1-[4-Amino-3,5-dibromo-N-[[4-(1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (315)     1-[4-Amino-3,5-dibromo-N-[[4-(1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (316)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (317)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-fluorophenyl)-piperazine -   (318)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorophenyl)-piperazine -   (319)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxo-quinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-fluorophenyl)-piperazine -   (320)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenyl-alanyl]-4-(2-fluorophenyl)-piperazine -   (321)     1-[3,5-Dibromo-N-[[4-(1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (322)     trans-1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-cyclohexyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (323)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-6,7-dimethoxy-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (324)     1-[N-[[4-(5-Chloro-3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (325)     1-[3,5-Dibromo-N-[[3-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-pyrrolidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (326)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (327)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (328)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-8-methoxy-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (329)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-(4-methoxyphenyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (330)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(4-methoxy-phenyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (331)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(4-methoxy-phenyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (332)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (333)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (334)     1-[N-[[4-(1,3-dihydro-4-[3-(trifluoromethyl)-phenyl]-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-3-(4-pyridinyl)-D,L-alanyl]-4-(4-pyridinyl)-piperazine -   (335)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (336)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (337)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (338)     (R)-1-[3-(4-Amino-3,5-dibromophenyl)-2-[N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine -   (339)     (R)-1-[3-(4-Amino-3,5-dibromophenyl)-2-[N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine -   (340)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (341)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (342)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(3-thienyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (343)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-(3-thienyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (344)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (345)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (346)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (347)     1-[4-Amino-3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (348)     1-[4-Amino-3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (349)     1-[4-Amino-3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (350)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (351)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (352)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (353)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-(3-thienyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (354)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D,L-tyrosyl]-4-(4-pyridinyl)-piperidine -   (355)     1-[4-Amino-3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (356)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine -   (357)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(3-thienyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (358)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (359)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (360)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenyl-alanyl]-4-(1-piperidinyl)-piperidine -   (361)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (362)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (363)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (364)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (365)     1-[N2-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (366)     1-[4-Amino-3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperidine -   (367)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperidine -   (368)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperidine -   (369)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[4-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperazine -   (370)     1-[4-Amino-3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperazine -   (371)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperazine -   (372)     4-(1-Acetyl-4-piperidinyl)-1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-piperidine -   (373)     1-[4-Amino-N-[[4-(6-bromo-3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (374)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-5-methyl-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (375)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(3-nitrophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (376)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (377)     1-[47Amino-N-[[4-[4-(3-bromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (378)     1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine -   (379)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorophenyl)-piperazine -   (380)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-fluorophenyl)-piperazine -   (381)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(3-pyridinyl)-piperazine -   (382)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(3-pyridinyl)-piperazine -   (383)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(3-pyridinyl)-piperazine -   (384)     1-[3,5-Dibromo-N-[[4-[1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (385)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(3-pyridinyl)-piperazine -   (386)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (387)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-pyridinyl)-piperazine -   (388)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(2-pyridinyl)-piperazine -   (389)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(phenylaminocarbonylamino)-piperidine -   (390)     1-[4-Amino-3,5-dibromo-N-[[4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (391)     1-[3,5-Dibromo-N-[[4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (392)     1-[3,5-Dibromo-N-[[4-[4-phenyl-2(1H)-oxopyrimidin-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (393)     4-Cyano-1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-phenylpiperidine -   (394)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyrimidinyl)-piperazine -   (395)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyrimidinyl)-piperazine -   (396)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyrimidinyl)-piperazine -   (397)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyrimidinyl)-piperazine -   (398)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (399)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine -   (400)     1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (401)     2-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indole -   (402)     1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (403)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (404)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-ethylphenyl)-piperazine -   (405)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorophenyl)-1,2,5,6-tetrahydropyridine -   (406)     1-[3,5-Dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (407)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (408)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(1-oxoethyl)phenyl]-piperazine -   (409)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(1-oxoethyl)phenyl]-piperazine -   (410)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorobenzoyl)-piperidine -   (411)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-cyano-4-phenylpiperidine -   (412)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-fluorophenyl)-piperidine -   (413)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[(hexahydro-1-methyl-4-pyridinyl)carbonyl]-piperazine -   (414)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[3-(dimethylamino)propyl]-piperazine -   (415)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[3-(dimethylamino)propyl]-piperazine -   (416)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (417)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (418)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,l]oct-3-yl)-piperazine -   (419)     1-[N-[4-[[1,3-Dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine -   (420)     1-[3,5-Dibromo-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (421)     1-[3,5-Dibromo-N-[[4-[7-(hydroxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (422)     1-[3,5-Dibromo-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (423)     1-[3,5-Dibromo-N-[[4-[7-(hydroxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (424)     1-[4-Amino-3,5-dibromo-N-[[4-[7-(methylaminocarbonyl)-3,4-dihydro-2(1H)     -oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (425)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-morpholinyl)-piperidine -   (426)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxo-quinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(dimethylamino)-piperidine -   (427)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-pyrrolidinyl)-piperidine -   (428)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-morpholinyl)-piperidine -   (429)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(dimethylamino)-piperidine -   (430)     1-[4-Amino-3,5-dibromo-N-[[4-[7-[(4-methyl-1-piperazinyl)carbonyl]-3,4-dihydro-2(1H)     -oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (431)     1-[4-Amino-3,5-dibromo-N-[[4-(2,5-dioxo-4-phenylimidazolidin-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (432)     1-[3,5-Dibromo-N-[[4-(2,5-dioxo-4-phenylimidazolidin-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (433)     1-[4-Amino-3,5-dibromo-N-[[4-[2,5-dioxo-4-(phenyl-methyl)-imidazolidin-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (434)     1-[3,5-Dibromo-N-[[4-[2,5-dioxo-4-(phenylmethyl)imidazolidin-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (435)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-pyrrolidinyl)-piperidine -   (436)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (437)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (438)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-cyclohexylpiperazine -   (439)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-cyclohexylpiperazine -   (440)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2,2-dioxido-2,1,3-benzothiadiazin-3-yl)-1-piperidinyl]carbonyl]-D-phenyl-alanyl]-4-(1-piperidinyl)-piperidine -   (441)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2,2-dioxido-2,1,3-benzothiadiazin-3-yl)-1-piperidinyl]carbonyl]-D-phenyl-alanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (442)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2,2-dioxido-2,1,3-benzothiadiazin-3-yl)-1-piperidinyl]carbonyl]-D-phenyl-alanyl]-4-(4-pyridinyl)-piperidine -   (443)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (444)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (445)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperazine -   (446)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (447)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (448)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (449)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (450)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-N-methyl-D-tyrosyl]-4-(4-pyridinyl)-piperidine -   (451)     (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperazine -   (452)     (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperazine -   (453)     (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (454)     (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (455)     (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (456)     1-[3,4-Dichloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (457)     (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperidine -   (458)     (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (459)     (R,S)-1-[2-[(3,5-Dibromo-4-hydroxyphenyl)methyl]-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-1,4-dioxobutyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (460)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-cycloheptylpiperazine -   (461)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-cyclopentylpiperazine -   (462)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-4-methoxy-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (463)     1-[3,5-Bis-(trifluoromethyl)-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (464)     1-[3,5-Bis-(trifluoromethyl)-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (465)     1-[3,5-Bis-(trifluoromethyl)-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (466)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(4-biphenylyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (467)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(2-naphthyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (468)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(2-naphthyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (469)     1-[3-Bromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (470)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(4-biphenylyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (471)     1-[N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(4-biphenylyl)-D,L-alanyl]-4-(1-piperidinyl)-piperidine -   (472)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-biphenylyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (473)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-(2-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (474)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(2-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (475)     1-[3,5-Bis-(trifluoromethyl)-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (476)     1-[3,5-Bis-(trifluoromethyl)-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (477)     1-[3,4-Dichloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (478)     1-[3-Bromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (479)     1-[3-Bromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (480)     1-[3-Bromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (481)     1-[4-Amino-3,5-dibromo-N-[[4-[4-(3,4-dichlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (482)     1-[4-Amino-3,5-dibromo-N-[[4-[4-(3,4-dichlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (483)     1-[4-Amino-N-[[4-[4-(3-chlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (484)     1-[4-Amino-N-[[4-[4-(3-chlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (485)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-benzoyl-4-piperidinyl)-piperidine -   (486)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methylsulphonyl-4-piperidinyl)-piperidine -   (487)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(3-carboxy-1-oxopropyl)-4-piperidinyl]-piperidine -   (488)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-hexyl-4-piperidinyl)-piperidine -   (489)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-cyclopropylmethyl-4-piperidinyl)-piperidine -   (490)     1-[3,5-Dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (491)     1-[3,5-Dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (492)     1-[3,5-Dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (493)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(ethoxycarbonylmethyl)-4-piperidinyl]-piperidine -   (494)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(carboxymethyl)-4-piperidinyl]-piperidine -   (495)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4,5-diphenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (496)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[(4-pyridinyl)carbonyl]-piperazine -   (497)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-methyl-1-piperazinyl)piperidine -   (498)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)piperidine -   (499)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)piperidine -   (500)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[(1-methyl-4-piperidinyl)carbonyl]-piperazine -   (501)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-methyl-1-piperazinyl)piperidine -   (502)     1-[3,5-Dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)piperidine -   (503)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)piperidine -   (504)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-piperidine -   (505)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)carbonyl]-piperidine -   (506)     1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (507)     1-[3-Chloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (508)     (R,S)-1-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-2-[[3-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (509)     1-[4-Amino-3,5-dibromo-N-[[4-[4-(3-bromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine -   (510)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine -   (511)     1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-methoxy-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (512)     1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-methoxy-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (513)     1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-methoxy-D,L-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (514)     1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-methoxy-D,L-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine -   (515)     1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-methoxy-D,L-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperazine -   (516)     1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-L-tyrosyl]-D-lysyl]-4-(4-pyridinyl)-piperazine -   (517)     1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-D-lysyl]-4-(4-pyridinyl)-piperazine -   (518)     1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-L-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine -   (519)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(3-hydroxyphenyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (520)     1-[4-Amino-N-[[4-[4-[3,5-bis-(trifluoromethyl)phenyl]-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (521)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine -   (522)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-piperidinyl)-piperidine -   (523)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-4-(methylsulphonyloxy)-D-phenylalanyl]-4-[1-(methylsulphonyl)-4-piperidinyl]-piperidine -   (524) 1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2 (1H)     -oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(methylsulphonyl)-4-piperidinyl]-piperidine -   (525)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(cyclopropylmethyl)-4-piperidinyl]-piperidine -   (526)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(hydroxycarbonylmethyl)-4-piperidinyl]-piperidine -   (527)     1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-(2-methyl-4-thiazolyl)-D,L-alanyl]-4-(1-piperidinyl)-piperidine -   (528)     1-[N-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-3-(2-methyl-4-thiazolyl)-D,L-alanyl]-4-(4-pyridinyl)-piperazine -   (529)     (R,S)-1-[2-[(1-Naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperi-dinyl)-piperidine -   (530)     (R,S)-1-[2-[(1-Naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (531)     (R,S)-1-[2-[(3-Methoxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (532)     1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-ethenyl-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (533)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxopyrido-[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(l-piperidinyl)-piperidine -   (534)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (535)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperazinyl)-piperidine -   (536)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxopyrido[4,3-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (537)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxopyrido[4,3-d]pyrimidin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine -   (538)     (R,S)-1-[2-[(1-Naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (539)     (R,S)-1-[2-[(1-Naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperazinyl)-piperidine -   (540)     (R,S)-1-[2-[(1-Naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxopyrido[3,4-d]pyrimidin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (541)     (R,S)-1-[2-[(3-Ethoxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperazinyl)-piperidine -   (542) (R,S)-1-[2-[(3-Ethoxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)     -oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (543)     (R,S)-1-[2-[(3-Ethoxyphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (544)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(1-methylethoxy)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (545)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(1-methylethoxy)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperazinyl)-piperidine -   (546)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(1-methylethoxy)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (547)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (548)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperazinyl)-piperidine -   (549)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (550)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-[2-(dimethylamino)ethoxy]phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperazinyl)-piperidine -   (551)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[(1-methyl-4-piperazinyl)carbonyl]-piperidine -   (552)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(1-oxoethyl)-1-piperazinyl]-piperidine -   (553)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[4-(1-oxoethyl)-1-piperazinyl]-piperidine -   (554)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(1-oxoethyl)-1-piperazinyl]-piperidine -   (555)     1-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[4-(1-oxoethyl)-1-piperazinyl]-piperidine -   (556)     1-[4-Amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[(1-methyl-4-piperazinyl)carbonyl]-piperazine -   (557)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[(1-methyl-4-piperazinyl)carbonyl]-piperazine -   (558)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[(4-pyridinyl)carbonyl]-piperazine -   (559)     1-[4-Amino-3,5-dibromo-N-[(4-oxo-1-piperidinyl)carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (560)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-[4-(dimethylamino)butyl]phenyl]-piperazine -   (561)     1-[4-Amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-[4-(dimethylamino)butyl]phenyl]-piperazine -   (562)     1-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[(1-methyl-4-piperazinyl)carbonyl]-piperazine -   (563)     1-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[(1-methyl-4-piperazinyl)carbonyl]-piperazine -   (564)     1-[4-Amino-N-[(4-amino-1-piperidinyl)carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (565)     1-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine -   (566)     1-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine -   (567)     1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (568)     1-[4-Amino-3,5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine -   (569)     1-[3,5-Dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (570)     1-[N²-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (571)     1-[N²-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (572)     1-[N²-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (573)     1-[N²-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (574)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (575)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (576)     1-[N²-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (577)     1-[N²-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (578)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromophenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (579)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromophenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (580)     1-[N²-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (581)     1-[N²-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (582)     1-[4-Amino-3,5-dibromo-N-[[4-(2,3-dihydro-4(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (583)     1-[N²-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine -   (584)     1-[N²-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-methyl-D-tryptyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine -   (585)     1-[4-Amino-N-[[4-[4-(4-amino-3,5-dibromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (586)     1-[4-Amino-N-[[4-[4-(4-amino-3,5-dibromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (587)     1-[N²-[[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine -   (588)     1-[N²-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-N′-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine -   (589)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromo-4-methylphenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (590)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromo-4-methylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (591)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3,4-difluoro-5-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (592)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3,4-difluoro-5-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (593)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(ethoxycarbonyl)-piperidine -   (594)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(ethoxycarbonylmethyl)-piperidine -   (595)     (R,S)-2-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-6-methyl-2,6-diazaspiro[3,4]octane -   (596)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(hydroxycarbonylmethyl)-piperidine -   (597)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (598)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (599)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (600)     (R,S)-1-[4-[4-(Aminocarbonylamino)-1-piperidinyl]-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (601)     (R,S)-1-[4-[4-(Aminocarbonylamino)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (602)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromo-4-methoxyphenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (603)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-carboxypiperidine -   (604)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromo-4-methoxyphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (605)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-fluor-3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (607)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-fluor-3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (607)     1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperazine -   (608)     1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (609)     1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (610)     1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(4-pyridinyl)-piperazine -   (611)     1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(trifluoromethyl)-D,L-phenylalanyl]-4-(4-pyridinyl)-piperidine -   (612)     (R,S)-1-[2-[(4-Amino-3,5-dibromophenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (613)     1-[3-Chloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (614)     1-[3-Chloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (615)     1-[3-Chloro-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(cyclopentyl)-piperazine -   (616)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3-methylphenyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (617)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(hexahydro-1H-1-azepinyl)-piperidine -   (618)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine -   (619)     1-[3-Bromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (620)     1-[3-cyano-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (621)     1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-methyl-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (622)     1-[N-[[4-(1,3-Dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-3-methyl-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (623)     1-[3-Methyl-N-[[4-[3,4-dihydro-2(1H)-oxothieno[3,4-d]-pyrimidin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (624)     1-[N-[[4-[1,3-Dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3-methyl-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (625)     1-[N-[[4-[1,3-Dihydro-4-[(3-(trifluoromethyl)-phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-3-methyl-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (626)     1-[3-Bromo-N-[[4-[1,3-dihydro-4-[(3-(trifluoromethyl)-phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (627)     1-[3-Bromo-N-[[4-[3,4-dihydro-2(1H)-oxothieno[3,4-d]-pyrimidin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (628)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (629)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperazine -   (630)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)-phenyl]methyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-piperazine -   (631)     (R,S)-4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-4-oxo-2-[[3-(trifluoromethyl)-phenyl]methyl]-N-[2-(4-methyl-1-piperazinyl)ethyl]-butanamide -   (632)     1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-(1H-tetrazol-5-yl)-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (633)     1-[3-Bromo-N-[[4-[1,3-dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine -   (634)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(2-naphthyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (635)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[2-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (636)     1-[N-[[4-[3,4-Dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-nitro-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (637)     (R,S)-1-[2-[(4-Amino-3,5-dibromophenyl)methyl]-4-[4-(3,4-dihydro-2(1H)     -oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (638)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[2-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (639)     (R,S)-1-[2-[[3,5-Bis-(trifluoromethyl)phenyl]methyl]-4-[4-(3,4-dihydro-2     (1H)     -oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (640)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dimethoxyphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (641)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(2-naphthyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (642)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dimethoxyphenyl)methyl]-1,4-dioxobutyl)-4-(1-piperidinyl)-piperidine -   (643)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(4-piperidinyl)-piperidine -   (644)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (645)     (R,S)-1-[2-[(3-Bromophenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (646)     (R,S)-1-[2-[(3-Bromophenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (647)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(1-propen-3-yl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (648)     (R,S)-1-[2-[3-(Biphenylyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (649)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(pyridinyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (650)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(2-thiazolyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (651)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(2-furyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (652)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3-propylphenyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (653)     (R,S)-1-[4-(2,4-Dihydro-5-phenyl-3(3H)-oxotriazol-2-yl)-1-piperidinyl]-2-[[3-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (654)     (R,S)-1-[4-[1,3-Dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl]-1-piperidinyl]-2-[[3-(trifluoromethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (655)     (R,S)-1-[2-[(4-Quinolinyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (656)     (R,S)-1-[2-[(4-Quinolinyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (657)     1-[2-[(1,2,3,4-Tetrahydro-1-naphthyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine     (mixture of diastereomers) -   (658)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dibromophenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (659)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dibromophenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (660)     (R,S)-1-[2-[(4-Quinolinyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (661)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (662)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (663)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (664)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-methoxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine -   (665)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-methoxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (666)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-methoxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (667)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(1-naphthyl)methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine -   (668)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(1-naphthyl)methyl]-1,4-dioxobutyl]-4-(1-methylsulphonyl-4-piperidinyl)-piperidine -   (669)     (R,S)-1-[2-[3,5-Dibromo-4-methylphenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-[4-[4-(dimethylamino)butyl]phenyl]-piperazine -   (670)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (671)     (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine -   (672)     (R,S)-1-[2-[(3,4-Dichlorophenyl)methyl]-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-[4-(dimethylaminomethyl)phenyl]-piperidine     and the salts thereof.

The compounds of general formula I are prepared by methods which are known in principle, particularly using processes derived from peptide chemistry (cf. for example Houben-Weyl, Methoden der Organischen Chemie, Vol. 15/2). The amino protecting groups used may be those described in Houben-Weyl, Methoden der Organischen Chemie, Vol. 15/1, of which urethane protecting groups such as the fluorenylmethoxycarbonyl, phenylmethoxycarbonyl or tert.-butyloxycarbonyl group are preferred. Any functional groups present in the groups R² and/or A of the compounds of general formula I or in the precursors thereof are additionally protected by suitable protecting groups in order to prevent side reactions (cf. for example: G. B. Fields et al., Int. J. Peptide Protein Res. 35, 161 (1990); T. W. Greene, Protective Groups in Organic Synthesis). Examples of side-chain-protected amino acids of this kind include, in particular, Arg(NO₂), Arg(Mtr), Arg(di-Z), Arg(Pmc), Lys(Boc), Lys(Z), Orn(Boc), Orn(Z), Lys(Cl-Z) which are commercially obtainable, possibly in the form of derivatives. Particular care should be taken to ensure that so-called orthogonal combinations of protecting groups are used to protect the α-amino and the side chain amino group, e.g.:

Protection of the N (side chain) N^(α)-protection p-Toluenesulphonyl Phenylmethoxycarbonyl tert.Butyloxycarbonyl Phenylmethoxycarbonyl (4-Methoxyphenyl)methoxycarbonyl tert.Butoxycarbonyl Adamantyloxycarbonyl Biphenylylisopropyloxycarbonyl Isonicotinoyloxycarbonyl o-Nitrophenylsulphenyl Formyl tert.Butoxycarbonyl Phenylmethoxycarbonyl p-Toluenesulphonyl o-Nitrophenylsulphenyl Biphenylylisopropyloxycarbonyl 9-Fluorenylmethoxycarbonyl Acetyl, Trifluoroacetyl, tert.Butyloxycarbonyl Formyl, (2-Chlorophenyl)- methoxycarbonyl, (4-Chloro- phenyl)methoxycarbonyl, 4-(Nitrophenyl)methoxycar- bonyl, Phthaloyl Instead of protecting amino groups in the side chain, amino acids or derivatives thereof which carry precursor functions and in particular are substituted by nitro or cyano in the side chain, such as 5-o-cyanonorvalin may also be used.

The basic functions in the side chains of α-amino acids which are not commercially obtainable and which are characterised, for example, by (aminoiminomethyl) groups, may be protected in the same way as is used for protecting the side chains of arginine and its derivatives (cf. also M. Bodanszky, “Peptide Chemistry”, Springer-Verlag, 1988, p. 94-97); protecting groups which are particularly suitable for the (aminoiminomethyl)- group are the p-toluenesulphonyl, mesitylene sulphonyl- (Mts), methoxytrimethylphenylsulphonyl- (Mtr), 2,2,5,7,8-pentamethyl-chroman-6-sulphonyl- (Pmc), pentachlorophenoxycarbonyl- and nitro-protecting groups.

For the actual coupling, the methods known from peptide chemistry are used (see Houben-Weyl, for example, Methoden der Organischen Chemie, Vol. 15/2). It is preferable to use carbodiimides such as dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC) or ethyl-(3-dimethylaminopropyl)-carbodiimide, O-(1H-benzotriazol-1-yl)N,N-N′,N′-tetramethyluronium-hexafluorophosphate (HBTU) or tetrafluoroborate (TBTU) or 1H-benzotriazol-1-yloxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP). By the addition of 1-hydroxybenzotriazole (HOBt) or 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (HOObt) racemisation may additionally be suppressed, if desired, or the reaction rate may be increased. The couplings are normally carried out with equimolar amounts of the coupling components and the coupling reagent in solvents such as dichloromethane, tetrahydrofuran, acetonitrile, dimethylformamide (DMF), dimethylacetamide (DMA), N-methylpyrrolidone (NMP) or mixtures thereof and at temperatures between −30 and +30° C., preferably between −20 and +20° C. If necessary, N-ethyl-diisopropylamine (DIEA) is preferred as an additional auxiliary base (Hünig base).

The so-called “anhydride method” (cf. also M. Bodanszky, “Peptide Chemistry”, Springer-Verlag 1988, p. 58-59; M. Bodanszky, “Principles of Peptide Synthesis”, Springer-Verlag 1984, p. 21-27) was used as another coupling method for the synthesis of compounds of general formula I. The “mixed anhydride method” is preferred, in the variant according to Vaughan (J. R. Vaughan Jr., J. Amer. Chem. Soc. 73, 3547 (1951)), in which the mixed anhydride is obtained from the optionally N²-protected α-amino acid which is to be coupled, and the mono-isobutylcarbonate, using isobutylchlorocarbonate in the presence of base such as 4-methylmorpholine or 4-ethylmorpholine. The preparation of this mixed anhydride and the coupling with amines are carried out in a one-pot process using the above-mentioned solvents at temperatures between −20 and +20° C., preferably between 0 and +20° C.

Any protecting groups present in the side chains of α-amino acid partial structures are finally cleaved, after the formation of the N— and C-terminally substituted amino acid derivative, with suitable reagents which are also known from the literature in principle, specifically arylsulphonyl and hetarylsulphonyl protecting groups, preferably by acidolysis, i.e. by the action of strong acids, preferably trifluoroacetic acid, nitro- and arylmethoxycarbonyl protecting groups are preferably cleaved by hydrogenolysis, e.g. using hydrogen in the presence of palladium black and with glacial acetic acid as solvent. If the substrate contains functions which are sensitive to hydrogenolysis, e.g. halogen atoms such as chlorine, bromine or iodine, a phenylmethanol or hetarylmethanol function or some other benzyl heteroatom bond, particularly a benzyl-oxygen bond, the nitro group may also be cleaved non-hydrogenolytically, e.g. with zinc/2N trifluoroacetic acid (cf. also A. Turan, A. Patthy and S. Bajusz, Acta Chim. Acad. Sci. Hung, Tom. 85 (3), 327-332 [1975]; C.A. 83, 206526y [1975]), with tin(II)-chloride in 60% aqueous formic acid (see also: SUNSTAR KK, JA-A-3271-299), with zinc in the presence of acetic acid (cf. also: A. Malabarba, P. Ferrari, G. Cietto, R. Pallanza and M. Berti, J. Antibiot. 42 (12), 1800-1816 (1989)) or excess aqueous 20% titanium(III)-chloride in aqueous methanol and in the presence of aqueous ammonium acetate buffer at 24° C. (see also: R. M. Freidinger, R. Hirschmann and D. F. Veber, J. Org. Chem. 43 (25), 4800-4803 [1978]).

Any precursor functions which may be present in the side chain of the α-amino acid may also subsequently be converted by hydrogenolysis into the desired amino functions; nitroalkyl groups yield aminoalkyl groups under conditions which will be familiar to the chemist, whilst the cyano group is converted into the aminomethyl group.

Alternatively, nitrile functions may also be reduced with complex hydrides which are selective in relation to other critical functions contained in the molecule, particularly amide groups (cf. also: J. Seyden-Penne, “Reductions by the Alumino- and Borohydrides in Organic Synthesis”, VCH Publishers Inc., 1991, p. 132ff.), e.g. with sodium borohydride in methanol and in the presence of cobalt(II)-chloride, with sodium borohydride in tetrahydrofuran in the presence of trifluoroacetic acid or with tetrakis-(n-butyl)-ammonium borohydride in dichloromethane; the reduction of aliphatic nitro function to the primary amino-function is also possible with sodium borohydride in the presence of tin(II)-chloride or copper(II)-acetylacetonate, without affecting the carboxamide groups present in type I compounds (see also: J. Seyden-Penne, ibid. p. 137ff.).

The following methods are particularly suitable for preparing the compounds of general Formula I according to the invention:

-   a) In order to prepare compounds of general formula I, wherein -   R denotes an unbranched C₁₋₇-alkyl group which may be substituted in     the ω-position     -   by a C₄₋₁₀-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         biphenylyl group,     -   by a 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-2H-2-oxoimidazopyridinyl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         1,3-dihydro-2H-2-oxoimidazol-1-yl or         3,4-dihydro-2(1H)-oxopyrimidin-3-yl group, wherein the latter         two groups may each be mono- or disubstituted in the 4- and/or         5-position or in the 5- and/or 6-position by lower straight         chained or branched alkyl groups, by phenyl, biphenylyl,         pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl,         1,3-thiazolyl, isoxazolyl, pyrazolyl-1-methylpyrazolyl,         imidazolyl- or 1-methylimidazolyl-groups and the substituents         may be identical or different,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         which contains a nitrogen, oxygen or sulphur atom or, in         addition to a nitrogen atom, contains an oxygen, sulphur or         additional nitrogen atom, whilst a nitrogen atom of an imino         group may be substituted by an alkyl group,     -   or by a 6-membered heteroaromatic ring linked via a carbon atom,         which contains one, two or three nitrogen atoms,     -   whilst a 1,4-butadienylene group may be attached both to the         above-mentioned 5-membered heteroaromatic monocyclic rings and         to the 6-membered heteroaromatic monocyclic rings, in each case         via two adjacent carbon atoms, and the bicyclic heteroaromatic         rings thus formed may also be bound via a carbon atom of the         1,4-butadienylene group, and         whilst the phenyl, naphthyl and biphenylyl groups mentioned         above for the substitution of the alkyl groups in the         (ω-position and optionally also partially hydrogenated mono- and         bicyclic heteroaromatic rings in the carbon skeleton may         additionally be mono-, di- or trisubstituted by fluorine,         chlorine or bromine atoms or by alkyl groups, C₃₋₈-cycloalkyl         groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl,         alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl,         dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino,         benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1H-azepin-1-yl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,         alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups,         wherein the substituents may be identical or different and the         above-mentioned benzoyl, benzoylamino and benzoylmethylamino         groups may in turn additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom or by an alkyl,         trifluoromethyl, amino or acetylamino group,         or the group of formula

wherein

-   R⁵, R⁶, R⁷, R^(N), Y¹, o and p are as hereinbefore defined, -   Y² denotes a CH— group and -   Z denotes an NR¹— group, wherein R¹ is as hereinbefore defined: -   coupling carboxylic acids of general formula VII,     RCO₂H   (VII)     wherein     R is as hereinbefore defined,     with compounds of general formula VIII,

wherein R², R³, R⁴, R¹¹, A, X, m and n are as hereinbefore defined, and Z denotes an NR¹— group, wherein R¹ is as hereinbefore defined, and, if necessary, subsequently cleaving any protecting groups or modifying precursor functions in accordance with the methods described hereinbefore.

The coupling is carried out using the methods known from peptide chemistry described above, particularly using DCC, DIC, HBTU, TBTU or BOP as reagents or using the mixed anhydride method.

-   b) In order to prepare compounds of general formula I wherein R is     defined as in a), Z denotes the NR¹— group and R¹, R², R³, R⁴, R¹¹,     A, X, m and n are as hereinbefore defined:     coupling compounds of general formula IX,     R—CO—Nu   (IX)     wherein     R is defined as in a) and     Nu denotes a leaving group, for example a halogen atom such as the     chlorine, bromine- or iodine atom, an alkylsulphonyloxy group having     1 to 10 carbon atoms in the alkyl moiety, a phenylsulphonyloxy or     naphthylsulphonyloxy group optionally mono-, di- or trisubstituted     by chlorine or bromine atoms or by methyl- or nitro groups, wherein     the substituents may be identical or different, a 1H-imidazol-1-yl,     a 1H-pyrazol-1-yl-optionally substituted by 1 or 2 methyl groups in     the carbon skeleton, a 1H-1,2,4-triazol-1-yl, 1H-1,2,3-triazol-1-yl,     1H-1,2,3,4-tetrazol-1-yl, a vinyl, propargyl, p-nitrophenyl,     2,4-dinitrophenyl, trichlorophenyl, pentachlorophenyl,     pentafluorophenyl, pyranyl or pyridinyl, a dimethylaminyloxy,     2(1H)-oxopyridin-1-yloxy, 2,5-dioxopyrrolidin-1-yloxy,     phthalimidyloxy, 1H-benzotriazol-1-yloxy or azide group,     with compounds of general formula VIII,

wherein R², R³, R⁴, R¹¹, A, X, m and n are as hereinbefore defined and Z denotes an NR¹— group, whilst R¹ is as hereinbefore defined, and, if necessary, subsequently cleaving protecting groups or modifying precursor functions using the methods described above.

The reaction is carried out under Schotten-Baumann- or Einhorn-conditions, i.e. the components are reacted in the presence of at least one equivalent of an auxiliary base at temperatures between −50° C. and +120° C., preferably between −10° C. and +30° C., optionally in the presence of solvents. Auxiliary bases which may be used are preferably alkali-metal and alkaline earth metal hydroxides, e.g. sodium hydroxide, potassium hydroxide or barium hydroxide, alkali metal carbonates, e.g. sodium carbonate, potassium carbonate or cesium carbonate, alkali metal acetate, e.g. sodium- or potassium acetate, as well as tertiary amines, e.g. pyridine, 2,4,6-trimethylpyridine, quinoline, triethylamine, N-ethyl-diisopropylamine, N-ethyl-dicyclohexylamine, 1,4-Diazabicyclo[2,2,2]octane or 1,8-diazabicyclo-[5,4,0]undec-7-ene, whilst the solvents which may be used include, for example, dichloromethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, dimethylformamide, dimethylacetamide, N-methyl-pyrrolidone or mixtures thereof; if alkali metal or alkaline earth metal hydroxides, alkali metal carbonates or -acetates are used as auxiliary bases, water may also be added to the reaction mixture as a cosolvent.

-   c) In order to prepare compounds of general formula I wherein -   R denotes an unbranched C₁₋₆-alkylamino group optionally substituted     at the nitrogen atom by a C₁₋₆-alkyl group or by a phenylmethyl     group, which may be substituted in the ω-position     -   by a C₄₋₁₀-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl- or         biphenylyl group,     -   by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl,         1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl,         3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or         1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl-group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         which contains a nitrogen, oxygen or sulphur atom or, in         addition to a nitrogen atom, contains an oxygen, sulphur or an         additional nitrogen atom, whilst a nitrogen atom of an imino         group may be substituted by an alkyl group, or     -   by a 6-membered heteroaromatic ring linked via a carbon atom and         containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene         group may be attached both to the 5-membered and to the         6-membered heteroaromatic monocyclic rings via two adjacent         carbon atoms in each case and the bicyclic heteroaromatic rings         thus formed may also be bound via a carbon atom of the         1,4-butadienylene group,         whilst the phenyl, naphthyl and biphenylyl groups mentioned         above for the substitution of the alkyl moiety of the alkylamino         groups in the ω-position and optionally partially hydrogenated         mono- and bicyclic heteroaromatic rings in the carbon skeleton         may additionally be mono-, di- or trisubstituted by fluorine,         chlorine or bromine atoms, by alkyl groups, C₃₋₈-cycloalkyl         groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl,         alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl,         dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino,         benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1H-azepin-1-yl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,         alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups,         whilst the substituents may be identical or different and the         above-mentioned benzoyl, benzoylamino- and benzoylmethylamino         groups in turn may additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom or by an alkyl,         trifluoromethyl, amino- or acetylamino group,         or the group of formula

wherein

-   R⁵, R⁶, R⁷, R^(N), Y¹, o and p are as hereinbefore defined, -   Y² denotes the N-atom and -   Z denotes the NR¹— group, wherein R¹ is as hereinbefore defined:     reacting amines of general formula X     R—H   (X)     wherein -   R is as hereinbefore defined, with carbonic acid derivatives of     general XI

wherein

-   X¹ is a nucleofugic group, preferably the 1H-imidazol-1-yl,     1H-1,2,4-triazol-1-yl, trichloromethoxy- or     2,5-dioxopyrrolidin-1-yloxy group,     and with compounds of general formula VIII,

wherein

-   R², R³, R⁴, R¹¹, A, X, m and n are as hereinbefore defined and -   Z denotes an NR¹— group, wherein R¹ is as hereinbefore defined, -   and, if necessary, subsequently cleaving any protecting groups or     modifying any precursor functions using the method described     hereinbefore.

The theoretically two-step reactions are generally carried out as one-pot processes, preferably by reacting one of the two components X or VIII with equimolar amounts of the carbonic acid derivative of general formula XI in a suitable solvent at fairly low temperature, in the first step, and then adding at least equimolar amounts of the other component VIII or X and finishing the reaction at elevated temperature. The reactions with bis-(trichloromethyl)-carbonate are preferably carried out in the presence of at least 2 equivalents (based on bis-(trichloromethyl)-carbonat) of a tertiary base, e.g. triethylamine, N-ethyl-diisopropylamine, pyridine, 1,5-diazabicyclo[4,3,0]non-5-ene, 1,4-diazabicyclo[2,2,2]octane or 1,8-diazabicyclo-[5,4,0]undec-7-ene. Examples of solvent, which should be anhydrous, include tetrahydrofuran, dioxane, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone or acetonitrile, if bis-(trichloromethyl)-carbonate is used as the carbonyl component, anhydrous chlorohydrocarbons such as dichloromethane, 1,2-dichloroethane or trichloroethylene are preferred. The reaction temperatures are between −30 and +25° C. for the first step of the reaction, preferably between −5 and +10° C., and between +15° C. and the boiling temperature of the solvent used, preferably between +20° C. and +70° C. for the second step of the reaction (cf. also: H. A. Staab and W. Rohr, “Synthesen mit heterocyclischen Amiden (Azoliden)”, Neuere Methoden der Praparativen Organischen Chemie, Band V, p. 53-93, Verlag Chemie, Weinheim/Bergstr., 1967; P. Majer and R. S. Randad, J. Org. Chem. 59, 1937-1938 (1994); K. Takeda, Y. Akagi, A. Saiki, T. Sukahara und H. Ogura, Tetrahedron Letters 24 (42), 4569 -4572 (1983)).

-   d) In order to prepare compounds of general formula I wherein the     carbonyl group linked to the groups R and Z denotes a urea carbonyl     group, in which the urea carbonyl is flanked by at least one NH—     group, and wherein -   R denotes an unbranched C₁₋₆-alkylamino group optionally     additionally substituted at the nitrogen atom by a C₁₋₆-alkyl group     or by a phenylmethyl group, which may be substituted in the     ω-position     -   by a C₄₋₁₀-cycloalkyl group,     -   by one or two phenyl groups, by a l-naphthyl, 2-naphthyl- or         biphenylyl group,     -   by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl,         1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl,         3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or         1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl-group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         which contains a nitrogen, oxygen or sulphur atom or, in         addition to a nitrogen atom, contains an oxygen, sulphur or an         additional nitrogen atom, whilst a nitrogen atom of an imino         group may be substituted by an alkyl group, or     -   by a 6-membered heteroaromatic ring linked via a carbon atom and         containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene         group may be attached both to the 5-membered and to the         6-membered heteroaromatic monocyclic rings via two adjacent         carbon atoms in each case and the bicyclic heteroaromatic rings         thus formed may also be bound via a carbon atom of the         1,4-butadienylene group,         whilst the phenyl, naphthyl and biphenylyl groups mentioned         above for the substitution of the alkyl moiety of the alkylamino         groups in the ω-position and optionally partially hydrogenated         mono- and bicyclic heteroaromatic rings in the carbon skeleton         may additionally be mono-, di- or trisubstituted by fluorine,         chlorine or bromine atoms, by alkyl groups, C₃₋₈-cycloalkyl         groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl,         alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl,         dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino,         benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1H-azepin-1-yl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,         alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups,         whilst the substituents may be identical or different and the         above-mentioned benzoyl, benzoylamino- and benzoylmethylamino         groups in turn may additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom or by an alkyl,         trifluoromethyl, amino or acetylamino group, -   or the group of formula

wherein

-   -   R⁵, R⁶, R⁷, R^(N), Y¹, o and p are as hereinbefore defined and     -   Y² denotes the N-atom,

-   Z denotes the group NR¹ and     -   R¹ denotes a hydrogen atom or, provided that, R denotes an         unbranched alkylamino group unsubstituted at the nitrogen atom         and optionally substituted in the ω-position, R¹ may also denote         an alkyl or phenylalkyl group:         Reacting amines of general formula X′,         R—H   (X′)         wherein R is as hereinbefore defined,         with carbonic acid derivatives of general formula XI′,

wherein

-   X² denotes a phenoxy group, if X³ is the (1H)-1,2,3,4-tetrazol-1-yl     group, the 4-nitrophenoxy group, if X³ is the 4-nitropheoxy group,     and the chlorine atom if X³ is the 2,4,5-trichlorophenoxy group, and     with compounds of general formula VIII′,

wherein

-   R², R³, R⁴, R¹¹, X, A, m and n are as hereinbefore defined and -   R¹ denotes a hydrogen atom or, provided that R is an unbranched     alkylamino group unsubstituted at the nitrogen and optionally     substituted in the ω-position, R¹ may also denote an alkyl or     phenylalkyl group, and     if necessary, subsequently cleaving protecting groups or modifying     precursor functions using the methods described hereinbefore.

The reactions are in two steps, in principle, with intermediate formation of urethanes, which can be isolated. However, the reactions may also be carried out as one-pot reactions. Preferably, in the first step, one of the two components X′ or VIII′ is reacted with equimolar amounts of the carbonic acid derivative of general formula XI′in a suitable solvent at low temperature, then at least equimolar amounts of the other component VIII′ or X′ are added and the reaction is completed at elevated temperature. The reactions are preferably carried out in anhydrous solvents, e.g. in tetrahydrofuran, dioxane, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone, acetonitrile or anhydrous chlorohydrocarbons e.g. dichloromethane, 1,2-dichloroethane or trichloroethylene. The reaction temperatures are between −15 and +40° C., preferably between −10 and +25° C. for the first step, between +20° C. and the boiling temperature of the solvent used, preferably between +20° C. and 100° C. for the second reaction step (cf. also: R. W. Adamiak and J. Stawinski, Tetrahedron Letters 1977, 22, 1935 -1936; A. W. Lipkowski, S. W. Tam and P. S. Portoghese, J. Med. Chem. 29, 1222 -1225 (1986); J. Izdebski and D. Pawlak, Synthesis 1989, 423 -425).

-   e) In order to prepare compounds of general formula I wherein Z     denotes the group NH and -   R denotes an unbranched C₁₋₆-alkylamino group optionally substituted     at the nitrogen atom by a Cl₁₆-alkyl group or by a phenylmethyl     group, which may be substituted in the ω-position     -   by a C₄₋₁₀-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         biphenylyl group,     -   by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl,         1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl,         3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl or         1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         which contains a nitrogen, oxygen or sulphur atom or, in         addition to a nitrogen atom, contains an oxygen, sulphur or an         additional nitrogen atom, whilst a nitrogen atom of an imino         group may be substituted by an alkyl group, or     -   by a 6-membered heteroaromatic ring linked via a carbon atom and         containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene         group may be attached both to the 5-membered and to the         6-membered heteroaromatic monocyclic rings via two adjacent         carbon atoms in each case and the bicyclic heteroaromatic rings         thus formed may also be bound via a carbon atom of the         1,4-butadienylene group,         whilst the phenyl, naphthyl and biphenylyl groups mentioned         above for the substitution of the alkyl groups in the ω-position         and optionally partially hydrogenated mono- and bicyclic         heteroaromatic rings in the carbon skeleton may additionally be         mono-, di- or trisubstituted by fluorine, chlorine or bromine         atoms, by alkyl groups, C₃₋₈-cycloalkyl groups, nitro, alkoxy,         phenyl, phenylalkoxy, trifluoromethyl, alkoxycarbonyl,         alkoxycarbonylalkyl, carboxy, carboxyalkyl, dialkylaminoalkyl,         hydroxy, amino, acetylamino, propionylamino, benzoyl,         benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1H-azepin-1-yl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,         alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl or trifluoromethylsulphonyl groups,         whilst the substituents may be identical or different and the         above-mentioned benzoyl, benzoylamino- and benzoylmethylamino         groups in turn may additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom or by an alkyl,         trifluoromethyl, amino or acetylamino group,         or the group of formula

wherein

-   R⁵, R⁶, R⁷, R^(N), Y¹, o and p are as hereinbefore defined and Y²     denotes an N-atom:     Reacting isocyanates of general formula XII,

wherein

-   R², R³, R⁴, R¹¹, A, X, m and n are as hereinbefore defined, with     amines of general formula X,     R—H   (X)     wherein -   R is as hereinbefore defined and, if necessary, subsequently     cleaving protecting groups or modifying precursor functions using     the processes described above.

The reaction is carried out at temperatures between 0° C. and 150° C., preferably between 20° C. and 100° C., optionally in the presence of anhydrous solvents, e.g. tetrahydrofuran, 1,4-dioxane, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone or 1,3-dimethyl-2-imidazolidinone or mixtures thereof.

-   f) In order to prepare compounds of general formula I wherein -   R denotes an unbranched C₁₋₆-alkylamino group unsubstituted at the     nitrogen atom, which may be substituted in the ω-position     -   by a C₄₋₁₀-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl- or         biphenylyl group,     -   by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl,         1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl,         3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or         1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl-group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         which contains a nitrogen, oxygen or sulphur atom or, in         addition to a nitrogen atom, contains an oxygen, sulphur or an         additional nitrogen atom, whilst a nitrogen atom of an imino         group may be substituted by an alkyl group, or     -   by a 6-membered heteroaromatic ring linked via a carbon atom and         containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene         group may be attached both to the 5-membered and to the         6-membered heteroaromatic monocyclic rings via two adjacent         carbon atoms in each case and the bicyclic heteroaromatic rings         thus formed may also be bound via a carbon atom of the         1,4-butadienylene group,         whilst the phenyl, naphthyl and biphenylyl groups mentioned         above for the substitution of the alkylamino groups in the         ω-position and optionally partially hydrogenated mono- and         bicyclic heteroaromatic rings in the carbon skeleton may         additionally be mono-, di- or trisubstituted by fluorine,         chlorine or bromine atoms, by alkyl groups, C₃₋₈-cycloalkyl         groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl,         alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl,         dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino,         benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1H-azepin-1-yl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,         alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl- or trifluoromethylsulphonyl groups,         whilst the substituents may be identical or different and the         above-mentioned benzoyl, benzoylamino- and benzoylmethylamino         groups in turn may additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom or by an alkyl,         trifluoromethyl, amino- or acetylamino group, and -   Z denotes the NR¹— group wherein R¹ is as hereinbefore defined:     Reacting isocyanates of general formula XIII,     R═C═O   (XIII)     wherein R is as hereinbefore defined, with compounds of general     formula VIII,

wherein R², R³, R⁴, R¹¹, A, X, m and n are as hereinbefore defined and

-   Z denotes an NR¹— group, wherein R¹ is as hereinbefore defined,     and, if necessary, subsequently cleaving any protecting groups or     modifying the precursor functions using the methods described     hereinbefore.

The reaction is carried out at temperatures between 0 and 150° C., preferably at temperatures between 20 and 100° C., and optionally in the presence of anhydrous solvents, e.g. tetrahydrofuran, 1,4-dioxane, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone or 1,3-dimethyl-2-imidazolidinone.

-   g) In order to prepare compounds of general formula I wherein R, Z,     R², R³, R⁴, R¹¹, A, m and n have the meanings given hereinbefore and     X is as hereinbefore defined, provided that A does not denote a bond     or X denotes an oxygen atom, if A denotes a single bond:     Coupling carboxylic acids of general formula XIV,

wherein

-   R, Z, R¹¹, m and n are as hereinbefore defined, -   R²′ has the meanings given for R² hereinbefore or denotes a group R²     substituted by the above-mentioned protecting groups, A′ has the     meanings given for A hereinbefore or, if A denotes the divalent     group of an amino acid, it optionally bears in the side chain a     precursor group for the group R⁹, e.g. a cyanopropyl group,     to compounds of general formula XV,     H—NR³R⁴   (XV)     wherein -   R³ and R⁴ are as hereinbefore defined,     and if necessary subsequent cleaving of protective groups or     modification of precursor functions using the methods described     above.

The coupling is carried out using the methods known from peptide chemistry and described hereinbefore, particularly using DCC, DIC, HBTU, TBTU or BOP as reagents or using the mixed anhydride method.

If the starting compound XIV used is enantiomerically pure, partial racemisation of the C-terminal amino acid must be expected during the coupling step and possibly quantitative racemisation must be expected if triethylamine is used as the auxiliary base and dimethylformamide, dimethylacetamide or N-methyl-pyrrolidone is used as solvent.

-   h) In order to prepare compounds of general formula I wherein X     denotes the oxygen atom:     Coupling carboxylic acids of general formula XVI,

wherein

-   R, Z, R¹¹, m and n are as hereinbefore defined and -   R²′ has the meanings given for R² hereinbefore or denotes a group R²     substituted by the above-mentioned protecting groups,     to compounds of general formula XVII,

wherein

-   A′ has the meanings given for A hereinbefore or, if A denotes the     divalent group of an amino acid, A′ optionally bears in the side     chain a precursor group for the group R⁹, e.g. a cyanopropyl group,     and -   R³ and R⁴ are as hereinbefore defined, -   and if necessary subsequently cleaving protecting groups or     modifying precursor functions using the methods described above.

The coupling is carried out using the methods known from peptide chemistry and described above, particularly using DCC, DIC, HBTU, TBTU or BOP as reagents or using the mixed anhydride method.

If the starting compound XVI used is enantiomerically pure, during the coupling step partial racemisation must be expected or, if triethylamine is used as the auxiliary base and dimethylformamide, dimethylacetamide or N-methyl-pyrrolidone is used as solvent, quantitative racemisation must be expected based on the chiral centre of XVI.

-   i) In order to prepare compounds of general formula I wherein -   R denotes an unbranched C₁₋₆-alkylamino group optionally substituted     at the nitrogen atom by a C₁₋₆-alkyl group or by a phenylmethyl     group, which may be substituted in the ω-position     -   by a C₄₋₁₀-cycloalkyl group,     -   by one or two phenyl groups, by a 1-naphthyl, 2-naphthyl or         biphenylyl group,     -   by a 1H-indol-3-yl, 1,3-dihydro-2H-2-oxobenzimidazol-1-yl,         2,4(1H,3H)-dioxoquinazolin-1-yl,         2,4(1H,3H)-dioxoquinazolin-3-yl,         2,4(1H,3H)-dioxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,4-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-3-yl,         3,4-dihydro-2(1H)-oxothieno[3,2-d]pyrimidin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-1-yl,         3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 2(1H)-oxoquinolin-3-yl,         2(1H)-oxoquinoxalin-3-yl,         1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl,         1,3-dihydro-4-(3-thienyl)-2H-2-oxoimidazol-1-yl,         1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl,         1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl,         3,4-dihydro-5-phenyl-2(1H)-oxopyrimidin-3-yl,         3,4-dihydro-6-phenyl-2(1H)-oxopyrimidin-3-yl- or         1,3-dihydro-2H-2-oxoimidazo[4,5-b]pyridin-3-yl-group,     -   by a 5-membered heteroaromatic ring linked via a carbon atom,         which contains a nitrogen, oxygen or sulphur atom or, in         addition to a nitrogen atom, contains an oxygen, sulphur or an         additional nitrogen atom, whilst a nitrogen atom of an imino         group may be substituted by an alkyl group, or     -   by a 6-membered heteroaromatic ring linked via a carbon atom and         containing 1, 2 or 3 nitrogen atoms, whilst a 1,4-butadienylene         group may be attached both to the 5-membered and to the         6-membered heteroaromatic monocyclic rings via two adjacent         carbon atoms in each case and the bicyclic heteroaromatic rings         thus formed may also be bound via a carbon atom of the         1,4-butadienylene group,         whilst the phenyl, naphthyl and biphenylyl groups mentioned         above for the substitution of the alkyl moiety of the alkylamino         groups in the ω-position and optionally partially hydrogenated         mono- and bicyclic heteroaromatic rings in the carbon skeleton         may additionally be mono-, di- or trisubstituted by fluorine,         chlorine or bromine atoms, by alkyl groups, C₃₋₈-cycloalkyl         groups, nitro, alkoxy, phenyl, phenylalkoxy, trifluoromethyl,         alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl,         dialkylaminoalkyl, hydroxy, amino, acetylamino, propionylamino,         benzoyl, benzoylamino, benzoylmethylamino, aminocarbonyl,         alkylaminocarbonyl, dialkylaminocarbonyl,         (1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl,         (hexahydro-1H-azepin-1-yl)carbonyl,         (4-methyl-1-piperazinyl)carbonyl, (4-morpholinyl)carbonyl,         alkanoyl, cyano, trifluoromethoxy, trifluoromethylthio,         trifluoromethylsulphinyl or trifluoromethylsulphonyl groups,         whilst the substituents may be identical or different and the         above-mentioned benzoyl, benzoylamino and benzoylmethylamino         groups in turn may additionally be substituted in the phenyl         moiety by a fluorine, chlorine or bromine atom or by an alkyl,         trifluoromethyl, amino or acetylamino group,         or the group of formula

wherein

-   -   R⁵, R⁶, R⁷, R^(N), Y¹, o and p are as hereinbefore defined and         Y² denotes an N-atom,

-   Z represents the methylene group,

-   X denotes two hydrogen atoms,

-   A denotes a single bond,

-   m denotes the value 1 and

-   n denotes the value 0:     Coupling carboxylic acids of general formula XVIII,

wherein

-   R², R³ and R⁴ are as hereinbefore defined,     with amines of general formula X,     R—H   (X) -   wherein R is as hereinbefore defined.

The coupling is carried out using the methods known from peptide chemistry and described above, particularly using DCC, DIC, HBTU, TBTU or BOP as reagents or using the mixed anhydride method.

-   j) In order to prepare compounds of general formula I wherein R³ and     R⁴ have the meanings given hereinbefore with the exception of the     hydrogen atoms, Z denotes a methylene group, X denotes two hydrogen     atoms, A denotes a single bond, m is the number 1 and n is the     number 0:     Reacting secondary amines of general formula XVa,     H—NR³′R⁴′  (XVa)     wherein     R³′ and R⁴′ have the meanings given for R³ and R⁴ hereinbefore with     the exception of hydrogen atoms,     with formaldehyde and CH-acid compounds of general formula XIX,

wherein

-   R is as hereinbefore defined and -   R² is as hereinbefore defined, but with the proviso that any acid     functions present such as hydroxy groups are appropriately protected     by suitable protecting groups.

The reaction is preferably carried out in a slightly acidic medium, using alcohols, e.g. methanol or ethanol, or lower aliphatic carboxylic acids, such as glacial acetic acid, as solvents and at temperatures between room temperature and the boiling point of the solvent in question. In a preferred variant, an inorganic acid salt such as the hydrochloride of a secondary amine of general formula XVa is heated with paraformaldehyde and a ketone of general formula XIX in glacial acetic acid to temperatures between 50° C. and 80° C.

-   k) In order to prepare compounds of general formula I wherein -   R, R², R³, R⁴, R¹¹, X, Z, m and n are as hereinbefore defined and A     denotes the divalent group of formula III

(linked to the NR³R⁴-group via the —CX— group) wherein

-   -   R⁸ denotes the hydrogen atom or an alkyl or phenylalkyl group         and     -   R⁹ denotes an unbranched C₁₋₅-alkyl group substituted in the         ω-position by an aminoiminomethylamino group:         Reacting compounds of general formula XX,

wherein

-   -   R, R², R³, R⁴, R¹¹, X, Z, m and n are as hereinbefore defined,     -   R⁸ denotes a hydrogen atom or an alkyl or phenylalkyl group and     -   R⁹ denotes an unbranched C₁₋₅-alkyl group substituted in the         ω-position by a primary amino group,         with carbonic acid derivatives of general formula XXI,

wherein

-   Nu² is a leaving group, e.g. an alkoxy, alkylthio, alkylsulphinyl or     alkylsulphonyl group each having 1 to 10 carbon atoms in alkyl     moiety, e.g. a methoxy, ethoxy, methylthio, ethylthio,     methylsulphinyl, ethylsulphinyl, propylsulphinyl,     isopropylsulphinyl, methylsulphonyl or ethylsulphonyl group, the     chlorine atom, the SO₂H, SO₃H— or OPOCl₂— group, or the group of     general formula XXII,

wherein

-   R¹⁵ and R¹⁶, which may be identical or different, denote hydrogen     atoms or C₁₋₃-alkyl groups.

Occasionally, for example when Nu² is an alkoxy group, instead of using the compounds of general formula XXI it is advantageous to use the inorganic acid salts thereof, e.g. the neutral sulphates or hydrochlorides thereof.

The reactions are carried out analogously to methods known from the literature (see G. B. L. Smith, J. Amer. Chem. Soc. 51, 476 [1929]; B. Rathke, Chem. Ber. 17, 297 [1884]; R. Phillips and H. T. Clarke, J. Amer. Chem. Soc. 45, 1755 [1923]; S. J. Angyal and W. K. Warburton, J. Amer. Chem. Soc. 73, 2492 [1951]; H. Lecher and F. Graf, Chem. Ber. 56, 1326 [1923]; J. Wityak, S. J. Gould, S. J. Hein and D. A. Keszler, J. Org. Chem. 52, 2179 [1987]; T. Teraji, Y. Nakai, G. J. Durant, WO-A-81/00109, Chem. Abstr. 94, 192336z [1981]; C. A. Maryanoff, R. C. Stanzione, J. N. Plampin and J. E. Mills, J. Org. Chem. 51, 1882-1884 [1986]; A.E. Miller and J.J. Bischoff, Synthesis 1986, 777; R. A. B. Bannard, A. A. Casselman, W. F. Cockburn and G. M. Brown, Can. J. Chem. 36, 1541 [1958]; Aktieselskabet Grea, Kopenhagen, DE 28 26 452-C2; K. Kim. Y-T. Lin and H. S. Mosher, Tetrah. Letters, 29, 3183-3186 [1988]; H. B. Arzeno et al., Synth. Commun. 20, 3433-3437 [1990]; H. Bredereck and K. Bredereck, Chem. Ber. 94, 2278 [1961]; H. Eilingsfeld, G. Neubauer, M. Seefelder and H. Weidinger, Chem. Ber. 97, 1232 [1964]; P. Pruszynski, Can. J. Chem. 65, 626 [1987]; D. F. Gavin, W. J. Schnabel, E. Kober and M. A. Robinson, J. Org. Chem. 32, 2511 [1967]; N. K. Hart, S. R. Johns, J. A. Lamberton and R. I. Willing, Aust. J. Chem. 23, 1679 [1970]; CIBA Ltd., Belgisches Patent 655 403; Chem. Abstr. 64, 17481 [1966]; R. A. B. Bannard, A. A. Casselman, W. F. Cockburn and G. M. Brown, Can. J. Chem. 36, 1541 [1958]; J. P. Greenstein, J. Org. Chem. 2, 480 [1937]; F. L. Scott and J. Reilly, J. Amer. Chem. Soc. 74, 4562 [1952]; W. R. Roush and A. E. Walts, J. Amer. Chem. Soc. 106, 721 [1984], M. S. Bernatowicz, Y. Wu and G. R. Matsueda, J. Org. Chem. 57, 2497-2502 [1992]; H. Tsunematsu, T. Imamura and S. Makisumi, J. Biochem. 94, 123-128 [1983]) at temperatures between 0° C. and +100° C., preferably between +40° C. and +80° C., using inert solvents, e.g. dichloromethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, dimethylformamide, dimethylacetamide, N-methyl-pyrrolidone or mixtures thereof and, depending on the nature of the Nu²-group, frequently in the presence of auxiliary bases, especially alkali metal carbonates such as sodium- or potassium carbonate, or tertiary amines, preferably N-ethyl-diisopropylamine or triethylamine.

The amino acids of general formula I modified according to the invention contain at least one chiral centre. If the group A is also chiral, the compounds may occur in the form of two diastereomeric pairs of antipodes. The invention includes the individual isomers as well as the mixtures thereof.

The diastereomers are separated on the basis of their different physicochemical properties, e.g. by fractional crystallisation from suitable solvents, by high pressure liquid or column chromatography using chiral or preferably achiral stationary phases.

Racemates covered by general formula I may be separated, for example, by HPLC on suitable chiral stationary phases (e.g. Chiral AGP, Chiralpak AD). Racemates which contain a basic or acidic function can also be separated by means of the diastereomeric optically active salts which are formed on reacting with an optically active acid, e.g. (+)- or (−)-tartaric acid, (+)- or (−)-diacetyl tartaric acid, (+)- or (−)-monomethyltartrate or (+)-camphor sulphonic acid or an optically active base such as (R)-(+)-1-phenylethylamine, (S)-(−)-1-phenylethylamine or (S)-brucine.

According to a conventional process for separating isomers, the racemate of a compound of general formula I is reacted with one of the above-mentioned optically active acids or bases in equimolar amounts in a solvent and the crystalline, diastereomeric, optically active salts obtained are separated on the basis of their different solubilities. This reaction may be carried out in solvents of any kind provided that they are sufficiently different in terms of the solubility of the salts. Preferably, methanol, ethanol or mixtures thereof are used, e.g. in a ratio by volume of 50:50. Then each of the optically active salts is dissolved in water, neutralised with a base such as sodium carbonate or potassium carbonate, sodium hydroxide solution or potassium hydroxide solution, and in this way the corresponding free compound is obtained in the (+)- or (−)-form.

The (R)-enantiomer alone or a mixture of two optically active diastereomeric compounds coming within the scope of general formula I may also be obtained by carrying out the syntheses described above with a suitable reaction component in the (R)-configuration.

The starting materials of general formulae VII, IX, X, X′, XI, XI′, XIII, XV, XVa, XVII, XXI, XXII required to synthesis the compounds of general formula I as well as the amino acids used are commercially available or may be prepared by methods known from the literature.

Compounds of general formula VIII wherein Z denotes the group NR¹ and those of general formula VIII′ wherein X denotes the oxygen atom may be obtained from commonly available starting materials using methods familiar to peptide chemists.

Isocyanates of general formula XII can easily be obtained from α-amino acid derivatives of general formula VIII′ wherein R¹ denotes a hydrogen atom and the other groups are as hereinbefore defined, or from the hydrochlorides thereof by reacting with phosgene, diphosgene or triphosgene in the presence of pyridine (see also: J. S. Nowick, N. A. Powell, T. M. Nguyen and G. Noronha, J. Org. Chem. 57, 7364-7366 [1992]).

Carboxylic acids of general formulae XIV and XVI may be obtained from the corresponding carboxylic acid esters by saponification, preferably in the presence of lithium hydroxide.

The carboxylic acids of general formula XVIII are obtained by saponifying corresponding carboxylic acid esters which are in turn prepared from suitable secondary amines, 4-aryl-4-oxobutanoic acid esters and formaldehyde by Mannich reaction.

Compounds of general formula XIX may be obtained from suitable 4-oxobutanoic acids and amines of general formula X using conventional methods.

The intermediate compounds of general formula XX come under general formula I and are thus within the scope of the present application. These compounds may be obtained, for example, using processes a) to h) described herein.

The compounds of general formula I may be converted into their physiologically acceptable salts with inorganic or organic acids, particularly for pharmaceutical applications. Examples of suitable acids for this purpose include hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulphuric acid, methanesulphonic acid, p-toluenesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, mandelic acid, malic acid, citric acid, tartaric acid or maleic acid.

Moreover, if the new compounds of formula I thus obtained contain an acid function, for example a carboxy group, they may if desired be converted into the addition salts thereof with inorganic or organic bases, more particularly for pharmaceutical use, into the physiologically acceptable addition salts thereof. Bases which may be considered include, for example, sodium hydroxide, potassium hydroxide, ammonia, cyclohexylamine, dicyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

The new compounds of general formula I and the physiologically acceptable salts thereof have CGRP-antagonistic properties and exhibit good affinities in CGRP-receptor binding studies. The compounds exhibit CGRP-antagonistic properties in the pharmacological test systems described hereinafter.

The following experiments were carried out to demonstrate the affinity of compounds of general formula I for human CGRP-receptors and their antagonistic properties:

A. Binding Studies with SK-N-MC-Cells Expressing Human CGRP-Receptor

SK-N-MC-cells are cultivated in Dulbecco's modified Eagle Medium. The medium of confluent cultures is removed. The cells are washed twice with PBS-buffer (Gibco 041-04190 M), detached by the addition of PBS-buffer mixed with 0.02% EDTA and isolated by centrifuging. After resuspension in 20 ml of Balanced Salts Solution [BSS (in mM): NaCl 120, KC1 5.4, NaHCO₃ 16.2, MgSO₄ 0.8, NaHPO₄ 1.0, CaCl₂ 1.8, D-Glucose 5.5, HEPES 30, pH7.40] the cells are centrifuged twice at 100×g and resuspended in BSS. After the cell number has been determined the cells are homogenised using an Ultra-Turrax and centrifuged for 10 minutes at 3000×g. The supernatent is discarded and the pellet is recentrifuged and resuspended (1 ml/1000000 cells) in Tris-buffer (10 mM Tris, 50 mM NaCl, 5 mM MgCl₂, 1 mM EDTA, pH 7.40), enriched with 1% bovine serum albumin and 0.1% bacitracin. The homogenate is frozen at −80° C. The membrane preparations are stable for more than 6 weeks under these conditions.

After thawing, the homogenate is diluted 1:10 with assay buffer (50 mM Tris, 150 mM NaCl, 5 mM MgCl₂, 1 mM EDTA, pH 7.40) and homogenised for 30 seconds with an Ultra-Turrax. 230 μl of the homogenate are incubated at ambient temperature for 180 minutes with 50 pM of ¹²⁵I-Iodotyrosyl-Calcitonin-Gene-Related Peptide (Amersham) and increasing concentrations of the test substances in a total volume of 250 μl. Incubation is ended by rapid filtration using GF/B-glass fibre filters treated with polyethyleneimine (0.1%) by means of a cell harvester. The protein-bound radioactivity is measured using a gammacounter. The non-specific binding is defined as the radioactivity bound after the presence of 1 μM of human CGRP-alpha during incubation.

The concentration binding curves are analysed using a computer-aided non-linear curve adaptation.

The compounds of general formula I show IC₅₀ values≦10000 nM in the test described.

B. CGRP-Antagonism in SK-N-MC-cells

SK-N-MC-cells (1 million cells) are washed twice with 250 μl of incubation buffer (Hanks' HEPES, 1 mM 3-isobutyl-1-methylxanthine, 1% BSA, pH 7.4) and pre-incubated at 37° C. for 15 minutes. After the addition of CGRP (10 μl) as agonist in increasing concentrations (10⁻¹¹ to 10⁻⁶ M) or additionally of substance in 3 to 4 different concentrations, incubation is continued for a further 15 minutes.

Intracellular cAMP is then extracted by the addition of 20 μl of 1M HCl and centrifugation (2000×g, 4° C. for 15 minutes). The supernatants are frozen in liquid nitrogen and stored at −20° C.

The cAMP contents of the samples are determined by radioimmunoassay (Amersham) and the pA₂-values of antagonistically acting substances are determined graphically.

The compounds of general formula I display CGRP-antagonistic properties in a dosage range between 10⁻¹¹ and 10⁻⁵ M in the in vitro test model described.

In view of their pharmacological properties the compounds of general formula I and the salts thereof with physiologically acceptable acids or bases are thus suitable for acute and prophylactic treatment of headache, particularly migraine and cluster headaches. Moreover, the compounds of general formula I also have a beneficial effect on the following diseases: non-insulin-dependent diabetes mellitis (NIDDM), cardiovascular diseases, skin diseases, particularly thermal and radiation-induced skin damage including sunburn, inflammatory diseases, e.g. inflammatory joint diseases (arthritis), inflammatory lung diseases, allergic rhinitis, asthma, diseases which involve excessive vasodilation and resultant reductions in circulation, e.g. shock and sepsis, as well as morphine tolerance. In addition, the compounds of general formula I have the effect of alleviating pain in general.

The dosage needed to achieve such effects is appropriately 0.0001 to 3 mg/kg of body weight, preferably 0.01 to 1 mg/kg of body weight, by intravenous or subcutaneous route, and 0.01 to 10 mg/kg of body weight, preferably 0.1 to 10 mg/kg of body weight, when administered orally, nasally or by inhalation, in each case 1 to 3 times a day.

For this purpose, the compounds of general formula I prepared according to the invention may be formulated, optionally in combination with other active substances, such as antiemetics, prokinetics, neuroleptics, antidepressants, neurokinin-antagonists, anti-convulsants, histamine-H1-receptor antagonists, antimuscarinics, β-blockers, α-agonists and α-antagonists, ergot alkaloids, mild analgesics, non-steroidal antiphlogistics, corticosteroids, calcium-antagonists, 5-HT_(1D)-agonists or other antimigraine agents, together with one or more inert conventional carriers and/or diluents, e.g. corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetylstearylalcohol, carboxymethyl-cellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions, solutions, metering aerosol or suppositories.

Thus, additional active substances which may be considered for the above-mentioned combinations include, for example, meloxicam, ergotamine, dihydroergotamine, metoclopramide, domperidon, diphenhydramine, cyclizine, promethazine, chlorpromazine, dexamethasone, flunarizine, dextropropoxyphene, meperidine, propranolol, nadolol, atenolol, clonidine, indoramine, carbamazepine, phenytoin, valproate, amitryptilin, lidocaine, diltiazem or sumatriptan and other 5-HT_(1D)-agonists such as naratriptan, zolmitriptan, avitriptan, rizatriptan and eletriptan. The dosage for these active substances is appropriately 1/5 of the lowest dose normally recommended up to 1/1 of the normally recommended dosage, i.e. 20 to 100 mg of sumatriptan, for example.

The invention further relates to the use of the compounds of general formula I as valuable auxiliary agents for the production and purification (by affinity chromatography) of antibodies and, after suitable radiolabelling, e.g. by direct labelling with ¹²⁵I or ¹³¹I or by tritiation of suitable precursors for example by replacing halogen atoms with tritium, in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

The Examples which follow are intended to illustrate the invention:

Preliminary Remarks:

There are satisfactory elementary analyses, IR, UV, ¹H-NMR and generally mass spectra as well, for all the compounds. Unless otherwise specified, R_(f) values were determined using TLC ready-made plates of silica gel 60 F₂₅₄ (E. Merck, Darmstadt, Product No. 5729) without chamber saturation. If there are no details of configuration, it is undecided whether this is the pure enantiomer or whether partial or total racemisation has occurred. The following eluants or eluant mixtures were used for chromatography:

-   FM1=dichloromethane/cyclohexane/methanol/ammonia 7/1.5/1.5/0.2     (v/v/v/v) -   FM2=dichloromethane/methanol/ammonia 7.5/2.5/0.5 (v/v/v) -   FM3=dichloromethane/methanol 8/2 (v/v) -   FM4=dichloromethane/ethyl acetate/methanol/cyclohexane/conc. aqueous     ammonia=59/25/7,5/7,5/1 (v/v/v/v/v) -   FM5=ethyl acetate/dichloromethane=7/3 (v/v) -   FM6=ethyl acetate/petroleum ether=1/1 (v/v) -   FM7=dichloromethane/methanol/conc. aqueous ammonia=80/20/1 (v/v/v)

The following abbreviations were used in the descriptions of the experiments:

-   Mp.: melting point -   (D): (decomposition) -   DIEA: N,N-diisopropyl-ethylamine -   Boc: (1,1-dimethylethoxy)carbonyl -   TBTU:     2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate -   HOBt: 1-hydroxybenzotriazole-hydrate -   CDT: 1,1′-carbonyldi(1,2,4-triazole) -   THF: tetrahydrofuran -   DMF: dimethylformamide -   Fmoc: (9-fluorenylmethoxy)carbonyl -   EE: ethyl acetate -   PE: petroleum ether -   LM: solvent -   Lfd. No.: item number

The meanings of the symbols made up of letters and numbers used in the Examples are given in the following summary:

A. Preparation of Intermediate Compounds EXAMPLE A1

Preparation of compounds of the general structure:

1,3-dihydro-4-(3-methoxyphenyl)-1-(4-piperidinyl)-2H-imidazol-2-one a) 4-[1,3-dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

To a mixture of 20.0 g (0.10 mol) of 4-amino-1-(1,1-dimethylethoxycarbonyl)piperidine, 8.2 g (0.1 mol) of anhydrous sodium acetate and 150 ml of dichloromethane was added dropwise, with stirring and whilst maintaining a reaction temperature of from 0° C. to +10° C., a solution of 25.0 g (0.109 mol) of 3-methoxyphenacylbromide in 50 ml of dichloromethane was added dropwise. The mixture was stirred for 5 hours at room temperature, then 19.5 g (0.296 mol) of sodium cyanate, 18 ml of glacial acetic acid and 10 ml of water were added and stirring was continued for 12 hours at room temperature. The mixture was stirred into 1 l of ice water, the dichloromethane phase was separated off, washed twice with 200 ml of water, 5% aqueous sodium hydrogen carbonate solution, 20% aqueous citric acid solution and once more with water, dried over magnesium sulphate and evaporated down in vacuo. The residue was taken up in methanol.

It was left to stand overnight, the precipitate which crystallised out was suction filtered, washed thoroughly with tert. butyl-methylether and after drying in vacuo 11.5 g (30.8% of theory) of colourless crystals were obtained.

MS: M⁺=373

The following were obtained accordingly:

-   (1)     4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

R_(f): 0.51 (FM4)

(2) 4-[1,3-dihydro-4-(4-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 23.8% of theory

-   (3)     4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

IR(KBr): 1685.7 cm⁻¹ (C═O)

-   (4)     4-[1,3-dihydro-5-methyl-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

R_(f): 0.23 (dichloromethane/methanol 9/1 v/v)

IR(KBr): 1687.6 cm⁻¹ (C═O)

MS: M⁺=357

-   (5)     4-[1,3-dihydro-4-(3-nitrophenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 29.1% of theory

MS: M⁺=388

-   (6)     4-[4-(3-bromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 13.1% of theory

IR(KBr): 1685 cm⁻¹ (C═O)

MS: M⁺=421/423 (Br)

-   (7)     4-[1,3-dihydro-4,5-diphenyl-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

IR(KBr): 1680, 1699 cm⁻¹ (C═O)

MS: M⁺=419

-   (8)     4-[1,3-dihydro-4-(4-fluorophenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

IR(KBr): 1682 cm⁻¹ (C═O)

MS: M⁺=388

-   (9)     4-[4-(4-biphenylyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 21.6% of theory, colourless crystals

R_(f): 0.6 (ethyl acetate)

IR(KBr): 1681.8 cm⁻¹ (C═O)

-   (10)     4-[1,3-dihydro-4-(2-naphthyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 30% of theory, crystals

IR(KBr): 1679.9 cm⁻¹ (C═O)

-   (11)     4-[1,3-dihydro-4-(2-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

R_(f): 0.86 (FM1)

-   (12)     4-[4-(3,4-dichlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 62% of theory, colourless crystals

R_(f): 0.34 (ethyl acetate)

IR(KBr): 1687 cm⁻¹ (C═O)

-   (13)     4-[4-(3-chlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

yield: 21% of theory

R_(f): 0.6 (ethyl acetate/methanol 9/1 v/v)

-   (14)     4-[1,3-dihydro-4-(3-hydroxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

Yield: 60% of theory

IR(KBr): 1682 cm⁻¹ (C═O)

MS: M⁺=359

-   (15)     4-[4-[3,5-bis-(trifluoromethyl)phenyl]-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

Yield: 3.2% of theory

IR(KBr): 1687.6 cm⁻¹ (C═O)

R_(f): 0.95 (dichloromethane/methanol 9/1 v/v)

-   (16)     4-[4-(4-amino-3,5-dibromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxycarbonyl)-piperidine

Yield: 4.6% of theory

IR(KBr): 1684 cm⁻¹ (C═O)

R_(f): 0.48 (FM4; Macherey-Nagel POLYGRAM® SIL G/TV₂₅₄ ready-made films for TLC)

b) 1,3-dihydro-4-(3-methoxyphenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

The solution of 11.5 g (0.0308 mol) of 4-[1,3-dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-1-yl]-1-(1,1-dimethylethoxy-carbonyl)-piperidine in 150 ml of dichloromethane was mixed with 15 ml of trifluoroacetic acid and then stirred overnight at room temperature. The reaction mixture was evaporated down in vacuo, the residue was taken up in 10 ml of water and made distinctly ammoniacal. The resulting precipitate was suction filtered, washed thoroughly with water and dried overnight at 50° C. in vacuo. 7.0 g (83.1% of theory) of colourless crystals were obtained, R_(f) value 0.2 (dichloromethane/methanol 9/1 v/v).

The following were obtained accordingly:

-   (1) 1,3-dihydro-4-phenyl-1-(4-piperidinyl)-2H-imidazol-2-one,

R_(f): 0.22 (FM1; Macherey-Nagel POLYGRAM® SIL G/UV₂₅₄ ready-made films for TLC)

IR(KBr): 1672 cm⁻¹ (C═O)

-   (2)     1,3-dihydro-4-(4-methoxyphenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

IR(KBr): 1670 cm⁻¹ (C═O)

MS: M⁺=273

-   (3)     1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-1-(4-piperidinyl)-2H-imidazol-2-one

IR(KBr): 1687.6 cm⁻¹ (C═O)

-   (4)     1,3-dihydro-5-methyl-4-phenyl-1-(4-piperidinyl)-2H-imidazol-2-one

yield: 76.2% of theory

IR (KBr): 1679.9 cm⁻¹ (C═O)

MS: M⁺=257

-   (5)     1,3-dihydro-4-(3-nitrophenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

yield: 94% of theory

IR(KBr): 1677.8 (C═O); 1137.8, 1197.6, 1349.9 (NO₂) cm⁻¹

-   (6)     4-(3-bromophenyl)-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

yield: quantitative

IR(KBr): 1676 cm⁻¹ (C═O)

-   (7) 1,3-dihydro-4,5-diphenyl-1-(4-piperidinyl)-2H-imidazol-2-one

IR(KBr): 1670 cm⁻¹ (C═O)

MS: M⁺=319

-   (8)     1,3-dihydro-4-(4-fluorophenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

yield: 30% of theory

R_(f): 0.2 (eluant: ethyl acetate/methanol/conc. ammonia 9/1/0.3 v/v/v)

IR(KBr): 1682 cm⁻¹ (C═O)

-   (9) 4-(4-biphenylyl)-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

yield: quantitative

IR(KBr) of the trifluoroacetate: 1679.9 cm⁻¹ (C═O)

-   (10) 1,3-dihydro-4-(2-naphthyl)-1-(4-piperidinyl)-2H-imidazol-2-one

yield: 28.2% of theory

R_(f): 0.03 (FM1)

IR(KBr) of the trifluoroacetate: 1678 cm⁻¹ (C═O)

-   (11) 7-(2-methoxyphenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

yield: 18.8% of theory

R_(f): 0.22 (FM1)

IR(KBr) of the trifluoroacetate: 1681.6 cm⁻¹ (C═O)

-   (12)     4-(3,4-dichlorophenyl)-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

yield: quantitative

IR(KBr) of the trifluoroacetate: 3197 (N—H); 1685 (C═O)cm⁻¹

-   (13)     4-(3-chlorophenyl)-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

Yield: 98% of theory

R_(f): 0.25 (eluant: ethyl ethanoate/methanol/conc. ammonia 9/1/0.3 v/v/v)

-   (14)     1,3-dihydro-4-(3-hydroxyphenyl)-1-(4-piperidinyl)-2H-imidazol-2-one

Yield: 90% of theory

R_(f): 0.075 (FM1)

IR(KBr): 1670 (C═O) cm⁻¹

MS: M⁺=259

-   (15)     4-[3,5-bis-(trifluoromethyl)phenyl]-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

Yield: 71% of theory

R_(f): 0.15 (FM1)

IR(KBr): 1701 (C═O) cm⁻¹

MS: M⁺=379

-   (16)     4-(4-amino-3,5-dibromophenyl)-1,3-dihydro-1-(4-piperidinyl)-2H-imidazol-2-one

Yield: 44% of theory

R_(f): 0.71 (FM1; Macherey-Nagel POLYGRAM® SIL G/UV₂₅₄ ready-made films for TLC)

IR(KBr): 1676 (C═O) cm⁻¹

EXAMPLE A2 2,4-dihydro-5-phenyl-2-(4-piperidinyl)-3H-1,2,4-triazol-3-one a) 1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinone-(1,1-dimethylethoxycarbonyl)hydrazone

A mixture of 16.0 g (0.05 mol) of 1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinone, 7.25 g (0.055 mol) of tert. butyl hydrazinoformate and 250 ml of ethanol was refluxed for 1 hour. The solvent was distilled off in vacuo, the oily residue remaining was triturated with diethylether. The crystalline precipitate thus formed was suction filtered and washed with a little diethylether. After the product had been dried in vacuo 21.7 g (99.7% of theory) of colourless crystals were obtained, m.p. 156-158° C. (decomposition).

b) N-(1,1-dimethylethoxycarbonyl)-N′-[1-(9H-fluoren-9-yl-methoxycarbonyl)-4-piperidinyl]-hydrazine

A solution of 21.7 g (0.05 mol) of 1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinone-(1,1-dimethylethoxycarbonyl)-hydrazone in 200 ml of glacial acetic acid was hydrogenated in the presence 2.0 g platinum (IV) oxide at room temperature and 3 bar of hydrogen pressure until the calculated volume of hydrogen had been taken up. The catalyst was filtered off, the filtrate was evaporated down in vacuo and the residue was dissolved in a little diethylether. The crystals precipitated after standing for 3 hours at room temperature were suction filtered, washed with a little diethylether and dried in vacuo at room temperature. 21.8 g (99.6% of theory) of colourless crystals of m.p. 135-137° C. and R_(f)=0.235 (eluant 3) were obtained.

ESI-MS: (M+H)⁺=438

c) [1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinyl]-hydrazine-hydrochloride

21.8 g (0.0498 mol) of N-(1,1-dimethylethoxycarbonyl)-N′-[1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinyl]-hydrazine were dissolved in 100 ml of trifluoroacetic acid and stirred for 1 hour at room temperature. The excess trifluoroacetic acid was removed in vacuo, the residue was dissolved in 50 ml of water and made alkaline with 10% aqueous sodium carbonate solution. The solution was extracted thoroughly with dichloromethane, the combined extracts were dried over magnesium sulphate and evaporated down in vacuo. The residue thus obtained was taken up in ethyl acetate and converted into the hydrochloride by the addition of ethereal hydrogen chloride solution. After recrystallisation from anhydrous ethanol 6.2 g (33.3% of theory) of colourless crystals of melting point 160-162° C. were obtained.

C₂₀H₂₃N₃O₂+HCl (373.88)

Calculated: C 64.25 H 6.47 N 11.24 Cl 9.48 Found: 64.14 6.46 10.99 9.46

d) 2,4-dihydro-5-phenyl-2-[1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinyl]-3H-1,2,4-triazol-3-one

The solutions of 5.56 g (0.0165 mol) of [1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinyl]-hydrazine in 60 ml of tetrahydrofuran and 3.7 g (0.0177 mol) of N-(ethoxycarbonyl)-benzothionamide in 30 ml of tetrahydrofuran were combined and refluxed for 1 hour, whereupon hydrogen sulphide was released. The solvent was distilled off in vacuo, the oily residue remaining was boiled with a little acetonitrile. The mixture was allowed to cool, then additionally cooled from outside with ice water and the resulting precipitate was suction filtered. 4.0 g (52% of theory) of colourless crystals were obtained, melting point 142° C. and R_(f)=0.38 (eluant 4).

IR (KBr): 1685.7 cm⁻¹ (C═O)

e) 2,4-dihydro-5-phenyl-2-(4-piperidinyl)-3H-1,2,4-triazol-3-one

A mixture of 9.0 g (0.0193 mol) of 2,4-dihydro-5-phenyl-2-[1-(9H-fluoren-9-ylmethoxycarbonyl)-4-piperidinyl]-3H-1,2,4-triazol-3-one, 50 ml of tetrahydrofuran and 70 ml of diethylamine was stirred at room temperature until the end of the reaction monitored by thin layer chromatography. The solvent was removed in vacuo, the residue remaining was mixed with 300 ml of water and subjected to ultrasound treatment for 30 minutes. The insoluble matter was separated off by suction filtering and the aqueous filtrate was evaporated down in vacuo. The residue thus obtained was boiled with a little methanol and after cooling it was suction filtered. After drying 0.58 g (12.3% of theory) of colourless crystals of melting point 294° C. (D) and R_(f)=0.1 (eluant 1) were obtained.

IR (KBr): 1681.8 cm⁻¹ (C═O)

EXAMPLE A3

Preparation of Compounds of General Structure:

3,4-dihydro-3-(4-piperidinyl)-2 (1H-pyrido[2,3-d]-pyrimidinone a) N-(2-Pyridinyl)-2,2-dimethylpropanamide

To a solution of 94.1 g (1.0 mol) of 2-aminopyridine and 173 ml (1.25 mol) of triethylamine in 400 ml of dichloromethane were added dropwise, whilst cooling with ice water, 132.5 g (1.099 mol) of pivaloyl chloride in 150 ml of dichloromethane. The. mixture was stirred for 2 hours at room temperature and filtered to remove the triethylamine hydrochloride formed. The filtrate was washed with water and twice with 5% aqueous sodium hydrogen carbonate solution, then dried over sodium sulphate. After working up in the usual way 157.5 g (88.4% of theory) of colourless crystals of melting point 74-76° C. were obtained.

The following was obtained in the same way:

N-(4-Pyridinyl)-2,2-dimethylpropanamide

Yield: 74% of theory

Mp. 137-140° C. (diisopropylether)

IR (KBr): 1687 cm⁻¹ (C═O)

b) N-(3-formyl-2-pyridinyl) -2,2-dimethylpropanamide

whilst maintaining a reaction temperature of −78° C., 781 ml (1.25 mol) of a 1.6-molar solution of n-butyllithium in n-hexane were added dropwise to a solution of 89.1 g (0.5 mol) of N-(2-pyridinyl)-2,2-dimethylpropanamide in 300 ml of anhydrous tetrahydrofuran. The mixture was allowed to heat slowly up to 0° C. and stirred for 3 hours at this temperature. Then the mixture was again cooled to −78° C. and whilst maintaining this temperature the solution of 109.6 g (1.5 mol) of dimethyformamide in 150 ml of anhydrous tetrahydrofuran was added dropwise thereto. The mixture was allowed to come up to 0° C. and then stirred into 1 l of ice water. It was initially acidified with 12% aqueous hydrochloric acid, then made alkaline by the addition of solid potassium carbonate and extracted thoroughly with diethylether. The combined ether extracts were dried over sodium sulphate and evaporated down. The crystalline residue, after recrystallisation from diisopropylether, had an m.p. of 83° C. Yield: 94.0 g (91.2% of theory).

The following were obtained in the same way:

-   (1) N-(4-formyl-3-pyridinyl)-2,2-dimethylpropanamide

Yield: 52% of theory

R_(f): 0.5 (dichloromethane/methanol/conc. ammonia 90/10/0.1 v/v/v)

IR (KBr) of the hydrochloride: 1695 cm⁻¹ (C═O)

MS: M⁺=206

-   (2) N-(3-formyl-4-pyridinyl)-2,2-dimethylpropanamide

The reddish oil obtained in a quantitative yield was further processed without more purification

c) N-[3-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-2-pyridinyl]-2,2-dimethylpropanamide

A solution of 8.2 g (0.0398 mol) of N-(3-formyl-2-pyridinyl)-2,2-dimethylpropanamide and 7.6 g (0.04 mol) of 4-amino-1-(phenylmethyl)piperidine in 80 ml of methanol was combined in batches with a total of 1.7 g (0.045 mol) of sodium borohydride and refluxed for a total of 24 hours. The solvent was removed in vacuo, the residue was distributed between water and ethyl acetate. The organic phase was dried over sodium sulphate and freed from solvent. The residue was triturated with diisopropylether and suction filtered. 6.0 g (39.6% of theory) of colourless crystals of melting point 138° C. were obtained.

The following were obtained in the same way:

-   (1)     N-[4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-3-pyridinyl]-2,2-dimethylpropanamide

Yield: 94% of theory

R_(f): 0.4 (dichloromethane/methanol/conc. ammonia 90/10/0.1 v/v/v)

The yellowish oil was used in the following stage without further purification

-   (2)     N-[3-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-4-pyridinyl]-2,2-dimethylpropanamide

Yield: 11.6% of theory

IR(KBr): 1689 (C═O) cm⁻¹

d) 2-amino-3-[[[1-(phenylmethyl)-4-piperidinyl]-amino]methyl]-pyridine

A mixture of 6.0 g (0.0158 mol) of N-[3-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-2-pyridinyl]-2,2-dimethylpropanamide and 100 ml of conc. hydrochloric acid was refluxed for 3 hours. The mixture was evaporated down in vacuo, the residue remaining was dissolved in a little water and made alkaline by the addition of solid potassium carbonate. It was extracted thoroughly with ethyl acetate, the combined extracts were dried over sodium sulphate and evaporated down in vacuo. The residue was thoroughly triturated with diisopropylether and yielded 4.2 g (89.7% of theory) of colourless crystals of melting point 114° C.

The following were obtained in the same way:

-   (1)     3-amino-4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-pyridine

Yield: 96% of theory

R_(f): 0.42 (dichloromethane/methanol/conc. ammonia 90/10/0.1 v/v/v)

The yellowish oil was used in the following stage without further purification

-   (2)     4-amino-3-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-pyridine

Yield: quantitative

The yellowish oil was used in the following stage without further purification

e) 3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-pyrido[2,3-d]-pyrimidinone

A mixture of 4.2 g (0.0142 mol) of 2-amino-3-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-pyridine, 2.4 g (0.0148 mol) of N,N′-carbonyldiimidazole and 50 ml of dimethylformamide was heated to 100° C. for 30 minutes. The still warm mixture was stirred into 300 ml of ice water, the precipitate formed was suction filtered and recrystallised from acetonitrile. After drying in vacuo 4.5 g (98.3% of theory) of colourless crystals of melting point 187° C. were obtained.

The following were obtained in the same way:

-   (1)     3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-pyrido[3,4-d]-pyrimidinone     Colourless crystals

Yield: 33% of theory

IR (KBr): 1676 cm⁻¹ (C═O)

MS: M⁺=322

-   (2)     3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-pydrio[4,3-d]-pyrimidinone

Mp. 155° C. (D)

Yield: 99% of theory

IR (KBr): 1680 cm⁻¹ (C═O)

f) 3,4-dihydro-3-(4-piperidinyl]-2(1H)-pyrido[2,3-d]-pyrimidinone

A solution of 4.7 g (0.0146 mol) of 3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-pyrido[2,3-d]-pyrimidinone in 50 ml of methanol was hydrogenated at a temperature of 50° C. and in the presence of 2.0 g of 20% palladium/charcoal until the uptake of hydrogen ceased. After removal of the catalyst and solvent 3.3 g (97.3% of theory) of a colourless oil of R_(f)=0.35 (FM1) were obtained.

IR (KBr): 1660.6 cm⁻¹ (C═O)

The following were obtained in the same way:

-   (1) 3,4-dihydro-3-(4-piperidinyl]-2(1H)-pyrido[3,4-d]-pyrimidinone

Colourless crystals

Yield: 95% of theory

IR (KBr): 1662 cm⁻¹ (C═O)

MS: M⁺=232

-   (2) 3,4-dihydro-3-(4-piperidinyl]-2(1H)-pyrido[4,3-d]-pyrimidinone

Yellowish resin

Yield: 97% of theory

IR (KBr): 1672 cm⁻¹ (C═O)

R_(f): 0.12 (FM1)

EXAMPLE A4 Methyl 3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazoline-7-carboxylate a) (E)-1-(dimethylamino)-2-[4-(methoxycarbonyl)-2-nitrophenyl]-ethene

A mixture of 98.3 g (0.504 mol) of methyl 4-methyl-3-nitrobenzoate, 78.0 g (0.655 mol) of N,N-dimethylformamide dimethylacetal and 1 l of dimethylformamide was heated to 140° C. for 3 hours. The solvent was distilled off in vacuo, the residue was triturated thoroughly with 1 l methanol. After drying in vacuo 119.5 g (94.7% of theory) of a red amorphous substance was obtained, which was further processed without any more purification.

b) 4-(Methoxycarbonyl)-2-nitrobenzaldehyde

To a mixture of 119.5 g (0.478 mol) of (E)-1-(dimethylamino)-2-[4-(methoxycarbonyl)-2-nitrophenyl]-ethene and 1.3 l of water/tetrahydrofuran mixture (1/1 v/v) were added, in batches, 308.0 g (1.44 mol) of sodium metaperiodate, whilst the reaction temperature was regulated at under +30° C. by external cooling with ice water. The mixture was stirred for a further 2.5 hours at room temperature and then filtered. The precipitate was thoroughly washed with ethyl acetate. The organic phase was separated off, the aqueous phase was thoroughly extracted with ethyl acetate. The combined ethyl acetate phases were dried over sodium sulphate and evaporated down in vacuo. The oil which crystallised after one day was further processed without any more purification. Yield: 87 g (87% of theory).

c) Methyl 4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-3-nitrobenzoate

To a solution of 41.0 g (0.215 mol) of 4-amino-1-(phenylmethyl)-piperidine and 45.0 g (0.215 mol) of 4-(methoxycarbonyl)-2-nitrobenzaldehyde in 1 l methanol were added in batches, at room temperature, 8.3 g (0.22 mol) of sodium borohydride and the mixture was then stirred for 30 minutes at the same temperature. The mixture was stirred into 1 l of ice water and thoroughly extracted with tert. butyl-methylether. The combined extracts were dried over sodium sulphate and evaporated down in vacuo, the residue was dissolved in as little methanol as possible and converted into the hydrochloride by treatment with methanolic hydrogen chloride solution. The crystalline salt was suction filtered, washed with methanol and diethylether, then taken up in water and made alkaline with saturated aqueous potassium carbonate solution. The mixture obtained was extracted thoroughly with ethyl acetate, the combined ethyl acetate extracts were dried over sodium sulphate and evaporated down. 58.2 g (70.6% of theory) of a brownish-yellow oil were obtained, which was further processed without any more purification.

d) Methyl 3-amino-4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-benzoate

A solution of 58.0 g (0.151 mol) of methyl 4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-3-nitrobenzoate in 800 ml of methanol was hydrogenated in the presence of 10 g of 5% rhodium/charcoal for 7 hours at room temperature. The catalyst was filtered off, the filtrate was evaporated down in vacuo. 50.0 g (93.7% of theory) of colourless crystals were obtained, which were further processed without any more purification.

e) Methyl 3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-oxoquinazolin-7-carboxylate

Prepared analogously to Example A3e) from methyl 3-amino-4-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-benzoate and N,N′-carbonyl-diimidazole in a yield of 66.3% of theory.

Slightly yellowish crystals.

IR (KBr): 1714.6; 1664.5 cm⁻¹ (C═O)

f) Methyl 3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazolin-7-carboxylate

A solution of 35.5 g (0.0936 mol) of methyl 3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-oxoquinazolin-7-carboxylate in 400 ml of methanol was hydrogenated in the presence of 5 g of 10% palladium/charcoal for 5 hours at 50° C. The catalyst was filtered off, the filtrate was evaporated down in vacuo. The residue was triturated with 150 ml of ethyl acetate and then suction filtered. After drying in vacuo 20.4 g (75.3w of theory) of colourless crystals were obtained, which were further processed without any more purification.

IR (KBr): 1718.5; 1672.2 cm⁻¹ (C═O)

The following were prepared analogously:

-   (1) 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone

R_(f): 0.3 (FM1)

IR (KBr): 1662.5 cm⁻¹ (C═O)

-   (2) 3,4-dihydro-8-methoxy-3-(4-piperidinyl)-2(1H)-quinazolinone

R_(f): 0.35 (FM1)

(3) 3,4-dihydro-6,7-dimethoxy-3-(4-piperidinyl)-2(1H)-quinazolinone

R_(f): 0.40 (FM1)

EXAMPLE A5 3,4-dihydro-3-(4-piperidinyl)-1H-thieno[3,4-d]pyrimidin-2-one-trifluoroacetate a) Methyl 4-(ethoxycarbonylamino)-thiophene-3-carboxylate

A mixture of 50.0 g (0.258 mol) of methyl 4-aminothiophen-3-carboxylate-hydrochloride, 700 ml of toluene, 26 g (0.257 mol) of triethylamine and 27 ml (0.283 mol) of ethyl chlorocarbonate was refluxed for 5 hours. The insoluble matter was filtered off, the filtrate was evaporated down in vacuo and the residue was crystallised from petroleum ether. 59.0 g (99.8% of theory) of colourless crystals of melting point 52° C. were obtained.

In the same way, crystalline methyl 3-(ethoxycarbonylamino)-thiophen-2-carboxylate was obtained from methyl 3-aminothiophene-2-carboxylate and ethyl chlorocarbonate in a yield of 98.7% of theory.

IR (KBr): 1739.7; 1622 cm⁻¹ (C═O, C═C)

b) 4-(ethoxycarbonylamino)-thiophene-3-carboxaldehyde

Into an ice-cold suspension of 12.9 g (0.34 mol) of lithium aluminium hydride in 800 ml of tert. butyl-methylether was added dropwise, at a reaction temperature of about 0° C., a solution of 59.1 g (0.258 mol) of methyl 4-(ethoxycarbonylamino)-thiophene-3-carboxylate in 200 ml of tert. butyl-methylether, and the mixture was then stirred for a further 2 hours at 10° C. Then 13 ml of water, 13 ml of 2N aqueous sodium hydroxide solution and 39 ml of water were added dropwise one after another and the mixture was stirred for 1 hour at room temperature. It was filtered, and 500 g of activated manganese (IV) oxide were added in batches to the filtrate with stirring. After the completion of the reaction, which could be monitored by thin layer chromatography, the mixture was filtered again and the filtrate was then evaporated down in vacuo. The crystalline residue which solidified was further processed without any more purification. yield: 28.2 g (54.9% of theory).

In the same way 3-(ethoxycarbonylamino)-thiophene-2-carboxaldehyde was obtained from methyl 3-(ethoxycarbonylamino)-thiophene-2-carboxylate in a yield of 71.9% of theory.

c) 4-[[[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]amino]methyl]-3-(ethoxycarbonylamino)-thiophene

A mixture of 28.2 g (0.142 mol) of 4-(ethoxycarbonyl-amino)-thiophene-3-carboxaldehyde, 28.2 g (0.141 mol) of 4-amino-1-(1,1-dimethyl-ethoxycarbonyl)piperidine and 300 ml of toluene was refluxed using a water separator until water formation had ceased. The solvent was removed in vacuo, the residue was dissolved in 300 ml of methanol and at room temperature combined batchwise with 5.5 g (0.145 mol) of sodium borohydride. The mixture was stirred for a further hour at room temperature, then evaporated down in vacuo and the residue was distributed between water and tert. butyl-methylether. The organic phase was dried over sodium sulphate and freed from solvent in vacuo. The oily residue was further processed without purification.

Yield: 54.0 g (99.9% of theory).

In the same way 2-[[[1-(1,1-dimpethylethoxycarbonyl)-4-piperidinyl]amino]methyl]-3-(ethoxycarbonylamino)-thiophene was obtained from 3-(ethoxycarbonylamino)-thiophene-2-carboxaldehyde, 4-amino-1-(1,1-dimethylethoxycarbonyl)piperidine and sodium borohydride in a yield of 100% of theory.

IR (KBr): 1728.1; 1693.4 cm⁻¹ (C═O)

d) 3,4-dihydro-3-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-1H-thieno[3,4-d]pyrimidin-2-one

A solution of 54.0 g (0.141 mol) of 4-[[[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]amino]methyl]-3-(ethoxycarbonylamino)-thiophene in 300 ml of dimethylformamide was refluxed for 4 hours. After the end of the reaction, which could be monitored by thin layer chromatography, the still warm mixture was stirred into 1 l of ice water. The crystalline precipitate was suction filtered and dried at 30° C. in a circulating air drier.

Yield: 47.5 g (99.8% of theory).

In the same way 3,4-dihydro-3-[1-(1,1-dimthylethoxycarbonyl)-4-piperidinyl]-1H-thieno[3,2-d]pyrimidin-2-one was obtained from 2-[[[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]amino]methyl]-3-(ethoxycarbonyl-amino)-thiophene in a yield of 71% of theory. Colourless crystals of melting point 200° C. (acetonitrile).

IR (KBr): 1683.8; 1654.8 cm⁻¹ (C═O)

e) 3,4-dihydro-3-(4-piperidinyl)-1H-thieno[3,4-d]pyrimidin-2-one-trifluoroacetate

A mixture of 10.0 g (0.0296 mol) of 3,4-dihydro-3-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-1H-thieno[3,4-d]pyrimidin-2-one and 50 ml of trifluoroacetic acid was stirred at room temperature for 30 minutes. The residue remaining after removal of the excess trifluoroacetic acid was triturated with diethylether and suction filtered. 5.8 g (55.8% of theory) of colourless crystals were obtained, which were used without further purification.

IR (KBr): 1664.5 cm⁻¹ (C═O)

In the same way, crystalline 3,4-dihydro-3-(4-piperidinyl)-1H-thieno[3,2-d]pyrimidin-2-one-trifluoracetate was obtained from 3,4-dihydro-3-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-1H-thieno-[3,2-d]pyrimidin-2-one and trifluoroacetic acid in a yield of 100% of theory.

IR (KBr): 1685.7; 1656.8 cm⁻¹ (C═O)

EXAMPLE A6 3,4-dihydro-3-(4-piperidinyl)-2(1H)quinolone-hydrochloride

A mixture of 1.1 g (4.949 mmol) of 3-(4-pyridinyl)-2(1H)-quinolone (D. R. Bragg and D. G. Wibberley, J. Chem. Soc. 1961, 5074-5077), 100 ml of ethanol, 5 ml (5 mmol) of 1N hydrochloric acid and 0.2 g platinum (IV) oxide was hydrogenated for 4 hours at room temperature. The catalyst was filtered off, the filtrate evaporated down in vacuo and the residue was triturated with isopropanol. The precipitated crystals were suction filtered, washed with isopropanol and diethylether and dried in vacuo. Yield: 0.64 g (56.2% of theory).

IR (KBr): 1666.4 cm⁻¹ (C═O)

MS: M⁺=230 m/e=146, 84

EXAMPLE A7 3-(4-Piperidinyl-2(1H)-quinolone

A mixture of 8.6 g (0.0387 mol) of 3-(4-pyridinyl)-2(1H)-quinolone, 1.2 l of ethanol, 39 ml (0.039 mol) of 1N hydrochloric acid and 8.0 g of 10% palladium/charcoal was hydrogenated at a temperature of 40° C. until about 0.08 mol of hydrogen had been taken up. The mixture was freed from catalyst, the filtrate was evaporated down in vacuo, the residue was taken up in 200 ml of water and made ammoniacal. Common salt was added up to saturation point and the mixture was continuously extracted with dichloromethane using a perforator. The dichloromethane phase was evaporated down, the residue remaining was separated from byproducts by chromatography over silica gel using FM1 as eluant. The appropriate fractions were combined, freed from solvent, dissolved in a little isopropanol and converted with ethanolic hydrogen chloride solution into the hydrochloride. Colourless crystals. Yield: 2.68 g (26.2% of theory).

MS: M⁺=228

IR (KBr): 1651 cm⁻¹ (C═O)

EXAMPLE A8 5-chloro-3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone

An ice-cold solution of 6.3 g (0.0177 mol) of 5-chloro-3,4-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-quinazolinone (prepared analogously to Example A4e)) in 50 ml of dichloromethane was mixed dropwise with 3.34 g (0.0234 mol) of (α-chloroethyl chlorocarbonate whilst maintaining a reaction temperature of 0° C., after which the mixture was allowed to come back slowly to room temperature. The reaction mixture was evaporated down in vacuo, the residue was taken up in 50 ml of methanol and refluxed for 4 hours. After cooling, the colourless precipitate formed was suction filtered. Yield: 2.0 g (42.5% of theory).

IR (KBr): 1666.4 cm⁻¹ (C═O)

6-bromo-3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone-hydrobromide

To a solution of 6.16 g (0.075 mol) of sodium acetate and 11.565 g (0.05 mol) of 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone in a mixture of 150 ml of glacial acetic acid and 35 ml of water a solution of 8.8 g (0.055 mol) of anhydrous bromine in 20 ml of glacial acetic acid was added dropwise, with stirring and whilst maintaining a reaction temperature of 13 to 15° C. The mixture was filtered and the filtrate was evaporated down in vacuo. To remove any inorganic components the residue was taken up five times in 50 ml of dichloromethane, filtered and evaporated down, then triturated with a little acetonitrile, whereupon crystallisation occurred. The crystals were suction filtered, washed with acetonitrile/diethylether (1/1 v/v) and after drying in vacuo 5.5 g of colourless crystals of melting point 288° C. (decomposition) were obtained. By working up the mother liquors a further 4.5 g of material of the same quality was obtained. Total yield: 10.0 g (51% of theory).

C₁₃H₁₇Br2N₃O (391.10)

Calculated: C 39.92 H 4.38 Br 40.86 N 10.74 Found: 39.72 4.36 41.56 10.24 IR (KBr): 1670.3 cm − 1 (C═O)

EXAMPLE A10 3-(4-piperidinyl)-2,4 (1H,3H)-quinazolindione a) 2-amino-N-[1-(phenylmethyl)-4-piperidinyl]-benzamide

To an ice-cold solution of 28 ml (134 mmol) of 4-amino-1-(phenylmethyl)piperidine in 200 ml of tetrahydrofuran were added, batchwise, 21.9 g (134 mmol) of isatoic acid anhydride. The resulting suspension was stirred for 2½ hours at room temperature and 2½ hours at reflux temperature, then freed from solvent. The residue was dissolved in 100 ml of hot ethanol, the resulting solution was filtered whilst hot after the addition of 5 g of activated charcoal. The crystal mass precipitated after cooling was suction filtered, washed with diisopropylether and dried in vacuo at 50° C. 28.3 g of colourless crystals were obtained. A further 5.1 g of a product of the same quality were isolated from the combined mother liquors. Total yield: 33.4 g (80.6% of theory).

IR (KBr): 1620 cm⁻¹ (C═O)

MS: M⁺=309

b) 3-[1-(phenylmethyl)-4-piperidinyl]-2,4(1H,3H)-quinazolindione

Prepared analogously to Example A3e) from 2-amino-N-[1-(phenylmethyl)-4-piperidinyl]-benzamide and N,N′-carbonyldiimidazole in a yield of 97.8% of theory. Colourless crystals of melting point 223° C.

IR (KBr): 1720; 1647 cm⁻¹ (C═O)

MS: M⁺=335

c) 3-(4-piperidinyl)-2,4(1H,3H)-qinazolindione

Prepared analogously to Example A3f) from 3-[1-(phenylmethyl)-4-piperidinyl]-2,4(1H,3H)-quinazolindione by hydrogenolysis in the presence of palladium/charcoal in a yield of 70% of theory.

R_(f): 0.075 (FM1)

IR (KBr): 1703; 1657 cm⁻¹ (C═O)

EXAMPLE A11 3,4-dihydro-3-[1-(4-piperidinyl)-4-piperidinyl]-2(1H)-quinazolinone a) 3,4-dihydro-3-[1-[1-(phenylmethyl)-4-piperidinyl]-4-piperidinyl]-2(1H)-quinazolinone

A mixture of 5.75 g (0.0249 mol) of 3,4-dihydro-3-(4-piperidinyl-2(1H)-quinazolinone, 4.75 g (0.0251 mol) of 1-(phenylmethyl)-4-piperidinone and 100 ml of ethanol was treated for 30 minutes in an ultrasound bath, then mixed with 9.5 ml (0.031 mol) of titanium (IV) isopropoxide, whereby after 10 minutes a crystal mass was formed. Then heating was continued using the ultrasound bath for a further 2½ hours to a maximum of 35° C., the mixture was allowed to cool to room temperature and 1.05 g (0.0167 mol) of sodium cyanoborohydride were then added in batches, whilst maintaining the pH at 5-6 using dilute methanolic hydrogen chloride solution, and it was then kept for 24 hours at room temperature. After this time another 1.05 g (0.0167 mol) of sodium cyanoborohydride were added and the same procedure was used as above. After a total of 48 hours reaction time the mixture was decomposed by the addition of water and worked up in the usual way. The crude product obtained was purified by column chromatography over silica gel using FM4 as eluant. 7.05 g (70% of theory)of a colourless crystalline substance were obtained.

In the same way exo-4-(8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-1-(phenylmethyl)piperazine was obtained from tropinone and 1-(phenylmethyl)piperazine in a yield of 48.9% of theory.

Colourless, amorphous substance, R_(f)=0.36 (FM1).

b) 3,4-dihydro-3-[l-(4-piperidinyl)-4-piperidinyl]-2(1H)-quinazolinone

Prepared analogously to Example A3f) from 3,4-dihydro-3-[1-[1-(phenylmethyl)-4-piperidinyl]-4-piperidinyl]-2(1H)-quinazolinone by hydrogenolysis, but using Pearlman's catalyst, in a yield of 92% of theory. Colourless crystals, R_(f)=0.48 (Macherey-Nagel, POLYGRAM® SIL G/UV₂₅₄ready-made films for TLC; eluant: dichloromethane/methanol/cyclohexane/conc. ammonia 68/20/10/5 v/v/v/v).

IR (KBr): 1660.6 cm⁻¹ (C═O)

MS: M⁺=314

EXAMPLE A12 3-(4-piperidinyl)-3,4,4a,5,6,7,8,8a-octahydro-2(1H)-quinazolinone-acetate

A solution of 5.0 g (17.17 mmol) of 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone-acetate in 70 ml of methanol was hydrogenated at room temperature and in the presence of 1.0 g rhodium (III) oxide-platinum (IV) oxide hydrate catalyst (46.45% rhodium, 20.15% platinum) until the hydrogen uptake had ceased. The catalyst and solvent were removed, the residue was triturated with 10 ml of diisopropylether and a few drops of isopropanol and the resulting crystals were suction filtered. After drying in vacuo 4.4 g (86.2% of theory) of colourless crystals were obtained, R_(f)=0.3 (eluant: dichloromethane/methanol/conc. ammonia 7.5/2.5/0.5 v/v/v).

IR (KBr): 1641 cm⁻¹ (C═O)

MS: M⁺=237

EXAMPLE A13 1,1-dioxido-2-(4-piperidinyl)-3(4H-1,2,4-benzothiadiazinone a) 2-nitro-N-[1-(phenylmethyl)-4-piperidinyl]-benzenesulphonic acid amide

Whilst carrying out external cooling with ice water a solution of 44.3 g (0.2 mol) of 2-nitrobenzenesulphonyl chloride in 250 ml of chloroform was added dropwise to a solution of 38.0 g (0.2 mol) of 4-amino-1-(phenylmethyl)piperidine and 22.0 g (0.22 mol) of triethylamine in 250 ml of chloroform. After the cooling was stopped the mixture was stirred for a further 30 minutes at room temperature, the reaction mixture was then extracted twice with 1 l water. The aqueous extracts were extracted once more with 100 ml of dichloromethane, the combined organic phases were then dried over sodium sulphate and evaporated down in vacuo. The highly viscous light-brown substance obtained in a yield of 75.0 g (99.9% of theory) was further processed without any more purification.

IR (KBr): 3363.7 (NH); 1541.0 (NO₂); 1365.5 (NO₂ or SO₂); 1346.2 (NO₂ or SO₂); 1168.8 (SO₂) cm⁻¹

b) 2-amino-N-[1-(phenylmethyl)-4-piperidinyl]-benzenesulphonic acid amide

To a solution of 75.0 g (0.2 mol) of 2-nitro-N-[1-(phenylmethyl)-4-piperidinyl]-benzenesulphonic acid amide in 2.0 l ethanol was added dropwise, at room temperature, a solution of 174.0 g ( 0.828 mol) of sodium dithionite-dihydrate in 700 ml of water. After the heat of the exothermic reaction had died away the mixture was refluxed for 4.5 hours, then the ethanol was distilled off and the aqueous phase remaining was extracted thoroughly with dichloromethane.

The combined dichloromethane extracts were dried over sodium sulphate and evaporated down, the residue remaining was purified by column chromatography over silica gel using dichloromethane/methanol/conc. ammonia 80/20/0.25 (v/v/v) as eluant. 6.5 g (8.6% of theory) of a highly viscous oil were obtained.

IR(KBr): 1319.2, 1153.4 cm⁻¹ (SO₂)

c) 1,1-dioxido-2-[1-(phenylmethyl)-4-piperidinyl]-3(4H)-1,2,4-benzothiadiazinone

Prepared analogously to Example A3e) from 2-amino-N-[1-(phenylmethyl)-4-piperidinyl]-benzenesulphonic acid amide and N, N′-carbonyldiimidazole in a yield of 78% of theory. Colourless crystals of melting point 169-171° C.

IR(KBr): 1693.4 (C═O); 1359.7, 1340.4, 1188.1 (SO₂) cm⁻¹

d) 1,1-dioxido-2-(4-piperidinyl)-3(4H)-1,2,4-benzothiadiazinone

Prepared analogously to Example A3f), but using Pearlman's catalyst instead of palladium/charcoal, in a yield of 90% of theory. Colourless, amorphous substance.

IR(KBr): 1705.0 (C═O) cm⁻¹

EXAMPLE A14 3,4-dihydro-2,2-dioxido-3-(4-piperidinyl)-2,1,3-benzothiadiazine a) 3,4-dihydro-2,2-dioxido-3-[1-(phenylmethyl)-4-piperidinyl]-2,1,3-benzothiadiazine

A solution of 11.0 g (0.0372 mol) of 2-amino-N-[1-(phenylmethyl)-4-piperidinyl]-benzenemethanamine in 200 ml of pyridine was added dropwise within 1.5 hours and at reflux temperature to a solution of 3.4 g (0.0354 mol) of sulphamide in 200 ml of pyridine and the mixture was then refluxed for 6 hours. The mixture was freed from solvent, the residue was purified by column chromatography using ethyl acetate/methanol 9/1 (v/v) as eluant. 5.5 g (43.5% of theory) of a colourless amorphous substance were obtained.

IR(KBr): 1344.3, 1166.9 cm⁻¹ (SO₂)

b) 3,4-dihydro-2,2-dioxido-3-(4-piperidinyl)-2,1,3-benzothiadiazine

Prepared analogously to Example A3f) from 3,4-dihydro-2,2-dioxide-3-[1-(phenylmethyl)-4-piperidinyl]-2,1,3-benzothiadiazine by catalytic hydrogenation in the presence of palladium/charcoal in a quantitative yield. Colourless, amorphous substance.

IR(KBr): 1263.3, 1105.1 cm⁻¹ (SO₂)

EXAMPLE A15 D,L-4-phenyl-1-(4-piperidinyl)-imidazolidine-2,5-dione a) N²-(1,1-dimethylethoxycarbonyl)-N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylglycinamide

A mixture of 10.0 g (0.0398 mol) of N²-(1,1-dimethylethoxycarbonyl)-D,L-phenylglycine, 7.57 g (0.0398 mol) of 4-amino-1-(phenylmethyl)piperidine, 10 ml of triethylamine, 12.8 g (0.0399 mol) of TBTU and 5.4 g (0.0353 mol) of N-hydroxy-benzotriazole-hydrate in 200 ml of THF-DMF mixture (1/1 v/v) was stirred overnight at room temperature. The residue remaining after removal of the solvent was taken up in ethyl acetate, washed with saturated sodium hydrogen carbonate solution, dried over sodium sulphate and evaporated down in vacuo. 14.8 g (87.8% of theory) of a colourless, amorphous substance were obtained.

IR(KBr): 1701.1, 1676.0, 1652.9 cm⁻¹ (C═O)

Analogously N²-(1,1-dimethylethoxycarbonyl)-N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylalaninamide was obtained from N²-(1,1-dimethylethoxycarbonyl)-D,L-phenylalanine and 4-amino-1-(phenylmethyl)piperidine in a yield of 85% of theory. Colourless, amorphous substance, R_(f)=0.83 (eluant: dichloromethane/cyclohexane/metha-nol/conc. ammonia=70/15/15/2 v/v/v/v).

IR(KBr): 1683.8, 1651.0 cm⁻¹ (C═O)

b) N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylglycinamide-bis-trifluoroacetate

Prepared analogously to Example A5e) from N²-(1,1-dimethylethoxycarbonyl)-N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylglycinamide and trifluoroacetic acid in a quantitative yield. Colourless, amorphous substance, R_(f)=0.56 (FM1)

Analogously N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylalaninamide-bis-trifluoracetate was obtained from N²-(1,1-dimethylethoxycarbonyl)-N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylalaninamide in a yield of 92% of theory.

IR(KBr): 1670.3 cm⁻¹ (C═O)

c) D,L-4-phenyl-1-[1-(phenylmethyl)-4-piperidinyl]-imidazolidine-2,5-dione

Prepared analogously to Example A3e) from N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylglycinamide and N, N′-carbonyldiimidazole in a yield of 57.3% of theory. Colourless crystals,

-   R_(f)=0.68. IR(KBr): 1774.4, 1712.7 cm⁻¹ (C═O)

Analogously D,L-4-(phenylmethyl)-1-[1-(phenylmethyl)-4-piperidinyl]-imidazolidine-2,5-dione was obtained from N-[1-(phenylmethyl)-4-piperidinyl]-D,L-phenylalaninamide in a yield of 93% of theory. Colourless, fine crystals, R_(f)=0.6 (eluant: dichloromethane/methanol/cyclohexane/conc. ammonia=7/1.5/1.5/0.2 v/v/v/v).

IR(KBr): 1764.8, 1708.8 cm⁻¹ (C═O)

MS: M⁺=363

d) D,L-4-phenyl-1-(4-piperidinyl)-imidazolidine-2,5-dione

Prepared analogously to Example A3f) from D,L-4-phenyl-1-[1-(phenylmethyl)-4-piperidinyl]-imidazolidine-2,5-dione by hydrogenolysis in the presence of palladium/charcoal in a yield of 84.3% of theory. Colourless, amorphous substance, R_(f)=0.5.

IR(KBr): 1766.7, 1706.9 cm⁻¹ (C═O)

Analogously D,L-4-(phenylmethyl)-1-(4-piperidinyl)-imidazolidine-2,5-dione was obtained from D,L-4-(phenylmethyl)-1-[1-(phenylmethyl)-4-piperidinyl]-imidazolidine-2,5-dione. Colourless crystals, R_(f)=0.24 (eluant: dichloromethane/methanol/cyclohexane/conc. ammonia=7/1.5/1.5/0.2 v/v/v/v).

IR(KBr): 1766.7, 1705.0 cm⁻¹ (C═O)

EXAMPLE A16 1,3-dihydro-3-(4-piperidinyl)-2(2H)-imidazo[4,5-c]quinolone a) 1-[2-(acetylamino)phenyl]-2-bromoethanone

45.0 g (0.282 mol) of dry bromine were added dropwise to a boiling solution of 50.0 g (0.282 mol) of 1-[2-(acetylamino)phenyl]ethanone in 400 ml of chloroform at room temperature. The solvent was distilled off, the residue was distributed between dichloromethane and saturated ice-cold sodium hydrogen carbonate solution. The organic phase was dried over sodium sulphate, evaporated down in vacuo, the residue was triturated with diethylether and suction filtered. After drying in vacuo 35.4 g (49% of theory) of colourless crystals were obtained, R_(f)=0.48 (eluant: petroleum ether/ethyl acetate 2/1 v/v).

IR(KBr): 1685.69, 1664.47 cm⁻¹ (C═O)

MS: M⁺=255/257 (Br)

b) 4-[2-(acetylamino)phenyl]-1,3-dihydro-1-[1-(phenylmethyl)-4-piperidinyl]-2H-benzimidazol-2-one

To a solution of 26.3 g (0.138 mol) of 4-amino-1-(phenylmethyl)piperidine and 17.8 g (0.138 mol) of DIEA in 300 ml of dichloromethane was added dropwise a solution of 35.4 g (0.138 mol) of 1-[2-(acetylamino)phenyl]-2-bromoethanone in 150 ml of dichloromethane and the mixture was kept for a further 2 hours at room temperature. With external cooling with ice 13.5 g (0.20 mol) of sodium cyanate and 12 ml of glacial acetic acid were then added and the mixture was stirred overnight in a thawing ice bath. It was washed with water and saturated sodium hydrogen carbonate solution, dried over sodium sulphate and freed from solvent. The residue was triturated with 50 ml of ethyl acetate-methanol mixture (9/1 v/v), the resulting crystals were suction filtered, washed with ethyl acetate and dried in vacuo. 37.0 g (68.7% of theory) of colourless crystals were obtained, R_(f)=0.41 (eluant: dichloromethane/methanol 9/1 v/v).

IR(KBr): 1678 cm⁻¹ (C═O)

MS: M⁺=390 (Br)

c) 4-(2-aminophenyl)-1,3-dihydro-1-[1-(phenylmethyl)-4-piperidinyl]-2H-imidazol-2-one

A mixture of 3.0 g (7.68 mmol) of 4-[2-(acetylamino)phenyl]-1,3-dihydro-1-[1-(phenylmethyl)-4-piperidinyl]-2H-imidazol-2-one, 50 ml of 5 N sodium hydroxide solution and 25 ml of ethanol was refluxed for 3 hours. After cooling the organic phase was separated off, dried over sodium sulphate and evaporated down in vacuo. A colourless amorphous substance was obtained in a quantitative yield, R_(f)=0.53 (eluant: dichloromethane/methanol 9/1 v/v).

d) 1,3-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(2H)-imidazo[4,5-c]quinolone

A solution of 2.67 g (7.66 mmol) of 4-(2-aminophenyl)-1,3-dihydro-1-[1-(phenylmethyl)-4-piperidinyl]-2H-imidazol-2-one in 50 ml of chloroform was mixed with 3.0 g of paraformaldehyde and refluxed for 3.5 hours. The residue remaining after evaporation of the solvent was taken up in 100 ml of methanol and acidified with methanolic hydrogen chloride solution. After stirring for one hour at room temperature the mixture was poured into 300 ml of saturated sodium hydrogen carbonate solution. The resulting mixture was extracted thoroughly with ethyl acetate, the combined extracts were dried over sodium sulphate and evaporated down in vacuo. The residue was purified by column chromatography over silica gel using FM4 as eluant. From the appropriate fractions 0.5 g (18.2% of theory) of a colourless, amorphous substance were isolated, R_(f)=0.24 (FM4).

IR(KBr): 1689 cm⁻¹ (C═O)

MS: M⁺=358 (Br)

e) 1,3-dihydro-3-(4-piperidinyl)-2(2H)-imidazo[4,5-c]quinolone

Prepared analogously to Example A3f) from 1,3-dihydro-3-[1-(phenylmethyl)-4-piperidinyl]-2(2H)-imidazo[4,5-c]quinolone by hydrogenolysis in the presence of palladium/charcoal in a yield of 98.5% of theory. Colourless crystals, R_(f)=0.63 (FM1).

EXAMPLE A17 Preparation of β-(methoxycarbonyl)-arenebutanoic acids 3,5-dibromo-4-hydroxy-β-(methoxycarhonyl)-benzenebutanoic acid a) 4-(phenylmethoxy)-benzaldehyde

To a solution of 36.6 g (0.3 mol) of 4-hydroxybenzaldehyde in 100 ml of ethanol were added dropwise, one after another, a solution of 12.0 g (0.3 mol) of sodium hydroxide in 100 ml of water and a solution of 36.5 ml of (0.307 mol) of benzylbromide in 100 ml of ethanol and the mixture was then kept for 1 hour at 50° C. The ethanol was extensively distilled off, finally in vacuo, the remaining aqueous emulsion was divided between water and ethyl acetate. The ethyl acetate phase was dried over sodium sulphate and evaporated down in vacuo. The residue remaining crystallised on trituration with petroleum ether and was recrystallised from diisopropylether. 48.0 g (75.4% of theory) of colourless crystals of melting point 118-122° C. were obtained.

b) 3-(methoxycarbonyl)-4-[(4-phenylmethoxy)phenyl]-3-butenoic acid

To a freshly prepared solution of 2.3 g (0.1 mol) of sodium in 300 ml of anhydrous methanol were added 14.6 g (0.1 mol) of dimethyl succinate and after half an hour's stirring a solution of 21.2 g (0.1 mol) of 4-(phenylmethoxy)-benzaldehyde in 100 ml of anhydrous methanol were added dropwise. Then the mixture was refluxed for 6 hours, the methanol was distilled off under normal pressure and the remaining residue was kept for 30 minutes at a reaction temperature of 80° C. The viscous slurry obtained was stirred into 1 l of a glacial acetic acid-water mixture (1/1 v/v), the resulting mixture was extracted thoroughly with ethyl acetate. The combined ethyl acetate extracts were in turn extracted with saturated potassium carbonate solution. The potassium carbonate extracts were carefully acidified with acetic acid and then extracted thoroughly with ethyl acetate. These extracts were washed with water, dried over sodium sulphate and freed from solvent in vacuo. The residue was purified by column chromatography over silica gel using dichloromethane/petroleum ether/glacial acetic acid 25/74/1 (v/v/v). The colourless, partly crystallised mixture of diastereomers was obtained in a yield of 16.0 g (49% of theory). R_(f)=0.68 (eluant: ethyl acetate/petroleum ether 1:2 v/v).

IR(KBr): 1699.2 cm⁻¹ (C═O)

The following were obtained analogously:

-   (1) 3-(methoxycarbanyl)-4-[3-(trifluoromethyl)phenyl]-3-butenoic     acid was obtained from 3-(trifluoromethyl)benzaldehyde and dimethyl     succinate in a yield of 21% of theory.

IR (KBr): 1738, 1726 cm⁻¹ (C═0) ESI-MS: (M − H)⁻ = 287 (M + H)⁺ = 289 (M + Na)⁺ = 311

-   (2) 3-(methoxycarbonyl)-4-(1-naphthyl)-3-butenoic acid was obtained     from 1-naphthaldehyde and dimethyl succinate in a yield of 60% of     theory.

Colourless oil

IR(KBr): 1712 cm⁻¹ (C═O)

MS: M⁺=270

-   (3)     3-(methoxycarbonyl)-4-[3,5-dimethyl-4-phenylmethoxyphenyl]-3-butenoic     acid was obtained from 3,5-dimethyl-4-phenyl-methoxybenzaldehyde and     dimethyl succinate in a yield of 66% of theory.

Colourless oil which could be further processed without purification.

-   (4) 4-(4-amino-3,5-dibromophenyl)-3-(methoxycarbonyl)-3-butenoic     acid was obtained from 4-amino-3,5-dibromobenzaldehyde and dimethyl     succinate in a yield of 21% of theory. -   (5) 3-(Methoxycarbonyl)-4-(3-phenylmethoxyphenyl)-3-butenoic acid     was obtained from 3-phenylmethoxybenzaldehyde and dimethyl succinate     in a yield of 37% of theory.

c) 4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid

Prepared analogously to Example A3f) from 3-(methoxycarbonyl)-4-[(4-phenylmethoxy)phenyl]-3-butenoic acid by hydrogenolysis in the presence of palladium/charcoal in a yield of 96% of theory. Colourless oil, R_(f)=0.5 (eluant: ethyl acetate/petroleum ether/glacial acetic acid 66.3/33.3/0.4 v/v/v).

The following were obtained analogously:

-   (1) β-(methoxycarbonyl)-3-(trifluoromethyl)-benzenebutanoic acid was     obtained from     3-(methoxycarbonyl)-4-[3-(trifluoromethyl)phenyl]-3-butenoic acid in     a yield of 80% of theory. R_(f)=0.59 (eluant: ethyl     acetate/petroleum ether 1/1/ v/v).

ESI-MS: (M−H)⁻=289

-   (2) β-(methoxycarhonyl)-1-naphthalinebutanoic acid was obtained from     3-(methoxycarbonyl)-4-(1-naphthyl)-3-butenoic acid, however using     platinum(IV)-oxide as a catalyst, in a yield of 31% of theory.

IR (KBr): 1734, 1711 (C═O) cm⁻¹

MS: M⁺=272

β-(methoxycarbonyl)-1,2,3,4-tetrahydro-1-naphthaline-butanoic acid was isolated as a by-product in a yield of 8.4% of theory

IR (KBr): 1736, 1712 (C═O) cm⁻¹

MS: M⁺=276

-   (3) 3,5-dimethyl-4-hydroxy-β-(methoxycarbonyl)-benzene butanoic acid     was obtained from     3-(methoxycarbonyl)-4-[3,5-dimethyl-4-phenylmethoxyphenyl]-3-butenoic     acid in a yield of 48% of theory.

R_(f)=0.11 (FM1)

IR (KBr): 1716 (C═O) cm⁻¹

MS: M⁺=266

-   (4) 3-Hydroxy-β-(methoxycarbonyl)-benzene butanoic acid was obtained     from 3-(Methoxycarbonyl)-4-(3-phenylmethoxyphenyl)-3-butenoic acid     in a yield of 59% of theory.

R_(f)=0.24 (petroleum ether/ethyl acetate/glacial acetic acid 6/4/0.2 v/v/v)

IR (KBr): 1714 (C═O) cm⁻¹

MS: M⁺=238

-   (5) 4-Amino-β-(methoxycarbonyl)-benzene butanoic acid was obtained     from 3-(methoxycarbonyl)-4-(4-amino-3,5-dibromophenyl)-3-butenoic     acid and in the presence of triethylamine in a quantitative yield.

R_(f)=0.53 (eluant: dichloromethane/methanol/glacial acetic acid 90/10/1.5 v/v/v))

IR (KBr): 1728 (C═O) cm⁻¹

MS: M⁺=237

d) 3,5-dibromo-4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid

To a solution of 12.0 g (0.05 mol) of 4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid in 200 ml of glacial acetic acid were added 150 ml of water and 8.0 g sodium acetate and then a solution of 15.58 g (0.0975 mol) of bromine in 60 ml of glacial acetic acid was added dropwise. The mixture was stirred for a further hour at room temperature, then evaporated down to two thirds in vacuo and the residue was divided between water and ethyl acetate. The ethyl acetate extracts were washed with water, dried over sodium sulphate and evaporated down in vacuo. After stirring with diisopropylether a colourless crystal was obtained. Yield: 12.0 g (62.2% of theory). R_(f)=0.4 (eluant: ethyl acetate/petroleum ether/glacial acetic acid 49.8/49.8/0.4 v/v/v).

IR(KBr): 1724 cm⁻¹ (C═O)

MS: M⁺=394/396/398 (Br₂)

EXAMPLE A18 1-(3-pyridinyl)piperazine a) 1-(phenylmethyl)-3-(3-pyridinyl)piperazine

To a solution of 5.0 g (0.0515 mol) of 3-fluoropyridine and 43.5 ml of 1-(phenylmethyl)piperazine in 300 ml of anhydrous diethylether was added dropwise, at boiling temperature, within 2.5 hours, 56 ml (0.112 mol) of a 2 molar solution of phenyl-lithium in a cyclohexane-diethylether mixture (7/3 v/v) and the resulting mixture was then kept at reflux temperature for a further 4 hours. The crude reaction product obtained as an oil after working up in the usual way was purified by column chromatography over silica gel (30-60 μm) using FM1/cyclohexane (7/3 v/v) as eluant. 12.0 g (92% of theory) of a colourless oil were obtained, R_(f) 0.52 (FM4; Macherey-Nagel, POLYGRAM® SIL G/UV₂₅₄ Pre-coated plastic sheets for TLC).

MS: M⁺=253

b) 1-(3-Pyridinyl)piperazine

Prepared analogously to Example A3f) from 1-(phenylmethyl)-3-(3-pyridinyl)piperazine by hydrogenolysis in the presence of palladium/charcoal in a yield of 55% of theory. Colourless oil,

R_(f) 0.35 (FM1).

IR(KBr): 1652.9 cm¹ (C═N)

EXAMPLE A19 1-(1-cyclohexyl-4-piperidinyl)piperazine-tris-trifuoroacetate a) 1-(1,1-dimethylethoxycarbonyl)-4-[1-(phenylmethyl)-4-piperidinyl]piperazine

A solution of 15.0 g ( 0.8054 mol) of 1-(1,1-dimethylethoxycarbonyl)piperazine and 14.26 ml (0.08053 mol) of 1-(phenylmethyl)-4-piperidinone in 250 ml of methanol was adjusted to a pH of between 5 and 6 by dropwise addition of acetic acid and mixed in batches with a total of 4.13 g ( 0.0624 mol) of 95% sodium cyanoborohydride, whilst taking care to maintain a pH of 5 to 6 by further dropwise addition of acetic acid. After stirring for 18 hours at room temperature the mixture was evaporated down in vacuo, the residue was made alkaline with soda and divided between water and ethyl acetate. After working up the ethyl acetate phase in the usual way 21.76 g (75.2% of theory) of a highly viscous colourless oil were obtained, R_(f) 0.66 (FM1).

b) 1-(1,1-dimethylethoxycarbonyl)-4-(4-piperidinyl)piperazine

Prepared analogously to Example A3f) from 1-(1,1-dimethyl-ethoxycarbonyl)-4-[1-(phenylmethyl)-4-piperidinyl]piperazine by hydrogenolysis, but using Pearlman's catalyst instead of palladium/charcoal, in a yield of 79.7% of theory.

Colourless crystals, R_(f)=0.3 (FM1).

c) 1-(1,1-dimethylethoxycarbonyl)-4-(1-cyclohexyl-4-piperidinyl)piperazine

Prepared analogously to Example A19a) from 1-(1,1-dimethyl-ethoxycarbonyl)-4-(4-piperidinyl)piperazine and cyclohexanone in a yield of 99% of theory. Colourless, highly viscous oil.

MS: M⁺=251

d) 1-(1-cyclohexyl-4-piperidinyl)piperazine-tris-trifluoroacetate

Prepared analogously to Example A5e) from 1-(1,1-dimethylethoxycarbonyl)-4-(1-cyclohexyl-4-piperidinyl)piperazine and trifluoroacetic acid in a quantitative yield. Colourless crystals, R_(f)=0.2 (FM1).

EXAMPLE A20 1-(1 -ethyl-4-piperidinyl)piperazine-trihydrochloride a) 1-(1-ethyl-4-piperidinyl)-4-(phenylmethyl)piperazine

Prepared analogously to Example A19a) from 1-ethyl-4-piperidinone and 1-(phenylmethyl)piperazine in a yield of 71% of theory. Colourless, amorphous substance, R_(f)=0.46 (FM4).

b) 1-(1-ethyl-4-piperidinyl)piperazine-trihydrochloride

A mixture of 36.3 g (0.126 mol) of 1-(1-ethyl-4-piperidinyl)-4-(phenylmethyl)piperazine, 300 ml of 1N hydrochloric acid and 200 ml of methanol was hydrogenated at room temperature and in the presence of 4.0 g of 10% palladium/charcoal until the up-take of hydrogen had ceased. After working up in the usual way 22.9 g (59.3% of theory) of a colourless, crystalline substance was obtained.

MS: M⁺=197

In the same way exo-1-(8-methyl-8-azabicyclo[3,2,1]oct-3-yl)piperazine-trihydrochloride was obtained from exo-4-(8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-1-(phenylmethyl)piperazine (see Example A11a)) by hydrogenolysis in the presence of palladium/charcoal in a yield of 91% of theory.

MS: M⁺=209

EXAMPLE A21 1-ethyl-4-(4 -piperidinyl)piperidine a) 1-(phenylmethoxycarbonyl)-4-(4-piperidinyl)piperidine

To a mixture of 72.375 g (0.3 mol) of bipiperidine-dihydrochloride, 1500 ml of methanol, 75 ml of water and 100 mg of bromophenol blue were added dropwise, simultaneously, with stirring and at room temperature, a solution of 51.18 g (0.3 mol) of benzyl chlorocarbonate in 75 ml of toluene and 6 N sodium hydroxide solution (about 80 ml) were added, so that the indicator colour changed continuously. After all had been added, which took about 4 hours, the mixture was diluted with 300 ml of water and the organic solvent was distilled off in vacuo. The aqueous phase remaining was acidified with hydrochloric acid, whilst being externally cooled, extracted thoroughly with diethylether and then made alkaline with 50% potassium hydroxide solution. The mixture was extracted thoroughly with dichloromethane, the combined dichloromethane extracts were dried over magnesium sulphate and evaporated down in vacuo. The colourless, highly viscous, slowly crystallising oil remaining was further processed without any more purification.

Yield: 87.3 g (96.2% of theory).

IR(KBr): 1701.1 cm⁻¹ (C═O)

b) 1-ethyl-4-[1-(phenylmethoxycarbonyl)-4-piperidinyl]piperidine

To a solution of 18.14 g (0.061 mol) of 1-(phenylmethoxycarbonyl)-4-(4-piperidinyl)piperidine in 450 ml of a methanol/water mixture (1/1 v/v) were added, with stirring, whilst maintaining a temperature of 15 to 20° C., 10.05 g (0.152 mol) of 95% sodium cyanoborohydride and 50 mg of bromocresol purple. Then a solution of 10.57 g (0.24 mol) of acetaldehyde in 50 ml of methanol and 1N hydrochloric acid were alternately added dropwise so that the colour of the mixture changed continuously from blue to yellow. After all had been added and the reaction had finished the mixture was adjusted to pH 2 with hydrochloric acid and extracted twice with 200 ml of diethylether. The aqueous phase was then made alkaline and extracted thoroughly with dichloromethane. The combined dichloromethane extracts were dried over magnesium sulphate and evaporated down in vacuo. The colourless crystallising residue remaining was purified by column chromatography over silica gel (30-60 μm) using FM1 as eluant. Yield of colourless crystals of melting point 93-96° C.: 7.9 g (39.2% of theory).

IR(KBr): 1699.2 cm⁻¹ (C═O)

c) 1-ethyl-4-(4-piperidinyl)piperidine

A solution of 7.6 g (0.023 mol) of 1-ethyl-4-[1-(phenylmethoxy-carbonyl)-4-piperidinyl]piperidine in a mixture of 70 ml of methanol, 30 ml of water and 10 ml of glacial acetic acid was hydrogenated in the presence of 10% palladium/charcoal at room temperature and 3 bar of hydrogen pressure until the uptake of hydrogen had ceased. After working up in the usual way the desired compound was obtained as a colourless oil in a quantitative yield.

EXAMPLE A22 Hexahydro-1-methyl-4-(4-piperidinyl)-1H-1,4-diazepine a) Hexahydro-1-methyl-4-[1-(phenylmethyl)-4-piperidinyl]-1H-1,4-diazepine

Prepared analogously to Example A11a) from hexahydro-1-methyl-1H-1,4-diazepine and 1-(phenylmethyl)-4-piperidinone in a yield of 35% of theory. Colourless viscous oil.

MS: M⁺=287

The following were prepared in the same way:

-   (1) 1-methyl-4-[1-(phenylmethyl)-4-piperidinyl]-piperazine from     1-methylpiperazine and 1-(phenylmethyl)-4-piperidinone

Yield: 39.9% of theory, colourless viscous oil

-   (2) 1-acetyl-4-[1-(phenylmethyl)-4-peridinyl]piperazine from     1-acetylpiperazine and 1-(phenylmethyl)-4-piperidinone

Yield: 24.2% of theory, colourless viscous oil

R_(f): 0.46 (eluant: ethyl acetate/methanol/conc. ammonia 50/50/2 v/v/v)

IR(KBr): 1647 cm⁻¹ (C═O)

MS: M⁺=301

(3) 4-(dimethylamino)-1-[1-(phenylmethyl)-4-piperidinyl]-piperidine from 4-(dimethylamino)piperidine and 1-(phenylmethyl)-4-piperidinone

Yield: 28.9% of theory; colourless viscous oil

R_(f): 0.58 (eluant: ethyl acetate/methanol/conc. ammonia 50/50/2 v/v/v)

MS: M⁺=301

-   (4)     1-(1,1-dimethylethoxycarbonyl)-4-[4-(phenylmethyl)-1-piperazinyl]piperidine

from 1-(1,1-dimethylethoxycarbonyl)-4-piperidinone and 1-(phenylmethyl)piperazine

Yield: 86.6% of theory. Colourless, amorphous substance

R_(f): 0.58 (eluant: dichloromethane/methanol 9/1 v/v)

b) Hexahydro-1-methyl-4-(4 -piperidinyl)-1H-1,4-diazepine

Prepared analogously to Example A3f) from hexahydro-1-methyl-4-[1-(phenylmethyl)-4-piperidinyl]-1H-1,4-diazepine by hydrogenolysis, but using Pearlman's catalyst instead of palladium/charcoal, in a quantitative yield. Colourless viscous oil.

MS: M⁺=197

The following were obtained in the same way:

-   (1) 1-methyl-4-(4-piperidinyl)piperazine from     1-methyl-4-[1-(phenylmethyl)-4-piperidinyl]piperazine in a     quantitative yield. Colourless viscous oil.

MS: M⁺=183

-   (2) 1-acetyl-4-(4-piperidinyl)piperazine from     1-acetyl-4-[1-(phenylmethyl)-4-piperidinyl]piperazine in a yield of     81.9% of theory. Colourless crystals.

IR(KBr): 1631 cm⁻¹ (C═O)

-   (3) 4-(dimethylamino)-1-(4-piperidinyl)piperidine from     4-(dimethylamino)-1-[1-(phenylmethyl)-4-piperidinyl]-piperidine in a     yield of 76.8% of theory. Colourless, amorphous substance. -   (4)     1-(1,1-dimethylethoxycarbonyl)-4-(1-piperazinyl)piperidine-hydrochloride     from     1-(1,1-dimethylethoxycarbonyl)-4-[4-(phenylmethyl)-1-piperazinyl]piperidine-hydrochloride.

Yield: 96% of theory. Colourless crystals

R_(f): 0.23 (eluant: dichloromethane/methanol 9/1 v/v)

EXAMPLE A23 4-[(4-methyl-1-piperazinyl)carbonyl]-piperidine-bis-trifluoroacetate a) 1-(1,1-dimethylethoxycarbonyl)-4-piperidinecarboxylic acid

To a mixture of 25.9 g (0.2 mol) of piperidine-4-carboxylic acid, 200 ml (0.2 mol) of 1N sodium hydroxide solution and 200 ml of tetrahydrofuran were added 48.0 g (0.22 mol) of di-tert.-butyl pyrocarbonate and the mixture was stirred overnight at room temperature. The tetrahydrofuran was distilled off, finally in vacuo, and the remaining aqueous solution was acidified with citric acid. The colourless crystals precipitated were suction filtered and dried at 40° C. in a circulating air drier. Yield: 45.5 g (99.2% of theory).

IR(KBr): 1733.9, 1662.5 cm⁻¹ (C═O)

b) 1-(1,1-dimethylethoxycarbonyl)-4-[(4-methyl-1-piperazinyl)-carbonyl]-piperidine

Prepared analogously to Example A15a) from 1-(1,1-dimethylethoxycarbonyl)-4-piperidinecarboxylic acid and 1-methylpiperazine in the presence of TBTU in a yield of 76% of theory. Colourless, amorphous substance, R_(f)=0.64 (eluant: dichloromethane/methanol/conc. ammonia 50/50/1 v/v/v).

IR(KBr): 1693, 1678 cm⁻¹ (C═O)

The following were prepared in the same way:

-   (1)     1-methyl-4-[[4-(1,1-dimethylethoxycarbonyl)-1-piperazinyl]carbonyl]-piperidine     from 1-methyl-4-piperidinecarboxylic acid and     1-(1,1-dimethyl-ethoxycarbonyl)piperazine in a yield of 97% of     theory.

Colourless crystals.

IR(KBr): 1683.8, 1629.8 cm⁻¹ (C═O)

-   (2) 1-(1,1-methylethoxycarbonyl)-4-(isonicotinoyl)piperazine from     1-(1,1-dimethylethoxycarbonyl)-piperazine and 4-pyridine-carboxylic     acid in a yield of 76.8% of theory. Colourless crystals of melting     point 139.2-140.2° C. and R_(f)=0.84 (eluant:     dichloromethane/methanol/conc. ammonia 90/10/1 v/v/v).

IR(KBr): 1689.5, 1625.9 cm⁻¹ (C═O)

c) 4-[(4-methyl-1-piperazinyl)carbonyl]-piperidine-bis-trifluoroacetate

prepared analogously to Example A5e) from 1-(1,1-dimethyl-ethoxycarbonyl)-4-[(4-methyl-1-piperazinyl)carbonyl]-piperidine and trifluoroacetic acid in a yield of 89% of theory.

Colourless, amorphous substance.

The following were prepared in the same way:

-   (1) 1-methyl-4-[(1-piperazinyl)carbonyl]-piperidine from     1-methyl-4-[[4-(1,1-dimethylethoxycarbonyl)-1-piperazinyl]carbonyl]-piperidine     and trifluoroacetic acid in a yield of 57% of theory. Colourless,     amorphous substance.

IR(KBr): 1679.9, 1645.2 cm⁻¹ (C═O)

MS: M⁺=211

-   (2) 4-(isonicotinoyl)piperazine-trifluoroacetate from     1-(1,1-dimethylethoxycarbonyl)-4-(isonicotinoyl)piperazine and     trifluoroacetic acid in a yield of 98.3% of theory.

Colourless, amorphous substance.

IR(KBr): 1676.0 cm⁻¹ (C═O)

EXAMPLE A24

Preparation of Compounds of the General Structure: Boc-A-NR³R⁴

1-[N²-(1,1-dimethylethoxycarbonyl)-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine

To a mixture of 18.8 g (0.0494 mol) of Boc-Lys(Z)-OH, 6.5 g (0.05 mol) of DIEA, 16 g (0.05 mol) of TBTU, 6.6 g (0.049 mol) of HOBt and 100 ml of dimethylformamide were added dropwise, with stirring, 8.1 g (0.0494 mol) of 1-(4-pyridinyl)piperazine, dissolved in 40 ml of DMF, and the mixture was stirred over-night at room temperature. The solvent was removed in vacuo and the residue was taken up in ethyl acetate. The ethyl acetate phase was then washed three times successively with 70 ml of saturated aqueous sodium hydrogen carbonate solution and once with 70 ml of saturated aqueous saline solution, dried over sodium sulphate and evaporated down in vacuo. 24.2 g (93.2% of theory) of a yellowish oil were obtained, which was used for the following reactions without further purification.

IR (KBr): 1650, 1713 cm⁻¹ (C═O)

R_(f) (FM1): 0.59

The following were prepared analogously:

% A NR³R⁴ Remarks Yield R_(f) Eluant IR [cm⁻¹] A9 C1 THF as LM 63.2 0.4 FM1 (KBr): C═O KHSO₄/NaCl 1705.0; 1649 soln A4 C1 93.2 0.59 FM1 (KBr): C═O 1647.7; 1712.7 A5 C1 66 0.55 FM1 (KBr): C═O 1655; 1709 A5 C8 54 0.8 FM1 (KBr): C═O 1653; 1713 A6 C8 91 0.8 FM1 (KBr): C═O 1645; 1710.8 A10 C1 63 0.5 FM1 (KBr): C═O 1665; 1695 A10 C8 30 0.41 FM4 (KBr): C═O 1662; 1699

EXAMPLE A25

Preparation of Compounds ofGeneralFormula: Cbz-A-NR³R⁴

1-[N²-(phenylmethoxycarbonyl)-N⁶-(1,1-dimethyl-ethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine

To a mixture of 100 g (0.263 mol) of Z-Lys(Boc)-OH, 86.1 g (0.268 mol) of TBTU and 36.3 g (0.263 mol) of HOBt in 600 ml of dimethylformamide were added 43.0 g (0.263 mol) of 1-(4-pyridinyl)-piperazine and 47.2 ml (0.268 mol) of DIEA with stirring and the mixture was stirred overnight at room temperature. The reaction mixture was evaporated down in vacuo and the residue divided between ethyl acetate and aqueous saturated sodium hydrogen carbonate solution. The aqueous phase was extracted twice more with a mixture of ethyl acetate/methanol (10/1, v/v) and the combined organic phases were washed once with saturated sodium hydrogen carbonate solution. The organic phase was, after drying over sodium sulphate, evaporated down in vacuo and the residue was taken up in 750 ml of ethyl acetate and washed four times with 100 ml of water, six times with 100 ml of 1% potassium hydrogen sulphate solution, once with 100 ml of water, twice with 100 ml of 3% aqueous ammonia solution and twice with 100 ml of water. The organic phase was evaporated down after drying over sodium sulphate. 120 g (87% of theory) of the desired product were obtained as an oil, which was used without further purification for the subsequent reactions.

IR (KBr): 1709 cm⁻¹ (C═O)

R_(f) (FM1): 0.59

EI-MS: M⁺=525

The following were prepared analogously:

% A NR³R⁴ Remarks Yield MS R_(f) Eluant IR [cm⁻¹] A3 C4 100 A3 C3 Triethylamine as 100 0.8 FM1 (KBr): C═O base 1643.3; 1710.8 A11 C1 98.8 0.5 FM1 (KBr): C═O 1705.0; 1643.3 A3 C1 81 EI: M + = 525 0.59 FM1 (KBr): C═O 1708.8; A3 C5 LC/SiO₂/FM4 95 YED: M = 525 0.67 FM4 A3 C6 THF, LC/SiO₂/FM4 92 0.82 FM4 (KBr): C═O 1710.8; 1641.3 A3 C8 Further reacted as 100 crude product

EXAMPLE 26

Preparation of Compounds ofGeneralFormula: H-A-NR³R⁴

1-[N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine

To a mixture of 24.2 g (46 mmol) of 1-[N²-(1,1-dimethylethoxycarbonyl)-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine and 150 ml of methylene chloride were added 50 ml of trifluoroacetic acid and the reaction mixture was stirred overnight at room temperature. The reaction mixture was neutralised by the addition of saturated aqueous sodium hydrogen carbonate solution, the organic phase was dried and evaporated down in vacuo. 12 g (62% of theory) of the desired compound were obtained as a colourless oil.

IR (KBr): 1648 cm⁻¹ (C═O)

R_(f) (FMI) 0.5

The following were prepared analogously:

A NR³R⁴ Remarks % Yield R_(f) Eluant IR [cm⁻¹] A9 C1 100 0.4 FM2 (KBr): C═O 1676.0; 1645.2 A4 C1 61.5 0.48 FM1 (KBr): C═O 1647.7; 1712.7 A5 C1 55 0.42 FM1 (KBr): C═O 1651 A5 C8 further 100 0.19 FM1 reacted as crude product A6 C1 82 0.3 FM1 (KBr): C═O 1647; 1676 A6 C8 further 100 0.23 FM1 (KBr): C═O reacted as 1674 crude product A10 C1 38 0.55 FM1 (KBr): C═O 1643 A10 C8 further 100 0.15 FM1 reacted as crude product

EXAMPLE A27

Preparation of Compounds ofGeneralFormula: H-A-NR³R⁴

1-[N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

A solution of 120 g (0.228 mol) of 1-[N²-(phenylmethoxycarbonyl)-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine in 1000 ml of methanol and 240 ml of 1M aqueous potassium hydrogen sulphate solution was hydrogenated in the presence of 30 g palladium on charcoal (10%) at 20° C. and 3 bar of hydrogen pressure until the uptake of hydrogen had ceased. The catalyst was filtered off, the filtrate evaporated down in vacuo, the residue was taken up in isopropanol/methanol and adjusted to pH 7-8 by the addition of a concentrated aqueous ammonia solution. The solution was filtered and evaporated to dryness. 87 g (97w of theory) of an oil were obtained.

IR (KBr): 1634, 1701 cm⁻¹ (C═O) R_(f): 0.79 (ethyl acetate/methanol/conc. aqueous ammonia=6/4/1 (v/v/v)

The following were prepared analogously:

A NR³R⁴ Remarks % Yield MS R_(f) Eluant IR [cm⁻¹] A3 C4 93 ESI: M + H = 391 0.6 FM1 (KBr): C═O (M + Na = 413) 1637.5; 1706.9 A3 C3 100 0.3 FM1 (KBr): C═O 1641.3; 1705 A11 C1 78.5 0.2 FM1 (KBr): C═O 1701.1; 1641.3 A7 C1 without KHSO₄ 80.2 0.2 FM7 A3 C1 97 0.79 ethyl (KBr): C═O acetate/methanol/ 1633.6; 1701.1 conc. aqueous ammonia 6/4/1 (v/v/v) A3 C5 without KHSO₄ 53 0.39 FM4 (KBr): C═O 1733.9; 1624.0 A3 C6 without KHSO₄ 89 0.38 FM4 (KBr): C═O 1706.9; 1645.2 A3 C8 further reacted as 100 0.3 FM1 crude product

EXAMPLE A28

Preparation of Compounds ofGeneralFormula:

1-[N²—[N-(1,1-dimethylethoxycarbonyl)-3,5-dibromo-D-tyrosyl]-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

To a mixture of 2.58 g (5.88 mmol) of N-[(1,1-dimethylethoxy)-carbonyl]-3,5-dibromo-D-tyrosine, 1.03 g (8 mmol) of DIEA, 1.93 g (6 mmol) of TBTU, 0.79 g (5.8 mmol) of HOBt and 100 ml of dimethylformamide were added dropwise, 2.5 g (5.88 mmol) of 1-[N⁶-[(phenylmethoxy)-carbonyl]-L-lysyl]-4-(4-pyridinyl)piperazine, dissolved in 50 ml of dimethylformamide, with stirring. The reaction mixture was stirred overnight at room temperature, then evaporated down in vacuo and the residue was taken up in ethyl acetate. The organic phase was washed twice with aqueous saturated sodium hydrogen carbonate solution and once with aqueous saturated saline solution, dried and evaporated down in vacuo. The purification was carried out by column chromatography (aluminium oxide, activity stage III (6% water content) (ICN Biomedical), eluant: ethyl acetate/methanol/ammonia=8/2/0.5 (v/v/v), followed by methanol/ammonia=7/3 (v/v)). 4.0 g (80% of theory) of an amorphous substance were obtained.

IR (KBr): 1643, 1709 cm⁻¹ (C═O)

R_(f): 0.52(FM1)

ESI-MS: (M+H)⁺=845/847/849 (Br₂)

The following were prepared analogously (in each case n=1):

R² A NR³R⁴ Remarks % Yield MS R_(f) Eluant IR [cm⁻¹] AS7 A0 C4 LM: THF; 100 reacted as crude product AS1 A0 C11 reacted as 69 crude product AS4 A0 C20 59 ESI: (M + H)⁺ = (KBr): C═O 600/2/4 (Br₂) 1639; 1707 AS1 A0 C4 71 AS4 A0 C11 53 0.5 FM1 AS7 A0 C1 reacted as 100 (KBr): C═O crude product 1644 AS4 A7 C1 NEt₃ as base; 100 0.4 FM8 reacted as crude product AS1 A4 C1 80 ESI: (M + H)⁺ = 0.52 FM1 (KBr): C═O 845/7/9 (Br₂) 1643.3; 1708.8 AS4 A0 C5 Boc-AS4 83 EI: M⁺ = 0.69 FM5 (KBr): C═O LC/SiO₂/FM5 581/3/5(Br₂) 1706.9; 1641.3 AS4 A0 C15 LC/SiO₂/FM4 86 EI: M⁺ = 0.83 FM4 (KBr): C═O 382/4/6(Br₂) 1706.9; 1641.3 AS1 A0 C5 LC/SiO₂/FM5 81 0.5 FM5 (KBr): C═O 1705.0; 1637.5 AS4 A0 C16 LC/SiO₂/FM4 85 EI: (M + H)⁺ = 0.42 FM4 (KBr): C═O THF 582/4/6(Br₂) 1706.9; 1643.3 AS1 A0 C15 THF 76 0.53 FM4 (KBr): C═O LC/SiO₂/FM4 1701.1; 1637.5 AS4 A0 C3 LC/SiO₂/FM6 83 ESI: (M + H)⁺ = 0.71 FM6 (KBr): C═O 598/600/2(Br₂) 1706.9; 1641.3 AS1 A0 C16 LC/SiO₂/FM4 85 0.35 FM1 (KBr): C═O 1705; 1641.3 AS1 A0 C6 LC/SiO₂/FM6 84 0.54 FM6 (KBr): C═O 1701.1; 1635.5 AS4 A0 C18 LC/SiO₂/FM4 95 0.66 FM4 (KBr): C═O 1705; 1641.3 AS1 A0 C37 90 0.43 FM1 (KBr): C═O 1645; 1714.5 AS4 A0 C37 95 0.51 FM4 (KBr): C═O 1643.3; 1705 AS4 A0 C22 75 (KBr): C═O 1635.5; 1708.8 AS4 A0 C21 92 M⁺ = 0.42 FM4 (KBr): C═O 582/4/6(Br₂) 1643; 1705 AS4 A5 C1 69 ESI: (M + H)⁺ = (KBr): C═O 939/41/43(Br₂) 1653; 1709 AS4 A0 C23 85 (KBr): C═O 1645; 1709 AS4 A10 C1 65 M⁺: 652/4/6 (KBr): C═O 1649; 1707 AS4 A0 C24 79 M⁺: 589/91/93 (KBr): C═O 1643; 1707 AS4 A5 C8 76 (KBr): C═O 1643; 1713 AS4 A6 C1 95 (KBr): C═O 1645; 1710.8 AS4 A6 C8 88 M⁺: 657/9/61 (KBr): C═O 1628; 1713 AS4 A10 C8 46 ESI: (M + H)⁺ = (KBr): C═O 858/60/62(Br₂) 1647; 1707 AS4 A0 C26 46 (KBr): C═O 1637.5; 1707 AS1 A0 C1 further 100 reacted as crude product AS1 A0 C8 55 0.3 dichloro- (KBr): C═O methane/ 1632 methanol 9/1 AS1 A0 C18 84 ESI: (M + H)⁺ = 0.4 FM4 (KBr): C═O 613/5/7(Br₂) 1641; 1707 AS1 A0 C3 81 (KBr): C═O 1638; 1701 AS1 A0 C21 70 0.28 FM4 (KBr): C═O 1643; 1707 AS4 A0 C6 47 (KBr): C═O 1639; 1707 AS4 A0 C19 90 (KBr): C═O 1639; 1707 AS9 A0 C1 further 47 reacted as crude product AS1 A7 C1 NEt₃ as base; 83 0.28 FM1 further reacted as crude product AS4 A0 C38 67 0.5 FM1 AS4 A0 C37 84 AS4 A0 C39 100 0.68 FM1 (raw) AS4 A0 C40 36 AS1 A0 C42 90 0.43 FM1 (KBr): C═O 1645/1715 AS4 A0 C42 100 0.51 FM4 (KBr): C═O 1643/1705 AS1 A0 C43 78 0.9 EE/MeOH (KBr): C═O 95/5 1636/1676/ 1659 AS1 A0 C44 47 0.9 EE/MeOH (KBr): C═O 95/5 1638/1701 AS1 A0 C45 72 EI: M⁺ = 0.9 EE/MeOH (KBr): C═O 591/3/5 (Br₂) 9/1 1638/1695 AS1 A0 C47 80 EI: M⁺ = 0.95 EE/MeOH (KBr): C═O 596/98/600 9/1 1636/1705 (Br₂) AS1 A0 C49 89 0.9 EE/MeOH (KBr): C═O 9/1 1636/1684 AS4 A0 C44 69 0.9 EE/MeOH (KBr): C═O 9/1 1643/1707; CN 2235 AS1 A0 C50 93 EI: M⁺ = 0.9 EE/MeOH (KBr): C═O 598/600/602 9/1 1636/1705 (Br₂) AS1 A0 C51 100 0.1 EE/MeOH/ (KBr): C═O NH₄OH 1638/1707 5/5/0.1 AS4 A0 C52 63 0.56 FM1 (KBr): C═O 1641/1705 AS4 A0 C53 83 EI: M⁺ = (KBr): C═O 601/3/5 (Br₂) 1638/1705 AS4 A0 C64 41 ESI: (M + H)⁺ = (KBr): C═O 610/12/14 1639/1701 (Br₂) AS1 A0 C53 66 0.45 CH₂Cl₂/ (KBr): C═O MeOH/ 1639/1709 NH₄OH 70/30/1 AS4 A0 C51 88 0.35 CH₂Cl₂/ (KBr): C═O MeOH/ 1641/1691 NH₄OH 50/50/0.5 AS4 A0 C66 77 EI: M⁺ = 0.75 CH₂Cl₂/ (KBr): C═O 629/31/33 MeOH/ 1641/1707 (Br₂) NH₄OH 9/1/0.1 AS16 A0 C8 100 0.8 FM1 AS16 A0 C1 56 0.5 EE/MeOH/ (KBr): C═O NH₄OH 1695 9/1/1 AS4 A0 C8 100 AS1 A0 C53 70.0 EI: M⁺ = 0.10 CH₂Cl₂/MeOH/ (KBr): C═O 502/4/6 (Br₂) NH4OH 70/30/1 1676 AS4 A0 C70 47.0 (KBr): C═O 1645/1707 AS1 A0 C64 31.0 0.50 CH₂Cl₂/MeOH/ (KBr): C═O NH4OH 90/10/1 1639/1707 AS1 A0 C70 20.0 AS4 A0 C72 50.0 0.50 CH₂Cl₂/MeOH/ NH4OH 90/10/1 AS19 A0 C8 98.0 AS35 A0 C8 92.0 0.70 FM1 AS36 A0 C8 65.0

EXAMPLE A29

Preparation of Compounds ofGeneralFormula:

1-(4-amino-3,5-dibromo-D-phenylalanyl)-4-(4-pyridinyl)-piperazine

A mixture of 39 g (0.089 mol) of 4-amino-3,5-dibromo-N-[(1,1-dimethylethoxy)carbonyl]-D-phenylalanine, 35.7 g (0.111 mol) of TBTU, 12.3 g (0.089 mol) of HOBt, 14.5 g.(0.089 mol) of 1-(4-pyridinyl)-piperazine and 19.6 ml of (0.111 mol) of DIEA in 1000 ml of tetrahydrofuran was stirred overnight at room temperature. The reaction mixture was extracted once with saturated aqueous saline solution and twice with saturated aqueous sodium hydrogen carbonate solution. The combined aqueous phases were extracted once with tetrahydrofuran and the combined tetrahydrofuran phases were washed once with saturated aqueous saline solution. After drying the organic phase with sodium sulphate it was evaporated down in vacuo and the residue was taken up in ethyl acetate. The ethyl acetate phase was filtered after drying again and evaporated down in vacuo. 52.5 g of the intermediate compound were obtained as a viscous oil, which was then mixed with 300 ml of methylene chloride and 8.0 ml of trifluoroacetic acid and stirred overnight at room temperature. The reaction mixture was evaporated down in vacuo, the residue formed was triturated with ether. 45.8 g (72% of theory) of the desired product were obtained as a white amorphous solid.

IR (KBr): 1643, 1674 cm⁻¹ (C═O)

R_(f): 0.36 (ethyl acetate/methanol=6/4 (v/v))

The following were prepared analogously (in each case n=1):

R² A NR³R⁴ Remarks % Yield MS R_(f) Eluant IR [cm⁻¹] AS7 A0 C8 Crude product; 84 Boc-cleaving with pure TFA AS4 A0 C8 63 ESI: (M + H)⁺ = (KBr): C═O 486/88/90(Br₂) 1632 AS4 A0 C4 63 ESI: (M + H)⁺ = (KBr): C═O 481/3/5(Br₂) 1620 AS1 A9 C1 55 0.25 FM2 (KBr): C═O 1674.1; 1643.3 AS4 A0 C8 81 ESI: (M + H)⁺ = 0.6 FM2 (KBr): C═O 486/8/90(Br₂) 1629.8 AS4 A0 C1 72 0.38 ethyl acetate/ (KBr): C═O methanol = 6/4 1643.3; 1674.1 (v/v) AS1 A0 C20 30 AS4 A0 C65 41 EI: M⁺ = (KBr): C═O 515/17/19(Br₂) 1618 AS1 A0 C65 15 ESI: (M + H)⁺ = 0.08 FM1 (KBr): C═O 517/19/21(Br₂) 1635 AS4 A0 C78 77.0 ESI: (M + H)⁺ = 0.30 CH₂Cl₂/MeOH/ (KBr): C═O 529/31/33(Br₂) NH4OH = 90/10/1 1674 AS1 A0 C78 60.0 ESI: (M + H)⁺ = 0.10 CH₂Cl₂/MeOH/ (KBr): C═O 531/33/35(Br₂) NH₄OH = 80/20/1 1670 AS4 A0 C71 43.0 0.20 CH₂Cl₂/MeOH/ (KBr): C═O NH₄OH = 90/10/1 1678 AS31 A0 C20 39.0 EI: M⁺ = 382 0.30 CH₂Cl₂/MeOH/ (KBr): C═O NH₄OH = 80/20/1 1678 AS31 A0 C53 83.0 EI: M⁺ = 383 (KBr): C═O 1678

EXAMPLE A30

Preparation of Compounds ofGeneralFormula:

1-[N²—[N-(9-fluorenylmethoxycarbonyl)-3,5-dibromo-D-tyrosyl]-N6-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

A mixture of 63 g (0.1123 mol) of N-[(9-fluorenylmethoxy)-carbonyl]-3,5-dibromo-D-tyrosine, 44 g (0.1123 mol) of 1-[N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine, 39.7 g (0.1235 mol) of TBTU, 15.5 g (0.1123 mol) of HOBt, 21.7 ml (0.1235 mol) of DIEA and 600 ml of dimethylformamide was stirred for 20 hours at room temperature. The reaction mixture was evaporated down in vacuo and the residue divided between ethyl acetate/methanol (10/1 v/v) and saturated aqueous sodium hydrogen carbonate solution. The organic phase was washed once with saturated aqueous sodium hydrogen carbonate solution and after drying evaporated down in vacuo. The residue was recrystallised twice from isopropanol (22.6 g; 22% of theory), the mother liquors were combined, evaporated down and purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM; eluant: ethyl acetate/methanol=8/2 (v/v)). A further 28.0 g (26.7% of theory)of the desired end product were obtained. Total yield: 49% of theory.

IR (KBr): 1641, 1705 cm⁻¹ (C═O)

R_(f): 0.46 (ethyl acetate/methanol=6/4 (v/v))

ESI-MS: (M+H)⁺=933/935/937 (Br₂)

The following were prepared analogously:

R² A NR³R⁴ Remarks % Yield MS R_(f) Eluant IR [cm⁻¹] AS1 A3 C1 48 ESI: (M + H)⁺ = 0.46 Ethyl acetate/ (KBr): C═O 933/5/7(Br₂) methanol = 6/4 1641.3; 1705.5 (v/v) AS1 A3 C5 THF/SiO₂/FM4 80 ESI: (M + H)⁺ = 0.72 FM1 (KBr): C═O 933/5/7(Br₂) 1701.1; 1635.5 AS1 A3 C6 THF 60 ESI: M⁻ = 0.47 FM4 (KBr): C═O 960/2/4(Br₂) 1712.7; 1631.7 AS5 A3 C1 THF 61 ESI: (M + H)⁺ = 0.36 FM4 (KBr): C═O LC/SiO₂/FM4 917/19/21(Br₂) 1708.8; 1645.2 Diastereomers AS10 A0 C1 THF 90 0.52 FM4 AS1 A3 C18 73 0.46 FM1 (KBr): C═O 1635.5; 1712.7 AS10 A3 C1 THF 85 (KBr): C═O 1643.3; 1708.8 AS10 A3 C4 THF 82 (KBr): C═O 1639.4; 1710.8 AS10 A3 C1 THF 85 (KBr): C═O 1643; 1709 AS4 A3 C18 94 ESI: (M + H)⁺ = (KBr): C═O 963/5/7(Br₂) 1633.6; 1711 AS15 A0 C8 90 (KBr): C═O 1635.5; 1617.5 AS12 A0 C8 44 ESI: (M + H)⁺ = (KBr): C═O 577 1630; 1714.6 AS10 A0 C4 88 0.49 FM4 (KBr): C═O 1635.5; 1716.5 AS1 A3 C1 70 0.7 FM7

EXAMPLE A31

Preparation of Compounds ofGeneralFormula:

1-[N²-(3,5-dibromo-D-tyrosyl)-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

To a mixture of 63 g (0.1123 mol) of N-[(9-fluorenylmethoxy)-carbonyl]-3,5-dibromo-D-tyrosine, 44 g (0.1123 mol) of 1-[N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine, 39.7 g (0.1235 mol) of TBTU, 15.5 g (0.1123 mol) of HOBt and 1500 ml of tetrahydrofuran were slowly added dropwise 21.7 ml (0.1235 mol) of DIEA and the reaction mixture was then stirred for 2 hours at room temperature. After the addition of 200 ml of diethylamine the mixture was again stirred overnight at room temperature. The reaction mixture was mixed with 1000 ml of saturated saline solution, stirred thoroughly and the aqueous phase was separated off. After extracting the aqueous phase three times with 500 ml of tetrahydrofuran and combining the organic phases the mixture was washed three times with 500 ml of saturated aqueous saline solution, three times with 200 ml of saturated aqueous sodium hydrogen carbonate solution and once with 500 ml of saturated aqueous saline solution. The organic phase was dried and then evaporated down in vacuo. The residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol/conc. aqueous ammonia=8/1/0.25 (v/v/v)). 40.0 g (50w of theory)of the desired end product were obtained.

IR (KBr): 1641, 1699 cm⁻¹ (C═O)

R_(f): 0.2 (ethyl acetate/methanol/conc. aqueous ammonia=6/4/1 (v/v/v))

ESI-MS: (M+H)⁺=711/713/715 (Br₂)

The following were prepared analogously (in each case n=1):

R² A NR³R⁴ Remarks % Yield MS R_(f) Eluant IR [cm⁻¹] AS4 A3 C8 crude 43 AS4 A3 C1 crude 100 0.4 FM1 AS4 A3 C4 79 ESI: (M + H)⁺ = 0.7 FM7 (KBr): C═O 709/11/13 1637.5; 1705 (Br₂) AS4 A0 C69 82 ESI: (M + H)⁺ = (KBr): C═O 587/9/81 1618/1645/ (Br₂) 1690 AS4 A0 C46 38 0.55 CH₂Cl₂/ (KBr): C═O MeOH/ 1614/1639 NH₄OH 90/10/1 AS4 A0 C48 54 EI: M⁺ = 0.52 CH₂Cl₂/ (KBr): C═O 522/4/6(Br₂) MeOH/ 1638 NH₄OH 90/10/2 AS11 A0 C53 71.0 EI: M⁺ = 469 0.20 CH₂Cl₂/ (KBr): C═O MeOH/ 1637/1732 NH4OH 90/10/1 AS11 A0 C20 45.0 EI: M⁺ = 468 0.40 CH₂Cl₂/ (KBr): C═O MeOH/ 1635/1732 NH₄OH 90/10/1 AS31 A0 C72 100.0 EI: M⁺ = 411 0.45 FM1 (KBr): C═O 1664 AS11 A0 C72 33.0 EI: M⁺ = 497 0.30 FM1 (KBr): C═O 1630/1641

EXAMPLE A32

Preparation of Compounds ofGeneralFormula:

1-[N²-(3,5-dibromo-D-tyrosyl)-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4 -pyridinyl)-piperazine

To a mixture of 4 g (4.7 mmol) of 1-[N²—[N-(1,1-dimethylethoxycarbonyl)-3,5-dibromo-D-tyrosyl]-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine and 80 ml of methylene chloride were added 20 ml of trifluoroacetic acid and the reaction mixture was stirred overnight at room temperature. The reaction mixture was neutralised by the addition of saturated aqueous sodium hydrogen carbonate solution, the organic phase was dried over sodium sulphate and evaporated down in vacuo. 2.2 g (64% of theory) of an amorphous solid were obtained.

IR (KBr): 1643, 1680 cm⁻¹ (C═O)

R_(f): 0.5 (FM1)

ESI-MS: (M+H)⁺=745/747/749 (Br₂)

The following were prepared analogously (in each case n=1):

% R² A NR³R⁴ Remarks Yield MS R_(f) Eluant IR [cm⁻¹] Mp. (°C.) AS7 A0 C4 crude product; 51 0.30 FM1 pure TFA AS1 A0 C11 95 ESI: (M + H)⁺ = (KBr): C═O 503/5/7 (Br₂) 1676 AS4 A0 C20 100 ESI: (M + H)⁺ = 500/2/4 (Br₂) AS1 A0 C4 100 ESI: (M + H)⁺ = (KBr): C═O 481/3/5 (Br₂) 1678 AS4 A0 C11 74 AS7 A0 C1 reacted as 100 crude product AS4 A7 C1 reacted as 100 0.40 EE/MeOH crude 7/3 v/v product AS1 A4 C1 64 ESI: (M + H)⁺ = 0.50 FM1 (KBr): C═O 745/7/9 (Br₂) 1643.3; 1679.9 AS4 A0 C5 89 0.32 FM4 (KBr): C═O 1637.5 AS4 A0 C15 93 0.33 FM4 (KBr): C═O 1618.2 AS1 A0 C5 89 0.25 FM4 (KBr): C═O 154-157 1639.4 AS4 A0 C16 LC/SiO₂/ 90 0.30 FM4 (KBr): C═O FM4 1635.5 AS1 A0 C15 89 0.20 FM4 (KBr): C═O 160-164 1639.4 AS4 A0 C3 LC/SiO₂/ 98 0.37 FM4 (KBr): C═O FM4 1683.8; AS4 A0 C6 89 0.28 FM4 (KBr): C═O 1637.5 AS1 A0 C16 95 0.57 FM1 (KBr): C═O 1683.8 AS1 A0 C6 LC/SiO₂/ 56 EI: M⁺ = 0.24 FM4 (KBr): C═O FM4 511/3/5 (Br₂) 1637.5 AS4 A0 C18 90 EI: M⁺ = 0.50 FM1 (KBr): C═O 512/4/6 (Br₂) 1624.0 AS4 A0 C37 93 0.24 FM4 (KBr): C═O 1635.5; 1684 AS4 A0 C22 88 M⁺ = (KBr): C═O 502/4/6 (Br₂) 1618.2 AS4 A0 C21 52 M⁺ = 0.55 FM1 (KBr): C═O 482/4/6 (Br₂) 1681.8 AS1 A0 C37 89 0.32 FM1 (KBr): C═O 1681.8 AS4 A5 C1 crude (KBr): C═O 1645; 1676 AS4 A0 C23 88 (KBr): C═O 1643 AS4 A10 C1 47 ESI: (M + H)⁺ = (KBr): C═O 553/5/7 (Br₂) 1653 AS4 A5 C8 67 M⁺ = 543/5/7 (KBr): C═O 1645 AS4 A6 C1 59 (KBr): C═O 1643 AS4 A0 C24 94 M⁺ = (KBr): C═O 489/91/93 1618; 1637.5 AS4 A6 C8 70 (KBr): C═O 1639.4 AS4 A10 C8 82 M⁺ = 557/9/61 (KBr): C═O 1651 AS4 A0 C26 88 (KBr): C═O 1626 AS1 A0 C1 96 ESI: (M + H)⁺ = 0.18 FM1 (KBr): C═O 483/5/7 (Br₂) 1680 AS1 A0 C8 crude 69 AS1 A0 C18 82 0.27 FM1 (KBr): C═O 1684 AS1 A0 C3 100 0.38 FM1 (KBr): C═O 1682 AS1 A0 C21 89 0.26 FM1 (KBr): C═O 1595; 1615 AS4 A0 C3 99 0.37 FM4 (KBr): C═O 1618; 1636; 1683 AS4 A0 C19 98 ESI: (M + H)⁺ = 0.47 FM4 (KBr): C═O 498/500/502 (Br₂) 1638; 1682 AS9 A0 C1 Crude 96 product AS1 A7 C1 37 0.42 FM7 AS4 A0 C38 80 0.25 FM1 AS4 A0 C37 86 AS4 A0 C39 73 AS4 A0 C40 92 EI: M⁺ = 515/7/9 (KBr): C═O 1674 AS1 A0 C42 100 0.32 FM1 (KBr): C═O crude 1682 AS4 A0 C42 95 0.24 FM4 (KBr): C═O 1636/1684 AS1 A0 C43 66 0.1 FM7 (KBr): C═O 1659 AS1 A0 C44 59 0.15 CH₂Cl₂/ (KBr): C═O MeOH/ 1676 NH₄OH 90/10/1 AS1 A0 C45 82 ESI: (M + H)⁺ = 0.10 EE/MeOH (KBr): C═O 492/4/6 (Br₂) 9/1 1678 AS1 A0 C47 89 0.52 FM7 (KBr): C═O 1634/1666 AS1 A0 C49 84 0.15 CH₂Cl₂/ (KBr): C═O MeOH/ 1678 NH₄OH AS4 A0 C44 93 EI: M⁺ = 0.45 EE/ (KBr): C═O 504/6/8 (Br₂) MeOH 9/1 1653; CN 2239 AS1 A0 C50 100 EI: M⁺ = 0.10 EE/ (KBr): C═O 498/500/502 (Br₂) MeOH 9/1 1636 AS1 A0 C51 100 EI: M⁺ = 0.05 EE/ (KBr): C═O 530/2/4 (Br₂) MeOH/ 1678 NH4OH 5/5/0.1 AS4 A0 C52 97 0.15 FM1 (KBr): C═O 1620/1688 AS4 A0 C53 58 ESI: (M + H)M⁺ = 0.05 EE/MeOH/ (KBr): C═O 502/4/6 (Br₂) NH₄OH 5/5/0.1 1678 AS4 A0 C64 100 (KBr): C═O 1647/1678 AS1 A0 C53 70 EI: M⁺ = 0.15 CH₂Cl₂/MeOH/ (KBr): C═O 502/4/6 (Br₂) NH₄OH 70/30/1 1676 AS4 A0 C51 100 0.05 CH₂Cl₂/MeOH/ (KBr): C═O NH₄OH 1680 AS4 A0 C66 100 0.27 CH₂Cl₂/MeOH/ NH₄OH AS16 A0 C8 76 0.40 FM1 AS16 A0 C1 28 0.20 EE/MeOH/ NH₄OH 9/1/1 AS4 A0 C70 96 0.20 EE/MeOH/ (KBr): C═O NH₄OH 1676 80/20/0.5 AS1 A0 C64 100 EI: M⁺ = (KBr): C═O 510/1214 1674 AS1 A0 C70 100 (KBr): C═O 1674 AS4 A0 C72 100 ESI: (M + H)M⁺ = 0.10 CH₂Cl₂/MeOH/ (KBr): C═O 530/2/4 (Br₂) NH₄OH 80/20/1 1678 AS19 A0 C8 100 AS35 A0 C8 72 0.60 FM1 AS36 A0 C8 80 0.52 FM1 (KBr): C═O 1674

EXAMPLE A33 4-(4-pyridinyl)-1-[3-(4-pyridinyl)-D,L-alanyl]-piperazine-hydrochloride

16.4 g (0.04 mol) of 1-[N-[(1,1-dimethylethoxy)carbonyl]-3-(4-pyridinyl)-D,L-alanyl]-4-(4-pyridinyl)-piperazine, dissolved in 100 ml of methanol, were mixed with 20 ml of ethereal hydrochloric acid and the reaction mixture was heated to 40° C. The desired compound crystallised out of the reaction mixture.

yield: 9.2 g (60% of theory)

R_(f): 0.1 (FM1)

Mp.: 198-200° C.

EXAMPLE A34

Preparation of Compounds ofGeneralFormula:

1-[N²-(3,5-dibromo-D-tyrosyl)-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

A mixture of 50 g (53.5 mmol) of 1-[N²—[N-(9-fluorenylmethoxycarbonyl)-3,5-dibromo-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine and 300 ml of diethylamine was heated to 60° C. with stirring. 100 ml of methanol were added and stirring was continued for a further 5 hours at 60° C. The reaction mixture was evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol=6/4 (v/v)). 26 g (68% of theory) of a white foam were obtained.

IR (KBr): 1641, 1691 cm⁻¹ (C═O)

R_(f): 0.2 (ethyl acetate/methanol/conc. aqueous ammonia=6/4/1 (v/v/v))

ESI-MS: (M+H)⁺=710/712/714 (Br₂)

The following were prepared analogously:

% R² A NR³R⁴ n Remarks Yield MS R_(f) Eluant IR [cm⁻¹] AS1 A3 C4 1 85 ESI: M + H = 0.2 FM1 (KBr): C═O 710/2/4(Br₂) 1635.5; 1695.3 AS1 A3 C8 1 98 (KBr): C═O 1635; 1705 AS1 A3 C1 1 68 EI: 0.2 ethyl (KBr): C═O M⁺ = 71 0/2/4 acetate/ 1641.3; 1691.5 (Br₂) methanol/ NH₄OH = 6/4/1 (v/v/v) AS1 A3 C5 1 THF as solvent; purified by 56 ESI: M + H = 0.3 FM1 (KBR):C═O column chromatography: 711/3/5(Br₂) 1695.3; 1635.5 silica gel/FM1 AS1 A3 C6 1 THF as solvent; purified by 90 EI: M⁺ = 0.49 FM1 (KBr): C═O column chromatography: 739/41/43 1695.3; 1629.8 silica gel/FM1 (Br₂) AS5 A3 C1 1 THF as solvent; purified by 93 0.25/ FM4 (KBr): C═O column chromatography: 0.37 1705.0; 1643.3 silica gel/FM4; diastereomers AS10 A0 C1 1 71 0.5 FM1 (KBr): C═O 1641.3 AS1 A3 C18 1 94 (KBr): C═O 1647; 1722.5 AS10 A3 C1 1 49 M⁺ = 694/6/8 (KBr): C═O (Br₂) 1643; 1703 AS10 A3 C4 1 46 ESI: M + H = (KBr): C═O 694/6/8 (Br₂) 1639.4; 1705 AS10 A3 C4 1 46 ESI: M + H = (KBr): C═O 694/6/8(Br₂) 1639.4; 1705 AS10 A3 C1 1 49 M⁺ = (KBr): C═O 694/68/70 1643; 1703 (Br₂) AS4 A3 C18 1 46 ESI: M + H = (KBr): C═O 741/3/5 (Br₂) 1641.3; 1705 AS15 A0 C8 1 100 M⁺: 321 (KBr): C═O 1637.5 AS12 A0 C8 1 81 (KBr): C═O 1630 AS10 A0 C4 1 THF as solvent 68 0.38 FM4 (KBr): C═O 1635.5 AS1 A3 C1 0 crude product 100 0.3 FM7

EXAMPLE A35 1-[N²—[N-[[[2-(2-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

To a solution of 1.0 g (1.34 mmol) of 1-[N²-(-3,5-dibromo-D-tyrosyl)-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine in 80 ml of tetrahydrofuran were added 0.28 g (1.6 mmol) of 2-methoxyphenethyl isocyanate and the mixture was stirred for 3 days at room temperature. The reaction mixture was evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: methylene chloride/methanol/cyclohexane/ammonia=350/75/75/10 (v/v/v/v)). 0.5 g (40% of theory) of a colourless amorphous solid was obtained.

IR (KBr): 1639 cm¹ (C═O)

R_(f): 0.49 (FM1)

ESI-MS: (M+H)⁺=922/924/926 (Br₂)

EXAMPLE A36

Preparation of Compounds ofGeneralFormula:

methyl 4-amino-3,5-dibromo-N²-[[(2-phenylethyl)amino]-carbonyl]-D-phenylalanine

A mixture of 1.27 g (7.73 mmol) of CDT in 150 ml of tetrahydrofuran was mixed, whilst cooling with ice, with 0.72 ml (5.15 mmol) of triethylamine and 2.0 g (5.15 mmol) of methyl-4-amino-3,5-dibromo-D-phenylalanine-hydrochloride, stirred for a further 30 minutes whilst cooling with ice and stirred for 1 hour at room temperature. Then 0.82 ml (6.44 mmol) of benzene ethanamine were added and the mixture was refluxed for 5 hours. The reaction mixture was evaporated down in vacuo, the residue was taken up in ethyl acetate and washed with saturated aqueous sodium hydrogen carbonate solution. After drying the organic phase the solvent was removed in vacuo, the residue was stirred with ether and the precipitate was filtered off. 1.69 g (66% of theory) of an amorphous solid were obtained.

IR (KBr): 1632, 1732 cm⁻¹ (C═O)

R^(f): 0.63 (ethyl acetate)

ESI-MS: (M+H)⁺=498/500/502 (Br₂)

The following were prepared in the same way (in each case n=1):

% RCO R² Remarks Yield MS R_(f) Eluant IR [cm⁻¹] N6 AS1 further reacted 100 0.60 FM1 as crude product N15 AS6 DMF/THF = 1/1 100 ESI: 0.65 FM1 (KBr): C═O (v/v) as solvent (M + H)⁺ = 517/9 1745.5; 1676.0 (Br) N2 AS1 99 0.53 FM1 (KBr): C═O 1716.5 N8 AS4 66 ESI: (M + H)⁺ = 0.63 ethyl acetate (KBr): C═O 498/500/502 1631.7; 1732.0 (Br₂) N15 AS4 92 0.85 ethyl acetate/ (KBr): C═O methanol = 8/2 1620.1; 1737.8 (v/v) N23 AS4 95 EI: M⁺ = 0.86 ethyl acetate/ (KBr): C═O 572/4/6/8 methanol = 8/2 1732.0; 1641.3 (Br₂Cl) (v/v) N2 AS2 100 EI: M⁺ = 406 0.86 FM1 (KBr): C═O 1629.8; 1722.3; 1741.6 N15 AS1 DIEA 47 0.75 FM1 N15 AS3 38 0.60 t-butyl- (KBr): C═O methylether/ 1695.5 petroleum ether = 9/1 (v/v) N66 AS21 76 0.60 EE (KBr): C═O 1662/1734 N66 AS1 100 N66 AS4 63 0.56 FM1 N122 AS1 95 N122 AS4 88 N66 AS17 22 ESI: (M + H)⁺ = 0.25 FM1 (KBr): C═O 623/5/7 (Br₂) 1663/1740 N66 AS18 65 0.53 EE N66 AS19 79 0.50 FM1 (KBr): C═O 1663/1734 N66 ASS 90 ESI: (M + H)⁺ = 0.78 FM1 (KBr): C═O 607/09/11 (Br₂) 1637/1663/ 1740 N66 AS22 68 0.74 FM1 N66 AS23 100 (KBr): C═O 1738/1662 N66 AS25 100 ESI: (M + H)⁺ = 0.52 FM1 472 N66 AS49 100 0.80 FM1

EXAMPLE A37

Preparation of Compounds ofGeneralFormula:

4-amino-3,5-dibromo-N²-[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-D-phenylalanine

To a solution of 2.8 g (4.9 mmol) of methyl 4-amino-3,5-dibromo-N²-[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-D-phenyl-alanine in a mixture of 30 ml of methanol and 20 ml of water were added 0.25 g (10.0 mmol) of lithium hydroxide and the mixture was then stirred for 3 hours at room temperature. After the addition of 2.0 g (50 mmol) of sodium hydroxide the mixture was diluted with 50 ml of water. The reaction mixture was stirred for 15 minutes in an ultrasound bath, then stirred over-night at room temperature and evaporated down in vacuo. The residue was mixed with 100 ml of water and the aqueous phase was extracted twice with 50 ml of ether. By the addition of 2 M aqueous hydrochloric acid the aqueous phase was adjusted to a pH of 3-4 and extracted three times with ethyl acetate. The combined ethyl acetate phases were washed once with water, then dried and evaporated down in vacuo. 1.6 g (58% of theory) of a yellowish-brown oil were obtained.

IR (KBr): 1616, 1724 cm⁻¹ (C═O)

R_(f): 0.33 (ethyl acetate/methanol=8/2 (v/v))

ESI-MS: (M+H)⁺=557/559/561/563 (Br₂, Cl)

The following were prepared in the same way (in each case n=1):

% RCO Z R² Remarks Yield MS R_(f) Eluant IR [cm⁻¹] N8 N—H AS4 62 ESI: (M − H)⁻ = 0.61 Ethyl acetate/ (KBr): C═O 482/4/6 (Br₂) methanol = 6/4 1612.4; (v/v) 1724.3; —OH, —NH— 3386.8; 3483.2 N15 N—H AS4 64 ESI: (M − H)⁻ = 0.10 Ethyl acetate/ (KBr): C═O 578/80/82 methanol = 8/2 1703.0 (Br₂); (M + H)⁺ = (v/v) 580/2/4 (Br₂); (M + Na)⁺ = 602/4/6 (Br₂) N23 N—H AS4 58 ESI: (M − H)⁻ = 0.33 Ethyl acetate/ (KBr): C═O 557/59/61/63 methanol = 8/2 1616.3; (Br₂, Cl) (v/v) 1724.3 N15 N—H AS1 No addition 59 ESI: (M − H)⁻ = 0.72 EE/MeOH/ (KBr): C═O of sodium 579/81/83 (Br₂) NH₄OH = 6/4/1 1695.3 hydroxide (v/v/v) N66 N—H AS21 95 0.48 EE/AcOH (KBr): C═O 10/0.02 (v/v) 1639 N66 CH₂ AS1 85 0.38 CH₂Cl₂/MeOH/ AcOH 9/1/0.15 (v/v/v) N71 CH₂ AS1 66.6 ESI: (M + H)⁺ = 0.38 CH₂Cl₂/MeOH/ (KBr): C═O 606/08/10 (Br₂) AcOH 9/1/0.15 1622/1680 (v/v/v) N66 N—H AS18 100 ESI: (M − H)⁻ = 0.26 EE/AcOH 9/0.01 557 (v/v) N66 N—H AS19 98 0.22 CH₂Cl₂/MeOH/ (KBr): C═O AcOH 9/1/0.15 1665/1740 (v/v/v) N66 N—H ASS 73 ESI: (M − H)⁻ = 0.23 FM1 (KBr): C═O 577/79/81 (Br₂) 1632/1705 N66 N—H AS22 78 0.30 FM1 (KBr): C═O 1668/1739 N66 CH₂ AS21 79 0.34 EE/AcOH 9/0.01 (KBr): C═O (v/v) 1643/1703 N66 CH₂ AS1 90 0.30 EE/MeOH 9/1 (v/v) N15 CH₂ AS1 78 ESI: (M − H)⁻ = 0.30 EE/AcOH 9/0.01 (KBr): C═O 578/80/82 (Br₂) (v/v) 1728/1672 N66 N—H AS25 99 N66 CH₂ AS2 100 (KBr): C═O 1645/1712 N66 CH₂ AS23 70 N139 CH₂ AS2 50 (KBr): C═O 1630/1662/ 1707 N66 CH₂ AS27 93 0.20 FM1 N66 CH₂ AS28 LiOH 100 0.30 FM1 N66 CH₂ AS4 72 0.53 FM1 (KBr): C═O 1639/1701 N66 CH₂ AS36 74 ESI: (M − H)⁻ = 0.36 FM1 (KBr): C═O 434 1645/1701 N66 CH₂ AS38 69 N66 CH₂ AS48 47 EI: M⁺ = 0.30 FM1 (KBr): C═O 489 1645 N66 N—H AS49 47 0.10 FM1 N66 CH₂ AS18 60 0.15 EE N66 CH₂ AS39 96 N109 CH₂ AS21 81 N113 CH₂ AS21 76 0.20 EE/AcOH 99/1 N134 CH₂ AS21 89 0.15 EE/AcOH 99/1 N66 CH₂ AS47 100 ESI: (M + H)⁺ = (KBr): C═O 476 1645/1716 N66 CH₂ AS7 60 0.20 FM1 (KBr): C═O 1649/1722 N66 CH₂ AS52 95 ESI: (M + H)⁺ = 0.15 FM1 (KBr): C═O 480 1643/1722

EXAMPLE A38

Preparation of Compounds ofGeneralFormula:

3,5-dibromo-N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-D-tyrosine

A mixture of 24 g (46.3 mmol) of methyl 3,5-dibromo-N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-D-tyrosine and 5.0 g (50 mmol) of lithium hydroxide in 200 ml of water was stirred for 1 hour at 60 C. The solid product was suction filtered and the filtrate was washed with 200 ml of ethyl acetate. By the addition of 1 M aqueous hydrochloric acid the aqueous phase was adjusted to a pH of 3-4 and extracted 3 times with 150 ml of ethyl acetate. The combined ethyl acetate phases were washed once with water, dried over sodium sulphate and evaporated down in vacuo. The residue was triturated with ether. 9.1 g (38% of theory) of a colourless solid were obtained.

IR (KBr): 1719 cm⁻¹ (C═O)

R_(f): 0.57 (ethyl acetate/methanol/glacial acetic acid=9.5/0.5/0.2 (v/v/v))

The following were prepared in the same way (in each case n=1):

% RCO Z R² Remarks Yield MS R₁ Eluant IR [cm⁻¹] N6 N—H AS1 100 0.20 FM1 (KBr): C═O 1625.9; 1730 N15 N—H AS6 H₂O/MeOH = 85 ESI: 0.53 EE/MeOH/ (KBr): C═O 1/1 (v/v) as (M − H)⁻ = AcOH = 9/1/0.1 1695.3 solvent 501/3 (Br) (v/v/v) N2 N—H AS1 75 0.57 EE/methanol/ (KBr): C═O glacial acetic 1718.5 acid = 9.5/0.5/0.2 (v/v/v) N2 N—H AS2 71 0.20 FM1 (KBr): C═O 1625.9; 1693.4; 1718.5; —NH— 3357.9 N15 N—H AS3 H₂O/MeOH = 57 0.30 EE/MeOH = 1/1 (KBr): C═O 1/1 (v/v) as (v/v) 1693.4 solvent N66 AS1 75 0.05 EE/MeOH 8/2 N66 AS4 85 N122 AS1 44 N122 AS4 85 N66 N—CH₃ AS1 58 ESI: (M − H)⁻ = 0.20 EE (KBr): C═O 607/09/11 (Br₂) 1607/1655/ 1711 N66 N—H AS17 55 0.03 FM1 N15 CH₂ AS1 78 ESI: (M − H)⁻ = 0.30 EE/MeOH 9/1 (KBr): C═O 578/80/82 (Br₂) (v/v) 1672/1728 N66 N—H AS23 79.0 0.22 FM1 (KBr): C═O 1738/1664

EXAMPLE A39 methyl N⁶-[(1,1-dimethylethoxy)carbonyl]-N²—[N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysine

To a mixture of 10 g (19.4 mmol) of 3,5-dibromo-N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-D-tyrosine, 2.6 g (20 mmol) of DIEA, 6.4 g (20 mmol) of TBTU, 2.64 g (19.5 mmol) of HOBt and 200 ml of dimethylformamide was added dropwise, with stirring, a solution of 5.04 g (19.4 mmol) of H-Lys(Boc)-OMe in 50 ml of dimethylformamide and the mixture was stirred over-night at room temperature. The reaction mixture was evaporated down in vacuo and the residue was taken up in 250 ml of ethyl acetate. The ethyl acetate phase was then washed twice with 100 ml of saturated aqueous sodium hydrogen carbonate solution, once with 100 ml of 20% aqueous citric acid solution and finally once with 100 ml of saturated aqueous saline solution. The organic phase was dried with sodium sulphate, evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/petroleum ether=2/1 (v/v)). After removal of the solvent in vacuo the residue was triturated with ether, the amorphous solid obtained (9.5 g; 660 of theory) was suction filtered and dried.

IR (KBr): 1632, 1657, 1682, 1734 cm⁻¹ (C═0) R_(f): 0.64 (ethyl acetate) ESI-MS: (M + H)⁺ = 757/759/761 (Br₂) (M + Na)⁺ = 779/781/783 (Br₂)

EXAMPLE A40 N⁶-[(1,1-dimethylethoxy)carbonyl]-N²—[N-[[(2-(3-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-n-tyrosyl]-L-lysine

A mixture of 7.75 g (10.4 mmol) of methyl N⁶-[(1,1-dimethyl-ethoxy)carbonyl]-N²-[N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysine, 3.5 g (140 mmol) of lithium hydroxide and 150 ml of water was stirred overnight at room temperature. The aqueous phase was washed once with ethyl acetate, acidified by the addition of 1 M aqueous potassium hydrogen sulphate solution and then extracted with ethyl acetate. The organic phase was dried over sodium sulphate and evaporated down in vacuo. 6.9 g (910 of theory) of a yellowish oil were obtained.

IR (KBr): 1653 cm⁻¹ (C═O)

R_(f): 0.7 (ethyl acetate/methanol/glacial acetic acid=9/0.5/0.5 (v/v/v))

ESI-MS (M-H)⁻=741/743/745 (Br₂)

EXAMPLE A41 1-[N²—[N-(phenylmethoxycarbonyl)-3,5-dichloro-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

A mixture of 5 g (13.0 mmol) of 3,5-dichloro-N-[(phenylmethoxy)carbonyl]-D-tyrosine, 5.1 g (13.0 mmol) of 1-[N⁶-[(1,1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, 1.81 g (14 mmol) of DIEA, 4.17 g (13 mmol) of TBTU, 1.75 g (13.0 mmol) of HOBt and 200 ml of tetrahydrofuran was stirred at room temperature overnight. The reaction mixture was evaporated down in vacuo, the residue was taken up in ethyl acetate/methanol (95/5) and washed twice with saturated aqueous sodium hydrogen carbonate solution. The organic phase was dried, evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol=6/4 (v/v)). 6.0 g (61% of theory) of a yellowish oil were obtained.

R_(f): 0.47 (FM1)

ESI-MS (M+H)⁺=757/759/761 (Cl₂)

EXAMPLE A42

Preparation of Compounds ofGeneralFormula:

1-[N²—[N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-N6-[(1,1-dimethylethoxy)-carbonyl]-L-lysyl]-4-(1-methyl-4 -]piperidinyl)-piperazine

To a mixture of 1.1 g (1.5 mmol) of N⁶-[(dimethylethoxy)-carbonyl]-N²-[N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysine, 0.79 g (6.1 mmol) of DIEA, 0.52 g (1.6 mmol) of TBTU, 0.2 g (1.5 mmol) of HOBt and 100 ml of dimethylformamide was added dropwise a solution of 0.44 g (1.5 mmol) of 1-(1-methyl-4-piperidinyl)-piperazine in 30 ml of dimethylformamide at room temperature, the mixture was then stirred overnight and evaporated down in vacuo. The residue was taken up in ethyl acetate/methanol (95/5), washed twice with 70 ml of aqueous saturated sodium hydrogen carbonate solution, dried over sodium sulphate and evaporated down in vacuo. 1.1 g (81% of theory) of a colourless foam were obtained.

-   R_(f): 0.34 (ethyl acetate/methanol/conc. aqueous ammonia 7/2/1     (v/v/v))

The following was prepared analogously (n=1)

% RCO R² A NR³R⁴ Remarks Yield R_(f) Eluant IR [cm⁻¹] N15 AS1 A11 C1 KHSO₄ solution 70 0.40 FM3 (KBr): C═O 1697.3; 1641.3

EXAMPLE A43 1-[N²-(3,5-dichloro-D-tyrosyl)-N⁶-[(1,1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

A solution of 6 g (7.9 mmol) of 1-[N²—[N-[(phenylmethoxy)carbonyl]-3,5-dichloro-D-tyrosyl]-N⁶-[(1,1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine in a mixture of 200 ml of methanol and 20 ml of aqueous 1 M potassium hydrogen sulphate solution was hydrogenated in the presence of 0.5 g palladium black as catalyst at room temperature under 3 bar of hydrogen pressure for 40 minutes. The catalyst was filtered off, the reaction mixture was evaporated to dryness in vacuo and the residue adjusted to a pH of about 10 by the addition of 2 ml of concentrated aqueous ammonia solution. The product was extracted several times with isopropanol, the combined isopropanol extracts were evaporated down in vacuo and the residue was purified by column chromatography (LiChroprep, Si60 particle size: 20-40 μm, Messrs. Merck (Darmstadt); eluant: methylene chloride/methanol/ammonia=350/75/75/10 (v/v/v/v)). 2.5 g (51% of theory) of a colourless amorphous solid substance were obtained.

IR (KBr): 1641, 1705 cm⁻¹ (C═O)

R_(f): 0.27 (FM1)

EXAMPLE A44

Preparation of Compounds ofGeneralFormula: Fmoc-A-NR³R⁴

1-[N²-[(9-fluorenylmethoxy)carbonyl]-N^(G)-(2,2,5,7,8-pentamethylchroman-6-sulphonyl)-L-arginyl]-4-(4-pyridinyl)-piperazine

To a mixture of 7.0 g (10.6 mmol) of Fmoc-Arg(Pmc)-OH, 1.42 g (11.0 mmol) of DIEA, 3.53 g (11.0 mmol) of TBTU, 1.35 g (11.0 mmol) of HOBt and 50 ml of DMF was added dropwise with stirring a solution of 1.74 g (10.6 mmol) of 1-(4-pyridinyl)-piperazine in 20 ml of DMF. The reaction mixture was stirred for a further 3.5 hours at room temperature and then evaporated down at 40° C. in a high vacuum. The residue was dissolved in ethyl acetate, the organic phase was washed twice with saturated aqueous sodium hydrogen carbonate solution, dried over sodium sulphate and evaporated down in vacuo. The residue was triturated with diethylether, suction filtered and dried. 7.85 g (96% of theory) of the desired end product were obtained, which was reacted without further purification.

R_(f): 0.5 (FM1)

The following was prepared analogously:

% A NR³R⁴ Yield R_(f) Eluant IR [cm⁻¹] A3 C18 60 0.55 FM4 (KBr): C═O 1643; 1711

EXAMPLE A45

Preparation of compounds of general formula: H-A-NR³R⁴

1-[N^(G)-(2,2,5,7,8-pentamethylchroman-6-sulphonyl)-L-arginyl]-4-(4-pyridinyl )-piperazine

A solution of 8.5 g (11.1 mmol) of 1-[N²-[(9-fluorenylmethoxy)carbonyl]-N^(G)-(2,2,5,7,8-pentamethylchroman-6-sulphonyl)-L-arginyl]-4-(4-pyridinyl)-piperazine in 100 ml of THF was mixed with 16 ml of diethylamine and then stirred for 2.5 hours at room temperature. The reaction mixture was evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: FM1). 3.3 g (54% of theory) of an amorphous solid were obtained.

R_(f):=0.19(FM1)

IR(KBr): 1637 cm⁻¹ (C═O)

The following was prepared analogously:

% A NR³R⁴ Yield R_(f) Eluant IR [cm⁻¹] A3 C18 80 (KBr): C═O 1637.5; 1705

EXAMPLE A46 1-[N⁶,N⁶-dimethyl-N²-[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

9.6 g (18.3 mmol) of 1-[N⁶-[(1,1-dimethylethoxy)carbonyl]-N²-[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine were stirred overnight in 200 ml of a 5% solution of trifluoroacetic acid in dichloromethane. The reaction mixture was then evaporated down in vacuo. 13.47 g (97% of theory) of the desired 1-[N²-[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine were obtained as the trifluoroacetate salt. Then 7.0 g (9.1 mmol) of the crude product were dissolved in 200 ml of water and 4.1 ml of a 40% formaldehyde solution (45.6 mmol) were added whilst cooling with an ice bath. The reaction mixture was stirred for 10 minutes at room temperature, carefully mixed with 1.5 g (40 mmol) of sodium borohydride whilst cooling with an ice bath, then mixed with 4.1 ml of a 40% formaldehyde solution (45.6 mmol) whilst cooling externally with ice, after which the reaction mixture was stirred for a further 10 minutes at room temperature and again mixed with 1.5 g (40 mmol) of sodium borohydride whilst cooling with an ice bath. The pH of the reaction mixture was monitored continuously during the reaction and kept between pH 3 and pH 6 by dropwise addition of trifluoroacetic acid. The mixture was then stirred for 30 minutes at 5° C., adjusted to pH 10 by the addition of potassium carbonate and extracted four times with 50 ml of ethyl acetate. The combined organic phases were dried, evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol/conc. aqueous ammonia=6.5/3/0.3 (v/v/v)). 2.3 g (56% of theory) of a colourless oil were obtained.

IR (KBr): 1711, 1649 cm⁻¹ (C═O)

R_(f): 0.2 (FM7)

ESI-MS: (M+H)⁺=454.

EXAMPLE A47

Preparation of compounds of general formula:

methyl (R,S)-4-amino-3,5-dibromo-γ-oxo-β-[[4-(4-pyridinyl)-1-piperidinyl]methyl]-benzenebutanoate

A mixture of 10 g (27 mmol) of methyl 4-amino-3,5-dibromo-γ-oxo-benzenebutanoate, 5.4 g (27 mmol) of 4-(4-pyridinyl)-piperidine and 1.5 g (45 mmol) of paraformaldehyde was suspended in 20 ml of glacial acetic acid and heated with stirring in an oil bath (bath temperature: 100° C.). After 3 hours a further 1.5 g (45 mmol) of paraformaldehyde were added and the mixture was stirred for a further 3 hours at 100° C. and then for 1 hour at 125° C. The solvent was removed in vacuo and the residue was taken up in 800 ml of water. The aqueous phase was made alkaline by the addition of sodium carbonate and extracted twice with 500 ml of ethyl acetate. The combined ethyl acetate extracts were dried, evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey Nagel, 70-230 mesh ASTM, eluant: ethyl acetate/methanol=9:1)). 1.0 g (6.8% of theory) of the desired end product were obtained as an oil.

IR(KBr): 1716.5 cm⁻¹

R_(f): 0.7 (FM1)

The following was prepared analogously:

% A NR³R⁴ Yield R_(f) Eluant IR [cm⁻¹] AS4 C8 35 0.68 FM1 KBr: C═O 1672.2; 1733.9

EXAMPLE A48

Preparation of compounds of general formula:

(R,S)-4-amino-3,5-dibromo-γ-oxo-β-[[4-(4-pyridinyl)-1-piperidinyl]methyl]-benzenebutanoic acid

A mixture of 1.0 g (1.9 mmol) of methyl (R,S)-4-amino-3,5-dibromo-γ-oxo-β-[[4-(4-pyridinyl)-1-piperidinyl]methyl]-phenyl-butanoate, 5 ml of 1 N sodium hydroxide solution and 50 ml of dioxane was stirred overnight at room temperature and for 1 hour at 60° C. The reaction mixture was then neutralised by the addition of 5 ml of 1N hydrochloric acid, evaporated down in vacuo and the residue was dried in a vacuum drying chamber. 0.97 g (100% of theory) of the desired product was obtained, which was further reacted without any purification.

R_(f): 0.15 (FM1)

The following was prepared analogously:

% A NR³R⁴ Yield R_(f) Eluant IR [cm⁻¹] AS4 C8 96 0.2 FM1 KBr: C═O 1660

EXAMPLE A49 3,5-dibromo-4-hydroxy-β-(methoxycarbonyl)-benzenitannic acid

To a solution of 12 g (0.043 mol) of 4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid in 200 ml of acetic acid were added 150 ml of water and 8 g of sodium acetate, a solution of 5 ml of bromine in 60 ml of acetic acid was added dropwise with stirring, then the reaction mixture was extensively evaporated down in vacuo and the residue was stirred into water. The aqueous phase was repeatedly extracted with ethyl acetate, and the combined organic phases were washed with water. The organic extracts were dried, evaporated down in vacuo and the solid residue was recrystallised from diisopropylether. 12 g (70% of theory) of the desired end product were obtained.

R_(f): 0.4 (ethyl acetate/petroleum ether/glacial acetic acid=5/5/0.4 (v/v/v)

ESI-MS: (M+H)⁺=394/6/8 (Br₂)

EXAMPLE A50

Preparation of compounds of general formula:

methyl (R,S)-2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]-4-oxo-butanoate

A solution of 2.0 g (5 mmol) of 3,5-dibromo-4-hydroxy-β-(methoxycarbonyl)-benzenebutanoic acid in 80 ml of THF was mixed with 1.6 g (5 mmol) of TBTU, 0.76 g (5 mmol) of HOBt, 1.25 g (5 mmol) of 4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)piperidine and 1.03 g (8 mmol) of DIEA with stirring. The reaction mixture was stirred for 6 hours at room temperature and then evaporated down in vacuo. The residue was mixed with saturated aqueous sodium hydrogen carbonate solution and extracted several times with ethyl acetate. The combined organic extracts were washed successively with saturated aqueous sodium hydrogen carbonate solution and water, dried over sodium sulphate and evaporated down in vacuo. 3.0 g (50% of theory) of the desired product was obtained, which was further reacted without purification.

IR (KBr): 1714.8 cm⁻¹ (C═O)

R_(f): 0.7 (ethyl acetate/petroleum ether=7/3 (v/v))

The following were prepared analogously:

% RCO R² Yield MS R_(f) Eluant IR [cm⁻¹] N66 AS1 98 0.66 FM1 N66 AS2 100 0.77 FM1 (KBr): C═O 1664/1734 N139 AS2 100 EI: M⁺ = 0.30 FM1 (KBr): C═O 486 1643/1672/ 1732 N66 AS4 28 EI: M⁺ = 0.33 FM4 (KBr): C═O 606/08/10 1666/1734 (Br₂) N66 AS36 63 0.56 FM4 N66 AS38 92 N66 AS48 100 0.68 FM1 N66 AS18 22 N66 AS39 100 N109 AS21 39 0.35 EE (KBr): C═O 1639/1734 N113 AS21 57 0.15 EE/PE 95/5 N134 AS21 80 0.15 EE N66 AS7 100 0.75 FM1 N66 AS53 40

EXAMPLE A51 (R)-1-[2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propyl]-4-(1-piperidinyl)-piperidine

To a suspension of 3.8 g (100 mmol) of lithium aluminium hydride in 400 ml of THF were added in batches, with stirring and at room temperature, 14.4 g (20 mmol) of 1-(3,5-dibromo-D-tyrosyl)-4-(1-piperidinyl)-piperidine within 30 minutes. The reaction mixture was kept for 30 minutes at room temperature and refluxed for 2 hours and then neutralised by the careful addition of 1 ml of water and 5.1 ml of concentrated aqueous hydrochloric acid. After the addition of 100 ml of methanol the solid precipitate was suction filtered and the filtrate was evaporated down in vacuo. The residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: methylene chloride/methanol/conc. aqueous ammonia=8/2/0.2 (v/v/v)). 5.4 g (57% of theory) of the desired product was obtained as an amorphous solid.

IR (KBr): 3420 cm⁻¹ (NH₂)

R_(f): 0.4 (FM2)

ESI-MS: M⁺=473/475/477 (Br₂)

The following was prepared analogously:

(R)-1-[2-amino-3-(4-amino-3,5-dibromophenyl)propyl]-4-(1-piperidinyl)-piperidine from 1-(4-amino-3,5-dibromo-D-phenylalanyl)-4-(1-piperidinyl)-piperidine in a yield of 56.5% of theory, R_(f) 0.12 (eluant: dichloromethane/methanol/cyclohexane/conc. ammonia 7/1.5/1.5/0.2 (v/v/v/v)).

EXAMPLE A52 (R)-1-[3-(4-amino-3,5-dibromophenyl)-2-[N-[(1,1-dimethylethoxy)carbonyl]amino]propyl]-4-(1-piperidinyl)-piperidine

To a solution of 10 g (0.017 mol) of 1-[4-amino-3,5-dibromo-N-[(1,1-dimethylethoxy)carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine in 350 ml of dioxane were added 3.1 g (0.082 mol) of sodium borohydride and the reaction mixture was cooled to 5° C. Then a solution of 4.92 g (0.082 mol) of acetic acid in 100 ml of dioxane was added dropwise with stirring. The reaction mixture was stirred for a further hour at room temperature and for 3 hours at 85° C. Then ice water was added, the organic solvent was removed in vacuo and the aqueous residue was repeatedly extracted with methylene chloride. The combined organic phases were dried, evaporated down in vacuo and the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: methylene chloride/methanol/cyclohexane/conc. aqueous ammonia=3600/150/150/20 (v/v/v/v). 4.1 g (42% of theory) of a colourless foam were obtained.

IR (KBr): 1705 cm⁻¹ (C═O)

EXAMPLE A53 (R)-1-[2-amino-3-(4-amino-3,5-dibromophenyl)propyl]-4-(1-piperidinyl)-piperidine

To a mixture of 4 g (7 mmol) of (R)-1-[3-(4-amino-3,5-dibromophenyl)-2-[N-[(1,1-dimethylethoxy)carbonyl]-amino]propyl]-4-(1-piperidinyl)-piperidine and 100 ml of methylene chloride, 40 ml of trifluoroacetic acid were slowly added dropwise, with stirring, at 10° C. The reaction mixture was stirred for 2 hours at room temperature and then evaporated down in vacuo. The residue was mixed with ice water, made basic by the addition of concentrated aqueous ammonia solution and extracted three times with 200 ml of diethylether. The combined ether extracts were dried and evaporated down in vacuo. 3.4 g (100% of theory) of an amorphous solid were obtained.

IR (KBr): 1683.8, 1616.3 (C═O)

R_(f): 0.02(FM 4)

EXAMPLE A54 methyl (R,S)-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-4-oxo-2-[[3-(trifluoromethyl)phenyl]-methyl]-butannate

Prepared analogously to Example A15a) from methyl (R,S)-3-carboxy-2-[[3-(trifluoromethyl)phenyl]methyl]-propanoate and 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone in a yield of 27.3% of theory. Colourless, amorphous substance, R_(f)=0.25 (eluant: ethyl acetate).

MS: M⁺=503

The following was obtained in the same way:

methyl (R,S)-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-4-oxo-2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-butanoate from methyl (R,S)-3-carboxy-2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-propanoate and 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone in a yield of 98% of theory, R_(f)=0.66 (eluant: dichloromethane/cyclohexane/methanol/conc. ammonia 7/1.5/1.5/0.2 (v/v/v/v)).

EXAMPLE A55 (R,S)-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-4-oxo-2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-butanoic acid

A mixture of 3.0 g (4.92 mmol) of methyl (R,S)-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-4-oxo-2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-butanoate, 30 ml (30 mmol) of 1N sodium hydroxide solution and 20 ml of methanol was stirred for 3 hours at room temperature, then diluted with 100 ml of water and 30 ml of 1N hydrochloric acid were added dropwise. The precipitate was suction filtered and dried at 50° C. in a circulating air drier. Colourless, amorphous substance , R_(f)=0.38 (eluant: dichloromethane/methanol/glacial acetic acid 9/1/0.15 (v/v/v)). Yield: 2.5 g (85.4% of theory).

The following was obtained in the same way:

(R,S)-4-[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-4-oxo-2-[[3-(trifluoromethyl)phenyl]methyl]-butanoic acid from methyl(R,S)-4-[4-[3,4-dihydro-2(1H)-oxo-quinazolin-3-yl]-1-piperidinyl]-4-oxo-2-[[3-(trifluoromethyl)-phenyl]methyl]-butanoate in a yield of 79% of theory, R_(f)=0.34 (eluant: ethyl acetate/glacial acetic acid 99.8/0.2 (v/v)).

IR(KBr): 1703, 1643 cm⁻¹ (C═O)

EXAMPLE A56 Methyl 3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-N-methyl-D-tyrosine a) 1-(chlorocarbonyl)-4-[3,4-dihydro-2(1H)-oxoquinazolin-yl]piperidine

To a mixture of 7.0 ml (about 14 mmol) of a 20% solution of phosgene in toluene and 2.02 g (20 mmol) of triethylamine in 300 ml of tetrahydrofuran was added in batches, while maintaining a reaction temperature of about 0° C., a suspension of 1.5 g (5.60 mmol) of 4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]piperidine-hydrochloride in 100 ml of tetrahydrofuran. The mixture was stirred for another hour at a temperature between 0° C. and +5° C., filtered to remove the resulting triethylamine-hydrochloride and the filtrate was freed from solvent. The residue was triturated with diisopropyl ether and suction filtered. After drying in vacuo 0.7 g (42.6% of theory) of colourless crystals were obtained, R_(f)=0.17 (eluant: dichloromethane/acetone 9.5/0.5 (v/v)), which was further processed without any further purification.

b) Methyl 3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-N-methyl-D-tyrosine

To a solution of 4.9 g ( 13.3 mmol) of methyl 3,5-dibromo-N-methyl-D-tyrosine and 4.04 g (40 mmol) of triethylamine in 500 ml of tetrahydrofuran was added dropwise, at room temperature, within 3 hours, a solution of 3.92 g (13.34 mmol) of 1-(chlorocarbonyl)-4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]piperidine in 1 l tetrahydrofuran. The mixture was then heated for 12 hours to reflux temperature, left to cool and filtered to remove the precipitated triethylamine. The filtrate was evaporated down, the residue was divided between ethyl acetate and 20% aqueous citric acid. The organic phase was dried over sodium sulphate, again evaporated down in vacuo, the residue was purified by column chromatography over silica gel using ethyl acetate/petroleum ether 9/1 (v/v) as eluant. Working up the appropriate fractions yielded 3.2 g (38.5% of theory) of a colourless, amorphous substance, R_(f)=0.45 (eluant: ethyl acetate)

IR (KBr): 1739.7, 1660.6 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 623/625/627 (Br₂) (M + Na)⁺ = 0 645/647/649 (Br₂) (M + K)⁺ = 661/663/665 (Br₂)

EXAMPLE A57 Methyl 3,5-dibromo-4-methoxy-D-phenylalanine

To a mixture of 5.5 g (14.12 mmol) of 3,5-dibromo-4-methoxy-D-phenylalanine-hydrochloride and 55 ml of methanol were added 150 ml of a saturated methanolic hydrogen chloride solution and the mixture was stirred for 20 hours at room temperature. The residue remaining after evaporation of the solvent was stirred with 50 ml of water and adjusted to pH 8 with saturated sodium hydrogen carbonate solution. The precipitate was suction filtered, stirred with 10 ml of isopropanol and left to stand overnight. The insoluble matter was filtered off and the filtrate was evaporated down in vacuo. The residue was further reacted as a crude product. Yield: 1.0 g (28.7% of theory) of a colourless oil , R_(f)=0.55 (eluant:dichloromethane/ethyl acetate/cyclohexane/methanol/conc. ammonia=300/80/25/25/3 (v/v/v/v/v)).

EXAMPLE A58 1-(4-amino-3,5-dibromo-D-phenylalanyl)-4-(4-pyrimidinyl)-piperazine a) 1-(2-chloro-4-pyrimidinyl )-4-(phenylmethyl)piperazine

A mixture of 9.9 g (0.0664 mol) of 2,4-dichloropyrimidine, 200 ml of water and 11.7 ml (0.0673 mol) of 1-(phenylmethyl)piperazine was heated to 40° C. for 2 hours in an ultrasound bath. After cooling the mixture was made alkaline with potassium carbonate and extracted thoroughly with ethyl acetate. The crude product obtained after working up in the usual way was purified by column chromatography over silica gel (30-60 μm) using FM2 and FM4 (2/1 v/v) as eluant. Working up the appropriate fractions yielded 7.4 g (38.6% of theory) of a colourless oil, R_(f)=0.51 (FM4; Macherey-Nagel POLYGRAM® SIL G/UV₂₅₄, ready-made films for TLC).

MS: M⁺=288/290 (Cl)

b) 1-(4-pyrimidinyl)piperazine

A solution of 7.4 g (0.0256 mol) of 1-(2-chloro-4-pyrimidinyl)-4-(phenylmethyl)piperazine in 100 ml of ethanol was hydrogenated in the presence of 2 g of 10% palladium/charcoal for 4 hours at 40° C. under 5 bar of hydrogen pressure. The crude product obtained after conventional working up was purified by column chromatography over silica gel (30-60 μm) using FM1/cyclohexane 9/1 (v/v) as eluant. Colourless crystals, R_(f)=0.3 (FM1/cyclohexane 9/1 (v/v)); Macherey-Nagel POLYGRAM® SIL G/UV₂₅₄, ready-made films for TLC). Yield: 1.7 g (40.7% of theory).

c) 1-[4-amino-3,5-dibromo-N-(1,1-dimethylethoxycarbonyl)-D-phenylalanyl)-4-(4-pyrimidinyl)piperazine

Prepared analogously to Example A15a) from 4-amino-3,5-dibromo-N-(1,1-dimethylethoxycarbonyl)-D-phenylalanine and 1-(4-pyrimidinyl)piperazine in the presence of TBTU in a yield of 92% of theory. Colourless, amorphous substance, R_(f)=0.42 (FM4; Macherey-Nagel POLYGRAM® SIL G/UV₂₅₄, ready-made films for TLC).

IR(KBr): 1705.0, 1643.3 cm⁻¹ (C═O)

MS: M⁺=582/584/586 (Br₂)

d) 1-(4-amino-3,5-dibromo-D-phenylalanyl)-4-(4-pyrimidinyl)piperazine

Prepared analogously to Example A1b) from 1-[4-amino-3,5-dibromo-N-(1,1-dimethylethoxycarbonyl)-D-phenylalanyl)-4-(4-pyrimidinyl)piperazine in a yield of 52% of theory. Colourless, amorphous substance, R_(f)=0.55 (FM1; Macherey-Nagel POLYGRAM® SIL G/UV₂₅₄, ready-made films for TLC).

IR(KBr): 1681.8 cm⁻¹ (C═O)

MS: M⁺=482/484/486 (Br₂)

EXAMPLE A59

Preparation of Compounds ofGeneralFormula:

(R,S)-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-(1,1-dimpthylathyl)phenyl]methyl]-4-oxobutanoic acid

A mixture of 4.8 g (8.3 mMol) of ethyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-(1,1-dimethylethyl)-phenyl]methyl]-2-(ethoxycarbonyl)-4-oxobutanoate, 200 ml of ethanol and 41.5 ml of 1N sodium hydroxide solution was refluxed for 3 hours.

The ethanol was removed in vacuo, then the residue was diluted with 50 ml of water and adjusted to pH 3 with 1N aqueous hydrochloric acid. The precipitated substance was suction filtered, thoroughly washed with water and then dried in vacuo. 3.8 g (96w of theory) of colourless crystals of Mp. 139

141° C. were obtained, R_(f)=0.65 (eluant:EE/MeOH/glacial acetic acid 90/10/1 v/v/v).

IR(KBr): 1724, 1647 cm⁻¹ (C═O)

MS: no M⁺, m/e=246, 231, 147

The following were prepared analogously:

% R² Remarks Yield MS R_(f) Eluant IR [cm⁻¹] AS29 100 AS16 17 ESI: (M + H)⁺ = 0.30 EE/MeOH/ 488/90/92 (Cl₂) AcOH 80/10/1 ASS 62 0.60 CH₂Cl₂/MeOH/ NH₄OH 90/10/1 AS32 100 ESI: (M + Na)⁺ = 0.67 EE/MeOH/ (KBr): C═O 614/6/8 (Br₂) AcOH 90/10/1 1645/1728 AS33 90 EI: M⁺ = 525 0.20 EE/MeOH/ (KBr): C═O AcOH 90/10/1 1643/1701 AS31 100 0.20 CH₂Cl₂/MeOH/ NH₄OH 80/20/1 AS17 100 ESI: (M + H)⁺ = 0.50 EE/MeOH/ (KBr): C═O 608/10/12 (Br₂) AcOH 90/10/1 1643 AS34 76 ESI: (M − H)⁻ = 0.65 EE/MeOH/ 506 AcOH 90/10/1 AS19 70 0.46 EE/MeOH/ (KBr): C═O AcOH 9/1/0.5 1643/1701 AS46 78 ESI: (M − H)⁻ = 0.20 FM1 (KBr): C═O 471 1647 AS50 97 0.05 EE AS2 LiOH instead 86 ESI: (M + H)⁺ = (KBr): C═O of NaOH 472 1643/1705 AS29 100 ESI: (M − H)⁻ = (KBr): C═O 448 1645/1705 AS31 87

EXAMPLE A60

Preparation of Compounds ofGeneralFormula:

Ethyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[4-(1,1-dimethylethyl)phenyl]methyl]-2-(ethoxy-carbonyl)-4-oxobutanoate

A mixture of 2.31 g (10 mMol) of 4-(3,4-dihydro-2(1H)-oxo-quinazolin-3-yl)-piperidine, 3.64 g (10 mMol) of β,β-bis-(ethoxycarbonyl)-4-(1,1-dimethylethyl)-benzenebutanoic acid, 5 ml of triethylamine, 3.5 g (11 mMol) of TBTU, 200 ml of tetrahydrofuran and 20 ml dimethylformamide was stirred for 5 hours at room temperature. The solvent was removed in vacuo and the residue taken up in dichloromethane, the resulting solution was dried over sodium sulphate and freed from the solvent. After purification by column chromatography on 400 g of silica gel (Amicon, 35-70 μm, ethyl acetate as eluant), 4.8 g (83% of theory) of a colourless, amorphous substance were obtained, R_(f)=0.63 (eluant:EE).

IR(KBr): 1734, 1668, 1653 cm⁻¹ (C═O)

MS: M⁺=577 (Br₂)

The following were prepared analogously:

R² % Yield MS R_(f) Eluant IR [cm⁻¹] AS29 75 0.8 FM1 AS16 59 0.5 EE AS5 65 EI: M⁺ = 0.7 FM4 (KBr): C═O 677/79/81 1649/1668/ (Br₂) 1734 AS32 74 0.5 FM4 (KBr): C═O 1647/1668/ 1734 AS33 85 0.5 EE (KBr): C═O 1649/1734 AS31 82 EI: M⁺ = 574 0.5 CH₂Cl₂/MeOH/ (KBr): C═O NH₄OH 90/10/1 1658/1741 AS17 93 EI: M⁺ = 0.5 EE (KBr): C═O 707/09/11 1645/1666/ (Br₂) 1736/1759 AS34 75 EI: M⁺ = 607 0.8 EE (KBr): C═O 1649/1668/ 1736 AS19 67 0.8 FM1 (KBr): C═O 1647/1668/ 1734 AS46 80 EI: M⁺ = 572 0.8 FM1 (KBr): C═O 1737 AS50 78 EI: M⁺ = 0.6 EE (KBr): C═O 677/9/81 (Br₂) 1645/1666/ 1730 AS2 51

EXAMPLE A61

Preparation of Compounds ofGeneralFormula:

β,β-bis-(ethoxycarbonyl)-1-methyl-1H-indol-3-butanoic acid

Produced analogously to Example A1b) from tert.-butyl β,β-bis-(ethoxycarbonyl)-1-methyl-1H-indol-3-butanoate through the action of trifluoroacetic acid in dichloromethane in a yield of 63.5% of theory. Colourless crystals of Mp. 127-130° C. (diisopropylether).

IR(KBr): 1738, 1712 cm⁻(C═O)

The following were prepared analogously:

R² % Yield MS R_(f) Eluant IR [cm⁻¹] AS29 100 AS16 100 0.7 EE/MeOH/ AcOH 97.5/2.2/0.25 AS5 100 0.5 PE/EE 2/1 AS32 100 0.58 PE/EE 2/1 (KBr): C═O 1759/1711 AS33 100 (KBr): C═O 1736 AS17 52 (KBr): C═O 1707/1726/ 1755 AS34 90 0.8 EE/MeOH/ (KBr): C═O AcOH 1705/1743 97.5/2.5/0.25 AS19 100 0.76 PE/EE/ (KBr): C═O AcOH 6/3/1 1738 AS46 92 0.35 FM1 (KBr): C═O 1732 AS50 71 (KBr): C═O 1712/1734/ 1759 AS2 31 EI: M⁺ = 272 0.42 PE/EE/ (KBr): C═O AcOH 6/4/0.2 1711/1734

EXAMPLE A62

Preparation of Compounds ofGeneralFormula:

Tert.-butyl β,β-bis-(ethoxycarbonyl)-3,5-dimethylbenzene-butanoate

To a solution of 13.8 g (50.2 mMol) of diethyl [(1,1-dimethyl-ethoxycarbonyl)methyl]-malonoate in 400 ml of anhydrous tetrahydrofuran, 2.3 g (52.7 mMol) of sodium hydride was added whilst being externally cooled with iced water. After stirring for 30 minutes, and maintaining a reaction temperature of 0 to +5° C., the solution of 10.0 g (50.2 mMol) of 3,5-dimethylbenzylbromide in 80 ml tetrahydrofuran was added dropwise and the mixture allowed to warm to room temperature within 14 hours. The reaction mixture was freed from the solvent in vacuo, 200 ml of 10% citric acid was added to the residue and the resulting mixture was thoroughly extracted with ethyl acetate. After the usual working up, the combined extracts yielded 19.7 g (100% of theory) of a colourless oil of R_(f)=0.67 (eluant:dichloromethane), which was used in the following steps without further purification.

The following were prepared analogously:

R² Remarks % Yield MS R_(f) Eluant IR [cm⁻¹] AS29 100 AS16 62 0.6 CH₂Cl₂ AS5 91 ESI: (M + H)⁺ = 0.8 PE/EE (KBr): C═O 521/3/5 (Br₂) 2/1 1734 AS32 96 0.76 PE/EE (KBr): C═O 2/1 1734 AS33 78 0.55 CH₂Cl₂ (KBr): C═O 1736 AS31 with use of 3- 74 EI: M⁺ = 417 0.7 toluene/ (KBr): C═O (dimethylaminomethyl)- t-BME 4/1 1734 1-methyl-1H-indol- methoiodide AS17 70 EI: M⁺ = 0.5 CH₂Cl₂ (KBr): C═O 550/52/54 (Br₂) 1734 AS34 93 EI: M⁺ = 450 0.5 CH₂Cl₂/ (KBr): C═O PE 1/1 1736 AS19 87 0.89 CH₂Cl₂ (KBr): C═O 1736 AS46 54 EI: M⁺ = 415 0.7 FM4 AS50 60 EI: M⁺ = 0.7 CH₂Cl₂ (KBr): C═O 520/22/24 (Br₂) 1734

EXAMPLE A63 (phenylmethyl)-β,β-bis-(ethoxycarbonyl)-4-(1,1-dimethylethyl)-benzenebutanoate

Prepared analogously to Example A62 from diethyl[(phenylmethoxycarbonyl)methyl]-malonoate and 4-(1,1-dimethylethyl)-benzylbromide in the presence of sodium hydride in a yield of 53% of theory.

Colourless oil of R_(f)=0.21 (eluant:dichloromethane/petroleum ether 2/1 v/v).

IR(KBr): 1738 cm⁻¹ (C═O)

EXAMPLE A64 Methyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[[3-(1-methylethoxy)phenyl]methyl]-4-oxobutanoate

To a solution of 2.0 g (4.43 mMol) of methyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3-hydroxyphenyl)-methyl]-4-oxobutanoate in 30 ml of anhydrous dimethylformamide, 0.2 g (4.4 mMol) of a 55% suspension of sodium hydride in paraffin oil was added. After stirring for 30 minutes at room temperature, 0.5 ml (4.8 mMol) of isopropyliodide was added dropwise, and kept for two hours each at room temperature and at 70° C. The residue remaining after removal of the volatile constituents was divided between water and ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried over magnesium sulphate and was again evaporated down. The raw product was purified by column chromatography on silica gel (60 μm), first using dichloromethane, later methanol/conc. ammonia (9/1 v/v) as eluants. Yield was 0.9 g (42% of theory) of a colourless, amorphous substance of R_(f)=0.32 (FM4).

IR(KBr): 1734, 1668 cm⁻¹ (C═O)

MS: M⁺=493

In the same way, methyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3-ethoxyphenyl)methyl]-4 -oxobutanoate was obtained from methyl 4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3-hydroxyphenyl)methyl]-4-oxobutanoate and ethyliodide in a yield of 67% of theory. Colourless, amorphous substance of R_(f)=0.29 (FM4).

IR(KBr): 1734, 1666 cm⁻¹ (C═O)

MS: M⁺=479

EXAMPLE A65 β,β-bis-(ethoxycarbonyl)-4-(1,1-dimethylethyl)-benzenebutanoic acid

Prepared analogously to example A58b) from phenyl methyl β,β-bis-(ethoxycarbonyl)-4-(1,1-dimethylethyl)-benzenebutanoate by catalytic hydrogenation in the presence of palladium/charcoal in a yield of 95% of theory. Colourless, highly-viscous oil of R_(f)=0.16 (eluant:dichloromethane).

IR(KBr): 1739 cm⁻¹ (C═O)

EXAMPLE A66 1-methyl-4-[(1-piperazinyl)carbonyl]-piperazine-bis-(trifluoro-acetate) a) 4-[[4-(1,1-dimethylethoxycarbonyl)-1-piperazinyl]carbonyl]-1-methylpiperazine

To a solution of 1.1 g of triphosgene (3.7 mMol) in 20 ml of dichloromethane, a mixture of 1.2 g (10 mMol) of 1-methyl-piperazine, 0.38 ml (22 mMol) of DIEA and 35 ml of dichloromethane was added dropwise at room temperature within 30 minutes, and then the solution of 1.9 g (10 mMol) of 1-(1,1-dimethyl-ethoxycarbonyl)piperazine and 0.38 ml of DIEA in 20 ml dichloromethane were added. After stirring for an hour at room temperature, insoluble matter was filtered off and the filtrate evaporated down in vacuo. After purification of the raw product on silica gel (Amicon, 35-70 μm), using dichloromethane/methanol/conc. ammonia(80/20/1 v/v/v) for elution, 700 mg (22% of theory) of colourless crystals were obtained of Mp. 130° C.

IR(KBr): 1691, 1641 cm⁻¹ (C═O)

b) 1-methyl-4-[(1-piperazinyl)carbonyl]-piperazine-bis-(trifluoroacetate)

Prepared analogously to Example A1b), but omitting the treatment with aqueous ammonia, from 4-[[4-(1,1-dimethylethoxycarbonyl)-1-piperazinyl]carbonyl]-1-methylpiperazine and trifluoroacetic acid in a yield of 99.6% of theory. Colourless, amorphous substance of R_(f)=0.17 (eluant:dichloromethane/methanol/conc. ammonia 50/50/0.5).

IR(KBr): 1678 cm⁻¹ (C═O)

MS: M⁺=212

EXAMPLE A67 1-[4-[4-(dimethylamino)butyl]phenyl]-piperazine-dihydrochloride a) N,N-dimethyl-4-fluoro-γ-oxobenzenebutanoic acid amide

To a solution of 30.5 g (0.155 Mol) of 4-fluoro-γ-oxobenzenebutanoic acid in 470 ml tetrahydrofuran, 35.0 g (0.216 Mol) of N,N′-carbonyldiimidazole was added with stirring and at room temperature and held at room temperature for a further 2.5 hours. Then, 13.7 g (0.304 Mol) of dimethylamine was added under strong external cooling by means of an ice-ethanol mixture. After the mixture had stood at room temperature for 12 hours, the solvent was removed in vacuo, the residue was divided between dichloromethane and 10% aqueous citric acid solution, the organic phase was dried over sodium sulphate and once again evaporated down in vacuo. After purification by column chromatography (eluant:ethyl acetate) on silica gel the crude product yielded 30.22 g (87% of theory) of colourless crystals of R_(f)=0.31 (eluant:ethyl acetate/glacial acetic acid 99.99/0.01).

IR(KBr): 1680, 1647 cm⁻¹ (C═O)

b) N,N-dimethyl-γ-oxo-4-[4-(phenylmethyl)-1-piperazinyl]-benzenebutanoic acid amide

The mixture of 33.48 g (0.15 Mol) of N,N-dimethyl-4-fluoro-γ-oxobenzenebutanoic acid amide, 29.6 g (0.168 Mol) of 1-(phenyl-methyl)piperazine and 6 ml of DIEA was refluxed for 6 hours. Another 30 g (0.17 Mol) of (phenylmethyl)piperazine was added, and the mixture was refluxed for a further 7 hours. The mixture was taken up in a little dichloromethane, and purified by column chromatography on silica gel, using dichloromethane/methanol/conc. ammonia 99/1/0.5 for elution. The residue obtained from the appropriate fractions was stirred with diisopropylether, the formed crystals were then recrystallised from ethanol. 42.22 g (74% of theory) of colourless crystals were obtained, R_(f)=0.69 (eluant:dichloromethane/methanol/conc. ammonia 95/5/0.5 v/v/v).

IR(KBr): 1662, 1643 cm⁻¹ (C═O)

c) 4-[4-[4-(dimethylamino)-1-hydroxybutyl]phenyl]-1-(phenyl-methyl)piperazine

Prepared analogously to example A51 from N,N-dimethyl-γ-oxo-4-[4-(phenylmethyl)-1-piperazinyl]-benzenebutanoic acid amide by reduction with lithium aluminium hydride in a yield of 61% of theory. Colourless, amorphous substance of R_(f)=0.62 (eluant:ethyl acetate/methanol 1/1 v/v).

MS: Me⁺=367

d) 1-[4-[4-(dimethylamino)butyl]phenyl]-piperazine-dihydrochloride

Prepared analogously to example A20b) from 4-[4-[4-(dimethylamino)-1-hydroxybutyl]phenyl]-1-(phenylmethyl)piperazine by catalytic hydrogenation in the presence of palladium/charcoal and hydrochloric acid in a quantitative yield. Colourless, amorphous substance of R_(f)=0.37 (eluant:ethyl acetate/methanol 50/50/0.5 v/v/v).

B. Preparation of the Final Compounds EXAMPLE 1

Preparation of Compounds ofGeneralFormula:

1-[N-[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-4-(4-pyridinyl)-piperazine (No. 83)

A mixture of 2 g (3.44 mmol) of 3.5-dibromo-N²-[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl)-carbonyl]-D-tyrosine, 0.59 g (3.6 mmol) of 1-(4-pyridinyl)-piperazine, 1.27 g (3.96 mmol) of TBTU, 0.47 g (3.44 mmol) of HOBt, 0.7 ml (3.96 mmol) of DIEA and 100 ml tetrahydrofuran was stirred overnight at ambient temperature. The reaction mixture was extracted once with saturated aqueous saline solution, twice with saturated aqueous sodium hydrogen carbonate solution and again with saturated aqueous saline solution. The organic phase was dried, evaporated down in vacuo and the crude product was then purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant:ethyl acetate/methanol=9/1/(v/v/)). 550 mg (22% of theory) of an amorphous solid were obtained.

IR (KBr): 1601, 1636, 1696 cm⁻¹ (C═O)

R_(f): 0.67 (FM2)

ESI-MS: (M+H)⁺=726/728/730 (Br₂)

The following were prepared analogously (in each case n=1):

No. RCO Z R² A NR³R⁴ Remarks % Yield MS R_(f) Eluant IR [cm⁻¹] N6 N—H AS1 A3 C4 88 ESI: (M + H)⁺ = 0.8 FM1 (KBr): C═O 928/30/32 1629.8; (Br₂) 1708.8 193 N15 N—H AS6 A0 C7 DMF as 26 ESI: 0.9 EE/MeOH/ (KBr): C═O solvent (M + H)⁺ = AcOH 1693.4; 647/9 (Br) 75/23/2 v/v/v 1622.0 194 N66 N—H AS1 A0 C67 49 ESI: 0.33 FM1 (KBr): C═O (M + H)⁺ = 1622/1664 828/30/32 (Br₂) 202 N15 N—H AS1 A0 C36 DMF as 9 ESI: 0.49 FM1 (KBr): C═O solvent; (M + H)⁺ = 1695.3; DIEA 733/5/7 1622.0 (Br₂) NH 3417.7 203 N15 N—H AS1 A0 C29 DMF as 41 ESI: 0.58 EE/MeOH (KBr): C═O solvent; (M − H)⁻ = 9/1 v/v 1695.3 DIEA 718/20/22 (Br₂) 204 N15 N—H AS1 A0 C30 DMF as 27 ESI: 0.1 FM1 (KBr): C═O solvent; (M + H)⁺ = 1695.3; DIEA 691/3/5 1624.0 (Br₂) 205 N15 N—H AS6 A0 C8 DMF as 23 ESI: 0.46 FM1 (KBr): C═O solvent; (M + H)⁺ = 1695.3; DIEA 653/5 (Br) 1622.0 206 N15 N—H AS1 A0 C31 DMF as 33 ESI: 0.25 FM1 (KBr): C═O solvent; (M + H)⁺ = 1695.3; DIEA 717/19/21 1624.0 (Br₂) 207 N15 N—H AS1 A0 C32 DMF as 55 ESI: 0.46 FM1 (KBr): C═O solvent; (M − H)⁻ = 1690; 1650 DIEA 780/2/4 (Br₂) 212 N15 N—H AS1 A7 C1 DMF as 37 ESI: 0.27 FM1 (KBr): C═O solvent; (M + H)⁺ = 1697.3; DIEA 882/4/6 1639.4 (Br₂) NH 3423.4 217 N15 N—H AS6 A3 C1 51 0.9 FM1 (KBr): C═O 1693.4; 1641.3 222 N15 N—H AS1 A0 C27 THF/DMF 10 ESI: 0.35 FM1 (KBr): C═O 1/1 as (M + H)⁺ = 1695.3 solvent; NEt₃ 774/6/8 as base (Br₂) 286 N15 N—H AS1 A0 C28 THF/DMF 9 ESI: 0.4 FM1 (KBr): C═O 1/1 as (M + H)⁺ = 1699.2 solvent; NEt₃ 706/8/10 as base (Br₂) 81 N15 N—H AS4 A0 C4 64 ESI: (M + H)⁺ = 0.75 FM1 (KBr): C═O 724/6/8 1618.2; (Br₂); 1703.0 (M + Na)⁺= 746/48/50 (Br₂) 82 N15 N—H AS4 A0 C1 53 ESI: (M + H)⁺ = 0.55 FM3 (KBr): C═O 725/7/9 1620.1; 1703.0 (Br₂) 84 N66 N—H AS21 A0 C68 31 ESI: (M + H)⁺ = 0.52 FM1 (KBr): C═O 683 1608/1628/ 1666 85 N15 N—H AS4 A0 C7 42 ESI: (M + H)⁺ = 0.8 FM1 (KBr): C═O 724/6/8 1618.2; 1697.3; (Br₂); —NH—, —NH₂ (M + Na)⁺= 3379.1 746/48/50 (Br₂) 90 N15 N—H AS1 A0 C8 40 ESI: (M + H)⁺ = 0.78 FM2 (KBr): C═O 731/3/5 1624.0; 1697.3 (Br₂) N2 N—H AS2 A3 C1 DMF as 73 ESI: (M + H)⁺ = 0.42 FM1 (KBr): C═O solvent; 766 1654.2; 1708.8 DIEA 354 N15 N—H AS1 A0 C4 21 ESI: (M + H)⁺ = 0.76 FM2 (KBr): C═O 725/7/9 1622.0; 1695.3; (Br₂); —OH, —NH— (M + Na)⁺= 3417.7 747/49/51 (Br₂) 98 N15 N—H AS1 A0 C9 60 ESI: (M + H)⁺ = 0.41 FM2 (KBr): C═O 580/2/4 1624.0; 1685.7; (Br₂); (M − —OH, —NH— H)⁻= 3421.5 578/80/82 (Br₂); (M + Na)⁺ = 602/4/6 (Br₂) 102 N15 N—H AS1 A0 C12 43 ESI: (M + H)⁺ = 0.76 FM2 (KBr): C═O 636/38/40 1622.0; 1695.3; (Br₂); (M + Na)⁺= 658/60/62 (Br₂) 99 N15 N—H AS1 A0 C10 54 ESI: (M + H)⁺ = 0.61 FM2 (KBr): C═O 663/5/7 1622.9; 1700.9; (Br₂) —OH, —NH— 3421.5 100 N15 N—H AS1 A0 C11 54 ESI: (M + H)⁺ = 0.5 FM2 (KBr): C═O 746/48/50 1624.0; 1695.3; (Br₂) —NH—, —OH 3423.4; 101 N15 N—H AS1 A0 C7 62 ESI: (M + H)⁺ = 0.82 FM2 (KBr): C═O 725/7/9 1622.0; 1695.3; (Br₂); —OH, —NH— (M + Na)⁺= 3253.7 747/49/51 (Br₂) 103 N15 N—H AS1 A0 C13 37 ESI: (M + H)⁺ = 0.72 FM2 (KBr): C═O 679/81/83 1625.9; (Br₂) 1693.4; 1666.4; —OH, —NH— 3409.9 106 N15 N—H AS1 A0 C14 72 ESI: (M + H)⁺ = 0.66 FM1 (KBr): C═O 832/4/6 1674.1; (Br₂); 1689.5 (M + Na)⁺= 854/6/8 (Br₂) 104 N15 N—H AS6 A0 C4 36 ESI: (M + H)⁺ = 0.71 FM1 (KBr): C═O 647/9 (Br); 1695.3 (M + Na)⁺ = 669/71 (Br); (M − H)⁻ 645/7 (Br) 105 N15 N—H AS6 A0 C1 25 ESI: (M + H)⁺ = 0.25 FM3 (KBr): C═O 648/50 (Br) 1695.3 N2 N—H AS1 A12 C1 DMF as 72 ESI: 0.4 FM1 KBr: C═O solvent; (M + H)⁺ = 1641 DIEA 1082/4/6 (Br₂) 199 N15 N—H AS3 A0 C8 THF/DMF = 86 ESI: (M + H)⁺ = 0.37 ethyl KBr: C═O 9/1 (v/v) 643/5/7 acetate/ 1697; 1624 as solvent (Br₂) methanol/ petroleum ether = 1/2/1 (v/v/v) 200 N15 N—H AS3 A0 C1 40 ESI: (M + H)⁺ = 0.45 ethyl KBr: C═O 638/40/42 acetate/ 1695; 1636 (Br₂) methanol/ petroleum ether = 1/2/1 (v/v/v) 419 N66 N—H AS21 A0 C38 28 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O 682 1628/1662 425 N66 N—H AS1 A0 C36 42 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O 747/49/51 1624/1657 (Br₂) 426 N66 N—H AS4 A0 C30 66 ESI: (M + H)⁺ = 0.45 FM1 (KBr): C═O 704/6/8 1618/1663 (Br₂) 427 N66 N—H AS1 A0 C31 38 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 731/3/5 1630/1653 (Br₂) 428 N66 N—H AS4 A0 C36 40 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 746/48/50 1618/1662 (Br₂) 429 N66 N—H AS1 A0 C30 47 ESI: (M + H)⁺ = 0.15 FM1 (KBr): C═O 705/7/9 1635/1653 (Br₂) 435 N66 N—H AS4 A0 C31 20 ESI: (M + H)⁺ = 0.55 FM1 (KBr): C═O 730/2/4 1608/1631 (Br₂) 436 N66 N—H AS1 A0 C11 15 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O 760/2/4 (Br₂) 1624/1653 437 N66 N—H AS4 A0 C11 25 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 759/61/63 1622/1661 (Br₂) 438 N66 N—H AS4 A0 C54 13 ESI: (M + H)⁺ = 0.7 FM1 (KBr): C═O 744/6/8 1620/1660 (Br₂) 439 N66 N—H AS1 A0 C54 31 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 745/7/9 1626/1661 (Br₂) 443 N122 N—H AS1 A0 C11 44 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O 790/2/4 1624/1680 (Br₂) 444 N122 N—H AS1 A0 C8 62 ESI: (M + H)⁺ = 0.18 FM1 (KBr): C═O 775/7/9 1624/1678 (Br₂) 445 N122 N—H AS1 A0 C1 60 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 770/2/4 1630/1680 (Br₂) 446 N122 N—H AS1 A0 C20 59 ESI: (M + H)⁺ = 0.15 FM1 (KBr): C═O 789/91/93 1622/1680 (Br₂) 447 N122 N—H AS4 A0 C1 54 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 769/71/73 1622/1682 (Br₂) 448 N122 N—H AS4 A0 C20 68 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 788/90/92 1620/1682 (Br₂) 449 N122 N—H AS4 A0 C8 59 ESI: (M + H)⁺ = 0.58 FM1 (KBr): C═O 774/6/8 1620/1682 (Br₂) 450 N66 N—CH₃ AS1 A0 C4 36 ESI: (M + H)⁺ = 0.39 FM1 (KBr): C═O 753/5/7 1653 (Br₂) 451 N66 CH₂ AS1 A0 C1 20 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 739/41/43 1638 (Br₂) 452 N71 CH₂ AS1 A0 C1 16 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O 751/53/55 1638/1680 (Br₂) 453 N66 CH₂ AS1 A0 C11 17 ESI: (M + H)⁺ = 0.13 FM1 (KBr): C═O 758/60/62 1636 (Br₂) 454 N66 CH₂ AS1 A0 C20 33 ESI: (M + H)⁺ = 0.23 FM1 (KBr): C═O 757/59/61 1632 (Br₂) 455 N71 CH₂ AS1 A0 C8 35 EI: M⁺ = 0.42 FM1 (KBr): C═O 755/7/9 (Br₂) 1624/1684 457 N71 CH₂ AS1 A0 C4 49 ESI: (M + H)⁺ = 0.77 FM1 (KBr): C═O 750/2/4 1626/1682 (Br₂) 458 N71 CH₂ AS1 A0 C37 25 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 769/71/73 1638/1682 (Br₂) 459 N66 CH₂ AS1 A0 C37 50 EI: M⁺ = 0.2 FM1 (KBr): C═O 757/59/61 1636 (Br₂) 460 N66 N—H AS1 A0 C55 72 ESI: (M + H)⁺ = 0.27 EE/MeOH/ (KBr): C═O 759/61/63 NH₄OH = 1626/1661 (Br₂) 8/1.5/0.1 v/v/v 461 N66 N—H AS1 A0 C56 77 ESI: (M + H)⁺ = 0.77 FM1 (KBr): C═O 731/3/5 1626/1661 (Br₂) 462 N66 N—H AS17 A0 C8 51 ESI: (M + H)⁺ = 0.44 FM1 (KBr): C═O 759/61/63 1628/1663 (Br₂) 463 N66 N—H AS18 A0 C1 59 ESI: (M + H)⁺ = 0.7 FM1 (KBr): C═O 704 1661 464 N66 N—H AS18 A0 C8 51 ESI: (M + H)⁺ = 0.76 FM1 (KBr): C═O 709 1628/1663 465 N66 N—H AS18 A0 C37 73 ESI: (M + H)⁺ = 0.7 FM1 (KBr): C═O 723 1628/1663 469 N66 N—H AS19 A0 C8 34 ESI: (M + H)⁺ = 0.34 FM1 (KBr): C═O 651/53 (Br) 1626/1664 471 N66 N—H AS20 A0 C8 41 ESI: (M + H)⁺ = 0.68 FM1 (KBr): C═O 649 1624/1684 472 N66 N—H AS5 A0 C8 26 ESI: (M + H)⁺ = 0.73 FM1 (KBr): C═O 729/31/33 1626/1664 (Br₂) 475 N66 N—H AS18 A0 C20 58 ESI: (M + H)⁺ = 0.22 FM1 (KBr): C═O 723 1628/1664 476 N66 N—H AS18 A0 C11 44 ESI: (M + H)⁺ = 0.27 MeOH (KBr): C═O 724 1630/1662 478 N66 N—H AS19 A0 C37 62 ESI: (M + H)⁺ = 0.8 FM1 (KBr): C═O 665/7 (Br) 1626/1662 479 N66 N—H AS19 A0 C20 55 ESI: (M + H)⁺ = 0.64 FM1 (KBr): C═O 665/7 (Br) 1664 480 N66 N—H AS19 A0 C4 55 ESI: (M + H)⁺ = 0.77 FM1 (KBr): C═O 645/7 (Br) 1628/1662 506 N66 N—H AS21 A0 C20 46 ESI: (M + H)⁺ = 0.75 FM1 (KBr): C═O 655 1626/1664 507 N66 N—H AS22 A0 C8 65 ESI: (M + H)⁺ = 0.78 FM1 (KBr): C═O 607/9 (Cl) 1624/1664 508 N66 CH₂ AS21 A0 C20 15 ESI: (M + H)⁺ = 0.15 MeOH (KBr): C═O 654 1639/1670 246 N15 CH₂ AS1 A0 C8 19 ESI: (M + H)⁺ = 0.35 EE/MeOH/ (KBr): C═O 730/2/4 NH₄OH 1635/1707 (Br₂) 9/1/0.5 v/v/v 285 N15 CH₂ AS1 A0 C4 42 ESI: (M + H)⁺ = 0.45 EE/MeOH/ (KBr): C═O 724/6/8 NH₄OH 1684/1711 (Br₂) 9/1/0.5 v/v/v 289 N66 CH₂ AS1 A0 C8 40 ESI: (M + H)⁺ = 0.38 EE/MeOH/ (KBr): C═O 744/6/8 NH₄OH 1635/1668 (Br₂) 9/1/0.5 v/v/v 290 N66 CH₂ AS1 A0 C4 30 ESI: (M + H)⁺ = 0.45 EE/MeOH/ (KBr): C═O 738/40/42 NH₄OH 1634/1664 (Br₂) 9/1/0.5 v/v/v 511 N66 N—H AS23 A0 C8 DMF 80 ESI: (M + H)⁺ = 0.57 FM1 (KBr): C═O 603 1664/1626 512 N66 N—H AS23 A0 C11 DMF 60 ESI: (M + H)⁺ = 0.30 FM1 (KBr): C═O 618 1645 513 N66 N—H AS23 A0 C1 DMF 54 ESI: (M + H)⁺ = 0.50 FM1 (KBr): C═O 598 1662/1712 514 N66 N—H AS23 A0 C38 DMF 65 ESI: (M + H)⁺ = 0.20 FM1 (KBr): C═O 644 1664/1626/ 1712 515 N66 N—H AS23 A0 C40 DMF 7 ESI: (M + H)⁺ = 0.40 FM1 (KBr): C═O 632 1630/1662 527 N66 N—H AS25 A0 C8 49 ESI: (M + H)⁺ = 0.48 FM1 (KBr): C═O 594 1647 528 N66 N—H AS25 A0 C1 29 ESI: (M + H)⁺ = 0.48 FM1 (KBr): C═O 589 1646 529 N66 CH₂ AS2 A0 C8 27 ESI: (M + H)⁺ = 0.50 FM1 (KBr): C═O 622 1635/1668/ 1716 530 N66 CH₂ AS2 A0 C20 5 EI: M⁺ = 635 0.49 FM1 (KBr): C═O 1637/1668/ 1714 531 N66 CH₂ AS23 A0 C8 30 EI: M⁺ = 601 0.50 FM1 N66 CH₂ AS23 95 538 N139 CH₂ AS2 A0 C20 49 EI: M⁺ = 636 0.30 FM1 (KBr): C═O 1635/1674 539 N139 CH₂ AS2 A0 C53 52 EI: M⁺ = 637 0.30 FM1 (KBr): C═O 1637/1674 540 N139 CH₂ AS2 A0 C8 60 0.37 FM1 (KBr): C═O 1635/1674 541 N66 CH₂ AS27 A0 C53 32 EI: M⁺ = 630 0.65 FM1 (KBr): C═O 1639/1670 542 N66 CH₂ AS27 A0 C8 32 EI: M⁺ = 615 0.80 FM1 (KBr): C═O 1639/1670 543 N66 CH₂ AS27 A0 C20 21 EI: M⁺ = 629 0.59 FM1 (KBr): C═O 1639/1672 544 N66 CH₂ AS28 A0 C20 35 EI: M⁺ = 643 0.50 FM1 (KBr): C═O 1641/1670 545 N66 CH₂ AS28 A0 C53 54 EI: M⁺ = 644 0.50 FM1 (KBr): C═O 1639/1670 546 N66 CH₂ AS28 A0 C8 53 EI: M⁺ = 629 0.60 FM1 (KBr): C═O 1639/1672 547 N66 CH₂ AS29 A0 C8 14 EI: M⁺ = 599 0.53 FM1 (KBr): C═O 1630 548 N66 CH₂ AS29 A0 C53 12 EI: M⁺ = 614 0.48 FM1 549 N66 CH₂ AS29 A0 C20 15 EI: M⁺ = 613 0.48 FM1 (KBr): C═O 1637/1668 550 N66 CH₂ AS30 A0 C53 4 0.48 FM1 574 N66 CH₂ AS16 A0 C20 55 EI: M⁺ = 0.80 CH₂Cl₂/ (KBr): C═O 653/5/7 (Cl₂) MeOH/ 1635/1670 NH₄OH 80/20/1 575 N66 CH₂ AS16 A0 C53 54 EI: M⁺ = 0.20 EE/MeOH/ (KBr): C═O 654/6/8 (Cl₂) NH₄OH 1635/1668 70/30/3 578 N66 CH₂ AS5 A0 C53 32 EI: M⁺ = 0.30 FM5 (KBr): C═O 742/4/6 (Br₂) 1637/1670 579 N66 CH₂ AS5 A0 C20 37 EI: M⁺ = 0.50 FM5 (KBr): C═O 741/3/5 (Br₂) 1635/1670 589 N66 CH₂ AS32 A0 C53 49 EI: M⁺ = 0.33 FM5 (KBr): C═O 756/58/60 1639/1670 (Br₂) 590 N66 CH₂ AS32 A0 C20 36 EI: M⁺ = 0.47 FM5 (KBr): C═O 755/7/9 (Br₂) 1658/1672 591 N66 CH₂ AS33 A0 C20 43 EI: M⁺ = 689 0.40 EE/MeOH/ (KBr): C═O NH₄OH 1637/1670 50/50/0.5 592 N66 CH₂ AS33 A0 C53 52 EI: M⁺ = 690 0.20 EE/MeOH/ (KBr): C═O NH₄OH 1633/1668 70/30/5 593 N66 CH₂ AS16 A0 C29 11 EI: M⁺= 0.65 EE/MeOH (KBr): C═O 628/30/32 9/1 1606/1637/ (Cl₂) 1668/ 1728 594 N66 CH₂ AS16 A0 C73 48 EI: M⁺ = 0.50 EE/MeOH (KBr): C═O 628/30/32 9/1 1637/1668/ (Cl₂) 1736 595 N66 CH₂ AS16 A0 C74 10 EI: M⁺ = 0.30 EE/MeOH/ 597/99/601 NH₄OH (Cl₂) 50/50/0.5 597 N66 CH₂ AS31 A0 C53 25 EI: M⁺ = 639 0.30 CH₂Cl₂/ (KBr): C═O MeOH/ 1635/1668 NH₄OH 90/10/1 598 N66 CH₂ AS31 A0 C20 31 EI: M⁺ = 638 0.10 CH₂Cl₂/ (KBr): C═O MeOH/ 1635/1668 NH₄OH 90/10/0.3 600 N73 CH₂ AS31 A0 C20 10 ESI: (M + H)⁺ = 0.15 CH₂Cl₂/ (KBr): C═O 551 MeOH/ 1628 NH₄OH 90/10/1 602 N66 CH₂ AS17 A0 C53 56 EI: M⁺ = 0.25 EE/MeOH/ (KBr): C═O 772/4/6 (Br₂) NH₄OH 1637/1668 50/50/0.5 603 N66 CH₂ AS16 A0 C33 93 EI: M⁺ = 0.75 EE/MeOH/ (KBr): C═O 600/02/04 AcOH 70/30/1 1635/1716 (Br₂) 604 N66 CH₂ AS17 A0 C20 47 EI: M⁺ = 0.20 EE/MeOH/ (KBr): C═O 771/3/5 (Br₂) NH₄OH 1635/1668 50/50/0.5 605 N66 CH₂ AS34 A0 C53 70 EI: M⁺ = 672 0.25 EE/MeOH/ (KBr): C═O NH₄OH 1633/1666 60/40/0.5 606 N66 CH₂ AS34 A0 C20 45 EI: M⁺ = 671 0.15 EE/MeOH/ (KBr): C═O NH₄OH 1635/1668 50/50/0.5 607 N66 N—H AS21 A0 C40 27 ESI: (M + H)⁺ = 0.65 FM1 (KBr): C═O 670 1608/1628/ 1664 608 N66 N—H AS21 A0 C11 34 ESI: (M + H)⁺ = 0.50 FM1 (KBr): C═O 656 1606/1628/ 1664 609 N66 N—H AS21 A0 C8 30 ESI: (M + H)⁺ = 0.80 FM1 (KBr): C═O 641 1626/1664 610 N66 N—H AS21 A0 C1 55 ESI: (M + H)⁺ = 0.80 FM1 (KBr): C═O 636 1635/1662 611 N66 N—H AS21 A0 C4 80 ESI: (M + H)⁺ = 0.70 FM1 (KBr): C═O 635 1606/1628/ 1664 612 N66 CH₂ AS4 A0 C8 43 EI: M⁺ = 0.85 FM1 (KBr): C═O 742/4/6 (Br₂) 1668/1631/ 1606 613 N66 N—H AS22 A0 C20 62 ESI: (M + H)⁺ = 0.73 FM1 (KBr): C═O 621/23 (Cl) 1626/1664 614 N66 N—H AS22 A0 C37 55 ESI: (M + H)⁺ = 0.68 FM1 (KBr): C═O 621/23 (Cl) 1626/1664 615 N66 N—H AS22 A0 C56 77 ESI: (M + H)⁺ = 0.76 FM1 (KBr): C═O 593 1628/1664 616 N66 CH₂ AS36 A0 C8 32 ESI: (M + H)⁺ = 0.76 FM1 (KBr): C═O 585 1637/1668 617 N66 CH₂ AS21 A0 C37 15 EI: M⁺ = 653 0.15 MeOH (KBr): C═O 1639/1670 618 N66 CH₂ AS21 A0 C38 24 EI: M⁺ = 680 0.10 MeOH (KBr): C═O 1639/1670 628 N66 CH₂ AS21 A0 C8 31 EI: M⁺ = 639 0.25 MeOH (KBr): C═O 1639/1670 629 N66 CH₂ AS21 A0 C11 43 EI: M⁺ = 654 0.10 MeOH (KBr): C═O 1641/1668 630 N66 CH₂ AS21 A0 C1 74 EI: M⁺ = 634 0.10 MeOH (KBr): C═O 1641/1668 631 N66 CH₂ AS21 A0 C28 63 EI: M⁺ = 614 0.30 MeOH (KBr): C═O 1666 634 N66 CH₂ AS38 A0 C8 35 ESI: (M + H)⁺ = 0.25 MeOH (KBr): C═O 622 1635/1668 635 N66 CH₂ AS48 A0 C8 40 EI: M⁺ = 639 0.68 FM1 (KBr): C═O 1643/1670 636 N66 N—H AS49 A0 C20 25 ESI: (M + H)⁺ = 0.40 EE/MeOH/ (KBr): C═O 632 NH₄OH 1664 9/1/0.5 637 N66 CH₂ AS4 A0 C20 11 ESI: (M + H)⁺ = 0.60 FM1 (KBr): C═O 757/59/61 1635/1668 (Br₂) 638 N66 CH₂ AS48 A0 C20 11 ESI: (M + H)⁺ = 0.66 FM1 (KBr): C═O 654 1641/1668 639 N66 CH₂ AS18 A0 C20 4 EI: M⁺ = 721 0.10 MeOH (KBr): C═O 1637/1670 640 N66 CH₂ AS39 A0 C20 38 EI: M⁺ = 645 0.80 CH₂Cl₂/ (KBr): C═O MeOH/ 1635/1670 NH₄OH 8/2/0.3 641 N66 CH₂ AS38 A0 C20 49 EI: M⁺ = 635 0.80 CH₂Cl₂/ (KBr): C═O MeOH/ 1635/1668 NH₄OH 8/2/0.3 642 N66 CH₂ AS39 A0 C8 45 EI: M⁺ = 631 0.10 EE/MeOH/ (KBr): C═O NH₄OH 1635/1670 9/1/0.3 N66 CH₂ AS21 A0 C69 70 EI: M⁺ = 739 (KBr): C═O 1684 644 N109 CH₂ AS21 A0 C20 46 ESI: (M + H)⁺ = 0.10 MeOH (KBr): C═O 659 1643 645 N66 CH₂ AS19 A0 C20 21 EI: M⁺ = 0.53 FM1 (KBr): C═O 763/5 (Br) 1669/1634 646 N66 CH₂ AS19 A0 C8 45 EI: M⁺ = 0.60 FM1 (KBr): C═O 649/651 (Br) 1637/1668 653 N113 CH₂ AS21 A0 C20 55 EI: M⁺ = 666 0.60 FM1 (KBr): C═O 1630/1701 654 N134 CH₂ AS21 A0 C20 22 EI: M⁺ = 690 0.60 FM1 (KBr): C═O 1714 655 N66 CH₂ AS46 A0 C20 43 EI: M⁺ = 636 0.50 FM1 (KBr): C═O 1630/1664 656 N66 CH₂ AS46 A0 C8 71 EI: M⁺ = 622 0.60 FM1 (KBr): C═O 1635 657 N66 CH₂ AS47 A0 C20 63 EI: M⁺ = 639 0.50 FM1 (KBr): C═O 1635/ 1668/ 1716 658 N66 CH₂ AS50 A0 C20 70 ESI: (M + H)⁺ = 0.20 EE/MeOH/ (KBr): C═O 741/3/5 NH₄OH 1635/1668 (Br₂) 50/50/0.5 659 N66 CH₂ AS50 A0 C53 60 ESI: (M + H)⁺ = 0.20 EE/MeOH/ (KBr): C═O 743/5/7 NH₄OH 1635/1668 (Br₂) 50/50/0.5 660 N66 CH₂ AS46 A0 C53 41 EI: M⁺ = 637 0.65 FM1 (KBr): C═O 1630 661 N66 CH₂ AS7 A0 C8 75 EI: M⁺ = 615 0.70 FM1 (KBr): C═O 1626/1660 662 N66 CH₂ AS7 A0 C53 41 EI: M⁺ = 630 0.55 FM1 (KBr): C═O 1628/1662 663 N66 CH₂ AS7 A0 C20 78 EI: M⁺ = 629 0.60 FM1 (KBr): C═O 1628/1662 664 N66 CH₂ AS52 A0 C8 66 EI: M⁺ = 629 0.75 FM1 (KBr): C═O 1635 665 N66 CH₂ AS52 A0 C53 37 EI: M⁺ = 644 0.70 FM1 (KBr): C═O 1633/1664 666 N66 CH₂ AS52 A0 C20 61 EI: M⁺ = 643 0.80 FM1 (KBr): C═O 1635/1664 667 N66 CH₂ AS2 A0 C53 47 EI: M⁺ = 636 0.60 FM1 (KBr): C═O 1630/1664 N66 CH₂ AS2 A0 C69 78 0.75 FM1 669 N66 CH₂ AS32 A0 C71 44 EI: M⁺ = 0.20 EE/MeOH/ (KBr): C═O 834/6/8 (Br₂) NH₄OH 1641/1670 50/50/0.5 670 N66 CH₂ AS51 A0 C20 Prelimi- 47 EI: M⁺ = 641 0.15 EE/MeOH/ (KBr): C═O nary stage NH₄OH 1635/1664 special 50/50/0.5 cases 671 N66 CH₂ AS51 A0 C53 45 EI: M⁺ = 642 0.15 EE/MeOH/ (KBr): C═O NH₄OH 1637/1670 50/50/0.5 672 N66 CH₂ AS16 A0 C76 55 EI: M⁺ = 0.66 FM1 (KBr): C═O 689/91/93 1635 (Cl₂)

EXAMPLE 2

Preparation of Compounds ofGeneralFormula:

1-[N²-[4-amino-N-[[4-(2-chlorophenyl)-1-piperazinyl]-carbonyl]-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)piperazine-bis-(trifluoroacetate) (No. 61)

A mixture of 0.56 g (1.0 mmol) of 4-amino-N²-[[4-(2-chlorophenyl)-nyl)-1-piperazinyl]carbonyl]-3.5-dibromo-D-phenylalanine, 0.41 g (1.05 mmol) of 1-[N⁶-(1.1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine, 0.35 g (1.10 mmol) of TBTU, 0.14 g (1.0 mmol) of HOBt, 0.2 ml (1.10 mmol) of DIEA and 100 ml of dimethylformamide was stirred overnight at ambient temperature. The reaction mixture was evaporated down in vacuo and divided between methylene chloride and saturated aqueous sodium hydrogen carbonate solution. The organic phase was then extracted once with saturated aqueous sodium hydrogen carbonate solution and with water, dried and evaporated down in vacuo. The crude product was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant:ethyl acetate/methanol=8/2 (v/v/)), taken up in 30 ml of methylene chloride and stirred with 3 ml of trifluoroacetic acid for 3 hours at ambient temperature. The reaction mixture was evaporated down in vacuo, the residue was triturated with ether and the obtained amorphous solid (0.43 g, 37% of theory) was suction filtered.

IR (KBr): 1643, 1678 cm⁻¹ (C═O)

R_(f): 0.6 (FM1)

ESI-MS: (M+H)⁺=832/834/836/838 (Br₂, Cl)

The following were prepared analogously (in each case n=1):

No. RCO R² A NR³R⁴ % Yield MS R_(f) Eluant IR [cm⁻¹] 48 N6 AS1 A1 C3 79 ESI: M + H = 0.3 FM1 (KBr): C═O 946/48/50 1652.9; 1674.1 (Br₂) 213 N15 AS6 A1 C8 14.7 ESI: M + H = 0.45 FM2 (KBr): C═O 781/3 (Br) 1691.5; 1629.8 49 N8 AS4 A1 C1 57.14 ESI: M + H = 0.5 FM1 (KBr): C═O 757/59/61 1643.3; 1676.0 (Br₂) 58 N15 AS4 A1 C4 21 ESI: M + H = 0.57 FM1 (KBr): C═O 852/4/6 (Br₂) 1635.5; 1695.3 59 N15 AS4 A1 C1 45.6 ESI: M + H = 0.44 FM1 (KBr): C═O 853/5/7 (Br₂) 1635.5; 1695.3 60 N23 AS4 A1 C4 19.2 ESI: M + H = 0.65 FM1 (KBr): C═O 831/3/5/7 1633.6 (Br₂, Cl) 61 N23 AS4 A1 C1 36.6 ESI: M + H = 0.6 FM1 (KBr): C═O 832/4/6/8 1643.3; 1678.0 (Br₂, Cl)

EXAMPLE 3

Preparation of Compounds ofGeneralFormula:

1-[N²-[3,5-dibromo-N-[[[(2-methoxyphenyl)methyl]amino]-carbonyl]-D,L-tyrosyl]-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine

A tetrahydrofuran solution (50 ml) of 1.0 g (1.34 mmol) of 1-[N²-(3,5-dibromo-D-tyrosyl)-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine was added dropwise over a period of 40 minutes to a suspension of 0.33 g (2.01 mmol) of CDT in 50 ml of tetrahydrofuran cooled to −10 ° C. and stirred. The reaction mixture was then stirred for 2 hours at ambient temperature and mixed with 0.22 ml (1.675 mmol) of 2-methoxy-benzenemethanamine. Then the mixture was refluxed for 2 hours and stirred overnight at ambient temperature. The reaction mixture was evaporated down in vacuo, the residue was triturated with ether and the solid obtained (1.1 g; 90% of theory) was suction filtered and dried.

IR (KBr): 1641, 1717 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 908/910/912 (Br₂) (M + H + Na)⁺⁺ = 466.7 (Br₂)

The following were prepared analogously:

% Mp. No. RCO R² n X A NR³R⁴ Remarks Yield MS R_(f) Eluant IR [cm⁻¹] (° C.) 195 N15 AS1 1 O A3 C8 21 ESI: (M + H)⁺ = 0.8 FM7 (KBr): C═O 959/61/63 1699.2; (Br₂) 1635.5 196 N51 AS1 1 O A3 C8  26; ESI: (M + H)⁺ = 0.85 FM7 (KBr): C═O  1 929/31/33 1710; CN (Br₂) 2219.8 201 N101 AS4 1 O A0 C8 DIEA 34 ESI: (M + H)⁺ = 0.58 FM1 (KBr): C═O 746/8/50 1693.4; (Br₂) 1618.2 215 N15 AS1 1 O A0 C34 NEt₃ as 92 ESI: (M − H)⁻ = 0.36 FM1 (KBr): C═O base 778/80/82 1695.3 (Br₂) 216 N15 AS1 1 O A0 C35 NEt₃ as 69 ESI: (M − H)⁻ = 0.3 FM1 (KBr): C═O base 779/81/82 1701.1 (Br₂) 221 N15 AS4 1 O A7 C1 NEt₃ as 39 ESI: (M + H)⁺ = 0.38 FM1 (KBr): C═O base 881/3/5 1697.3; (Br₂) 1637.5 288 N85 AS1 1 O A0 C8 THF/DMF 30 ESI: (M + H)⁺ = 0.3 MeOH (KBr): C═O as solvent; 749/51/53 1683.8; NEt₃ as (Br₂) 1624.0; base OH 3429.2 293 N66 AS1 1 O A9 C1 DIEA 11 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O 910/2/4 1645.2 (Br₂) 295 N66 AS1 1 O A7 C1 NEt₃ as 70 ESI: (M + H)⁺ = 0.45 FM1 (KBr): C═O base 896/8/900 1716.5; (Br₂) 1647.1 303 N86 AS4 1 O A0 C8 DIEA 20 ESI: (M + H)⁺ = 0.7 FM 2 (KBr): C═O 747/9/51 1618.2 (Br₂) 304 N87 AS4 1 O A0 C8 THFas 30 ESI: (M + H)⁺ = 0.75 FM1 (KBr): C═O solvent; 802/4/6 1720.4; NEt₃ as (Br₂) 1668.3; base 1620.1; NH, NH2 3431.2; 3379.1 305 N88 AS4 1 O A0 C8 DIEA 45 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 782/4/6 1616; SO2 (Br₂) 1323.1; 1151.4 308 N90 AS4 1 O A0 C8 DIEA 27 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 750/2/4 1637.5 (Br₂) 80 N15 AS1 1 O A3 C1 62 ESI: (M + H)⁺ = 0.8 FM2 (KBr): C═O 954/6/8 1697.3; (Br₂) 1639.4 N8 AS1 1 O A3 C1 66 ESI: (M + H)⁺ = 0.22 EtOAc/ (KBr): C═O 858/60/62 methanol = 1641.3 (Br₂) 6/4 (v/v) N9 AS1 1 O A3 C1 59 ESI: (M + H)⁺ = 0.22 EtOAc/ (KBr): C═O 888/90/92 methanol = 1652.9 (Br₂) 6/4 (v/v) N2 AS1 1 O A4 C1 40 ESI: (M + H)⁺ = 0.45 FM1 (KBr): C═O 922/4/6 (Br₂); 1641.3; (M + Na)⁺= 1710.8; 944/6/8 (Br₂) OH, NH 3396.4 N4 AS1 1 O A4 C1 73 ESI: (M + H)⁺ = 0.13 FM1 (KBr): C═O 952/4/6 (Br₂) 1641.3; 1714.6 62 N15 AS1 1 O A3 C5 purified by 65 ESI: (M + H)⁺ = 0.27 FM1 (KBR): C═O column 1003/5/7 (Br₂); 1685.7; chromatog- (M + Na)⁺= 1635.5; OH, raphy: silica 1025/7/9 (Br₂) NH: 3419.6 gel/FM4 N15 AS1 1 O A3 C6 purified by 86 ESI: (M + H)⁺ = 0.45 FM1 (KBr): C═O column 983/5/7 (Br₂) 1695.3; chromatog- 1633.6 raphy: silica gel/FM4 73 N15 AS5 1 O A3 C1 purified by 64 ESI: (M + H)⁺ = 0.75 FM1 (KBr): column 938/40/42 (Br₂) C═O chromatog- 1699.2; raphy: silica 1641.3 gel/FM4; diastereo- mers 78 N45 AS5 1 O A3 C1 purified by 44 ESI: (M + H)⁺ = 0.73 FM1 (KBr): C═O column 952/4/6 (Br₂) 1712.7, chromatog- 1637.5; —NH— raphy: silica 3300.0 gel/FM4; diastereo- mers 110 N15 AS4 1 O A0 C5 purified by 82 ESI: (M + H)⁺ = 0.79 FM1 (KBr): C═O column 725/7/9 (Br₂) 1620.1; chromatog- 1514.0 raphy: silica gel/FM4 111 N15 AS4 1 O A0 C15 purified by 58 ESI: M⁺ = 0.77 FM1 (KBr): C═O column 726/28/30 (Br₂) 1697.3; chromatog- 1620.1 raphy: silica gel/FM4 114 N45 AS4 1 O A0 C5 purified by 75 ESI: (M + H)⁺ = 0.78 FM1 (KBr): C═O column 739/41/43 (Br₂) 1710.8; chromatog- 1620.1 raphy: silica gel/FM4 112 N15 AS1 1 O A0 C5 purified by 45 ESI: (M + H)⁺ = 0.33 FM1 (KBr): C═O column 726/28/30 (Br₂) 1695.3; chromatog- 1624.0 raphy: silica gel/FM4 115 N45 AS1 1 O A0 C5 purified by 28 ESI: (M + H)⁺ = 0.35 FM1 (KBr): C═O column 740/2/4 (Br₂) 1710.8; chromatog- 1622 raphy: silica gel/FM4 113 N15 AS4 1 O A0 C16 purified by 56 ESI: (M + H)⁺ = 0.68 FM1 (KBr): C═O 173-176 column 726/8/30 (Br₂) 1699.2; chromatog- 1618.2 raphy: silica gel/FM4 119 N45 AS4 1 O A0 C16 purified by 81 ESI: (M + H)⁺ = 0.69 FM1 (KBr): C═O 148-152 column 762/4/6 (Br₂) 1710.8; chromatog- 1618.2 raphy: silica gel/FM4 120 N15 AS1 1 O A0 C15 purified by 27 ESI: (M + H)⁺ = 0.31 FM1 (KBr): C═O 173-175 column 749/51/53 (Br₂) 1695.3 chromatog- raphy: silica gel/FM4 128 N15 AS4 1 O A0 C3 purified by 61 ESI: (M + Na)⁺ = 0.72 FM1 (KBr): C═O 174-177 column 764/6/8 (Br₂) 1699.2; chromatog- 1618.2 raphy: silica gel/FM4 130 N15 AS4 1 O A0 C6 purified by 60 ESI: (M + H)⁺ = 0.7 FM1 (KBr): C═O 150-154 column 754/6/8 (Br₂) 1703; chromatog- 1620.1 raphy: silica gel/FM4 129 N15 AS1 1 O A0 C16 purified by 18 ESI: (M − H)⁻ = 0.27 FM1 (KBr): C═O 173-176 column 725/7/9 (Br₂) 1693.4; chromatog- 1627.8 raphy: silica gel/FM4 131 N45 AS4 1 O A0 C6 purified by 69 ESI: (M + H)⁺ = 0.73 FM1 (KBr): C═O 159-162 column 768/70/72 (Br₂) 1712.7; chromatog- 1620.1 raphy: silica gel/FM4 132 N45 AS4 1 O A0 C3 purified by 27 ESI: (M + Na)⁺ = 0.72 FM1 (KBr): C═O 142-146 column 778/80/2 (Br₂) 1712.7; chromatog- 1618.2 raphy: silica gel/FM4 133 N15 AS1 1 O A0 C6 purified by 24 ESI: (M + H)⁺ = 0.33 FM1 (KBr): C═O 161-164 column 755/7/9 (Br₂) 1697.3; chromatog- 1624.0 raphy: silica gel/FM4 134 N15 AS4 1 O A0 C18 purified by 69 ESI: (M + H)⁺ = 0.59 FM1 (KBr): C═O 171-174 column 756/8/60 (Br₂) 1699.2; chromatog- 1618.2 raphy: silica gel/FM4 135 N15 AS1 1 O A0 C18 Purified by 17 ESI: (M + H)⁺ = 0.25 FM1 (KBr): C═O 74-77 column 757/9/61 (Br₂) 1691.5; 1625.9 chromatog- raphy: silica gel/FM4 N29 AS1 1 O A3 C1 61 ESI: (M + H)⁺ = 0.62 FM7 (KBr): C═O 903/5/7 (Br₂) 1641.3 N36 AS1 1 O A3 C1 33 ESI: (M + H)⁺ = 0.49 FM7 (KBr): C═O 915/7/9 (Br₂) 1641.3 44 N34 AS1 1 O A3 C1 35 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 936/38/40/42 1641.3 (Br₃) 378 N15 AS1 0 O A3 C1 30 ESI: (M + H)⁺ = 0.13 FM1 (KBr): C═O 940/2/4 (Br₂) 1701.1; 1641.3 N48 AS1 1 O A3 C1 52 0.58 FM7 (KBr): C═O 1641.3 N77 AS1 1 O A3 C4 32 ESI: (M + H)⁺ = (KBr): C═O 955/7/9 (Br,) 1645; 1713 294 N66 AS4 1 O A7 C1 NEt₃ as base 31 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 895/7/9 (Br₂) 1653; 1772.5; 1716.5 323 N104 AS1 1 O A0 C4 DIEA 18 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O 799/801/803 1624 (Br₂) 324 N105 AS1 1 O A0 C4 DIEA 24 ESI: (M + H)⁺ = 0.38 FM1 (KBr): C═O 773/5/7/9 1624/1667 (Br₂/Cl) 325 N106 AS1 1 O A0 C4 DIEA 22 ESI: (M + H)⁺ = 0.35 FM1 (KBr): C═O 725/7/9 (Br₂) 1626/1662.5 326 N71 AS1 1 O A0 C1 DIEA 20 ESI: (M + H)⁺ = 0.16 FM1 (KBr): C═O 752/4/6 (Br₂) 1624/1680 327 N71 AS4 1 O A0 C4 DIEA 24 ESI: (M + H)⁺ = 0.48 FM1 (KBr): C═O 750/2/4 (Br₂) 1618/1682 328 N107 AS1 1 O A0 C4 DIEA 17 ESI: (M + H)⁺ = 0.38 FM1 (KBr): C═O 769/71/73 (Br₇) 1651 329 N108 AS4 1 O A0 C4 DIEA 16 ESI: (M + H)⁺ = 0.31 FM1 (KBr): C═O 781/83/85 (Br₂) 1620/1674 330 N108 AS4 1 O A0 C1 DIEA/DMF 15 ESI: (M + H)⁺ = 0.45 FM1 (KBr): C═O 781/83/85 (Br₂) 1620/1678 331 N108 AS4 1 O A0 C20 DIEA/DMF 15 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O 800/802/804 1616/1680 (Br₂) 332 N109 AS1 1 O A0 C4 DIEA/DMF 39 ESI: (M + H)⁺ = 0.32 FM1 (KBr): C═O 745/7/9 (Br₂) 1665 333 N110 AS1 1 O A0 C4 DIEA/DMF 52 ESI: (M + H)⁺ = 0.34 FM1 (KBr): C═O 745/7/9 (Br₂) 1636 334 N111 AS14 1 O A0 C1 DIEA/DMF 18 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 649 1626/1688 335 N109 AS4 1 O A0 C4 DIEA/DMF 46 ESI: (M + H)⁺ = 0.47 FM1 (KBr): C═O 744/6/8 (Br₂) 1618 336 N110 AS1 1 O A0 C8 DIEA/DMF 25 ESI: (M + H)⁺ = 0.22 FM1 (KBr): C═O 751/3/5 (Br₂) 1645 337 N109 AS1 1 O A0 C8 DIEA/DMF 32 ESI: (M + H)⁺ = 0.21 FM1 (KBr): C═O 751/3/5 (Br₂) 1645 338 N109 AS4 1 H2 A0 C8 DIEA/ 38 ESI: (M + H)⁺ = 0.44 FM1 (KBr): C═O DMF 736/8/40 (Br₂) 1653 339 N110 AS4 1 H2 A0 C8 DIEA/ 39 ESI: (M + H)⁺ = 0.44 FM1 (KBr): C═O DMF 736/8/40 (Br₂) 1653 340 N66 AS1 1 O A0 C20 DIEA/ 33 ESI: (M + H)⁺ = 0.12 FM1 (KBr): C═O DMF 759/61/63 (Br₂) 1618/1657 341 N71 AS1 1 O A0 C20 DIEA/ 31 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O DMF 771/3/5 (Br₂) 1620/1680 342 N112 AS4 1 O A0 C20 DIEA/ 27 ESI: (M + H)⁺ = 0.47 FM1 (KBr): C═O DMF 776/8/80 (Br₂) 1618/1682 343 N112 AS1 1 O A0 C20 DIEA/ 26 ESI: (M + H)⁺ = 0.11 FM1 (KBr): C═O DMF 777/9/81 (Br₂) 1624/1678 344 N71 AS1 1 O A0 C37 DIEA/ 52 ESI: (M + H)⁺ = 0.65 FM1 (KBr): C═O DMF 771/3/5 (Br₂) 1622/1680 345 N66 AS1 1 O A0 C37 DIEA/ 50 ESI: (M + H)⁺ = 0.7 FM1 (KBr): C═O DMF 759/61/63 (Br₂) 1626/1659 346 N71 AS4 1 O A0 C37 DIEA/ 37 ESI: (M + H)⁺ = 0.75 FM1 (KBr): C═O DMF 770/72/74 (Br₂) 1620/1682 347 N6 AS4 1 O A0 C37 DIEA/ 45 ESI: (M + H)⁺ = 0.8 FM1 (KBr): C═O DMF 758/60/62 (Br₂) 1620/1663 348 N113 AS4 1 O A0 C20 DIEA/ 24 ESI: (M + H)⁺ = 0.8 FM1 (KBr): C═O DMF 771/3/5 (BR₂) 1616/1701 349 N113 AS4 1 O A0 C8 DIEA/ 40 ESI: (M + H)⁺ = 0.8 FM1 (KBr): C═O DMF 757/59/61 (Br₂) 1616/1699 350 N111 AS4 1 O A0 C20 33 ESI: (M + H)⁺ = 0.63 FM1 (KBr): C═O 838/40/42 (Br₂) 1620/1688 351 N111 AS4 1 O A0 C8 39 ESI: (M + H)⁺ = 0.64 FM1 (KBr): C═O 824/6/8 (Br₂) 1620/1688 352 N111 AS1 1 O A0 C8 36 ESI: (M + H)⁺ = 0.37 FM1 (KBr): C═O 825/7/9 (Br₂) 1644/1688 353 N112 AS1 1 O A0 C8 24 ESI: (M + H)⁺ = 0.28 FM1 (KBr): C═O 763/5/7 (Br₂) 1624/1684 355 N113 AS4 1 O A0 C11 DIEA/  6 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O DMF 772/4/6 (Br₂) 1620/1697 356 N66 AS4 1 O A0 C38 DIEA/ 31 ESI: (M + H)⁺ = 0.23 FM1 (KBr): C═O DMF 785/7/9 (Br₂) 1624/1664 357 N112 AS4 1 O A0 C11 DIEA/  5 ESI: (M + H)⁺ = 0.37 FM1 DMF 777/79/81 (Br₂) 358 N111 AS1 1 O A0 C11 DIEA/ 13 ESI: (M + H)⁺ = 0.09 FM1 (KBr): C═O DMF 840/42/44 (Br₂) 1624/1686 359 N111 AS4 1 O A0 C11 DIEA/ 24 0.39 FM1 (KBr): C═O DMF 1622/1686 360 N109 AS4 1 O A0 C8 DIEA/ 25 ESI: (M + H)⁺ = 0.7 FM1 (KBr): C═O DMF 750/52/54 (Br₂) 1618/1657 361 N110 AS4 1 O A0 C11 DIEA/ 35 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O DMF 750/52/54 (Br₂) 1622/1649 362 N110 AS4 1 O A0 C8 DIEA/ 24 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O DMF 750/52/54 (Br₂) 1649 363 N111 AS4 1 O A0 C37 DIEA/ 25 0.53 FM1 (KBr): C═O DMF 1622/1688 364 N111 AS1 1 O A0 C37 DIEA/ 24 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O DMF 839/41/43 (Br₂) 1624/1686 366 N66 AS4 1 O A0 C39 67 ESI: (M + H)⁺ = 0.53 FM1 (KBr): C═O 772/4/6 (Br₂) 1618/1665 367 N71 AS4 1 O A0 C39 DIEA/ 12 ESI: (M + H)⁺ = 0.52 FM1 (KBr): C═O DMF 784/6/8 (Br₂) 1618/1684 368 N111 AS4 1 O A0 C39 DIEA/ 37 ESI: (M + H)⁺ = 0.8 FM1 (KBr): C═O DMF 852/4/6 (Br₂) 1618/1686 369 N114 AS4 1 O A0 C8 15 ESI: (M + H)⁺ = 0.58 FM1 (KBr): C═O 824/6/8 (Br₂) 1618/1686 370 N66 AS4 1 O A0 C40 DIEA/ 35 ESI: (M + H)⁺ = 0.44 FM1 (KBr): C═O DMF 773/5/7 (Br₂) 1622/1660 371 N111 AS4 1 O A0 C40 DIEA/ 58 ESI: (M + H)⁺ = 0.44 FM1 (KBr): C═O DMF 853/5/7 (Br₂) 1622/1687 373 N115 AS4 1 O A0 C8 DIEA/ 43 ESI: (M + H)⁺ = 0.7 FM1 (KBr): C═O DMF 822/4/6/8 (Br₃) 1620/1670 374 N116 AS4 1 O A0 C20 27 ESI: (M + H)⁺ = 0.53 FM1 (KBr): C═O 784/6/8 (Br) 1618/1680 375 N117 AS4 1 O A0 C20 23 ESI: (M + H)⁺ = 0.52 FM1 (KBr): C═O 815/7/9 (Br) 1620/1687 376 N118 AS4 1 O A0 C20 30 0.56 FM1 (KBr): C═O 1620/1684 377 N119 AS4 1 O A0 C20 74 ESI: (M + H)⁺ = 0.61 FM1 (KBr): C═O 848/50/52/54 1616/1685 (Br₃) 418 N111 AS4 1 O A0 C38 DIEA/ 23 ESI: (M + H)⁺ = 0.27 FM1 (KBr): C═O DMF 865/7/9 (Br) 1622/1687 490 N113 AS1 1 O A0 C20 DIEA/ 37 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O DMF 772/4/6 (Br₂) 1622/1699 491 N113 AS1 1 O A0 C8 DIEA/ 94 ESI: (M + H)⁺ = 0.37 FM1 (KBr): C═O DMF 758/60/62 (Br₂) 1624/1691 492 N113 AS1 1 O A0 C11 DIEA/ 42 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O DMF 773/5/7 (Br₂) 1678 495 N133 AS4 1 O A0 C20 45 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 846/48/50 (Br₂) 1620/1682 379 N71 AS1 1 O A0 C3 39 ESI: (M + H)⁺ = 0.41 FM4 (KBr): C═O 769/71/73 (Br₂) 1680 380 N71 AS4 1 O A0 C3 40 ESI: (M + H)⁺ = 0.47 FM4 (KBr): C═O 768/70/72 (Br₂) 1618/1682 381 N71 AS1 1 O A0 C42 11 ESI: (M + H)⁺ = 0.53 FM1 (KBr): C═O 752/54/56 (Br₂) 1624/1682 382 N66 AS1 1 O A0 C42 18 ESI: (M + H)⁺ = 0.16 FM4 (KBr): C═O 740/42/44 (Br₂) 1630/1653 383 N66 AS4 1 O A0 C42 47 ESI: (M + H)⁺ = 0.25 FM4 (KBr): C═O 739/41/43 (Br₂) 1626/1659 384 N93 AS1 1 O A0 C1 11 ESI: (M + H)⁺ = 0.20 FM7 (KBr): C═O 790/92/94 (Br₂) 1636/1705 385 N71 AS4 1 O A0 C42 37 ESI: (M + H)⁺ = 0.30 FM4 (KBr): C═O 751/53/55 (Br₂) 1620/1680 386 N71 AS4 1 O A0 C18 26 ESI: (M + H)⁺ = 0.27 FM4 (KBr): C═O 782/4/6 (Br₂) 1620/1682 387 N66 AS4 1 O A0 C5 62 ESI: (M + H)⁺ = 0.38 FM4 (KBr): C═O 739/41/43 (Br₂) 1626/1663 388 N71 AS4 1 O A0 C5 55 ESI: (M + H)⁺ = 0.39 FM4 (KBr): C═O 751/3/5 (Br₂) 1618/1684 389 N66 AS1 1 O A0 C43 59 ESI: (M + H)⁺ = 0.32 CH₂Cl₂/MeOH/ (KBr): C═O 796/98/800 NH₄OH 9/1/0.1 1653 (Br₂) 390 N135 AS4 1 O A0 C18  5 ESI: (M + H)⁺ = 0.71 FM1 (KBr): C═O 853/5/7 (Br₂) 1622/1653 391 N135 AS1 1 O A0 C18  6 ESI: (M + H)⁺ = 0.54 FM1 (KBr): C═O 854/6/8 (Br₂) 1659 392 N120 AS1 1 O A0 C4 12 ESI: (M + H)⁺ = 0.41 CH₂Cl₂/MeOH/ (KBr): C═O 763/5/7 (Br₂) NH₄OH 9/1/0.1 1618/1639 393 N66 AS1 1 O A0 C44 28 ESI: (M + H)⁺ = 0.50 CH₂Cl₂/MeOH/ (KBr): C═O 763/5/7 (Br₂) NH₄OH 9/1/0.1 1659 394 N66 AS4 1 O A0 C21 37 ESI: (M + H)⁺ = 0.35 EE/MeOH/ (KBr): C═O 740/42/44 (Br₂) AcOH 75/25/0.5 1659 396 N71 AS1 1 O A0 C21 49 ESI: (M + H)+ = 0.30 EE/MeOH/ (KBr): C═O 753/5/7 (Br₂) AcOH 75/25/0.5 1622/1678 397 N66 AS1 1 O A0 C21 62 ESI: (M + H)⁺ = 0.35 EE/MeOH/ (KBr): C═O 741/3/5 (Br₂) AcOH 75/25/0.5 1649 398 N121 AS4 1 O A0 C8 80 ESI: (M + H)⁺ = 0.55 CH₂Cl₂/MeOH/ (KBr): C═O 743/5/7 (Br₂) NH₄OH 9/1/0.1 1618/1668 399 N122 AS4 1 O A0 C18 40 ESI: (M + H)+ = 0.62 FM1 (KBr): C═O 800/2/4 (Br₂) 1622/1682 400 N136 AS4 1 O A0 C8 11 ESI: (M + H)⁺ = 0.65 FM1 (KBr): C═O 741/3/5 (Br₂) 1622/1653 401 N66 AS1 1 O A0 C45 19 ESI: (M + H)⁺ = 0.65 CH₂Cl₂/MeOH/ (KBr): C═O 749/51/53 (Br₂) NH₄OH 9/1/0.1 1659 402 N136 AS4 1 O A0 C1 10 ESI: (M + H)⁺ = 0.42 CH₂Cl₂/MeOH/ (KBr): C═O 736/8/40 (Br₂) NH₄OH 9/1/0.1 1649 403 N121 AS4 1 O A0 C1 25 ESI: (M + H)⁺ = 0.43 CH₂Cl₂/MeOH/ (KBr): C═O 738/40/42 (Br₂) NH₄OH 9/1/0.1 1626/1676 404 N66 AS4 1 O A0 C46 58 ESI: (M + H)⁺ = 0.29 CH₂Cy MeOH/ (KBr): C═O 766/8/70 (Br₂) NH₄OH 9/1/0.1 1624/1663 405 N66 AS1 1 O A0 C47 40 ESI: (M − H)⁻ = 0.3 EE/MeOH 9/1 (KBr): C═O 752/4/6 (Br₂) 1659 406 N136 AS1 1 O A0 C1 16 ESI: (M + H)⁺ = 0.34 FM7 (KBr): C═O 737/39/41 (Br₂) 1645 407 N121 AS1 1 O A0 C1 15 ESI: (M + H)⁺ = 0.36 FM7 (KBr): C═O 739/41/43 (Br₂) 1638 408 N71 AS4 1 O A0 C48 47 ESI: (M + Hr = 0.17 CH₂Cl₂/MeOH/ (KBr): C═O 792/4/6 (Br₂) NH₄OH 9/1/0.1 1620/1680 409 N66 AS4 1 O A0 C48 31 ESI: (M + H)⁺ = 0.43 CH₂Cl₂/MeOH/ (KBr): C═O 780/2/4 (Br₂) NH₄OH 9/1/0.1 1665/1736 410 N66 AS1 1 O A0 C49 51 0.24 EE/MeOH 9/1 (KBr): C═O 1661 411 N71 AS4 1 O A0 C44 45 ESI: (M + Na)⁺ = 0.35 EE/MeOH 9/1 (KBr): C═O 796/98/800 1728 (Br₂) 412 N66 AS1 1 O A0 C50 58 ESI: (M + H)⁺ = 0.47 EE/MeOH 9/1 (KBr): C═O 756/58/60 (Br₂) 1642/1661 413 N66 AS1 1 O A0 C51 16 ESI: (M + H)⁺ = 0.47 EE/MeOH/ (KBr): C═O 788/90/92 (Br₂) NH₄OH 5/5/0.1 1631 414 N66 AS4 1 O A0 C52 34 ESI: (M + H)⁺ = 0.54 FM1 (KBr): C═O 747/49/51 (Br₂) 1622/1662 415 N71 AS4 1 O A0 C52 35 ESI: (M + H)⁺ = 0.52 FM1 (KBr): C═O 759/61/63 (Br₂) 1620/1682 416 N66 AS4 1 O A0 C53 53 ESI: (M + H)⁺ = 0.45 CH₂Cl₂/MeOH/ (KBr): C═O 759/61/63 (Br₂) NH₄OH 9/1/0.1 1620/1664 417 N71 AS4 1 O A0 C53 39 ESI: (M + H)⁺ = 0.43 (KBr): C═O 771/3/5 (Br₂) 1620/1684 496 N66 AS4 1 O A0 C64 57 0.5 CH₂Cl₂/MeOH/ (KBr): C═O NH₄OH 9/1/0.1 1635 497 N66 AS1 1 O A0 C53 60 ESI: (M + H)⁺ = 0.31 CH₂Cl₂/MeOH/ (KBr): C═O 760/2/4 (Br₂) NH₄OH 1676 50/50/0.5 498 N66 AS4 1 O A0 C65 60 ESI: (M + H)⁺ = 0.39 FM1 (KBr): C═O 760/2/4 (Br₂) 1676 499 N71 AS4 1 O A0 C65 53 ESI: (M + H)⁺ = 0.39 FM1 (KBr): C═O 785/7/9 (Br₂) 1618/1684 500 N66 AS4 1 O A0 C51 71 ESI: (M + H)⁺ = 0.15 CH₂Cl₂/MeOH/ (KBr): C═O 787/89/91 (Br₂) NH₄OH 9/1/0.1 1628 501 N71 AS1 1 O A0 C53 71 ESI: (M + H)⁺ = 0.25 CH₂Cl₂/MeOH/ (KBr): C═O 772/4/6 (Br₂) NH₄OH 1676 50/50/0.5 502 N66 AS1 1 O A0 C65 42 ESI: (M + H)⁺ = 0.15 FM1 (KBr): C═O 774/6/8 (Br₂) 1626/1657 503 N71 AS1 1 O A0 C65 48 ESI: M + H)⁺ = 0.12 FM1 (KBr): C═O 786/88/90 (Br₂) 1620/1682 504 N66 AS4 1 O A0 C66 67 ESI: (M + H)⁺ = 0.65 CH₂Cl₂MeOH/ (KBr): C═O 787/89/91 (Br₂) NH₄OH 1624 50/50/0.5 297 N71 AS4 1 H2 A0 C8  9 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 742/4/6 (Br₂) 1684 298 N71 AS13 1 H2 A0 C8  6 ESI: (M + H)⁺ = 0.16 FM1 (KBr): C═O 664/6 (Br) 1622/1682 299 N66 AS4 1 H2 A0 C8 21 ESI: (M + H)⁺ = 0.25 FM1 (KBr): C═O 730/2/4 (Br₂) 1666 300 N66 AS13 1 H2 A0 C8 14 ESI: (M + H)⁺ = 0.19 FM1 (KBr): C═O 652/4 (Br) 1666 301 N71 AS1 1 H2 A0 C8 26 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 743/5/7 (Br₂) 1682 420 N87 AS1 1 O A0 C4 45 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 797/99/801 1624/1665/ (Br₂) 1719 422 N87 AS1 1 O A0 C8 35 ESI: (M + H) ⁺ = 0.54 FM1 (KBr): C═O 805/7/9 (Br₂) 1628/1668/ 1720 431 N125 AS4 1 O A0 C8 89 ESI: (M + H)⁺ = 0.75 FM1 (KBr): C═O 772/4/6 (Br₂) 1713/1773 432 N125 AS1 1 O A0 C4 59 ESI: (M + H)⁺ = 0.65 FM1 (KBr): C═O 767/69/71 (Br₂) 1622/1711/ 1773 433 N126 AS4 1 O A0 C4 33 ESI: (M + H)⁺ = 0.65 FM1 (KBr): C═O 780/2/4 (Br₂) 1709/1769 434 N126 AS1 1 O A0 C8 53 ESI: (M + H)⁺ = 0.53 FM1 (KBr): C═O 787/89/91 (Br₂) 1626/1707 440 N127 AS4 1 O A0 C8 67 ESI: (M + H)⁺ = 0.67 FM1 (KBr): C═O 780/2/4 (Br₂) 1618 441 N127 AS4 1 O A0 C20 89 ESI: (M + H)⁺ = 0.24 EE/MeOH/ (KBr): C═O 794/6/8 (Br₂) NH₄OH 1618 8/1.5/0.3 442 N127 AS4 1 O A0 C4 83 ESI: (M + H)⁺ = 0.37 EE/MeOH/ (KBr): C═O 774/6/8 (Br₂) NH₄OH 1616/1732 8/1.5/0.3 456 N66 AS16 1 O A0 C8 83 ESI: (M + H)⁺ = 0.32 EE/MeOH/ (KBr): C═O 641/3/5 (Cl₂) NH₄OH 1624/1665 8/1.5/0.1 466 N128 AS4 1 O A0 C8 13 ESI: (M + H)⁺ = 0.63 FM1 (KBr): C═O 832/4/6 (Br₂) 1684 467 N129 AS4 1 O A0 C8 16 ESI: (M + H)⁺ = 0.63 FM1 (KBr): C═O 806/08/10 (Br₂) 1618/1682 468 N129 AS1 1 O A0 C8 28 ESI: (M + H)⁺ = 0.29 FM1 (KBr): C═O 807/09/11 (Br₂) 1630/1680 470 N128 AS1 1 O A0 C8 81 ESI: (M + H)⁺ = 0.63 FM1 (KBr): C═O 835/7/9 (Br₂) 1684 473 N130 AS1 1 O A0 C8 40 ESI: (M + H)⁺ = 0.51 FM1 (KBr): C═O 787/89/91 (Br₂) 1624/1678 474 N130 AS4 1 O A0 C8 17 ESI: (M + Hr = 0.71 FM1 (KBr): C═O 786/88/90 (Br₂) 1618/1684 477 N66 AS16 1 O A0 C1 33 ESI: (M + H)+ = 0.53 EE/MeOH/ (KBr): C═O 636/38/40 (Cl₂) NH₄OH 9/1/1 1661 (v/v/v) 481 N131 AS4 1 O A0 C37 30 ESI: (M + H)⁺ = 0.15 CH₂Cl₂/ (KBr): C═O 838/40/42/44 MeOH 7/3 1618/1685 (Br₂; Cl₂) (v/v) 482 N131 AS4 1 O A0 C20 24 ESI: (M + H)⁺ = 0.15 CH₂Cl₂/ (KBr): C═O 838/40/42/44 MeOH 7/3 1618/1685 (Br₂; Cl₂) (v/v) 483 N132 AS4 1 O A0 C20 62 ESI: (M + H)⁺ = 0.55 FM1 (KBr): C═O 804/6/8/10 1684 (Br₂; Cl) 484 N132 AS4 1 O A0 C37 85 ESI: (M + H)⁺ = 0.60 FM1 (KBr): C═O 804/6/8/10 1616/1686 (Br₂; Cl) 505 N134 AS4 1 O A0 C8 81 ESI: (M + H)⁺ = 0.74 FM1 (KBr): C═O 781/3/5 (Br₂) 1616/1714 292 N66 AS1 1 H2 A0 C8  6 ESI: (M + H)⁺ = 0.25 FM1 (KBr): C═O 731/3/5 (Br₂) 1607/1664 245 N72 AS4 1 H2 A0 C8 19 ESI: (M + H)⁺ = 0.30 FM1 (KBr): C═O 731/3/5 (Br₂) 1668 220 N15 AS1 1 H2 A0 C8  6 ESI: (M + H)⁺ = 0.30 FM1 (KBr): C═O 717/19/21 (Br₂) 1697.3 307 N87 AS4 1 O A0 C4 27 ESI: (M + H)⁺ = 0.50 FM1 (KBr): C═O 796/98/800 1618/1670/ (Br₂) 1718 178 N74 AS1 1 O A0 C4 33 ESI: (M + H)⁺ = 0.60 EE/MeOH/ (KBr): C═O 679/81/83 (Br₂) AcOH 1624 50/50/1 (v/v/v) 395 N71 AS4 1 O A0 C21 22 ESI: (M + H)⁺ = 0.25 EE/MeOH/ 752/4/6 (Br₂) AcOH 50/25/0.5 (v/v/v) 509 N119 AS4 1 O A0 C38 DMF 45 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 875/7/9/81 1687/1618 (Br₃) 510 N118 AS4 1 O A0 C38 DMF 34 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O 827/29/31 (Br₂) 1682/1620 519 N137 AS4 1 O A0 C20 THF/ 62 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O DMF 786/88/90 (Br₂) 1618/1678 520 N138 AS4 1 O A0 C20 THF/DMF 31 ESI: (M + H)⁺ = 0.45 FM1 (KBr): C═O 906/08/10 1693 (Br_(a)) N66 AS4 1 O A0 C69 DMF 100  533 N139 AS1 1 O A0 C8 44 ESI: (M + H)⁺ = 0.1 FM5 (KBr): C═O 746/48/50 1628 (Br₂) 534 N139 AS4 1 O A0 C20 60 ESI: (M + H)⁺ = 0.2 FM5 (KBr): C═O 759/61/63 1618/1672 (Br₂) 535 N139 AS1 1 O A0 C53 34 ESI: (M + H)⁺ = 0.1 FM5 (KBr): C═O 761/63/65 1624/1670 (Br₂) 536 N140 AS4 1 O A0 C8 40 ESI: (M + H)⁺ = 0.37 FM1 (KBr): C═O 745/7/9 1616/1676 (Br₂) 537 N140 AS1 1 O A0 C8   33.4 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 746/48/50 1614/1672 (Br₂) 551 N66 AS1 1 O A0 C66 41 ESI: (M + H)⁺ = 0.3 EE/MeOH/ (KBr): C═O 788/90/92 NH₄OH 1628 (Br₂) 50/50/0.5 552 N66 AS4 1 O A0 C78 83 ESI: (M + H)⁺ = 0.6 CH₂Cl₂/MeOH/ (KBr): C═O 787/89/91 NH₄OH 1620 (Br₂) 80/20/1 553 N66 AS1 1 O A0 C78 30 ESI: (M + H)⁺ = 0.5 CH₂Cl₂/MeOH/ (KBr): C═O 788/90/92 NH₄OH 1626 (Br₂) 80/20/1 554 N71 AS4 1 O A0 C78 67 ESI: (M + H)⁺ = 0.5 CH₂Cl₂/MeOH/ (KBr): C═O 799/801/803 NH₄OH 1622/1684 (Br₂) 80/20/1 555 N71 AS1 1 O A0 C78 26 ESI: (M + H)⁺ = 0.5 CH₂Cl₂/MeOH/ (KBr): C═O 800/02/04 NH₄OH 1624/1684 (Br₂) 80/20/1 556 N66 AS4 1 O A0 C70 71 ESI: (M + H)⁺ = 0.6 CH₂Cl₂/MeOH/ (KBr): C═O 788/90/92 NH₄OH 1653 (Br₂) 50/50/0.5 557 N71 AS4 1 O A0 C70 27 ESI: (M + H)⁺ = 0.8 CH₂Cl₂/MeOH/ 800/02/04 NH₄OH (Br₂) 50/50/0.5 558 N66 AS1 1 O A0 C64 61 ESI: (M + H)⁺ = 0.3 CH₂Cl₂/MeOH/ (KBr): C═O 790/92/94 NH₄OH 1635 (Br₂) 90/10/1 559 N141 AS4 1 O A0 C20 80 ESI: (M + H)⁺ = 0.3 CH₂Cl₂/MeOH/ (KBr): C═O 626/28/30 NH₄OH 1618/1714 (Br₂) 90/10/1 560 N66 AS4 1 O A0 C71 59 ESI: (M + H)⁺ = 0.3 CH₂Cl₂/MeOH/ (KBr): C═O 837/39/41 NH₄OH 1628/62 (Br₂) 90/10/1 561 N71 AS4 1 O A0 C71 56 ESI: (M + H)⁺ = 0.2 CH₂Cl₂/ (KBr): C═O 849/51/53 (Br₂) MeOH/ 1618/1684 NH₄OH 90/10/1 562 N66 AS1 1 O A0 C70 15 ESI: (M + H)⁺ = 0.6 CH₂Cl₂/ (KBr): C═O 789/91/93 (Br₂) MeOH/ 1676 NH₄OH 50/50/0.5 563 N71 AS1 1 O A0 C70 27 ESI: (M + H)⁺ = 0.6 CH₂Cl₂/ (KBr): C═O 801/3/5 (Br₂) MeOH/ 1678 NH₄OH 70/30/1 565 N66 AS4 1 O A0 C72 51 ESI: (M + H)⁺ = 0.2 CH₂Cl₂/ (KBr): C═O 787/89/91 (Br₂) MeOH/ 1622/1658 NH₄OH 80/20/1 566 N71 AS4 1 O A0 C72 65 ESI: (M + H)⁺ = 0.2 CH₂Cl₂/ (KBr): C═O 799/801/803 MeOH/ 1620/1682 (Br₂) NH₄OH 80/20/1 567 N136 AS4 1 O A0 C53 65 ESI: (M + H)⁺ = 0.5 CH₂Cl₂/ (KBr): C═O 756/58/60 (Br₂) MeOH/ 1641 NH₄OH 80/20/1 568 N136 AS4 1 O A0 C72 76 ESI: (M + H)⁺ = 0.2 CH₂Cl₂/ (KBr): C═O 784/6/8 (Br₂) MeOH/ 1637 NH₄OH 80/20/1 569 N136 AS1 1 O A0 C53 63 ESI: (M + H)⁺ = 0.4 CH₂Cl₂/ (KBr): C═O 757/59/61 (Br₂) MeOH/ 1643 NH₄OH 80/20/1 570 N66 AS31 1 O A0 C20 88 ESI: (M + H)⁺ = 0.6 CH₂Cl₂/ (KBr): C═O 640 MeOH/ 1622/1664 NH₄OH 80/20/1 571 N66 AS31 1 O A0 C53 82 ESI: (M + H)⁺ = 0.8 CH₂Cl₂/ (KBr): C═O 641 MeOH/ 1664 NH₄OH 80/20/1 572 N71 AS31 1 O A0 C20 100  ESI: (M + H)⁺ = 0.4 CH₂Cl₂/ (KBr): C═O 652 MeOH/ 1620/1684 NH₄OH 80/20/1 573 N71 AS31 1 O A0 C53 48 ESI: (M + H)⁺ = 0.4 CH₂Cl₂/ (KBr): C═O 653 MeOH/ 1622/1684 NH₄OH 80/20/1 576 N66 AS11 1 O A0 C53 35 ESI: (M + H)⁺ = 0.65 CH₂Cl₂/ (KBr): C═O 727 MeOH/ 1664/1732 NH₄OH 80/20/1 577 N71 AS11 1 O A0 C53 73 ESI: (M + H)⁺ = 0.18 EE/ (KBr): C═O 739 MeOH/ 1684/1734 NH₄OH 50/50/0.5 580 N66 AS11 1 O A0 C20 65 ESI: (M + H)⁺ = 0.5 CH₂Cl₂/ (KBr): C═O 706 MeOH/ 1664/1732 NH₄OH 80/20/1 581 N71 AS11 1 O A0 C20 38 ESI: (M + H)⁺ = 0.2 CH₂Cl₂/ (KBr): C═O 738 MeOH/ 1684/1734 NH₄OH 90/10/1 582 N143 AS4 1 O A0 C20 61 ESI: (M + H)⁺ = 0.5 CH₂Cl₂/ (KBr): C═O 758/60/62 MeOH/ 1615 NH₄OH 90/10/1 583 N66 AS31 1 O A0 C72 50 ESI: (M + H)⁺ = 0.35 FM1 (KBr): C═O 669 1664 584 N71 AS31 1 O A0 C72 68 ESI: (M + H)⁺ = 0.35 FM1 (KBr): C═O 681 1622/1684 585 N144 AS4 1 O A0 C8 50 ESI: (M + H)⁺ = 0.43 FM5 (KBr): C═O 927/29/31/33 1616/1684 (Br₄) 586 N144 AS4 1 O A0 C53 85 ESI: (M + H)⁺ = 0.67 FM1 (KBr): C═O 942/4/6/8 (Br₄) 1680 587 N66 AS11 1 O A0 C72 37 ESI: (M + H)⁺ = 0.35 FM1 (KBr): C═O 755 1622/1658/ 1732 588 N71 AS11 1 O A0 C72 81 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 767 1684/1732 619 N71 AS19 1 O A0 C8   27.9 0.3 EE/MeOH/ (KBr): C═O NH₄OH 1622/1684 9/1/0.3 620 N66 AS35 1 O A0 C8 36 ESI: (M − H)⁻ = 0.25 MeOH (KBr): C═O 598 1628/1664 621 N66 AS36 1 O A0 C8 32 ESI: (M − H)⁻ = 0.56 FM1 (KBr): C═O 587 1626/1666 622 N71 AS36 1 O A0 C8 32 ESI: (M − H)⁻ = 0.44 FM1 (KBr): C═O 599 1622/1684 623 N109 AS36 1 O A0 C8 37 ESI: (M − H)⁻ = 0.6 FM1 (KBr): C═O 593 1626/1649 624 N118 AS36 1 O A0 C8 55 ESI: (M − H)⁻ = 0.6 FM1 (KBr): C═O 629 1622/1684 625 N111 AS36 1 O A0 C8 47 ESI: (M − H)⁻ = 0.61 FM1 (KBr): C═O 667 1624/1687 626 N111 AS19 1 O A0 C8 20 ESI: (M − H)⁻ = 0.28 EE/MeOH/ (KBr): C═O 731/3 (Br) NH₄OH 1624/1687 9/1/0.3 627 N109 AS19 1 O A0 C8 16 ESI: (M − H)⁻ = 0.28 EE/MeOH/ (KBr): C═O 657/9 (Br) NH₄OH 1653 9/1/0.3 633 N118 AS19 1 O A0 C8 20 ESI: (M + H)⁺ = 0.18 EE/MeOH/ (KBr): C═O 693/5 (Br) NH₄OH 1622/1684 9/1/0.3 N66 AS1 1 O A0 C69 100  0.3 FM4 (KBr): C═O 1668

EXAMPLE 4

Preparation of Compounds ofGeneralFormula:

1-[4-amino-3,5-dibromo-N-[4-(1,3,3a,4,5,6,7,7a-octahydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine (No. 91)

A mixture of 0.35 g (2.1 mmol) of CDT, 1.0 g (1.4 mmol) of 4-(1,3,3a,4,5,6,7,7a-octahydro-2(2H)-oxobenzimidazol-1-yl)-piperidine, 0.5 ml of (2.8 mmol) of DIEA and 100 ml of tetrahydrofuran was stirred for 1 hour whilst cooling with ice and then for 30 minutes at ambient temperature. With stirring 0.46 g (1.75 mmol) of 1-(4-amino-3,5-dibromo-D-phenylalanyl)-4-(4-pyridinyl)piperazine and 0.32 ml of (1.8 mmol) of DIEA were added and refluxed for 3 hours. The reaction mixture was diluted with 100 ml of ethyl acetate and the organic phase was washed twice with aqueous saturated sodium hydrogen carbonate solution. The combined aqueous phases were then extracted once with ethyl acetate/tetrahydrofuran=1/1 (v/v) and the combined organic phases were washed once with saturated aqueous saline solution. After drying the organic phase and eliminating the solvent in vacuo the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant:ethyl acetate/methanol=9/1 (v/v)). 120 mg (12% of theory) of a colourless foam were obtained.

IR (KBr): 1626. 1686 cm⁻¹ (C═O)

IR (KBr): 1626. 1686 cm⁻¹ (C═O) Rf: 0.62 (FM3) ESI-MS: (M + H)⁺ = 731/733/735 (Br₂) (M + H + Na)⁺⁺ = 377/378/379 (Br₂)

The following were prepared analogously (in each case n=1):

% M.p. No. RCO R² A NR³R⁴ n Remarks Yield MS R_(f) Eluant IR [cm⁻¹] (° C.) N16 AS1 A3 C1 1 NEt₃ as base 31 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 974/6/8 (Br₂) 1641.3; 1695.3 86 N53 AS4 A0 C1 1 DMF as solvent 23 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 739/41/43 (Br₂) 1641.3; 1697.3 87 N54 AS4 A0 C1 1 DMF als 81 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O Lösemittel 739/41/43 (Br₂) 1620.1; 1697.3 92 N57 AS4 A0 C1 1 DMF as solvent 60 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 712/4/6 (Br₂) 1597; 1635.5 93 N47 AS4 A0 C1 1 23 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O 636/8/40 (Br₂) 1622; 1675 94 N45 AS4 A0 C1 1 45 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 739/41/43 (Br₂) 1598.9; 1620.1 95 N57 AS1 A0 C1 1 DMF as solvent 13 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 713/5/7 (Br₂) 1637.5 96 N53 AS1 A0 C1 1 DMF as solvent 15 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 740/2/4 (Br₂) 1633.6; 1687.6 97 N54 AS1 A0 C1 1 DMF as solvent 31 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 740/2/4 (Br₂) 1635.5; 1695.3 107 N59 AS4 A0 C1 1 76 ESI: (M + H)⁺ = 0.7 FM1 (KBr): C═O 694/6/8 (Br₂) 1597; 1635.5 108 N45 AS1 A0 C1 1 37 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 740/2/4 (Br₂) 1633.6; 1708.8 109 N59 AS1 A0 C1 1 30 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 695/7/9 (Br₂) 1647.4 116 N60 AS4 A0 C1 1 DMF as solvent 80 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 753/5/7 (Br₂) 1623.7; 1676.1; 1712.7 117 N60 AS1 A0 C1 1 DMF as solvent 50 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O 754/6/8 (Br₂) 1617; 1650; 1670; 1712.7 118 N47 AS1 A0 C1 1 29 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O 637/9/41 (Br₂) 1639.4 121 N61 AS1 A0 C1 1 12.4 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 727/9/31 (Br₂) 1635.5; 1705 122 N61 AS4 A0 C1 1 42 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 726/8/30 (Br₂) 1620.1; 1706.9 125 N15 AS7 A0 C1 1 NEt₃ as base 4.4 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 598 1708.8 126 N15 AS7 A0 C4 1 NEt₃ as base 57 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 188.0 597 1622; 1708.8 127 N15 AS7 A0 C8 1 NEt₃ as 16 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 168- base 603 1622; 1697.3 170 137 N94 AS4 A0 C4 1 42 ESI: (M + H)⁺ = 0.8 FM1 (KBr): C═O 708/10/12 (Br₂) 1618 138 N95 AS4 A0 C8 1 NEt₃ as 29 ESI: (M + H)⁺ = 0.8 FM1 (KBr): C═O base 743/5/7 (Br₂) 1713 139 N61 AS1 A3 C1 1 41 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O 955/7/9 (Br₂) 1640; 1709 140 N60 AS1 A3 C1 1 66 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 982/4/6 (Br₂) 1645; 1712 143 N66 AS1 A0 C4 1 DMF as 69 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O solvent 739/41/43 (Br₂) 1624; 1659 144 N96 AS1 A0 C4 1 54 ESI: (M + H)⁺ = 0.54 FM1 (KBr): C═O 725/7/9 (Br₂) 1616 145 N61 AS1 A0 C4 1 48 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 724/6/8 (Br₂) 1624; 1709 146 N15 AS14 A0 C1 1 DMF as 53 ESI: (M + H)⁺ = 0.15 FM1 (KBr): C═O solvent 555 1636; 1701 147 N61 AS4 A0 C11 1 30 ESI: (M + H)⁺ = 0.7 FM1 (KBr): C═O 746/48/50 (Br₂) 1620; 1713 148 N66 AS1 A0 C8 1 THF/DMF 58 ESI: (M + H)⁺ = 0.68 FM1 (KBr): C═O as solvent 745/7/9 (Br₂) 1628; 1663 149 N69 AS1 A0 C4 1 THF/DMF 61 ESI: (M + H)⁺ = 0.68 FM1 (KBr): C═O as solvent 739/41/43 (Br₂) 1624; 1675 150 N97 AS1 A0 C4 1 THF/DMSO 32 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O as solvent 783/85/87 (Br₂) 1709 152 N71 AS1 A0 C4 1 40 ESI: (M + H)⁺ = 0.68 FM1 (KBr): C═O 751/53/55 (Br₂) 1622; 1684 153 N65 AS1 A0 C4 1 51 ESI: (M + H)⁺ = 0.68 FM1 (KBr): C═O 751/53/55 (Br₂) 1626; 1678 N66 AS1 A3 C1 1 37 225 N66 AS1 A0 C1 1 THF/DMF 48 ESI: (M + H)⁺ = 0.35 FM1 (KBr): C═O as solvent 740/42/44 (Br₂) 1650; 1670 226 N66 AS4 A0 C8 1 THF/DMF 88 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O as solvent 744/6/8 (Br₂) 1618; 1661 227 N69 AS4 A0 C8 1 THF/DMF 72 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O as solvent 744/6/8 (Br₂) 1618; 1680 228 N69 AS1 A0 C8 1 THF/DMF 69 ESI: (M + H)⁺ = 0.45 FM1 (KBr): C═O as solvent 745/7/9 (Br₂) 1628 229 N70 AS1 A0 C4 1 THF/DMF 39 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O as solvent 727/29/31 (Br₂) 1730 230 N66 AS4 A0 C20 1 49 ESI: (M + H)⁺ = 0.55 FM1 (KBr): C═O 758/60/62 (Br₂) 1614 231 N99 AS4 A0 C8 1 THF/DMF as 68 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O solvent 758/60/62 (Br₂) 1624 239 N71 AS1 A0 C8 1 THF/DMF as 59 ESI: (M + H)⁺ = 0.45 FM1 (KBr): C═O solvent 757/59/61 (Br₂) 1626; 1680 240 N71 AS4 A0 C11 1 35 ESI: (M + H)⁺ = 0.68 FM1 (KBr): C═O 771/3/5 (Br₂) 1615; 1684 241 N71 AS4 A0 C8 1 88 ESI: (M + H)⁺ = 0.68 FM1 (KBr): C═O 756/58/60 (Br₂) 1620; 1682 242 N71 AS4 A0 C1 1 40 ESI: (M + H)⁺ = 0.64 FM1 (KBr): C═O 751/3/5 (Br₂) 1615; 1684 243 N71 AS4 A0 C20 1 38 ESI: (M + H)⁺ = 0.65 FM1 (KBr): C═O 770/2/4 (Br₂) 1618; 1684 244 N71 AS1 A0 C11 1 36 ESI: (M + H)⁺ = 0.35 FM1 (KBr): C═O 772/4/6 (Br₂) 1622; 1684 N5 AS1 A3 C1 1 NEt₃ as base 24 ESI: (M + H)⁺ = 0.06 FM1 (KBr): C═O 890/2/4 (Br₂) 1641.3 N10 AS1 A3 C1 1 NEt₃ as base 55 ESI: (M + H)⁺ = 0.38 FM1 (KBr): C═O 874/6/8 (Br₂) 1641.3 N12 AS1 A3 C1 1 NEt₃ as base 35480 ESI: (M + H)⁺ = 0.43 FM1 (KBr): C═O 902/4/6 (Br₂) 1639.4 N22 AS1 A3 C1 1 NEt₃ as base 35.5 0.5 FM1 N23 AS1 A3 C1 1 NEt₃ as base 31 0.5 FM1 N24 AS1 A3 C1 1 NEt₃ as base 35607 0.5 FM1 N46 AS1 A3 C1 1 NEt₃ as base 36.2 0.5 FM1 (KBr): C═O 1641.3 83 N15 AS1 A0 C1 1 36.7 ESI: (M + H)⁺ = 0.62 FM2 (KBr): C═O 726/28/30 (Br₂) 1641.3; 1695.3 84 N15 AS1 A0 C4 1 36.3 ESI: (M + H)⁺ = 0.69 FM2 (KBr): C═O 725/7/9 (Br₂); 1624.0; 1699.2 (M + Na)⁺= 747/49/51 (Br₂) 88 N55 AS4 A0 C1 1 93.6 ESI: (M + H)⁺ = 0.75 FM3 (KBr): C═O 793/5/7/9 (Br₂; Cl₂) 1641.3; 1708.8 89 N56 AS4 A0 C1 1 30 ESI: (M + H)⁺ = 0.81 FM1 (KBr): C═O 797/799/801 (Br₂) 1641.3; 1697.3; 1749.3 136 N15 AS9 A0 C1 1 14.6 ESI: (M + H)⁺ = 0.55 FM3 (KBr): C═O 570 1635.5; 1701.1 91 N64 AS4 A0 C1 1 11.7 ESI: (M + H)⁺ = 0.62 FM3 (KBr): C═O 731/733/735 1625.9; 1685.7 N16 AS1 A3 C5 1 Purification 74 ESI: (M + H)⁺ = 0.48 FM4 (KBr): C═O by column 974/976/978 (Br₂) 1685.7; 1635.5 chromatog- raphy: silica gel/FM4 155 N15 AS1 A0 C3 1 34 ESI: (M + H)⁺ = 0.45 FM1 (KBr): C═O 165-9 743/5/7 (Br₂) 1626; 1695 156 N15 AS1 A0 C19 1 40 ESI: (M + H)⁺ = 0.47 FM1 (KBr): C═O 155-9 743/5/7 (Br₂) 1624; 1695 157 N15 AS4 A0 C19 1 54 ESI: (M + H)⁺ = 0.79 FM1 (KBr): C═O 151-4 742/4/6 (Br₂) 1616; 1697 158 N79 AS4 A0 C1 1 15 ESI: (M + H)⁺ = 0.63 FM1 (KBr): C═O 132-5 727/29/31 (Br₂) 1616; 1695; 1732 159 N77 AS4 A0 C8 1 34 ESI: (M + H)⁺ = 0.63 FM1 (KBr): C═O 732/4/6 (Br₂) 1632 160 N73 AS1 A0 C4 1 12 ESI: (M − H)⁻ = 0.14 FM1 (KBr): C═O 649/651/653 (Br₂) 1626 170 N15 AS4 A0 C37 1 62 ESI: (M − H)⁻ = 0.45 FM1 (KBr): C═O 165-70 725/7/9 (Br₂) 1620; 1701 171 N79 AS1 A0 C1 1 60 ESI: (M + H)⁺ = 0.21 FM1 (KBr): C═O 193-7 728/30/32 (Br₂) 1637.5 172 N79 AS1 A0 C8 1 27 ESI: (M + H)⁺ = 0.32 FM1 (KBr): C═O 163-9 733/5/7 (Br₂) 1622 185 N77 AS4 A0 C4 1 66 ESI: (M + H)⁺ = 0.49 FM1 (KBr): C═O 726/28/30 (Br₂) 1624 186 N77 AS4 A0 C1 1 76 ESI: (M + H)⁺ = 0.63 FM1 (KBr): C═O 727/29/31 (Br₂) 1635.5 187 N77 AS1 A0 C4 1 67 ESI: (M + H)⁺ = 0.33 FM1 (KBr): C═O 727/29/31 (Br₂) 1627.8 188 N78 AS1 A3 C1 1 63 ESI: (M + H)⁺ = 0.45 FM1 (KBr): C═O 955/7/9 (Br₂) 1637.5; 1774.4; 1701 189 N103 AS4 A0 C8 1 50 ESI: (M + H)⁺ = 0.71 FM1 (KBr): C═O 713/5/7 (Br₂) 1616.3 192 N77 AS1 A0 C1 1 47 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 728/30/32 (Br₂) 1643.3 247 N15 AS10 A3 C4 1 60 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 937/39/41 (Br₂) 1639.4; 1701 249 N15 AS4 A0 C22 1 52 ESI: (M + H)⁺ = 0.59 FM1 (KBr): C═O 744/6/8 (Br₂) 1695.3 161 N15 AS4 A0 C21 1 32 ESI: (M + H)⁺ = 0.61 FM1 (KBr): C═O 163-7 726/28/30 (Br₂) 1622; 1701 162 N78 AS1 A0 C4 1 15 ESI: (M + H)⁺ = 0.48 FM1 (KBr): C═O 726/28/30 (Br₂) 1624; 1772.5 163 N73 AS1 A0 C1 1 43 ESI: (M + H)⁺ = 0.07 FM1 (KBr): C═O 752/4/6 (Br₂) 1637.5 164 N79 AS4 A0 C8 1 48 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 127-32 732/4/6 (Br₂) 1616.3 165 N15 AS1 A0 C21 1 27 ESI: (M + H)⁺ = 0.26 FM1 (KBr): C═O 184-9 727/29/31 (Br₂) 1697.3 166 N76 AS1 A0 C4 1 17 ESI: (M + H)⁺ = 0.23 FM1 (KBr): C═O 665/7/9 (Br₂) 1616; 1734 167 N75 AS1 A0 C4 1 20 ESI: (M + H)⁺ = 0.18 FM1 (KBr): C═O 665/7/9 (Br₂) 1624 168 N73 AS1 A3 C4 1 39 ESI: (M + H)⁺ = 0.15 FM1 (KBr): C═O 879/81/83 (Br₂) 1631.7 169 N15 AS1 A0 C37 1 17 ESI: (M + H)⁺ = 0.31 FM1 (KBr): C═O 156-61 726/28/30 (Br₂) 1627.8; 1697.3 173 N15 AS10 A0 C4 1 66 ESI: (M + H)⁺ = 0.68 FM1 (KBr): C═O 283-4 709/11/13 (Br₂) 1627.8; 1656.8; 1695.3 174 N15 AS10 A0 C1 1 42 ESI: (M + H)⁺ = 0.61 FM1 (KBr): C═O 266-9 710/2/4 (Br₂) 1706.9 175 N77 AS1 A0 C8 1 36 ESI: (M + H)⁺ = 0.24 FM1 (KBr): C═O 733/5/7 (Br₂) 1641.3 176 N76 AS1 A3 C4 1 47 ESI: (M + H)⁺ = 0.21 FM1 (KBr): C═O 893/5/7 (Br₂) 1635.5 177 N75 AS1 A3 C4 1 53 ESI: (M + H)⁺ = 0.14 FM1 (KBr): C═O 893/5/7 (Br₂) 1637.5 180 N74 AS1 A3 C4 1 44 ESI: (M + H)⁺ = 0.26 FM1 (KBr): C═O 907/9/11 (Br₂) 1631.7; 1689.5 190 N15 AS1 A3 C18 1 44 ESI: (M + H)⁺ = 0.38 FM1 (KBr): C═O 985/7/9 (Br₂) 1635.5; 1695.3 191 N15 AS10 A3 C1 1 64 ESI: (M + H)⁺ = 0.56 FM1 (KBr): C═O 938/40/42 (Br₂) 1645.2; 1701 N15 AS10 A3 C4 1 91 ESI: (M + H)⁺ = (KBr): C═O 937/39/41 (Br₂) 1643.3; 1701 N15 AS10 A3 C1 1 64 ESI: (M + H)⁺ = (KBr): C═O 938/40/42 (Br₂) 1645; 1701 254 N77 AS1 A3 C1 1 37 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 956/8/60 (Br₂) 1641 N15 AS4 A3 C18 1 90 ESI: (M + H)⁺ = (KBr): C═O 984/6/8 (Br₂) 1641.3; 1699 257 N15 AS4 A5 C1 1 17 ESI: (M + H)⁺ = 0.53 FM1 (KBr): C═O 782/4/6 (Br₂) 1643; 1697 258 N100 AS4 A0 C1 1 69 ESI: (M + H)⁺ = 0.54 FM1 (KBr): C═O 755/7/9 (Br₂) 1627.8; 1705 259 N100 AS4 A0 C8 1 70 ESI: (M + H)⁺ = 0.54 FM1 (KBr): C═O 760/2/4 (Br₂) 1695 260 N15 AS4 A0 C23 1 39 ESI: (M + H)⁺ = 0.36 FM1 (KBr): C═O 796/798/800 (Br₂) 1635.5; 1699 261 N15 AS4 A10 C1 1 26 ESI: (M + H)⁺ = 0.38 FM1 (KBr): C═O 796/798/800 (Br₂) 1631.4; 1701 265 N15 AS4 A5 C8 1 20 ESI: (M + H)⁺ = 0.41 FM1 (KBr): C═O 787/9/91 (Br₂) 1635.5; 1697 266 N15 AS4 A6 C1 1 24 ESI: (M + H)⁺ = 0.43 FM1 (KBr): C═O 796/798/800 (Br₂) 1647; 1689.5 262 N80 AS4 A0 C1 1 25 ESI: (M + H)⁺ = 0.54 FM1 (KBr): C═O 803/5/7 (Br₂) 1637.5 263 N15 AS15 A0 C8 1 64 ESI: (M + H)⁺ = 0.43 FM1 (KBr): C═O 565 1627.8; 1707 264 N15 AS4 A0 C24 1 62 ESI: (M + H)⁺ = 0.4 FM1 (KBr): C═O 733/5/7 (Br₂) 1622; 1701 267 N81 AS4 A3 C8 1 46 ESI: (M + H)⁺ = 0.55 FM1 (KBr): C═O 974/6/8 (Br₂) 1641; 1707 268 N15 AS4 A6 C8 1 27 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 801/3/5 (Br₂) 1633.6; 1697 269 N82 AS4 A0 C8 1 86 ESI: (M + H)⁺ = 0.66 FM1 (KBr): C═O 742/4/6 (Br₂) 1620; 1649 270 N82 AS4 A0 C1 1 56 ESI: (M + H)⁺ = 0.59 FM1 (KBr): C═O 737/39/41 (Br₂) 1641 272 N15 AS11 A0 C8 1 76 ESI: (M + H)⁺ = 0.6 FM1 (KBr): C═O 698 1627.8; 1714.6 273 N15 AS4 A10 C8 1 68 ESI: (M + H)⁺ = 0.52 FM1 (KBr): C═O 801/3/5 (Br₂) 1637.5; 1701 274 N102 AS4 A0 C1 1 76 ESI: (M + H)⁺ = 0.56 FM1 (KBr): C═O 738/40/42 (Br₂) 1664.5 275 N102 AS4 A0 C8 1 55 ESI: (M + H)⁺ = 0.59 FM1 (KBr): C═O 743/5/7 (Br₂) 1618; 1664.5 276 N83 AS4 A0 C1 1 30 ESI: (M + H)⁺ = 0.48 FM1 (KBr): C═O 745/7/9 (Br₂) 1633.6 277 N84 AS4 A0 C8 1 63 ESI: (M + H)⁺ = 0.54 FM1 (KBr): C═O 744/6/8 (Br₂) 1616; 1691.5 278 N84 AS4 A3 C4 1 88 ESI: (M + H)⁺ = 0.53 FM1 (KBr): C═O 966/8/70(Br₂) 1633.6; 1691.5 279 N15 AS4 A0 C26 1 75 ESI: (M + H)⁺ = 0.44 FM1 (KBr): C═O 732/4/6 (Br₂) 1618; 1709 281 N15 AS12 A0 C8 1 21 ESI: (M + H)⁺ = 0.42 FM1 (KBr): C═O 598 1697 282 N66 AS1 A0 C18 1 19 ESI: (M + H)⁺ = 0.51 FM1 (KBr): C═O 770/2/4 (Br₂) 1624; 1660.6; 1734 284 N66 AS1 A0 C18 1 29 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 771/3/5 (Br₂) 1630; 1655 314 N93 AS4 A0 C8 1 81 ESI: (M + H)⁺ = 0.5 FM1 (KBr): C═O 794/6/8 (Br₂) 1618; 1701 315 N93 AS4 A0 C1 1 77 ESI: (M + H)⁺ = 0.49 FM1 (KBr): C═O 789/91/93 (Br₂) 1627.6; 1705 316 N65 AS1 A0 C18 1 15 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 783/5/7 (Br₂) 1624; 1681.8 317 N66 AS4 A0 C3 1 51 ESI: (M + H)⁺ = 0.62 FM1 (KBr): C═O 778/80/82 (Br₂) 1627.6; 1662.5 318 N66 AS1 A0 C3 1 40 ESI: (M + H)⁺ = 0.41 FM1 (KBr): C═O 557/559/561 (Br₂) 1659 319 N66 AS4 A0 C19 1 55 ESI: (M + H)⁺ = 0.68 FM1 (KBr): C═O 778/780/782 (Br₂) 1664.5 320 N65 AS4 A0 C19 1 61 ESI: (M + H)⁺ = 0.62 FM1 (KBr): C═O 768/70/72 (Br₂) 1618; 1682 321 N93 AS1 A0 C4 1 29 ESI: (M + H)⁺ = 0.35 FM1 (KBr): C═O 789/91/93 (Br₂) 1622; 1705 N15 AS1 A3 C5 1 47 0.32 FM1 N19 AS1 A3 C1 1 80 ESI: (M + H)⁺ = (KBr): C═O 933/5/7 (Br₂) 1641.3

EXAMPLE 5

Preparation of Compounds ofGeneralFormula:

1-[N²—[N-(4-phenyl-1-piperazinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (No. 17)

To a solution of 800 mg (0.86 mmol) of 1-[N²—[N-(4-phenyl-1-piperazinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-[(1,1-dimethyl-ethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine in methanol were added 2 ml of methanol saturated with hydrogen chloride and the mixture was stirred overnight at ambient temperature. The reaction mixture was mixed with ethyl acetate until the hydrochloride was totally precipitated and the precipitate formed was filtered off. After washing the precipitate with water it was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant:ethyl acetate/methanol/conc. aqueous ammonia=5/5/0.5 (v/v/v)). 0.38 g (55% of theory) of an amorphous solid were obtained.

IR (KBr): 1639 cm⁻¹ (C═O) Rf: 0.55 (FM2) ESI-MS: (M + H)⁺ = 799/801/803 (Br₂) (M + 2H)⁺⁺ = 400/401/402 (Br₂)

The following were prepared analogously (in each case n=1):

No. RCO R² A n NR³R⁴ % Yield MS R_(f) Eluant IR [cm⁻¹] 11 N8 AS1 A1 1 C1 70 ESI: (M + H)⁺ = 0.43 FM2 (KBr): C═O 758/60/62 (Br₂) 1656.8 12 N9 AS1 A1 1 C1 60 ESI: (M + H)⁺ = 0.46 FM2 (KBr): C═O 788/90/92 (Br₂) 1643.3 8 N5 AS1 A1 1 C1 53.7 ESI: (M + H)⁺ = 0.2 methanol/ (KBr): C═O 790/2/4 (Br₂) glacial acetic 1641.3 acid/water = 9/1/1 (v/v/v) 15 N11 AS1 A1 1 C1 56 ESI: (M + H)⁺ = 0.4 FM2 773/5/7 (Br₂) 6 N2 AS1 A1 1 C11 66.4 ESI: (M + H)⁺ = 0.39 FM2 (KBr): C═O 808/10/12 (Br₂) 1656.8 7 N2 AS1 A1 1 C2 46.2 ESI: (M + H)⁺ = 0.13 FM2 (KBr): C═O 794/6/8 (Br₂) 1637.5 13 N2 AS2 A1 1 C1 84.7 ESI: (M + H)⁺ = 0.46 FM2 (KBr): C═O 666 1641.3

EXAMPLE 6

Preparation of Compounds ofGeneralFormula:

1-[4-amino-3,5-dibromo-N²—[N-[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine-bis-(trifluoroacetate) (No. 61)

To a mixture of 0.42 g (0.45 mmol) of 1-[4-amino-3,5-dibromo-N²-[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-D-phenylalanyl]-N6-[(1.1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine in 30 ml of methylene chloride were added 3 ml of trifluoroacetic acid. The reaction mixture was stirred for 3 hours at ambient temperature and then evaporated down in vacuo. The remaining residue was triturated with ether and the resulting beige amorphous solid (0.43 g; 37% of theory) was suction filtered.

IR (KBr): 1643, 1678 cm⁻¹ (C═O)

R_(f): 0.6 (FM1)

ESI-MS: (M+H)⁺=832/834/836/838 (Br₂, Cl)

The following were prepared analogously:

% No. RCO Z R² A NR³R⁴ n Remarks Yield MS R_(f) Eluant IR [cm⁻¹] 21 N6 N—H AS1 A1 C4 1 65 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 828/30/32 (Br₂) 1635.5 22 N16 N—H AS1 A1 C1 1 98 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 874/6/8 (Br₂) 1643.3; 1676 141 N61 N—H AS1 A1 C1 1 46 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O 855/7/9 (Br₂) 1634; 1705 142 N60 N—H AS1 A1 C1 1 50 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O 882/4/6 (Br₂) 1643; 1711 154 N66 N—H AS1 A1 C1 1 60 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O 868/70/72 (Br₂) 1645; 1653 197 N15 N—H AS1 A1 C8 1 21 ESI: (M + H)⁺ = 0.18 FM7 (KBr): C═O 859/61/63 (Br₂) 1678; 1201.6; CF3 1180.4; 1134.1 198 N51 N—H AS1 A1 C8 1 27 ESI: (M + H)⁺ = 0.22 FM7 (KBr): C═O 829/31/33 (Br₂) 1676; CN 2221.9; CF3 1203.5; 1180.4; 1132 218 N15 N—H AS6 A1 C1 1 25.7 ESI: (M + H)⁺ = 0.45 FM1 (KBr): C═O 776/8 (Br) 1695.3; 1635.5 287 N15 N—H AS1 A8 C1 1 36.5 ESI: (M + H)⁺ = 0.5 FM2 (KBr): C═O 840/2/4 (Br₂) 1695.3; 1637.5 19 N15 N—H AS1 A1 C1 1 44 ESI: (M + H)⁺ = 0.43 FM2 (KBr): C═O 854/6/8 (Br₂) 1695.3; 1637.5 14 N10 N—H AS1 A1 C1 1 25.5 ESI: (M + H)⁺ = 0.33 FM2 (KBr): C═O 774/6/8 (Br₂) 1683.8 16 N12 N—H AS1 A1 C1 1 64.4 ESI: (M + H)⁺ = 0.55 FM2 (KBr): C═O 802/4/6 (Br₂) 1639.4 29 N22 N—H AS1 A1 C1 1 91.2 ESI: (M + H)⁺ = 0.5 FM2 (KBr): —NH— 867/69/71 (Br₂) 3427.3; C═O 1643.3; 1678.0 30 N23 N—H AS1 A1 C1 1 83.3 ESI: (M + H)⁺ = 0.5 FM2 (KBr): C═O 833/5/7/9 (Br₂, Cl) 1643.3; 1676.0 31 N24 N—H AS1 A1 C1 1 100 ESI: (M + H)⁺ = 0.51 FM2 (KBr): C═O 843/5/7 (Br₂) 1645.2; 1676.0 63 N46 N—H AS1 A1 C1 1 100 ESI: (M + H)⁺ = 0.58 FM2 (KBr): C═O 764/6/8 (Br₂) 1643.3; 1676.0 68 N15 N—H AS1 A1 C6 1 80 ESI: (M + H)⁺ = 0.18 FM1 (KBr): C═O 833/5/7 (Br₂) 1683.8 69 N15 N—H AS1 A1 C5 1 74 ESI: (M + H)⁺ = 0.18 FM1 (KBr): C═O 854/6/8 (Br₂) 1683.8; 1639.4 70 N45 N—H AS1 A1 C6 1 89 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 897/9/901 (Br₂) 1695.3; 1676.0 71 N16 N—H AS1 A1 C5 1 82 ESI: (M + H)⁺ = 0.22 FM1 (KBr): C═O 874/6/8 (Br₂) 1678.0; 1639.4 72 N15 N—H AS5 A1 C1 1 97 ESI: (M + H)⁺ = 0.16/0.2 FM1 (KBr): C═O 838/40/42 (Br₂) 1685.7; 1643.3 77 N45 N—H AS5 A1 C1 1 66 ESI: (M + H)⁺ = 0.33/0.4 FM1 (KBr): C═O 852/4/6 (Br₂) 1683.8; 1645.2 NH₃ 3427.3 24 N18 N—H AS1 A1 C1 1 94 ESI: (M + H)⁺ = 0.11 FM1 (KBr): C═O 775/7/9 (Br₂) 1676.0; 1643.3 25 N19 N—H AS1 A1 C1 1 92 ESI: (M + H)⁺ = 0.13 FM1 (KBr): C═O 833/5/7 (Br₂) 1676.0; 1643.3 26 N20 N—H AS1 A1 C1 1 98 EI: M⁺ = 762/4/6 0.11 FM1 (KBr): C═O (Br₂) 1676.0; 1643.3 27 N21 N—H AS1 A1 C1 1 98 ESI: (M + H)⁺ = 0.04 FM1 (KBr): C═O 814/6/8 (Br₂) 1676.0; 1645.2 41 N34 N—H AS1 A1 C1 1 97 ESI: (M + H)⁺ = 0.08 FM1 (KBr): C═O 835/38/40/42 1676.0; 1643.3 (Br₃) 42 N35 N—H AS1 A1 C1 1 83 ESI: (M + H)⁺ = 0.09 FM1 (KBr): C═O 803/5/7 (Br₂) 1676.0; 1643.3 43 N36 N—H AS1 A1 C1 1 87 ESI: (M + H)⁺ = 0.04 FM1 (KBr): C═O 815/7/9 (Br₂) 1676.0; 1645.2 53 N42 N—H AS1 A1 C1 1 89 ESI: (M + H)⁺ = 0.11 FM1 (KBr): C═O 805/7/9 (Br₂) 1676.0; 1634.3 54 N43 N—H AS1 A1 C1 1 84 ESI: (M + H)⁺ = 0.11 FM1 (KBr): C═O 835/7/9/41 (Br₃) 1678.0; 1643.3 55 N44 N—H AS1 A1 C1 1 95 ESI: (M + H)⁺ = 0.07 FM1 (KBr): C═O 796/8/800 (Br₂) 1676.0; 1643.3 67 N48 N—H AS1 A1 C1 1 90 ESI: (M + H)⁺ = 0.06 FM1 (KBr): C═O 797/99/801 (Br₂) 1682.9; 1643.3 184 N77 N—H AS1 A1 C4 1 88 ESI: (M + H)⁺ = 0.11 FM1 (KBr): C═O 855/7/9 (Br₂) 1637.5; 1676 248 N78 N—H AS1 A1 C1 1 97 ESI: (M + H)⁺ = 0.14 FM1 (KBr): C═O 855/7/9 (Br₂) 1643.3; 1676; 1772.5 181 N75 N—H AS1 A1 C4 1 95 ESI: (M + H)⁺ = 0.04 FM1 (KBr): C═O 793/5/7 (Br₂) 1637.5; 1676 182 N76 N—H AS1 A1 C4 1 93 ESI: (M + H)⁺ = 0.04 FM1 (KBr): C═O 793/5/7 (Br₂) 1637.5; 1678 183 N74 N—H AS1 A1 C4 1 91 ESI: (M + H)⁺ = 0.08 FM1 (KBr): C═O 807/9/11 (Br₂) 1635.5; 1678 250 N15 N—H AS1 A1 C18 1 98 ESI: (M + H)⁺ = 0.14 FM1 (KBr): C═O 885/7/9 (Br₂) 1633.6; 1680 251 N15 N—H AS10 A1 C4 1 84 ESI: (M + H)⁺ = 0.27 FM1 (KBr): C═O 837/39/41 (Br₂) 1635.5; 1693.4 252 N15 N—H AS10 A1 C4 1 87 ESI: (M + H)⁺ = 0.31 FM1 (KBr): C═O 837/39/41 (Br₂) 1637.5; 1685.7 253 N15 N—H AS10 A1 C1 1 82 ESI: (M + H)⁺ = 0.18 FM1 (KBr): C═O 838/40/42 (Br₂) 1690 255 N77 N—H AS1 A1 C1 1 94 ESI: (M + H)⁺ = 0.08 FM1 (KBr): C═O 856/8/60 (Br₂) 1645; 1676 256 N15 N—H AS4 A1 C18 1 74 ESI: (M + H)⁺ = 0.28 FM1 (KBr): C═O 884/6/8 (Br₂) 1633.6; 1683.8 271 N81 N—H AS4 A1 C8 1 76 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 874/6/8 (Br₂) 1674 280 N84 N—H AS4 A1 C4 1 66 ESI: (M + H)⁺ = 0.26 FM1 (KBr): C═O 866/8/70 (Br₂) 1635.5; 1685.7 N15 N—H AS1 A1 C1 0 98 ESI: (M + H)⁺ = 0.2 ButOH/ (KBr): C═O 840/2/4 (Br₂) AcOH/H2O = 1643; 1680 4/1/1 (v/v/v) 179 N73 N—H AS1 A1 C4 1 86 ESI: (M + H)⁺ = 0.03 FM1 (KBr): C═O 779/81/83 (Br₂) 1642.8; 1676 N66 N—H AS4 A0 1 75 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 744/6/8 (Br₂) 1620/1666 516 N66 N—H AS1 A1 C1 1 Isomer to 82 0.1 FM1 No. (154) 517 N66 N—H AS1 A1 C1 1 Isomer to 80 0.1 FM1 No. (154) 518 N66 N—H AS1 A1 C1 1 Isomer to 89 0.1 FM1 No. (154) 521 N66 N—H AS4 A0 C17 1 THF/DMF 75 ESI: (M + H)⁺ = 0.15 FM1 (KBr): C═O 744/6/8 (Br₂) 1666/1620 522 N66 N—H AS1 A0 C17 1 THF/DMF 100 ESI: (M + H)⁺ = 0.15 FM1 (KBr): C═O 745/7/9 (Br₂) 1624/1655 643 N66 CH₂ AS21 A0 C17 1 53 ESI: (M + H)⁺ = 0.35 FM1 (KBr): C═O 640 1635/1668 N66 CH₂ AS2 A0 C17 1 100 EI: M⁺ = 621 0.35 FM1 (KBr): C═O 1670

EXAMPLE 7

Preparation of Compounds ofGeneralFormula:

1-[N²—[N-[[[(2-methoxyphenyl)methyl]amino]carbonyl]-3,5-dibromo-D,L-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

A mixture of 910 mg (1.0 mmol) of 1-[N²—[N-[[[2-(2-methoxy-phenyl)methyl]amino]carbonyl]-3,5-dibromo-D,L-tyrosyl]-N⁶-[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, 50 ml of glacial acetic acid, 25 ml of a 33% solution of hydrogen bromide in glacial acetic acid and 2 ml of anisole was stirred overnight at ambient temperature. The reaction mixture was stirred into diethylether and the sticky precipitate formed was suction filtered. The crude product was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant:ethyl acetate/methanol/conc. aqueous ammonia=8/2/0.2 (v/v/v)). 0.37 g (48% of theory) of an amorphous solid were obtained.

IR (KBr): 1630 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 774/776/778 (Br₂) (M + 2H)⁺⁺ = 387.7/388.7/389.7 (Br₂)

The following were prepared analogously (in each case n=1):

No. RCO R² A NR³R⁴ % Yield MS R_(f) Eluant IR [cm⁻¹] 1 N1 AS1 A1 C1 46.9 ESI: (M + H)⁺ = 0.36 FM1 (KBr): C═O 788/90/92 (Br₂) 1627.8 2 N2 AS1 A1 C1 100 ESI: (M + H)⁺ = 0.48 FM2 (KBr): C═O 788/90/92 (Br₂) 1641.3; NH, NH⁺ 3419.6 4 N4 AS1 A1 C1 2.8 ESI: (M + H)⁺ = 0.52 FM2 818/20/22 (Br₂)

EXAMPLE 8

Preparation of Compounds ofGeneralFormula:

1-[N²—[N-[4-(4-fluorophenyl)-1-oxobutyl]-3,5-dibromo-D-tyrosyl]-N⁶-[(1.1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

To a solution of 0.18 g (0.001 mol) 4-(4-fluorophenyl)-butanoic acid in a mixture of 4 ml of dimethylformamide and 10 ml of tetrahydrofuran was added with stirring a mixture of 0.71 g (0.001 mol) 1-[N2-(3,5-dibromo-D-tyrosyl)-N⁶-[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, 0.32 g (0.001 mol) TBTU and 0.13 g (0.001 mol) DIEA and the mixture was stirred in a nitrogen atmosphere for 2 days. The reaction mixture was then evaporated down in vacuo and the remaining residue was taken up in dichloromethane. The organic phase was with 20% aqueous citric acid solution and then extracted with 10% aqueous sodium hydrogen carbonate solution, dried over sodium sulphate, filtered and evaporated down in vacuo. After stirring the residue with ether 0.68 g (77% of theory) of the desired product remain as an amorphous residue.

IR (KBr): 1641, 1676 cm⁻¹ (C═0) R_(f): 0.65 (FM2) ESI-MS: (M + H)⁺ = 875/877/879 (Br₂) (M + H + Na)⁺⁺ = 449/450/451 (Br₂)

The following were prepared analogously (in each case n=1):

% No. RCO R² A NR³R⁴ Remarks Yield MS R_(f) Eluant IR [cm⁻¹] 123 N62 AS1 A0 C1 DMF/THF as 20 ESI: (M + H)⁺ = 0.3 FM 1 (KBr): C═O solvent 725/7/9 (Br₂) 1641.3; 1691.5 124 N63 AS1 A0 C1 DMF/THF as 53 ESI: (M + H)⁺ = 0.2 FM 1 (KBr): C═O solvent 725/7/9 (Br₂) 1641.3; 1691.5 322 N63 AS1 A0 C8 DMF/THF as 19 EI: M⁺ = 0.3 FM 1 (KBr): C═O solvent 729/31/33 (Br₂) 1629.8; 1695.3 N11 AS1 A3 C1 46 ESI: (M + H)⁺ = (KBr): C═O 873/5/7 (Br₂) 1625.9; 1645.2 N18 AS1 A3 C1 THF/DMF as 77 ESI: (M + H)⁺ = 0.78 FM7 (KBr): C═O solvent 875/7/9 (Br₂) 1641.3 N20 AS1 A3 C1 THF/DMF as 88 ESI: (M + H)⁺ = 0.67 FM7 (KBr): C═O solvent 863/5/7 (Br₂) 1643.3 N21 AS1 A3 C1 THF/DMF as 78 ESI: (M + H)⁺ = 0.47 FM7 (KBr): C═O solvent 917/6/8 (Br₂) 1643.3 N46 AS1 A3 C1 THF/DMF as 80 ESI: (M + H)⁺ = 0.65 FM7 (KBr): C═O solvent 905/7/9 (Br₂) 1643.3 N43 AS1 A3 C1 THF/DMF as 75 0.75 FM7 (KBr): C═O solvent 1645.2 N44 AS1 A3 C1 THF/DMF as 79 ESI: (M + H)⁺ = 0.65 FM7 (KBr): C═O solvent 896/98/900 (Br₂) 1629.8

EXAMPLE 9

Preparation of Compounds ofGeneralFormula:

1-[N²—[N-[[[(3-methoxyphenyl)ethyl]amino]carbonyl]-3,5-dichloro-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine-bis-(trifluoroacetate (No. 20)

To a suspension of 0.33 g (2 mmol) of CDT and 1 ml of triethylamine in about 30 ml of tetrahydrofuran, cooled to −10° C., was added dropwise, with stirring, a solution of 1.0 g (1.6 mmol) of 1-[N²(-3.5-dichloro-D-tyrosyl]-N⁶-[(1.1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine in 50 ml of tetrahydrofuran within 60 minutes. The reaction mixture was stirred for 1 hour at 0° C., then stirred for 2 hours at ambient temperature, mixed with a tetrahydrofuran solution of 0.24 g (1.6 mmol) of (3-methoxyphenyl)-ethanamine, refluxed for 3 hours and stirred overnight at ambient temperature. After elimination of the solvent in vacuo the residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant:FM1). The resulting intermediate compound was stirred in a mixture of 5 ml of trifluoroacetic acid and 80 ml of dichloromethane overnight, the solvent was eliminated in vacuo and the residue triturated with ether. 709 mg (43% of theory) of the desired compound as an amorphous solid.

IR (KBr): 1643, 1676 cm⁻¹ (C═0) R_(f): 0.41 (FM2) ESI-MS (M + H)⁺ = 700/702/704 (Br₂) (M + 2H)⁺⁺ = 350.7/351.7/352.7 (Br₂)

The following were prepared analogously (in each case n=1):

% No. RCO R² A NR³R⁴ Remarks Yield MS R_(f) Eluant IR [cm⁻¹] 23 N17 AS1 A1 C1 NEt₃ as base 55 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 798/800/802 (Br₂) 1643.3; 1676 47 N39 AS1 A1 C1 NEt₃ as base 69.4 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O 676/78/80 (Br₂) 1645.2; 1676 50 N64 AS1 A1 C1 NEt₃ as base 76 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 828/830/832 (Br₂) 1643.3; 1678 51 N40 AS1 A1 C1 NEt₃ as base; 79.7 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O dehydration 826/828/30 (Br₂) 1643.3; 1678 52 N41 AS1 A1 C1 NEt₃ as base; 21.8 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O dehydration 826/828/30 (Br₂) 1645.2; 1679.9 56 N16 AS1 A1 C4 NEt₃ as base 5 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 873/75/77 (Br₂) 1637.5; 1676 57 N45 AS1 A1 C4 NEt₃ as base 32 ESI: (M + H)⁺ = 0.2 FM1 (KBr): C═O 867/9/71 (Br₂) 1635.5; 1678 66 N47 AS1 A1 C4 NEt₃ as base 28.4 ESI: (M + H)⁺ = 0.1 FM1 (KBr): C═O 764/6/8 (Br₂) 1635.5; 1676 46 N38 AS1 A1 C1 NEt₃ as base 86 ESI: (M + H)⁺ = 0.35 FM1 (KBr): C═O 826/28/30 (Br₂) 1645.2; 1684 232 N66 AS4 A1 C8 69 ESI: (M + H)⁺ = 0.33 FM1 (KBr): C═O 872/4/6 (Br₂) 1645 233 N66 AS4 A1 C1 THF/DMF as 16 ESI: (M + H)⁺ = 0.32 FM1 (KBr): C═O solvent 867/69/71 (Br₂) 1653 234 N66 AS4 A1 C4 68 ESI: (M + H)⁺ = 0.42 FM1 (KBr): C═O 867/69/71 (Br₂) 1645 235 N66 AS1 A1 C8 26 ESI: (M + H)⁺ = 0.27 FM1 (KBr): C═O 873/5/7 (Br₂) 1645 236 N71 AS1 A1 C1 30 ESI: (M + H)⁺ = 0.22 FM1 (KBr): C═O 880/2/4 (Br₂) 1636; 1678 237 N71 AS4 A1 C8 28 ESI: (M + H)⁺ = 0.25 FM1 884/6/8 (Br₂) 238 N71 AS4 A1 C1 20 ESI: (M + H)⁺ = 0.3 FM1 (KBr): C═O 879/81/83 (Br₂) 1641; 1682 18 N14 AS1 A1 C1 Cleaving of Boc 26.3 ESI: (M + H)⁺ = 0.55 FM2 (KBr): C═O protecting group with 813/5/7 (Br₂) 1641.3; 1716.5 methanolic HCl solution 17 N13 AS1 A1 C1 Cleaving of Boc 55.2 ESI: (M + H)⁺ = 0.55 FM2 (KBr): C═O protecting group with 799/801/803 (Br₂) 1639.4 methanolic HCl solution 9 N6 AS1 A1 C1 Cleaving of Boc 41.3 ESI: (M + H)⁺ = 0.44 FM2 (KBr): C═O protecting group with 829/31/33 (Br₂) 1639.4 methanolic HCl solution 10 N7 AS1 A1 C1 Cleaving of Boc 57.6 ESI: (M + H)⁺ = 0.32 FM2 (KBr): C═O protecting group with 829/31/33 (Br₂) 1639.4 methanolic HCl solution 20 N2 AS5 A1 C1 43 ESI: (M + H)⁺ = 0.41 FM2 (KBr): C═O 700/2/4 (Br₂) 1643.3; 1676.0 283 N102 AS4 A3 C4 NEt₃ as base 65 ESI: (M + H)⁺ = 0.24 FM1 (KBr): C═O 864/6/8 (Br₂) 1637.5; 1676

EXAMPLE 10

Preparation of Compounds ofGeneralFormula:

1-[N²—[N-[4-(2,3-dichlorophenyl)-1-piperazinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine-tris-(trifluoroacetate) (No. 74)

To a solution of 0.35 g (2.1 mmol) of CDT in 50 ml of tetrahydrofuran were added with cooling (0° C.) and stirring 1.0 g (1.4 mmol) of 1-[N²-(3,5-dibromo-D-tyrosyl)-N⁶-[(1,1-dimethylethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine and the mixture was stirred for 30 minutes at 0° C. and for a further 30 minutes at ambient temperature. After the addition of 0.47 g (1.75 mmol) of 1-(2,3-dichlorophenyl)piperazine-hydrochloride and 0.25 ml of triethylamine the reaction mixture was refluxed for 5 hours and after cooling mixed with 70 ml of saturated aqueous sodium hydrogen carbonate solution. The organic phase was separated off, the aqueous phase was extracted twice with 50 ml of tetrahydrofuran. The combined organic phases were washed with saturated aqueous saline solution, dried over magnesium sulphate, filtered and evaporated down in vacuo. The residue was triturated with ether, suction filtered and then stirred for 2 hours with a mixture of 50 ml of dichloromethane and 5 ml of trifluoroacetic acid. After evaporation of the reaction mixture in vacuo and trituration of the residue with ether, 0.8 g (47% of theory) of an amorphous solid are left.

IR (KBr): 1643.3, 1676 cm⁻¹ (C═0) R_(f): 0.78 (FM7) ESI-MS: (M + H)⁺ = 867/869/871/873/875 (Br₂, Cl₂) (M + 2H)⁺⁺ = 434/435/436/437 (Br₂, Cl₂)

The following were prepared in the same way (in each case n=1):

% No. RCO R² A NR³R⁴ Yield MS R_(f) Eluant IR [cm⁻¹] 36 N29 AS1 A1 C1 17.3 ESI: (M + H)⁺ = 0.35 MeOH/NH₄OH = (KBr): C═O 889/91/93 (Br₂) 9/1 (v/v) 1643.3; 1674.1 208 N15 AS1 A1 C1 53.5 ESI: (M + H)⁺ = 0.43 FM2 (KBr): C═O 854/6/8 (Br₂) 1691.5; 1635.5 209 N15 AS1 A1 C1 47.7 ESI: (M + H)⁺ = 0.55 FM2 (KBr): C═O 854/6/8 (Br₂) 1695.3; 1637.5 210 N15 AS1 A1 C1 28 ESI: (M + H)⁺ = 0.48 FM2 (KBr): C═O 854/6/8 (Br₂) 1689.5; 1639.4 75 N50 AS1 A1 C1 16.5 ESI: (M + H)⁺ = 0.63 FM2 (KBr): C═O 867/69/71/73/75 1643.3; 1676.0; (Br₂, Cl₂) 74 N49 AS1 A1 C1 47 ESI: (M + H)⁺ = 0.65 FM2 (KBr): C═O 867/69/71/73/75 1643.3; 1676.0 (Br₂, Cl₂) 76 N51 AS1 A1 C1 13.4 ESI: (M + H)⁺ = 0.58 FM2 (KBr): C═O 824/6/8 (Br₂) 1643.3; 1676.0; CN 2219.9 79 N52 AS1 A1 C1 11.4 ESI: (M + H)⁺ = 0.59 FM2 (KBr): C═O 901/3/5/7 1645.2; 1676.3 (Br₂, Cl) 45 N37 AS1 A1 C1 43 ESI: (M + H)⁺ = 0.6 FM2 (KBr): C═O 784/6/8 (Br₂) 1643.3; 1678.0 39 N32 AS1 A1 C1 48.3 ESI: (M + H)⁺ = 0.57 FM2 (KBr): C═O 795/7/9 (Br₂) 1643.3; 1678.0 38 N31 AS1 A1 C1 54.1 ESI: (M + H)⁺ = 0.6 FM2 (KBr): C═O 844/6/8 (Br₂) 1643.3; 1678.0; NO2 1543.0 37 N30 AS1 A1 C1 61.6 ESI: (M + H)⁺ = 0.6 FM2 (KBr): C═O 813/5/7 (Br₂) 1643.3; 1676.0 35 N28 AS1 A1 C1 74.8 ESI: (M + H)⁺ = 0.55 FM2 (KBr): C═O 800/2/4 (Br₂) 1639.4; 34 N27 AS1 A1 C1 36.8 ESI: (M + H)⁺ = 0.43 FM2 (KBr): C═O 800/2/4 (Br₂) 1641.3; 1714.6; NH+ 3409.9 32 N25 AS1 A1 C1 50.0 ESI: (M + H)⁺ = 0.44 FM2 (KBr): C═O 737/39/41 (Br₂) 1645.2; 1678.3 33 N26 AS1 A1 C1 42 ESI: (M + H)⁺ = 0.33 FM2 (KBr): C═O 767/69/71 (Br₂) 1676.0 40 N33 AS1 A1 C1 14.5 ESI: (M + H)⁺ = 0.58 FM2 (KBr): C═O 802/4/6 (Br₂) 1643.3; 1676.0 28 N6 AS3 A1 C1 67.2 ESI: (M + H)⁺ = 0.43 FM2 (KBr): C═O 741/3/5 (Cl₂) 1641.3; 1716.5 64 N23 AS1 A1 C4 39 ESI: (M + H)⁺ = 0.68 FM2 (KBr): C═O 832/4/6/8 1627.8; 1678.0 (Br₂, Cl) 65 N15 AS1 A1 C4 41 ESI: (M + H)⁺ = 0.61 FM2 (KBr): C═O 853/5/7 (Br₂) 1631.7; 1695.3 365 N111 AS1 A1 C1 36.9 ESI: (M + H)⁺ = 0.09 FM1 (KBr): C═O 839/41/43 (Br₂) 1626/1676

EXAMPLE 11 1-[N2—[N-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]carbonyl]-3,5 dibromo-D,L-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (No. 3)

A mixture of 0.8 g (0.84 mmol) of 1-[N²—[N-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-[(phenylmethoxy)carbonyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, 50 ml of glacial acetic acid, 25 ml of a 33% solution of hydrogen bromide in glacial acetic acid and 2 ml of anisole was stirred for 12 hours at ambient temperature. The reaction mixture was stirred into diethylether and the resulting precipitate was suction filtered. The solid residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant:ethyl acetate/methanol/conc. aqueous ammonia=8/2/0.2 (v/v/v)). 0.3 g (44% of theory) of the desired product was obtained as an amorphous solid.

IR (KBr): 1643.3 cm⁻² ¹ (C═O) R_(f): 0.17 (ethyl acetate/methanol/conc. aqueous ammonia = 6/4/1) ESI-MS: (M + H)⁺ = 818/820/822 (Br₂) (M + 2H)⁺⁺ = 409.5/410.5/411.5 (Br₂)

EXAMPLE 12 1-[N²-[3,5-dibromo-N-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]-D-tyrosyl]-L-arginyl]-4-(4-pyridinyl)-piperazine-bis-(trifluoroacetate) (No. 4)

A stirred mixture of 20 ml of trifluoroacetic acid, 1.3 ml of anisole and 0.9 ml of ethanedithiol was mixed with 2.1 g (1.9 mmol) of solid 1-[N²-[3,5-dibromo-N-[[[2-(3-methoxyphenyl)-ethyl]amino]carbonyl]-N^(G)-(2,2,5,7,8-pentamethylchroman-6-sulphonyl)-D-tyrosyl]-L-arginyl]-4-(4-pyridinyl)-piperazine whilst cooling with ice and stirred for a further 45 minutes whilst cooling with ice, then for 3 hours at ambient temperature. The resulting precipitate was suction filtered and discarded, the filtrate was evaporated down in vacuo, the residue remaining was mixed with toluene and again evaporated down in vacuo. The resulting solid residue was triturated with a mixture of diethylether and acetone and the white solid formed was suction filtered and dried. 1.7 g (65% of theory) of the desired title compound were obtained.

IR (KBr): 1674, 1645 cm⁻² ¹ (C═O) R_(f): 0.15 (FM: BuOH/AcOH/H₂O 4/1/1 (v/v/v) ESI-MS: (M + H)⁺ = 816/818/820 (Br₂) (M + 2H)⁺⁺ = 408.6/409.6/410.6 (Br₂)

EXAMPLE 13

Preparation of Compounds of General Formula:

(R,S)-1-[2-(4-amino-3,5-dibromobenzoyl)-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-4-oxobutyl]-4-(4-pyridinyl)-piperidine (No. 291)

A mixture of 0.97 g (1.8 mmol) of (R,S)-4-amino-3,5-dibromo-γ-oxo-β-[[4-(4-pyridinyl)-1-piperidinyl]methyl]-benzenebutanoic acid, 0.48 g (1.8 mmol) of 4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-piperidine, 2 ml of triethylamine, 0.58 g (1.8 mmol) of TBTU, 0.24 g (1.8 mmol) of HOBt, 25 ml of THF and 25 ml of DMF was stirred for 4 hours at ambient temperature. The reaction mixture was evaporated down in vacuo, the residue was taken up in a mixture of ethyl acetate and methanol (95/5 (v/v)) and washed with saturated aqueous sodium hydrogen carbonate solution. The organic phase was dried and evaporated down in vacuo. The residue was purified by column chromatography (MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant:ethyl acetate/methanol=9/1 (v/v); then MN-silica gel 60, Macherey-Nagel, 70-230 mesh ASTM, eluant: methylene chloride/ethanol=9/1 (v/v)). 0.2 g (15% of theory) of the desired product were obtained as a white amorphous solid.

IR (KBr): 1668.3 cm⁻¹ (C═O) R_(f)): 0.5 (FM2) ESI-MS: (M + H)⁺ = 737/739/741 (Br₂) (M + Na)⁺ = 759/761/763 (Br₂)

The following were prepared analogously:

% No. RCO R² NR³R⁴ Yield MS R_(f) Eluant IR [cm⁻¹] 291 N66 AS4 C4 15 ESI: (M + H)⁺ = 0.36 CH₂Cl₂/ (KBr): C═O 737/39/41 (Br₂) EtOH 1668 296 N66 AS4 C8 14 ESI: (M + H)⁺ = 0.66 FM1 (KBr): C═O 743/5/7 (Br₂) 1668 302 N71 AS4 C8 19 ESI: (M + H)⁺ = 0.54 FM1 (KBr): C═O 755/7/9 (Br₂) 1682

EXAMPLE 14 1-[4-amino-N-[[4-[7-(aminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperdine (No. 312) a) 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine (No. 307)

Prepared analogously to Example 3 from methyl 3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazoline-7-carboxylate, 1-[4-amino-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperidine and CDT in a yield of 27.2% of theory. Colourless, amorphous substance, Rf 0.5 (eluant:dichloromethane/cyclohexane/methanol/conc. ammonia=7/1.5/1.5/0.2 (v/v/v/v)).

IR (KBr): 1718.5, 1670.3, 1618.2 cm⁻² ¹ (C═O) ESI-MS: (M + H)+ = 796/798/800 (Br₂) (M + Na)⁺ = 818/820/822 (Br₂)

The following were obtained accordingly:

From methyl-3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazoline-7-carboxylate, 1-[4-amino-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine and CDT in a yield of 30.3% of theory: 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine (No. 304), R_(f)=0.75 (FM1).

IR (KBr): 1720.4, 1668.3, 1620.1 cm⁻² ¹ (C═O) ESI-MS: (M + H)⁺ = 802/804/806 (Br₂) (M + Na)⁺ = 824/826/828 (Br₂)

From methyl-3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazoline-7-carboxylate, 1-(3,5-dibromo-D-tyrosyl)-4-(1-piperidinyl)-piperidine and CDT in a yield of 35% of theory: 1-[3,5-dibromo-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine (No. 422), R_(f) 0.54 (eluant:dichloromethane/cyclohexane/methanol/conc. ammonia=7/1.5/1.5/0.2 (v/v/v/v)).

IR (KBr): 1720.4, 1668.3, 1627.8 cm⁻² ¹ (C═O) ESI-MS: (M + H)⁺ = 803/805/807 (Br₂) (M + Na)⁺ = 825/827/829 (Br₂)

From methyl-3,4-dihydro-3-(4-piperidinyl)-2(1H)-oxoquinazoline-7-carboxylate, 1-(3,5-dibromo-D-tyrosyl)-4-(4-pyridinyl)-piperidine and CDT in a yield of 45% of theory: 1-[3,5-dibromro-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine

(No. 420), R_(f) 0.56 (FM1).

IR (KBr): 1718.5, 1664.5, 1624.0 cm⁻² ¹ (C═O) ESI-MS: (M + H)⁺ = 797/799/801 (Br₂) (M + Na)⁺ = 819/821/823 (Br₂)

b) 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine (No. 309)

Prepared analogously to Example A37) from 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine by saponification with lithium hydroxide in a yield of 95% of theory. Colourless, amorphous substance, R_(f) 0.25 (eluant:dichloromethane/methanol/conc. ammonia=7.5/2.5/0.5 (v/v/v)).

IR (KBr): 1666.4, 1614.3 cm⁻¹ (C═O)

ESI-MS: (M—H)⁻=780/782/784 (Br₂)

The following were obtained accordingly:

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(methoxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine in a yield of 60.2% of theory: 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine (No. 306), R_(f) 0.15 (FM1).

IR(KBr): 1635.5 cm⁻¹, broad (C═O) ESI-MS: (M + H)⁺ = 788/790/792 (Br₂) (M + Na)⁺ = 810/812/814 (Br₂)

From 1-[3,5-dibromo-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine in a yield of 62% of theory: 1-[3,5-dibromo-N-[[4-[7-(hydroxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine (No. 423), R_(f) 0.03 (eluant:dichloromethane/cyclohexane/methanol/conc. ammonia=7/1.5/1.5/0.2 (v/v/v/v)).

IR (KBr): 1635.5 cm⁻¹, broad(C≡O)

ESI-MS: (M+H)⁺=789/791/793 (Br₂)

From 1-[3,5-dibromo-N-[[4-(1,3-dihydro-5-(methoxycarbonyl)-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine in a yield of 80% of theory: 1-[3,5-dihbrcmo-N-[[4-(1,3-dihydro-5-(hydroxycarbonyl)-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine (No. 151). Colourless, amorphous substance.

IR(KBr): 1701.1, 1625.9 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 767/769/771 (Br₂) (M + 2H)⁺⁺ = 383/384/385 (Br₂)

From 1-[3,5-dibromo-N-[[4-[7-(methoxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine in a yield of 82% of theory: 1-[3,5-dibromo-N-[[4-[7-(hydroxycarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine (No. 421), R_(f) 0.03 (FM1). Colourless, amorphous substance.

IR (KBr): 1625 wide cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 783/785/787 (Br₂) (M + Na)⁺ = 805/807/809 (Br₂)

c) 1-[4-amino-N-[[4-[7-(aminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(4-pyridinyl)-piperidine (No. 312)

Prepared analogously to Example 1 from 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine and ammonium carbonate in the presence of TBTU in a yield of 40.6% of theory. Colourless, amorphous substance, R_(f) 0.8 (eluant:dichloromethane/methanol/conc. ammonia=7.5/2.5/0.5 (v/v/v)).

IR (KBr): 1670.3, 1616.3 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 781/783/785 (Br₂) (M + Na)⁺ = 803/805/807 (Br₂)

The following were obtained accordingly:

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine and ethanolamine in a yield of 34.6% of theory: 1-[4-amino-3,5-dibromo-N-[[4-[7-(2-hydroxyethylaminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine, (No. 313) R_(f)=0.7 (eluant:dichloromethane/methanol/conc. ammonia =7.5/2.5/0.5 v/v/v).

IR (KBr): 1662.5, 1618.2 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 825/827/829 (Br₂) (M + Na)⁺ = 847/849/851 (Br₂) (M + 2H)⁺⁺ = 413/414/415 (Br₂) (M + H + Na)⁺⁺ = 424/425/426 (Br₂)

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine and 1-methylpiperazine in a yield of 44.9% of theory: 1-[4-amino-3,5-dibromo-N-[[4-[7-[(4-methyl-1-piperazinyl)carbonyl]-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine, (No. 430) R_(f)=0.28 (eluant:ethyl acetate/methanol/conc. ammonia=8/1.5/0.3 v/v/v).

IR (KBr): 1618.2 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 864/866/868 (Br₂) (M + Na)⁺ = 886/888/890 (Br₂) (M + 2H)⁺⁺ = 432/433/434.7 (Br₂)

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine and methylammonium chloride in a yield of 37% of theory: 1-[4-amino-3,5-dibromo-N-[[4-[7-(methylaminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperidine, (No. 424) R_(f)=0.49 (FM1)

IR (KBr): 1662.5, 1622 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 795/797/799 (Br₂) (M + Na)⁺ = 817/819/821 (Br₂)

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine and ammonium carbonate in a yield of 12% of theory: 1-[4-amino-N-[[4-[7-(aminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-piperidinyl)-piperidine (No. 310), R_(f)=0.7 (eluant:dichloromethane/methanol/conc. ammonia=7.5/2.5/0.5 v/v/v)).

IR (KBr): 1670.3, 1618.2 cm⁻¹ (C═O)

ESI-MS: (M+H)⁺=787/789/791 (Br₂)

From 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-7-(hydroxycarbonyl)-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine and ethanolamine in a yield of 11.4% of theory: 1-[4-amino-3,5-dibromo-N-[[4-[7-(2-hydroxyethylaminocarbonyl)-3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine (No. 311), R_(f)=0.65 (eluant:dichloromethane/methanol/conc. ammonia=7.5/2.5/0.5 (v/v/v)).

IR (KBr): 1660.6, 1620.1 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 831/833/835 (Br₂) (M + 2H)⁺⁺ = 416/417/418 (Br₂) (M + H + Na)⁺⁺ = 427/428/429 (Br₂)

EXAMPLE 15 4-(1-acetyl-4-piperidinyl)-1-[4-amino-3,5-dibromo-N-([[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-phenylalanyl]-piperidine (No. 372) a) 1-[4-amino-3,5-dibromo-D-phenylalanyl]-4-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-piperidine

A mixture of 5.60 g (0.01 mol) of 4-amino-3,5-dibromo-N -(9-fluorenylmethoxycarbonyl)-D-phenylalanine, 1.35 g (0.01 mol) HOBt, 3.21 g (0.01 mol) TBTU, 1.29 g (0.01 mol) DIEA, 2.68 g (0.01 mol) 4-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-piperidine and 150 ml of tetrahydrofuran was stirred for 2 hours at room temperature. After the reaction was complete 20 ml of diethylamine were added and the mixture was stirred for a further 18 hours at room temperature. The reaction mixture was evaporated down in vacuo, the residue was taken up in 200 ml of dichloromethane and washed successively with 100 ml of saturated sodium chloride solution and saturated sodium hydrogen carbonate solution and dried over magnesium sulphate. The reddish oil remaining after elimination of the solvent was purified by column chromatography on silica gel (30-60 μm) using firstly dichloromethane, then FM4 as eluant. The title compound was obtained in the form of a colourless amorphous substance and in a yield of 4.31 g (73.3% of theory).

IR(KBr): 1687.6 cm^(+1 (C═O))

MS: M+=586/588/590 (Br₂)

b) 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-piperidine

Prepared analogously to Example 4 from 1-[4-amino-3,5-dibromo-D-phenylalanyl]-4-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-piperidine, CDT and 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone in a quantitative yield. Colourless, amorphous substance.

IR (KBr): 1676 cm⁻¹ (C═O) MS: (M + H)⁺ = 844/846/848 (Br₂) (M + Na)⁺ = 866/868/870 (Br₂)

c) 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine (No. 521)

Prepared analogously to Example A1b), but using sodium hydroxide solution instead of ammonia, from 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-phenylalanyl]-4-[1-(1,1-dimethylethoxycarbonyl)-4-piperidinyl]-piperidine by treating with trifluoroacetic acid in a yield of 75% of theory. Colourless, amorphous substance.

IR (KBr): 1666.4, 1620.1 cm⁻¹ (C═O) MS: (M + H)⁺ = 744/746/748 (Br₂) (M + 2H)⁺⁺ = 372/373/374.5 (Br₂)

d) 4-(1-acetyl-4-piperidinyl)-1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-piperidine (No. 372)

A solution of 0.372 g (0.499 mmol) of 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine and 0.07 g (5.5 mmol) of DIEA in 50 ml of dichloromethane was mixed with 0.043 g (5.48 mmol) of acetylene chloride dropwise whilst cooling externally with ice-water and then stirred for 1 hour at room temperature. The solvent was eliminated in vacuo, the residue was stirred with water and filtered. The filter residue was dried in vacuo and purified by column chromatography on silica gel (30-60 μm) using FM4 as eluant. The suitable eluates were evaporated down, the residue was triturated with diethylether and suction filtered. 230 mg (58.5% of theory) of colourless crystals were obtained.

IR (KBr): 1622 cm⁻¹ (C═O) MS: (M + H)⁺ = 786/788/790 (Br₂) (M + Na)⁺ = 808/810/812 (Br₂)

The following were obtained accordingly:

1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2 (1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-benzoyl-4-piperidinyl)-piperidine (No. (485).

Colourless crystals

R_(f) 0.74 (FM1)

IR(KBr): 1626,1668 cm⁻¹ (C═O)

ESI-MS: (M+H)⁺⁼848/850/852 (Br₂)

EXAMPLE 16 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methylsulfonyl-4-piperidinyl)-piperidine (No. 486)

A solution of 0.372 g (0.499 mmol) of 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine and 0.07 g (5.5 mmol) of DIEA in 50 ml of dichloromethane was mixed dropwise with 0.063 g (5.5 mmol) of methanesulphonylchloride whilst cooling externally with ice-water and then stirred for 1 hour at room temperature. The solvent was eliminated in vacuo, the residue was stirred with water and filtered. The filter residue was dried in vacuo and purified by column chromatography over silica gel (30-60 μm) using initially dichloromethane, then FM4 as eluant. The suitable eluates were evaporated down, the residue was triturated with diethylether and suction filtered. 220 mg (53.5% of theory) of colourless crystals were obtained.

IR (KBr): 1668, 1618 cm⁻¹ (C═O) MS: (M + H)⁺ = 822/824/826 (Br₂) (M + Na)⁺ = 844/846/848 (Br₂) (M + K)⁺ = 860/862/864 (Br₂)

The following were obtained accordingly:

(1) 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl-1-piperidinyl]carbonyl]-4-(methylsulphonyloxy)-D-phenylalanyl]-4-[1-(methylsulphonyl)-4-piperidinyl]-piperidine (No. (523)) in a yield of 12% of theory.

R_(f) 0.54 (FM1)

IR(KBr): 1628,1665 cm³¹ ¹ (C═O)

ESI-MS: (M+H)⁺⁼901/903/905 (Br₂)

(2) 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(methylsulphonyl)-4-piperidinyl]-piperidine (No. (524) in a yield of 12% of theory.

R_(f) 0.50 (FM1)

ESI-MS: (M+H)₊=833/825/827 (Br₂)

(3) (R,S)-1-[4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(1-naphthyl)methyl]-1,4-dioxobutyl]-4-(1-methylsulphonyl-4-piperidinyl)-piperidine (No. (668) in a yield of 56% of theory.

R_(f) 0. 70 (FM1)

IR(KBr): 1630,1666 cm⁻¹ (C═O)

MS: M⁺=699

EXAMPLE 17 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(3-carboxy-1-oxopropyl)-4-piperidinyl]-piperidine (No. 487)

A mixture of 0.372 g (0.499 mmol) of 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine, 0.11 g (1.1 mmol) of succinic anhydride and 150 ml of tetrahydrofuran was refluxed for 1 hour. The reaction mixture was freed from solvent in vacuo, the residue was purified by column chromatography on silica gel (30-60 μm) using FM1 as eluant. The suitable eluates were evaporated down, the residue was triturated with diethylether and suction filtered. 175 mg (41.5% of theory) of colourless crystals were obtained.

IR (KBr): 1668, 1608 cm⁻¹ (C═O) MS: (M − H)⁻ = 842/844/846 (Br₂) (M + Na)⁺ = 868/870/872 (Br₂)

EXAMPLE 18 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-hexyl-4-piperidinyl)-piperidine (No. 488)

A mixture of 0.372 g (0.499 mmol) of 1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(4-piperidinyl)-piperidine, 0.05 g (0.499 mmol) of hexanal, 0.03 g (0.5 mmol) of glacial acetic acid and 150 ml of tetrahydrofuran was stirred for 1 hour at room temperature. After the addition of 0.116 g (0.52 mmol) of 95% sodium triacetoxyborohydride the mixture was kept for a further 2.5 hours at room temperature. The solvent was eliminated in vacuo, the residue was divided between 20% aqueous sodium carbonate solution and dichloromethane, the organic phase was dried over magnesium sulphate and evaporated down. The residue was purified by column chromatography on silica gel (30-60 μm) using FM4 as eluant. The suitable eluates were evaporated down, the residue was triturated with diethylether and suction filtered. 100 mg (24.2% of theory) of colourless crystals were obtained.

IR (KBr): 1666, 1620 cm⁻¹ (C═O) MS: (M + H)⁺ = 828/830/832 (Br₂) (M + Na)⁺ = 850/852/854 (Br₂)

The following were obtained accordingly:

(1) 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-cyclopropylmethyl-4-piperidinyl)-piperidine (No. (489) in a yield of 23% of theory.

R_(f) 0.65 (FM1)

IR(KBr): 1622,1666 cm⁻¹ (C═O)

ESI-MS: (M+H)⁺=798/800/802 (Br₂)

(2) 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(ethoxycarbonylmethyl)-4-piperidinyl]-piperidine (No. (493) in a yield of 43% of theory.

R_(f) 0.72 (FM1)

IR(KBr): 1620,1666 cm⁻¹ (C═O)

ESI-MS: (M+H)⁺=730/732/734 (Br₂)

(3) 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(cyclopropylmethyl)-4-piperidinyl]-piperidine (No. (525) in a yield of 46.5% of theory.

R_(f) 0.50 (FM1)

IR(KBr): 1622,1662 cm⁻¹ (C═O)

ESI-MS: (M+H)⁺=799/801/803 (Br₂)

EXAMPLE 19

Preparation of Compounds of General Formula:

1-[N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-3-ethenyl-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine (No. 532)

The mixture of 200 mg (3 mmol) 1-[3-bromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine, 108 mg (0.33 mMol) vinyl-tributyl tin (ALDRICH No. 27143-8), 50 mg tetrakis-(triphenylphosphine)-palladium (Merck No. 818193), a trace of 2,6-di-tert.-butyl-4-methylphenol and 10 ml anhydrous toluene was refluxed for 5 hours. The cooled reaction mixture was filtered over an activated charcoal filter, the filtrate was evaporated in a vacuum. The residue was purified for elution by column chromatography over silica gel, initially using pure dichloromethane, then methanol/conc. ammonia (9/1 v/v). The suitable eluates were triturated and suction filtered with tert.-butyl-methylether. Yield was 60 mg (32.6% of theory) of colourless crystals of R_(f) 0.25 (FM1).

MS: M⁺=612

The following were prepared analogously: (in each case, n=1):

% No. RCO Z R² A NR³R⁴ Yield MS Eluant R_(f) IR [cm⁻¹] 647 N66 CH₂ AS40 A0 C8 75 EI: M⁺ = 611 FM1 0.6 (KBr): C═O 1639/1668 648 N66 CH₂ AS41 A0 C8 56 EI: M⁺ = 647 FM1 0.7 (KBr): C═O 1639/1668 649 N66 CH₂ AS42 A0 C8 8 EI: M⁺ = 648 FM1 0.6 (KBr): C═O 1635/1668 650 N66 CH₂ AS43 A0 C8 11 EI: M⁺ = 654 FM1 0.6 (KBr): C═O 1635/1666 651 N66 CH₂ AS44 A0 C8 84 EI: M⁺ = 637 FM1 0.6 (KBr): C═O 1633/1664 652 N66 CH₂ AS45 A0 C8 83 EI: M⁺ = 613 FM1 0.6 (KBr): C═O 1637/1667

EXAMPLE 20

Preparation of Compounds ofGeneralFormula:

(R,S)-1-[4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine (No. 599)

Produced analogously to Example 1 from (R,S)-4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-4-oxobutanoic acid, 4-(4-methyl-1-piperazinyl)piperidine and TBTU in a yield of 10% of theory. Colourless, amorphous substance of R_(f)=0.2 (dichloromethane/methanol/conc. ammonia 90/10/1 v/v/v).

IR (KBr): 1722, 1662, 1637 cm⁻¹ (C═O)

MS: M⁺=711

Accordingly, (R,S)-1-[4-[4-(amincocarbonylamino)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine (No. 601) was obtained from (R,S)-4-[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]-2-(ethoxycarbonyl)-2-[[1-methyl-1H-indol-3-yl]methyl]-4-oxobutanoic acid, 4-(4-methyl-1-piperazinyl)piperidine and TBTU in a yield of 20% of theory. Colourless, amorphous substance of R_(f)=0.25 (dichloromethane/methanol/conc. ammonia 90/10/1 v/v/v).

ESI-MS: (M + H)⁺ = 624 (M + Na)⁺ = 646 (M + H + Na)⁺ ⁺ = 323.8

EXAMPLE 21 1-[3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hydroxycarbonyl)-piperidine (No. 211)

Produced analogously to Example A38 from 1-[3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(ethoxycarbonyl)-piperidine and aqueous lithium hydroxide solution in a yield of 79% of theory. Colourless, amorphous substance of R_(f) 0.54 (ethyl ethanoate/methanol/glacial acetic acid 9/1/0.3 v/v/v).

IR(KBr): 1691.5,1622.0 cm⁻¹ (C═O) ESI-MS: (M−H)⁻=690/2/4 (Br₂)

EXAMPLE 22 1-[3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-piperidinyl)-piperazine (No. 214)

Produced analogously to Example A24 from 3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosine, 1-(1,1-dimethylethoxycarbonyl)-4-(1-piperazinyl)piperidine and TBTU, and additional conversion of the obtained intermediate product with trifluoroacetic acid (in accordance with Example A1b) in a yield of 4.2% of theory. Colourless, amorphous substance of R_(f) 0.25 (FM1).

IR(KBr): 1624.0 cm⁻¹ (C═O)

ESI-MS: (M+H)⁺=732/4/6 (Br₂)

EXAMPLE 23 (R)-1-[2-[N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-methylamino]-3-(3,5-dibromo-4-hydroxyphenyl)-propyl]-4-(1-piperidinyl)-piperidine (No. 219) a) 1-(chlorocarbonyl)-4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-piperidine

To a solution of 3.0 g (13.8 mmol) 4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)piperidine and 2.7 ml (15 mMol) DIEA in 100 ml toluene, a solution of 1.8 ml (14.9 mMol) diphosgene in 15 ml toluene was added dropwise under external cooling with iced water, and the mixture was additionally kept at room temperature for 17 hours. The precipitate was suction filtered, washed with petroleum ether and dissolved in 50 ml dichloromethane. The obtained solution was agitated twice each with 50 ml 7% aqueous sodium hydrogen carbonate solution, dried over sodium sulphate and evaporated in a vacuum. Yield was 3.0 g (78% of theory) of a colourless substance of R_(f) 0.25 (dichloromethane/acetone 9/1 v/v), which was further processed without more purification.

b) (R)-1-[3-(3,5-dibromo-4-hydroxyphenyl)-2-(N-methylamino)-propyl]-4-(1-piperidinyl)-piperidine

To a suspension of 2.3 g (60 mmol) lithium aluminium hydride in 100 ml anhydrous tetrahydrofuran, a solution of 11.0 g (18.66 mmol) 1-[3,5-dibromo-N-(1,1-dimethylethoxycarbonyl)-D-tyrosyl]-4-(1-piperidinyl)piperidine in 100 ml anhydrous tetrahydrofuran was added dropwise at room temperature whilst being stirred. It was stirred for a further 15 minutes at room temperature and then refluxed for 3 hours. 3 ml 20% aqueous ammonium chloride solution was added to the cooled mixture, then it was dried with magnesium sulphate. The filter cake was filtered and washed with 300 ml of an ethyl ethanoate-methanol mixture (1/1 v/v), and the combined filtrates were evaporated in a vacuum. The residue was purified by column chromatography over silica gel using ethyl ethanoate/methanol (8/2 v/v) for elution.

1. 2.9 g (31% of theory) of a colourless substance of R_(f) 0.13 (eluant: methanol) was isolated from the suitable fractions, which was identified as 1-(3,5-dibromo-N-methyl-D-tyrosyl)-4-(1-piperidinyl)piperidine:

IR(KBr): 1668.3 cm⁻¹ (C═O)

MS: M⁺=501/3/5 (Br₂)

and

2. 1.8 g (20% of theory) of a colourless substance of R_(f) 0.05 (eluant: methanol), which was identified as the sought compound:

ESI-MS: (M + H)⁺ = 488/490/492 (Br₂) (M + 2H)⁺⁺ = 244/245/246.5 (Br₂)

c) (R)-1-[2-[N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-N-methylamino]-3-(3,5-dibromo-4-hydroxyphenyl)-propyl]-4-(1-piperidinyl)-piperidine (No. 219)

A solution of 0.57 g (2.02 mmol) 1-(chlorocarbonyl)-4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-piperidine in 30 ml dimethylformamide was added dropwise to the mixture of 0.9 g (1.84 mmol) (R)-1-[3-(3,5-dibromo-4-hydroxyphenyl)-2-(N-methylamino)-propyl]-4-(1-piperidinyl)-piperidine and 0.65 ml (3.7 mmol) DIEA in a mixture of 50 ml tetrahydrofuran and 20 ml dimethylformamide. It was stirred overnight at room temperature and the deposit was evaporated in a vacuum. The residue was treated with 300 ml of a tetrahydrofuran ethyl ethanoate mixture (1/1 v/v) and the resulting solution was agitated twice each with 100 ml of a saturated aqueous solution of sodium hydrogen carbonate, dried over sodium sulphate and evaporated in a vacuum. The residue was purified over silica gel by column chromatography using dichloromethane/methanol (8.5/1.5 v/v) for elution. 390 mg (29% of theory) of a colourless substance of R_(f) 0.46 (dichloromethane cyclohexane/methanol/conc. ammonia 75/15/15/2 v/v/v/v) were isolated from the suitable fractions:

IR(KBr): 1695.3,1624.0 cm⁻¹ (C═O)

ESI-MS: (M+H)⁺=731/3/5 (Br₂)

EXAMPLE 24 1-[3,5-dibromo-N-[[4-[5-[(4-morpholinyl)carbonyl]-1,3-dihydro-2(2H)-oxobenzimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine (No. 223)

100 mg (0.6 mMol) N,N′-carbonyldiimidazole was added to a solution of 400 mg (0.5 mMol) 1-[3,5-dibromo-N-[[4-(1,3-dihydro-5-(hydroxycarbonyl)-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine in 10 ml anhydrous tetrahydrofuran at room temperature, heated to 50° C. for 30 minutes and then 90 mg (1 mMol) morpholine was added. After heating to 50-60° C. for two hours, the solution was removed in a vacuum and the residue was purified over silica gel(30-60 μm) by column chromatography, initially using dichloromethane, then dichloromethane/methanol 9/1 (v/v), and finally dichloromethane/methanol/conc. ammonia 9/1/0.2 (v/v/v) as eluants. 250 mg (60% of theory) of an amorphous, colourless substance was yielded from the suitable extracts.

IR (KBr): 1712.7, 1625.9 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 838/840/842 (Br₂) (M + 2H)⁺⁺ = 419/420/421.5 (Br₂)

The following were obtained accordingly:

1-[3,5-dibromo-N-[[4-[5-[(4-methyl-1-piperazinyl)carbonyl]-1,3-dihydro-2(2H)-oxobenzimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine (No. 224) from 1-[3,5-dibromo-N-[[4-(1,3-dihydro-5-(hydroxycarbonyl)-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)piperidine, 1-methylpiperazine and N,N′-carbonyldiimidazole in yield of 52% of theory. Colourless, amorphous substance.

IR (KBr): 1710.8, 1625.9 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 851/853/855 (Br₂) (M + 2H)⁺⁺ = 426/427/428 (Br₂)

EXAMPLE 25 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(carboxymethyl)-4-piperidinyl]-piperidine (No. 494)

Produced analogously to Example A37, but using tetrahydrofuran instead of methanol, from 1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-[1-(ethoxycarbonylmethyl)-4-piperidinyl]-piperidine by the action of aqueous lithium hydroxide solution in a yield of 51% of theory. Colourless, amorphous substance.

ESI-MS: (M − H)⁻ = 800/802/804 (Br₂) (M + H)⁺ = 802/804/806 (Br₂) (M + Na)⁺ = 824/826/828 (Br₂)

EXAMPLE 26 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(hydroxycarbonylmethyl)-4-piperidinyl]-piperidine (No. 526)

Produced analogously to Example 18 from 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-piperidinyl)-piperidine, ethyl glyoxylate and sodium triacetoxyborhydride and additional saponification with soda lye of the 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-[1-(ethoxycarbonylmethyl)-4-piperidinyl]-piperidine, obtained as an intermediate product but not characterised, according to Example A55. A colourless, amorphous substance is obtained in a yield of 35% of theory.

IR (KBr): 1625.9 wide cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 803/805/807 (Br₂) (M + Na)⁺ = 825/827/829 (Br₂)

EXAMPLE 27 1-[4-amino-N-[(4-amino-1-piperidinyl)carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine (No. 564)

653 mg (10.4 mMol) 95% sodium cyanoborohydride (Aldrich 15.615-9) was stirred into the mixture of 930 mg (1.48 mMol) 1-[4-amino-3,5-dibromo-N-[(4-oxo-1-piperidinyl)carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine, 1143 mg (14.8 mMol) ammonium acetate (Merck No. 1115) and 30 ml anhydrous methanol at room temperature, and was stirred overnight. The deposit was adjusted to pH ≦2 with conc. hydrochloric acid and was evaporated in a vacuum. The residue is taken up in water and made alkaline with 40% soda lye. Exhaustive extraction with dichloromethane followed, then the combined extracts were dried over sodium sulphate and evaporated in a vacuum. The residue was purified over 100 g silica gel (Amicon, 35-70 μm) by column chromatography using dichloromethane/methanol/conc. ammonia(60/40/5 v/v/v) for elution. From the suitable fractions, 250 mg (27% of theory) of the sought substance was isolated as a colourless, amorphous product of R_(f) 0.15 (dichloromethane/methanol/conc. ammonia 50/50/0.5 v/v/v).

IR (KBr): 1618 wide cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 627/629/631 (Br₂) (M + Na)⁺ = 649/651/653 (Br₂) (M + 2H)⁺⁺= 314/315/316 (Br₂)

EXAMPLE 28 (R,S)-1-[4-[4-(3,4-Dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorphenyl)methyl]-1,4-dioxobutyl]-4-(hydroxycarbonylmethyl)-piperidine (No. 596)

Produced analogously to Example A55 from (R,S)-1-[4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,4-dichlorophenyl)methyl]-1,4-dioxobutyl]-4-(ethoxycarbonylmethyl)-piperidine by saponification with soda lye in a yield of 86% of theory. Colourless, amorphous substance of R_(f) 0.76 (ethyl ethanoate/methanol/glacial acetic acid 70/30/1 v/v/v).

IR (KBr): 1716, 1635 cm⁻¹ (C═O) ESI-MS: (M − H)⁻= 613/615/617 (Cl₂) (M + H)⁺ = 615/617/619 (Cl₂) (M + Na)⁺ = 637/639/641 (Cl₂)

EXAMPLE 29 1-[N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]-carbonyl]-3-(1H-tetrazol-5-yl)-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine (No. 632)

8.5 g (35 mMol) tributyl tin(IV)-azide (Synthesis 1976, 330) was added to a solution of 1.6 g (2.68 mMol) 1-[3-cyano-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]carbonyl]-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine in 400 ml toluene and the mixture was refluxed for 4 days. The residue remaining after dispellation of the solvent was stirred with ethyl ethanoate, the obtained precipitate was suction filtered and purified over silica gel by column chromatography using FM1 as an eluent. After the usual further processing, yield is 400 mg (24% of theory) of colourless crystals of R_(f) 0.2 (FM1).

IR (KBr): 1653 cm⁻¹ (C═O) ESI-MS: (M + H)⁺ = 641 (M + Na)⁺ = 663

The following Examples describe the preparation of pharmaceutically useful forms which contain as active substance any desired compound of general formula I:

EXAMPLE I

Capsules for powder inhalation containing 1 mg of active substance Composition: 1 capsule for powder inhalation contains: Active substance  1.0 mg Lactose 20.0 mg Hard gelatine capsules 50.0 mg 71.0 mg

Method of Preparation:

The active substance is ground to the particle size required for inhalants. The ground active substance is homogeneously mixed with the lactose. The mixture is packed into hard gelatine capsules.

EXAMPLE II

Inhalable solution for Respimat ® containing 1 mg of active substance Composition: 1 stroke contains: Active substance 1.0 mg Benzalkonium chloride 0.002 mg Disodium edetate 0.0075 mg Purified water ad 15.0 μl

Method of Preparation:

The active substance and benzalkonium chloride are dissolved in water and transferred into Respimat® cartridges.

EXAMPLE III

Inhalable solution for nebulisers containing 1 mg of active substance Composition: 1 vial contains: Active substance 0.1 g Sodium chloride 0.18 g Benzalkonium chloride 0.002 g Purified water ad 20.0 ml

Method of Preparation:

Active substance, sodium chloride and benzalkonium chloride are dissolved in water.

EXAMPLE IV

Propellant gas metering aerosol containing 1 mg of active substance Composition: 1 stroke contains: Active substance 1.0 mg Lecithin 0.1% Propellant gas ad 50.0 μl

Method of Preparation:

The micronised active substance is homogeneously suspended in a mixture of lecithin and propellant gas. The suspension is transferred into a pressurised container with metering valve.

EXAMPLE V

Nasal spray containing 1 mg of active substance Composition: Active substance 1.0 mg Sodium chloride 0.9 mg Benzalkonium chloride 0.025 mg Disodium edetate 0.05 mg Purified water ad 0.1 ml

Method of Preparation:

The active substance and adjuvants are dissolved in water and transferred into a suitable container.

EXAMPLE VI

Injectable solution containing 5 mg of active substance per 5 ml Composition: Active substance 5 mg Glucose 250 mg Human-serum-albumin 10 mg Glycofurol 250 mg Water for injections ad 5 ml

Preparation:

Glycofurol and glucose are dissolved in water for injections (WfI); human-serum-albumin is added; active substance is dissolved with heating; solution is made up to required volume with WfI; transferred into ampoules under nitrogen gas.

EXAMPLE VII

Injectable solution containing 100 mg of active substance per 20 ml Composition: Active substance 100 mg Monopotassium dihydrogen phosphate = KH₂PO₄ 12 mg Disodium hydrogen phosphate = Na₂HPO₄•2H₂O 2 mg Sodium chloride 180 mg Human-serum-albumin 50 mg Polysorbate 80 20 mg Water for injections ad 20 ml

Preparation:

Polysorbate 80, sodium chloride, monopotassium dihydrogen phosphate and disodium hydrogen phosphate are dissolved in water for injections (WfI); human-serum-albumin is added; active substance is dissolved with heating; solution is made up to required volume with WfI; transferred into ampoules.

EXAMPLE VIII

Lyophilisate containing 10 mg of active substance Composition: Active substance 10 mg Mannitol 300 mg  Human-serum-albumin 20 mg

Preparation:

Mannitol is dissolved in water for injections (WfI); human-serum-albumin is added; active substance is dissolved with heating; solution is made up to required volume with WfI; transferred into vials and freeze-dried.

Solvent for lyophilisate: Polysorbate 80 = Tween 80 20 mg Mannitol 200 mg Water for injections ad 10 ml

Preparation:

Polysorbate 80 and mannitol are dissolved in water for injections (WfI) and transferred into ampoules.

EXAMPLE IX

Tablets containing 20 mg of active substance Composition: Active substance 20 mg Lactose 120 mg  Corn starch 40 mg Magnesium stearate  2 mg Povidon K 25 18 mg

Preparation:

Active substance, lactose and corn starch are homogeneously mixed; granulated with an aqueous solution of Povidon; mixed with magnesium stearate; pressed in a tablet press; weight of tablet 200 mg.

EXAMPLE X

Capsules containing 20 mg of active substance Composition: Active substance 20 mg Corn starch 80 mg Highly dispersed silicic acid  5 mg Magnesium stearate 2.5 mg 

Preparation:

Active substance, corn starch and silicic acid are homogeneously mixed; mixed with magnesium stearate; then the mixture is packed into size 3 hard gelatine capsules using a capsule filling machine.

EXAMPLE XI

Suppositories containing 50 mg of active substance Composition: Active substance 50 mg Hard fat (adeps solidus) q.s. ad 1700 mg 

Preparation:

Hard fat is melted at about 38° C.; ground active substance is homogeneously dispersed in the molten hard fat; then after cooling to about 35° C. the melt is poured into chilled moulds.

EXAMPLE XII

Aqueous solution for nasal application containing 10 mg active substance Composition: Active substance 10.0 mg Hydrochloric acid in quantity required 0.01 mg for formation of a neutral salt Methylparahydroxybenzoate (PHB) Propylparahydroxybenzoate (PHB) 0.005 mg Purified water ad 1.0 ml

Preparation:

The active substance is dissolved in purified water; Hydrochloric acid is added until the solution is clear; PHB methyl and propyl esters are added; the solution is made up to required volume with purified water; the solution is sterile-filtered and is transferred into an appropriate container.

EXAMPLE XIII

Aqueous solution for nasal application containing 5 mg active substance Composition: Active substance 5 mg 1,2-propandiol 300 mg Hydroxyethyl cellulose 5 mg Sorbic acid 1 mg Purified water ad 1 ml

Preparation:

The active substance is dissolved in 1,2-propandiol; a hydroxy-ethyl-cellulose solution is prepared in purified water containing sorbic acid and is added to the active substance solution; the solution is sterile-filtered and is transferred into an appropriate container.

EXAMPLE XIV

Aqueous solution for intravenous application containing 5 mg active substance Composition: Active substance 5 mg 1,2-propandiol 300 mg Mannitol 50 mg Water for injections (WfI) ad 1 ml

Preparation:

The active substance is dissolved in 1,2-propandiol; the solution is approximately made up to the required volume with WfI; the mannitol is added and the solution is made up to required volume with WfI; the solution is sterile-filtered, transferred into individual containers and autoclaved.

EXAMPLE XV

Liposomal formulation for intravenous injection containing 7.5 mg active substance Composition: Active substance 7.5 mg Egg-lecithin, e.g. lipoid E 80 100.0 mg Cholesterol 50.0 mg Glycerine 50.0 mg Water for injections ad 1.0 ml

Preparation:

The active substance is dissolved in a mixture of lecithin and cholesterol; the solution is added to a mixture of glycerine and WfI and is homogenised by means of high-pressure homogenisation or microfluidiser technology; the liposomal formulation obtained in this manner is transferred into an appropriate container under aseptic conditions.

EXAMPLE XVI

Suspension for nasal application containing 20 mg active substance Composition: Active substance 20.0 mg Carboxymethylcellulose (CMC) 20.0 mg Sodium monohydrogen phosphate/sodium- q.s. dihydrogen phosphate buffer pH 6.8 Sodium chloride 8.0 mg Methylparahydroxybenzoate 0.01 mg Propylparahydroxybenzoate 0.003 mg Purified water ad 1.0 ml

Preparation:

The active substance is suspended in an aqueous CMC solution; the other components are added to the suspension one after another and the suspension is made up to required volume with purified water.

EXAMPLE XVII

Aqueous solution for subcutaneous application containing 10 mg active substance Composition: Active substance 10.0 mg Sodium monohydrogen phosphate/sodium 7.0 dihydrogen phosphate buffer q.s. ad pH Sodium chloride 4.0 mg Water for injections ad 0.5 ml

Preparation:

The active substance is dissolved in the phosphate buffer solution, after addition of the sodium chloride the solution is made up to required volume with water. The solution is sterile-filtered and is autoclaved after being transferred into an appropriate container.

EXAMPLE XVIII

Aqueous solution for subcutaneous application containing 5 mg active substance Composition: Active substance 5.0 mg Polysorbate 80 0.5 mg Water for injections ad 0.5 ml

Preparation:

The active substance is suspended in the polysorbate 80 solution and is reduced to a particle size of approx. 1 μm by means of a suitable dispersion technique (e.g. wet milling, high-pressure homogenisation, micro-fluidisation, etc.). The suspension is transferred into an appropriate container under aseptic conditions. 

1. A compound of the formula I

wherein R denotes a group of formula

wherein p denotes the number 1, o denotes the number 2, Y¹ denotes the carbon atom, Y² denotes the nitrogen atom, R⁵, R⁶ and R⁷ each denote the hydrogen atom, R^(N) denotes a N-(aminocarbonyl)-N-phenylamino group or a mono- or bicyclic heterocycle selected from the group consisting of 1,3-dihydro-4-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-5-phenyl-2H-2-oxoimidazol-1-yl, 1,3-dihydro-2(2H)-oxobenzimidazol-1-yl, 3,4-dihydro-2(1H)-oxothieno [3,4-d]pyrimidin-3-yl, 1H-benzimidazol-1-yl, 3,4-dihydro-2(1H)-oxoquinazolin-3-yl, 3,4-dihydro-2(1H)-oxoquinazolin-1-yl, 2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl, 2(1H)-oxoquinolin-3-yl, or 1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-2-yl, wherein said mono- and bicyclic heterocycles optionally are monosubstituted in the carbon skeleton and/or at the phenyl groups contained in these groups by a chlorine atom, or by a methyl, or hydroxy group, X denotes an oxygen atom or 2 hydrogen atoms, Z denotes a methylene group or the group —NR¹, wherein R¹ denotes a hydrogen atom or a methyl group, R¹¹ denotes a hydrogen atom, n denotes the number 1 and m denotes the number 0 or n denotes the number 0 and m denotes the number 1, R² denotes an aromatic group selected from phenyl, 1-naphthyl and 2-naphthyl, wherein said aromatic group optionally is mono- or disubstituted by fluorine, chlorine or bromine atoms, by methyl, methoxy, hydroxy or amino groups and the substituents may be identical or different, or trisubstituted by two bromine atoms and either one hydroxy, one amino, one methyl, one methoxy group or trisubstituted by two chlorine atoms and one hydroxy group or trisubstituted by two methyl groups and either one hydroxy or one methoxy group, or R² denotes a 1H-indol-3-yl, 1-methyl-1H-indol-3-yl, 1-(1,1-dimethylethoxycarbonyl)-1H-indol-3-yl, 2-thienyl, 3-thienyl or pyridinyl group, A denotes the divalent group of formula

 (linked to the group —NR³R⁴ of formula (I) via the carbonyl group) wherein R⁸ denotes the hydrogen atom or the methyl group and R⁹ denotes the hydrogen atom or an unbranched C₁₋₄-alkyl group, which may be substituted in the ω-position by an amino, methylamino, dimethylamino or amino iminomethylamino group, R³ denotes a hydrogen atom or a C₁₋₄-alkyl group optionally substituted in the ω-position by an amino, methylamino or dimethylamino group, R⁴ denotes a hydrogen atom, a methyl or ethyl group, or R³ and R⁴ together with the enclosed nitrogen atom denote a group of general formula

wherein Y³ denotes the carbon atom or, if R¹² denotes a free pair of electrons, Y³ denotes a nitrogen atom, r denotes the number 1, q denotes the number 1, R¹⁰ denotes a C₁₋₃-alkyl group which may be substituted in the ω-position by a dialkylamino group having 1 to 3 carbon atoms in each alkyl moity, or a phenyl, pyridinyl or diazinyl group, each of which may be substituted in the carbon skeleton by methyl or methoxy group, a 1-pyrrolidinyl, 1-piperidinyl, 4-(dimethylamino)-1-piperidinyl or 4-piperidinyl group, wherein the nitrogen atom of the 4-piperidinyl group may be substituted by an alkyl group having 1 to 3 carbon atoms, R¹² denotes a hydrogen atom, or a free pair of electrons if Y³ denotes a nitrogen atom, and R¹³ and R¹⁴ each denote a hydrogen atom, or a tautomer or salt thereof
 2. A compound of the formula I according to claim 1, wherein the partial amino acid structure of the formula

is in the D- or (R)-configuration and is in the L- or (S)-configuration with regard to the partial amino acid structure of formula

which may be present in the group A, or wherein the partial structure of formula VI

is spatially constructed analogously to the (R)-configured partial structure of formula V.
 3. A compound selected from the group consisting of: 1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl ]-L-lysyl]-4-(4-pyridinyl)-piperazine; (22) 1-[N2-[N-(4,4-Diphenyl-1-piperidinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; (23) 1-[N2-[N-(4-Phenyl-1-piperidinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²—[N-[4-(2-Methoxyphenyl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²—[N-[4-(3-Methoxyphenyl)-1,2,5,6-tetrahydro-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl ]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²—[N-[4-(2-Methoxyphenyl)-1,2,5,6-tetrahydro-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl ]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²—[N-(4,4-Diphenyl-1-piperidinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-4-amino-3,5-dibromo-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl ]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(2-pyridinyl)-piperazine; 1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²—[N-[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(2-methoxyphenyl)-piperazine; 1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(2-pyridinyl)-piperazine; 1-[N²—[N-(4,4-Diphenyl-1-piperidinyl)carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(2-pyridinyl)-piperazine; 1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D,L-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D,L-phenylalanyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²—[N-[4-(1,3-Dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-(2,4(1H,3H)-dioxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²—[N-[[4-(Aminocarbonylamino)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-(methylaminocarbonylamino)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-[N-(aminocarbonyl)methylamino]-1piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²—[N-[[4-(Aminocarbonylamino)-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-[N-(methylaminocarbonyl)methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-[N-(aminocarbonyl)methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-[N-(methylaminocarbonyl)amino]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-[N-(methylaminocarbonyl)methylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²—[N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²—[N-[[4-[2(3H)-Oxobenzoxazol-3-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine; 1-[N²-[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(1-piperidinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl ]carbonyl]-D-tyrosyl]-L-lysyl]-4-(1-piperidinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl ]carbonyl]-L-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl ]carbonyl]-L-tyrosyl]-D-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl ]carbonyl]-D-tyrosyl]-D-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl ]carbonyl]-D-tyrosyl]-N⁶,N⁶-dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl ]carbonyl]-D-tyrosyl]-L-lysyl]-4-(1-piperidinyl)-piperidine; 1-[N²-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl ]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3-Bromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl ]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl ]carbonyl]-D-phenylalanyl]-N⁶,N⁶-dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl ]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(1-piperidinyl)-piperidine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl ]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)oxoquinazolin-3-yl)-1-piperidinyl ]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(1-piperidinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(1-piperidinyl)-piperidine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-[2(3H)-oxobenzoxazol-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine; 1-[N²-[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-L-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[2,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-[N-(Aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-[N-(methylaminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-phenylalanyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(1-piperidinyl)-piperidine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-[N-(methylaminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(1-piperidinyl)-piperidine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-4-methyl-1-piperidinyl]carbonyl]-D-phenylalanyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-4-methyl-1-piperidinyl]carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine; 1-[N²-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N⁶-Acetyl-N²-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[4-Amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N⁶,N⁶-dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶,N⁶-dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl)phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; 1[N2-[3,5-Dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)-piperazine; 1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-L-tyrosyl]-D-lysyl]-4-(4-pyridinyl)-piperazine; and 1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-L-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine; or a tautomer or salt thereof.
 4. A physiologically acceptable salt of a compound in accordance with claim 2, 1 or
 3. 5. A pharmaceutical composition containing a compound according to claim 2, 1 or 3 or a physiologically acceptable salt thereof, together with an inert carrier or diluent. 